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Abstract 
 
Ischemia modified-albumin (IMA®) is a useful early cardiac biomarker for the 
diagnosis of acute coronary syndrome.  In this study the diagnostic efficiency 
and the cost effectiveness of the oxidative stress biomarker (ischemia 
modified-albumin), myocardial necrosis (high sensitivity cardiac troponin, heart 
fatty-acid binding protein), vascular stress (copeptin) and myocardial 
dysfunction and hemodynamic stress (B-type natriuretic peptide) were 
evaluated for the diagnosis of acute myocardial infarction and cost benefit in 
low risk patients presenting to the emergency department with chest pain. 
This study was a retrospective observational study of a prospective 
randomised controlled trial.  A surplus of well characterised blood samples 
were analysed for the above biomarkers.  A meta-analysis study of the 
diagnostic performance of Ischemia modified-albumin assay in patients 
presenting with chest pain suggestive of acute coronary syndrome was 
conducted.  The-cost-benefit analysis was based on doctor on demand 
scenario. 
Four hundred and forty-four samples were made available for this study, of 
which 174 patients had samples taken on admission and at 90 min.  Three 
patients had a final diagnosis of acute myocardial infarction and one patient 
died.  The difference in ischemia modified-albumin concentration was 
statistically significant (p = 0.002) between patients presenting on admission 
and at 90 min after admission.  NT-pro-BNP had the highest diagnostic 
efficiency on admission with an area under the receiver operator curve (AUC) 
of 93% (95% CI, 82-93%).  IMA did not reach the desired diagnostic efficiency 
with an AUC ranging from 54%-58%.  The combined diagnostic efficiency of 
IMA plus high sensitivity cardiac troponin had a sensitivity and specificity of 
71% (95% CI, 56-82%) and 100% (95% CI, 98-100%) respectively.  The 
remaining biomarkers were not diagnostically efficient when combined with 
IMA.  All biomarkers demonstrated poor prognostic value in predicating major 
adverse cardiac events within 30 days.  Meta-analysis (n = 4295) 
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demonstrated a sensitivity of 77.73% (95% CI, 72.21-83.24%) and specificity 
of 72.71% (95% CI, 64.09-81.34%) respectively.  The negative predictive value 
and positive predictive was 80.13% (95% CI, 73.18-87.08%) and 67.91% (95% 
CI, 58.47-77.39%) respectively.  The implementation of high sensitivity 
troponin plus IMA on admission would cost £638.00 per high-risk patient, 
compared to £464.00 for troponin alone as per current protocol. 
In conclusion, IMA plus high sensitivity cardiac troponin is cost effective and 
could be used to rule-out acute myocardial infarction.  High sensitivity cardiac 
troponin is the most diagnostically efficient biomarker for early diagnosis of 
acute myocardial infarction.  IMA assay alone is not suitable for the diagnosis 
of acute myocardial infarction. 
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1.0 Introduction 
 
According to the World Health Organisation (WHO), non-communicable 
diseases (NCDs), such as cardiovascular disease (CVD) include: acute 
coronary syndrome (ACS), coronary artery disease (CAD) and stroke which 
are responsible for approximately 17 million deaths globally per year. The 2014 
Centre for Economics and Business Research (CEBR) report estimated that 
the UK’s total annual cost of CVD, including health care systems, informal care 
and loss of productivity, accounts for £15.2 billion annually. The CEBR also 
estimated that the total cost would rise to £18.7 billion in 2020 (European 
Research C.f.E.a.B., 2014). 
Since 2012, in the UK alone, CVD was responsible for an estimated 74,000 
annual deaths in people less than 75 years old (Bhatnagar, 2015). 
Surprisingly, since the 1970s, the actual trend of CVD associated deaths in 
England has decreased among the same population by as much as 44%. 
Interestingly, for the first time, CVD is no longer the biggest killer in UK. In 
2012, CVD reportedly caused 28% of all deaths, whereas cancer was 
attributable for 29% (Bhatnagar, 2015).  The trend of CVD prevalence is 
changing; new evidence suggests that younger people between the ages of 
35 to 54 years old are also affected (Ford, 2007; Gupta, Wang, Spertus et al., 
2014). 
The long-term consequences of coronary artery disease (CAD), including 
ACS, are characterised by inflammation and slow growing lesions in the 
coronary arteries, known as atherosclerotic plaque. The plaque matures and, 
following destabilisation and rupture, forms a thrombotic embolus within the 
lumen (Lusis, 2000).  This thrombotic embolus usually results in clinical 
complications such as acute myocardial infarction (AMI) and stroke. CAD 
involves two different processes: a fixed and rarely reversible process that 
gradually causes the narrowing of the arterial lumen and a dynamic process 
which is characterised by progressive and slow formation of atherosclerotic 
plaque with an unpredictable outcome such as thrombosis, vasospasm or both 
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(Fuster, 1992).  The narrowing of the vessels, especially around the lumen, 
causes ischaemia. Chest pain is directly linked to the narrowing of the coronary 
arterial lumen, and inflammation. The combined effect can cause the thrombus 
to dislodge, leading to partial or complete coronary artery blockage and 
myocardial cell damage (Finn, Nakano, Narula, Kolodgie, & Virmani, 2010). 
1.1 Brief overview of the mechanism of acute coronary 
syndrome 
1.1.1 Aetiology of an acute coronary syndrome 
 
Myocardial function requires a precise homeostatic balance; any changes due 
to insufficient oxygen supply, deprivation of nutrients, ischaemia reperfusion 
and decreased clearance of waste products can cause acute cellular changes 
including apoptosis (Saraste, 1997).  At a cellular level, these changes can 
manifest as a malfunction of the sodium-potassium pump, DNA fragmentation 
and leakage of cardiovascular specific proteins such as cardiac troponin and 
heart fatty-acid binding protein (H-FABP) (Kloner, 1993; Kerr, Wyllie, & Currie, 
1972). The myocardium can survive a short period (<1 h) of disruption to 
cellular homoeostasis; however, prolonged disruption results in irreversible 
damage and ultimately localised cell death (Fishbein, Wang, & Matijasevic et 
al., 2003). 
ACS start with a slow development of atherosclerotic plaque in the coronary 
arteries and is characterised by a sudden manifestation of an acute ischaemic 
cardiac disease which can include unstable angina pectoris (UA), stable 
angina (SA), non-ST-segment elevation myocardial infarction (NSTEMI) and 
ST-segment elevation myocardial infarction (STEMI). Thus, ACS includes a 
broad spectrum of diseases that share the same pathophysiological basis 
(Aroney, 2003).  Cardiovascular ischaemic disease due to atherosclerosis is 
the most common cause of death and disability worldwide. In 2010, WHO 
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estimated that cardiovascular disease represents around 30% of global deaths 
(Lozano, Naghavi, Foreman et al., 2012). 
Atherosclerosis is a long-term, silent chronic vascular pathology responsible 
for most patients admitted to emergency department (ED) with ACS. It is a 
chronic disease characterised by lipid deposition, plaque formation, immune 
cell infiltration and chronic  inflammation (Fuster et al., 1992a).  Atherosclerotic 
plaque formation is the result of a dynamic interaction between various 
components including modified lipid, monocyte-derived macrophages and 
activated vascular smooth muscle cells.  The interaction of all these 
components results in the formation of a lesion in the arterial wall (Fuster, 
Badimon, Badimon, & Chesebro, 1992b). 
The progression of vascular disease due to atherosclerotic plaque formation 
involves a combination of dysfunctional endothelial cells within the coronary 
arteries, lipid deposition such as low density lipoprotein (LDL), very low density 
Lipoprotein (VLDL) and apoE remnant in the intima, an exacerbated innate 
and adaptive immune system, the recruitment of other immune cells including 
mast cells, regulatory T-cells, T-helper cells, remodelling of the extracellular 
matrix, angiogenesis, free radicals and the proliferation of vascular smooth 
muscle (Linton, Yancey, Davies et al., 2000). 
In addition, advance atherosclerotic plaque is characterised by a lipid core 
surrounded by a fibrous cap containing smooth muscle cells (Halvorsen et al., 
2008).  Over time, the plaque becomes vulnerable and at risk of causing a 
cardiovascular event, especially when its necrotic core encounters the blood 
and intrudes into the lumen. The interaction between exposed atherosclerotic 
plaque constituents, platelet receptors and coagulation factors finally cause 
platelet activation, aggregation and the formation of thrombus. Thus, the 
clinical consequences of thrombus formation are usually patient’s presentation 
with an ACS. 
High-risk plaques are generally characterised by their large lipid-rich necrotic 
core and a thin fibrous cap (< 65 μm) which is usually infiltrated by 
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inflammatory cells such as macrophages and natural killer cells. Cycles of 
plaque rupture and healing are frequent and well recognised; continued 
remodelling of these plaques usually contributes to coronary narrowing and 
changes of plaque morphology sometimes with or without clinical symptoms 
(Kubo, Maehara, Mintz et al., 2010). 
Individuals with stable atherosclerotic plaques can lead a normal life without 
an apparent cardiovascular complication such as SA or UA. However, disease 
progression can lead to the occurrence of acute cardiovascular events such 
as acute myocardial infarction (AMI), UA, SA and sudden cardiac death (Ross, 
1999). 
The exact composition of the lesion is normally unknown in individual patients; 
however, atherosclerosis is generally found in patients with stable angina, 
whereas a thrombotic lesion usually represents a life-threatening situation and 
is associated with AMI (Falk, 2006).  The severity of findings on angioscopy 
and on coronary angiography reflects the clinical severity of ACS (Sherman, 
Litvack, Grundfest et al., 1986).  Generally, the white clots are found in patients 
with NSTEMI and UA; in contrast, the red clots are found in STEMI patients. 
This difference requires different therapeutic approaches in STEMI/UA 
antithrombotic therapy as appropriate in order to prevent thrombosis and to 
facilitate endogenous fibrinolysis to dissolve the thrombus and hopefully 
reduce the degree of stenosis (DeWood, Spores, Notske et al., 1980).  On the 
other hand, in STEMI, the arteries affected are almost always occluded, and 
an urgent pharmacological or catheter-based reperfusion is required; the goal 
here is to restore blood flow to the affected area. Other therapies, such as lipid-
lowering and anti-ischaemic therapies such as β-blockers are used in all cases 
to stabilise plaques over long term. 
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1.1.2 Molecular and cellular basis of atherosclerosis plaque 
formation 
 
Atherogenesis refers to the development of atheromatous plaques in the inner 
lining of the arteries. Histopathological studies of human and animal 
experiments have demonstrated that atherogenesis is a progressive change 
in the monolayer of endothelial cells that line the inner arterial surface. Under 
normal physiological conditions, endothelial cells resist attachment of the white 
blood cells (WBC) passing near them; however, when the WBC are subjected 
to irritative stimuli such as hypertension, dyslipidaemia or pro-inflammatory 
mediators, smoking, chronic infection and genetic predisposition they tend to 
adhere and infiltrate between arterial layers (tunica intima and the tunica 
media), causing inflammation and initiating the process of atherosclerotic 
plaque formation (figure 1). 
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Figure 1: (A) Healthy coronary lumen, completely flat and undamaged, the 
main three vascular layers tunica intima and tunica media not compromised 
by fatty steak infiltration. (B) Infiltration of fatty streak between the tunica intima 
and the tunica media. (C) Recruitment of monocyte activation of smooth 
muscles and an exaggerated immune response characterised by cytokine 
release, pro-inflammatory biomarkers such as C-reactive protein and 
proteinases. (D) Fibrous cup rupture, explosion of the thrombogenic core and 
platelet aggregation. (E) Obstructive atherosclerosis plaque is present which 
may cause SA. (F) Life threatening atherosclerosis plaque rupture or erosion 
resulting in thrombus formation and the potential for causing UA or AMI and 
death. During the final stage, cardiac biomarkers such as Troponins and CK-
MB may be present. (reproduced from healthline.com). 
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Although lipids have a central role in the pathogenesis of plaque formation, the 
mechanistic links between lipids and atherogenesis remain unclear (Linton, 
Yancey, Davies et al., 2000).  Atherosclerosis is initiated at the site of 
endothelial injuries which can be caused by a variety of factors, including 
hypertension, high serum level of low-density lipoprotein (LDL), low serum 
level of low-density lipoprotein (HDL), apolipoprotein B 100 (apoB), impaired 
cholesterol transport, insulin resistance, free radical generation, hypoxia, a 
pre-existing condition such as diabetes mellitus and chemical toxins such as 
those from cigarette smoke (Zaman, Helft, Worthley et al., 2000).   
Once the structure of these cells is damaged, LDL can penetrate the coronary 
vessels’ sub-endothelial space, i.e. the space between the tunica intima and 
the tunica media. Once the LDL is in the sub-endothelial space, it is modified 
by oxidation due to enzymes such as 5 lipo-oxygenase, phospholipase A2 and 
myeloperoxidase (Virmani, Kolodgie, Burke et al., 2005; Zaman, 
Helft,Worthley et al., 2000). The compromised and damaged endothelial cells 
express several adhesion molecules such as vascular cell adhesion molecule 
1, intercellular adhesion molecule-1 and selectin. These molecules collectively 
promote the binding of circulating monocyte to the compromised and damaged 
vascular endothelial cell walls (Finn, 2010; Virmani,Kolodgie,Burke et al., 
2005). 
Monocyte infiltration and localised production of stimulating factors cause the 
differentiation of monocyte to macrophages. Once these macrophages are 
exposed to LDL, they start to express scavenger receptors such as CD-36, 
that bind and promote the oxidation of LDL (Ridker, 2002; Rifai & Ridker, 
2002). As the number of macrophages in the sub-endothelial space increases, 
more cholesterol, cytosolic lipid droplets form, and macrophages take on the 
appearance of a lipid-laden foam cell.  At this stage, the T-lymphocyte and 
other inflammatory immune cells are recruited and start to infiltrate the 
developing lesion. T-lymphocyte infiltration is followed by the production of 
inflammatory cytokines such as interleukin-6 and interleukin-4, which in turn 
stimulate the production of the inflammatory biomarker C-reactive protein and 
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growth factors. The production of these proteins induces the smooth muscle 
cells to alter their cytoskeleton structure, and produce a matrix of 
metalloproteinase, and subsequently migrate from the media into the intimal 
space, where they proliferate and secrete extravascular matrix components 
that form a protective fibrous cap over the developing lesion (Ridker, 2002).  
Ongoing inflammatory process and the continuous recruitment of leukocyte 
infiltration will eventually lead to atherosclerotic lesion growth; at this stage, 
patient may experience SA symptoms. Over time, the atherosclerotic lesion 
continues to expand and becomes unstable. To make matters worse, activated 
macrophages exacerbate the stability of this lesion by the continued secretion 
of matrix metalloproteinase that degrade and weaken the matrix components 
of the lesion (fibrous cap). Moreover, activated macrophages continue to 
secrete various cytokines that inhibit smooth muscle proliferation and matrix 
production and subsequently promote smooth muscle cell apoptosis 
(Halvorsen et al. 2008).  The continued build-up of macrophages eventually 
causes the plaque to rapture, usually from the base of the fibrous cap where it 
is weaker and contains few endothelial cells. When the plaque ruptures, 
platelets and coagulation factors in circulating blood are exposed to the 
thrombogenic component of the plaque. Thereafter, the dislodged plaque and 
the thrombogenic components act as a vehicle that allows platelet aggregation 
and coagulation. The formation of thrombin and the subsequent conversion of 
fibrinogen to fibrin, and release of Von Willebrand factors from the activated 
platelets create a cross-linked network that allows a thrombus to form.  The 
thrombus size depends on the ruptured fibrous cap and the activity of the 
endogenous fibrinolytic pathway. The thrombus can both partially or 
completely occlude the coronary vessel lumen and initiate an acute coronary 
event such as an AMI. 
Thus, the thrombus formation is the main cause of AMI. Histological and post-
mortem studies have demonstrated that coronary luminal thrombus formation 
is the consequence of a ruptured or eroded atherosclerotic plaque. A study of 
1847 fatal coronary thrombus concluded that plaque rupture is the major cause 
of coronary thrombosis irrespective of age (> 60 years old: 77%; < 60 years 
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old: 64%) or gender (women 55%; men 76%) (Sakakura,Nakano,Otsuka et al., 
2013).  Conversely, thrombus over plaque erosion is frequently detected after 
coronary sudden death (Sakakura,Nakano,Otsuka et al., 2013). 
1.1.3 Brief overview of a vulnerable plaque 
 
During the atherosclerotic plaque formation process, factors such as 
inflammation, lipid accumulation, free radical generation, apoptosis, 
proteolysis, thrombosis and angiogenesis are critical in determining the 
vulnerability of the plaque. Advanced atherosclerotic plaque is characterised 
by a lipid core surrounded by a fibrous cap containing smooth muscle cells 
(Halvorsen et al. 2008).  Necrotic core expansion and the risk of plaque 
destabilisation and rupture is thought to involve the endoplasmic reticulum 
(ER) stress pathway (also known as unfold protein) as the main mechanism 
for smooth muscle cells and macrophage cell death in the core of the plaque 
(Gotoh, Endo, & Oike, 2011).  The ER stress pathway is a cellular response 
mechanism to a dangerous build-up of misfolded proteins in the ER. Activation 
of this pathway down regulates protein translation. The halting of protein 
translation allows the endothelial cells a chance to recover. However, if the 
activation of the ER stress pathway is prolonged which is the case in CAD, the 
endothelial cells will ultimately initiate cell death usually through apoptosis 
(Guo,Ma,Liu et al., 2017).  The accumulation of cell debris and the constant 
recruitment of inflammatory cells will weaken the atherosclerotic plaque and 
eventually cause ACS.  
 
1.1.3.1 The role of free radicals, hypoxia and vulnerable plaque 
 
A cardiac ischaemic episode is characterised by a decreased blood flow, free 
radical such as superoxide and hydroxyl radicals freely circulating in the blood. 
Free radicals can be produced from a vast spectrum of process including the 
metabolism of thiols, flavins, catecholamine, oxidation of xanthine, and 
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cyclooxygenases-mediated oxidation of arachidonate. The nature of the free 
radicals high reactivity is thought to be responsible for the alteration of a variety 
of proteins including nucleic acids, lipids and the subsequent post-ischaemic 
dysfunction (Bolli 1988). 
Hypoxia develops because of oxygen increase or decrease. Under normal 
physiological conditions, oxygen diffuses across the vessel wall (thickness 
approximately 100 to 250 μm); however, when this thickness of the vessel wall 
is increased either due atherosclerosis or thrombosis, the oxygen is unable to 
diffuse freely and hypoxia occurs (Torres Filho et al. 1994).  On the other hand, 
hypoxia may also arise from an increase in oxygen supply due to high demand 
of inflammatory cells (Murdoch et al. 2005).  Hypoxia is not exclusively present 
around macrophage foam cells, it seems that hypoxia depend more on 
inflammatory micro environment (Sluimer et al. 2008). Hypoxic cells such as 
CD68 positive macrophages and other proteins such as lipopolysaccharide 
and angiotensin (II) are known to activate hypoxia-induced transcription factors 
(HIF 1 & 2) which is an oxygen sensor that is degraded in normoxia but remain 
unchanged during hypoxia. Hypoxia itself strives to restore oxygen supply by 
stimulating HIF-1 production and angiogenesis (Blouin et al. 2004a; Page et 
al., 2002).  Atherosclerosis-induced hypoxia in humans correlates with HIF-1, 
Vascular endothelial growth factors and intraplaque angiogenesis (Sluimer, 
Gasc, van Wanroij, Kisters, Groeneweg, Sollewijn Gelpke, Cleutjens, van den 
Akker, Corvol, Wouters, Daemen, & Bijnens, 2008). 
Thus , hypoxia is the precursor for the activation of many genes that play a 
major role in the cellular and tissue adaptation during low oxygen supply, 
especially during acute or chronic decreases such as CAD (Semenza, 2001).  
These genes induce erythropoietin, glucose transporters and vascular 
endothelial growth factor. Hypoxic conditions promote HIF-1 proteins which 
regulate genes that are activated and induced by low oxygen conditions (1%) 
(Blouin et al., 2004b). The ability of HIF-1 expression is thought to be part of a 
protective mechanism, especially against strokes and myocardial ischaemia. 
The basis of this protective function is not fully appreciated (Semenza 2001).  
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Hypoxia participates in the mechanism of the regulation of neo-angiogenesis 
in physiological and pathological conditions including atherosclerosis.  
Hypoxia arises as a net result of calcification and thickened vessel wall around 
the atherosclerotic plaque; this physiological change to the arteries results in 
decreased oxygen diffusion capacity, while increasing oxygen consumption is  
a result of activated immune cells (Hermus et al., 2010).  Although the exact 
mechanism between hypoxia and atherosclerotic plaque formation is 
unknown, Sluimer et al. (2008) demonstrated a correlation between hypoxia in 
carotid artery plaques and the presence of macrophages, angiogenesis 
influence and thrombus formation (Sluimer, Gasc, van Wanroij, Kisters, 
Groeneweg, Sollewijn Gelpke, Cleutjens, van den Akker, Corvol, Wouters, 
Daemen, & Bijnens, 2008). Sluimer et al. (2008) also found that hypoxia is 
significantly present in advanced atheroma with thrombus and inflammation. 
 
1.1.3.2 Nitric oxide and vulnerable plaque 
 
Nitric oxide (NO) has potent anti-atherosclerotic properties, and deficiency in 
NO promotes endothelial dysfunction (Gotoh & Mori, 2006).  NO is released 
from the endothelial cells and reacts with prostacyclin to prevent platelet 
aggregation, the expression of adhesion molecules (ICAM and VCAM), 
neutrophil attachment to the endothelial wall and the proliferation of endothelial 
cells (Garg and Hassid 1989;Munzel, Sinning, Post, Warnholtz, & Schulz, 
2008). During endothelial dysfunction and chronic inflammation, NO is 
consumed by ROS such as superoxide and forms a highly reactive 
intermediate peroxynitrite (ONOO-).  This reaction with superoxide and ONOO- 
severely depletes NO bioavailability and subsequently its protection (Beckman 
& Koppenol, 1996).  Moreover, ONOO- is believed to act as a vasoconstrictor 
and a cytotoxic molecule capable of damaging proteins such as lipids and DNA 
(Beckman & Koppenol, 1996).  The mechanism and the pathology of 
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endothelial dysfunction is multifactorial and remains unclear (Munzel, Sinning, 
Post, Warnholtz, & Schulz, 2008). 
1.2 Overview of the pathological process that leads to the 
release of cardiac and non-cardiac specific biomarkers 
Acute myocardial infarction is pathologically defined as a cardiomyocyte death 
due to prolonged ischaemia resulting from oxygen imbalance between oxygen 
supply and demand. Severe ischaemia, combined with significant reduction in 
oxygen supply to the myocardium, provokes a cascade of detrimental events 
including anaerobic glycolysis, inhibition of ATP-dependent cell transport 
process, electrolyte shift, cellular oedema, free radical generation, protein 
kinase activation such as ERK ½ sodium hydrogen and exchanger kinase and 
finally loss of myocardium membrane integrity (Nigam, 2007) .  Once the 
membrane integrity is compromised, a steady release and the appearance of 
myocardium related biomarkers such as CK-MB, myoglobin, h-FABP, NT-pro-
BNP and troponin occurs in the blood stream (Nigam, 2007).  The release of 
cardiac specific proteins such as troponin, myoglobin and CK-MB is inevitable 
and expected; however, prolonged ischaemia or transient stress-induced 
ischaemia can also indirectly affect the release and the generation of other 
non-cardiac specific proteins such as copeptin and ischaemia modified-
albumin. For a part of this thesis we hypothesised that cardiac ischaemia may 
result in quantifiable circulating levels of non-cardiac specific proteins such as 
IMA and copeptin in patients presenting to ED with chest pain suggestive of 
AMI.  We also hypothesised that hs-cTn and other cardiac specific and non-
specific biomarkers may collectively or individually improve the diagnosis of 
patients presenting with chest pain suggestive of ACS. Moreover, these 
biomarkers promise to offer a window into a complex disease such as ACS.  
Blood biomarkers are often a by-product of the diseased state and may also 
directly participate in its pathogenesis. Among cardiovascular biomarkers, cTn, 
CK-MB and myoglobin are still considered as important diagnostic tools for 
detecting and predicting an onset of AMI in patients presenting to ED with 
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chest pain. A wealth of evidence and clinical trials exists to support the clinical 
and the diagnostic efficiencies of these cardiac specific biomarkers (Apple, 
2011; Apple, Jesse, Newby et al., 2007; Apple,Wu,Jaffe et al., 2008; Collinson, 
1998). 
On the other hand, evaluation of novel and non-cardiac specific and cardiac 
specific biomarkers such as IMA, h-FABP and copeptin requires specialised 
assays that are not available routinely within the national health service (NHS) 
biochemistry laboratories. Novel cardiovascular biomarkers should be 
clinically useful, cost-effective and evaluated to the point of influencing 
patients’ management and treatment. Hs-cTn, CK-MB and myoglobin have a 
large evidence for the diagnosis of AMI; BNP is also equally important in the 
diagnosis and the monitoring of heart failure (Di Marca,Rando,Cataudella et 
al., 2018; Salama,El-Moniem,El-Hefney et al., 2011a).  In contrast, other novel 
biomarkers such as IMA, copeptin and h-FABP are still in research state, and 
further evaluation is required and pending. In conclusion, the purpose of this 
project is to contribute to the current knowledge associated with these novel 
biomarkers in the diagnosis of ACS. 
1.2.1 An overview of the pathological processes that lead to the 
release of cardiac specific and non-specific biomarkers 
1.2.1.2 Copeptin 
 
The arginine vasopressin (AVP) released from the neurohypophysis into the 
circulation is primarily to induce water conservation by the kidney (figure 2). 
Although the main secretion of AVP is in response to hyperosmolarity, it can 
also be secreted in response to endogenous stress including hypoxia, acidosis 
and infection (Lukaszyk & Malyszko, 2015).  Copeptin is an arterial stress 
biomarker associated with disease severity in other conditions such as sepsis, 
stroke, lower respiratory tract infection and AMI (Reinstadler, Klug, Feistritzer, 
Metzler, & Mair, 2015).  Measurement of copeptin has been shown to have a 
very strong negative predictive value for AMI, especially when troponin is also 
negative (Reichlin,Hochholzer,Stelzig et al., 2009).  
16 
 
Synthesis of pre-pro-AVP in the magnocellular nuclei of 
hypothalamus
Cleavage of the signal peptide
Pro-AVP fold, placing AVP into a binding 
pocket of neurophysin II, protecting it from 
proteolysis and promoting high-density 
packing of neuro-secretory vesicles
Formation of seven disulfide bonds 
within neurophysin II and one within AVP 
glycosylation of copeptin
Pro-AVP is packaged into neuro-
secretory granules
Cleavage of pro-AVP that splits off AVP During axonal transport from the 
hypothalamic nuclei to the 
neurohypophysis
Cleavage that separates neurophysin II 
from copeptin
Processing is completed at the  
level of the neurohypophysis
1
3
2
4
5
6
7
8
 
Figure 2: Schematic presentation of copeptin generation and maturation. 
 
The diagnostic efficiency of copeptin as a standalone test is not promising for 
example measurement of copeptin concentration will be of little value for 
patient presenting late (> 3 h), as cTn will be already detectable (Bahrmann et 
al., 2013).  However, copeptin may be used to assess re-infraction when cTn 
is already elevated (Keller,Tzikas,Zeller et al., 2010).  In conclusion, various 
studies suggest that copeptin is a biomarker of non-specific stress response 
and cannot safely be used in an ED setting for the diagnosis of AMI 
(Nemec,Koller,Nickel et al., 2010; Nickel,Bingisser & Morgenthaler, 2012).  In 
this thesis, I will explore the combined diagnostic efficiency of copeptin and 
IMA in the diagnosis of AMI.  
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1.2.1.3 Heart fatty acid binding protein 
 
H-FABP participates in fatty acid metabolism by transporting fatty acid from 
the cell membrane to mitochondria for oxidation. H-FABP also protect against 
free radical accumulation during myocardial ischaemia (Jones, Prasad, & Das, 
1990) and is the main source of energy in the heart accounting for 10% of the 
total body turnover of fatty acid (Fournier & Richard, 1990).  The h-FABP has 
the advantage of an early release to the circulation as soon as the myocardial 
membrane is compromised.  Thus h-FABP may be used as an early biomarker 
of cardiac ischaemia (Chan,Sanderson,Glatz et al., 2004).  Soluble cytosolic 
protein such as h-FABP is readily released to the circulation before structural 
proteins such as troponin, CK-MB and myoglobin (Figure 3).  The main 
disadvantage of h-FABP is that it is not specific to the heart tissue and it is also 
present in skeletal muscle.  A meta-analysis suggests that h-FABP testing as 
a standalone test did not fulfil the diagnostic criteria in term of sensitivity, 
specificity and the predictive values for safe rule-out protocol for patients 
suspected of AMI (Bruins Slot,Reitsma,Rutten et al., 2010).  The combination 
of h-FABP and troponin has been shown to increase the sensitivity and the 
NPV for diagnosing AMI (Lippi, Mattiuzzi, & Cervellin, 2013).  However, the 
diagnostic efficiency of h-FABP and IMA is still to be established in patients 
with chest pain suggestive of AMI but not proven.  Thus, the current study will 
examine the diagnostic relationship amongst h-FABP, IMA and other 
biomarkers.  
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Figure 3 kinetic release of h-FABP during prolonged ischaemic cardiac events. H-
FABP is a low molecular weight (15 KDa) cytoplasmic protein which occupies 5-15% 
of cytosolic protein of the cardiomyocyte; as such, it is the first molecule to appear in 
the blood stream following a cardiac myocyte membrane dysfunction. In contrast, 
cardiac troponin appears in the circulation only after cardiac myocyte destruction. 
 
1.2.3.4 N-Terminal fragment of pro-BNP 
 
BNP is produced predominantly in the left ventricular myocardium in response 
to myocyte distension caused by ventricular volume expansion or pressure 
overload. The exact mechanism of its release is unclear; however, it appears 
that BNP is regulated by post-translational processing; as such, its presence 
in the circulation increases very rapidly in response to stimulus. 
Natriuretic hormones belong to the family of vasoactive peptides that regulate 
arterial and venous dilation. In the circulation, the pro-hormone is cleaved into 
BNP, the physiologically active form, and into the N-terminal fragment of the 
NT-pro-BNP. Under normal conditions, animal models have demonstrated that 
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BNP is produced primarily in the atria and is stored in secretory vesicles 
(Chopra,Cherian,Verghese et al., 2013). BNP expression is increased in 
response to stretch in both atrial and ventricular tissues in heart failure. 
Natriuretic peptides physiologically play an important role in the regulation of 
blood pressure; they induce natriuresis and diuresis, act as a vasodilator and 
inhibit the renin-angiotensin-system. BNP also appears to be counter-
regulatory molecule for the renin-angiotensin system. Thus, BNP increases 
glomerular filtration rate, increase sodium secretion by the kidneys, increase 
urine production while decreasing blood volume/blood pressure and have a 
diuretic and vasodilatory effect (Chopra,Cherian,Verghese et al., 2013). 
Natriuretic peptide exerts its effect by its ability to bind to three different types 
of membrane bound natriuretic peptide receptors (NPR) including NPR-A, 
NPR-B and NPR-C. It is important to mention that BNP mediates its biological 
actions by binding to NPR-A, as this type of receptor is the most abundant in 
the vascular endothelium system and is also present in the kidney, the adrenal 
gland and brain (Levin,Gardner & Samson, 1998).  The mechanism of the 
degradation and the elimination of BNP are not fully understood 
(Chopra,Cherian,Verghese et al., 2013). 
Presently, BNP is used as a powerful sensitive, specific and prognostic 
biomarker for the onset of acute heart failure and as a screening tool for 
detecting left ventricular systolic and diagnostic tool for detecting left 
ventricular systolic and diastolic function. 
BNP measurement is also used as a biological biomarker mainly in adult and 
elderly patients with heart failure. Clinically, the use of BNP and NT-pro-BNP 
is particularly useful in the diagnosis of heart failure in patients with acute 
dyspepsia and in ruling out heart failure. The diagnostic and the prognostic 
value of NT-pro-BNP are influenced by age, gender, obesity and renal 
function. There are only a few studies about BNP release in AMI; however; a 
study conducted by Richards et al., who, while studying patients with AMI, 
found significantly higher BNP plasma levels as compared with healthy 
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controls (Durak-Nalbantic,Dzubur,Dilic et al., 2012).  The current study will 
examine the diagnostic efficiency of NT-pro-BNP, IMA and other biomarkers. 
1.3 Human albumin metabolism 
 
Human albumin (HA) (7 x 10-4 M), which occupies 50% of plasma proteins in 
a healthy individual, is the main protein that regulates the oncotic pressure and 
plays an important role in modulating the distribution of fluids between body 
compartments. Although the plasma concentration of HA is 7 x 10-4 M, it is still 
dependent on its biosynthesis, degradation rate and distribution between 
intravascular and extravascular compartments. HA is predominantly an 
interstitial protein (concentration 3 x 10-4), and partially tissue-bound and 
therefore unavailable for circulation.  The intravascular mass of HA is about 
120 g and circulates from the blood into the capillary wall into the interstitial 
compartments including cerebrospinal fluid and returns to the blood through 
the lymphatic system. The trans capillary escape (movement of HA across 
capillary wall leaving intravascular space) of HA is 5% per hour (Margarson 
and Soni 1998;Mendez et al. 2005). 
During its long life (18–21 days), an HA molecule makes approximately about 
15,000 passes through the circulation transporting various kind of damaged 
proteins and accumulated ligands (Margarson & Soni 1998;Mendez, McClain, 
& Marsano 2005;Peters T 1996). 
The liver is the main site for HA biosynthesis; however, traces of mRNA was 
detected in the kidney and pancreas with no evidence to suggest that this 
mRNA in this extra-hepatic tissue was translated. Moreover, the presence and 
the origin of HA in milk is still debatable (Peters, 1996).  Interestingly, a small 
amount HA can also be produced in bone tissue and the microglial cells in 
brain (Ahn et al. 2008;Yamaguchi et al. 2010). 
Several organs participate in the catabolism of HA at a rate of 14 g per day in 
a 70 kg healthy adult (Nicholson et al. 2000).  HA in plasma often decreases 
during stress, trauma or sepsis; this drop can be the result of redistribution 
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from intravascular compartment into the extravascular compartments, 
decreased synthesis, and increased catabolism. Decreased HA during injury 
and infection can be as much as 2 x 10-4 M within 5 days, whereas, in healthy 
HA, it can also be excreted through the GI tract at the rate of 1 g per day and 
through the kidney at only a few milligrams (Peters, 1996). 
 
Human albumin consists of non-glycosylated single chain polypeptide chain 
containing 585 amino acids. HA represents the most abundant protein in the 
human body (35 to 50 g/l) of all proteins in the plasma of healthy individuals 
and exerts a range of physiological and pharmacological functions including 
as antioxidant and transports small molecules such as drugs, fatty acids and 
bilirubin (Evans 2002;Rondeau and Bourdon 2011a).  In vivo free circulating 
nitric oxide (NO) is readily taken by HA through its free thiol of Cys34 and 
releases NO to tissue exposed to low pH and hypoxia.  However, during 
hypoxia, HA undergoes structural transition and releases NO in order to 
maintain the vascular tone (Minamiyama et al. 1996).  Although the delivery 
mechanism of HA through a receptor is not clear, a receptor-mediated 
endocytosis has been postulated (Fasano et al. 2007;van der Vusse 2009). 
The ability of HA to carry out these functions is believed to be due to its 
structure. HA is organised into three domains I, II and III from which each is 
further subdivided into subdomains A and B (Rondeau & Bourdon 2011a).  The 
subdomains are linked with 17 intra-molecular disulphide bonds, which 
contribute to their rigidity without compromising on flexibility in shape and size 
of HA in response to pH changes or other biophysiological changes (Scatchard 
et al. 1944).  HA is sensitive to glycation because of its long life (19 to 21 days) 
and high concentration (Charonis et al. 1990). 
Under pH changes, HS could acquire a reversible conformational 
isomerisation. In physiological condition HA exert is buffering capability 
through its 16 histidine imidazole residues (Caironi and Gattinoni 
2009;Colombo et al. 2012a;Pavone et al. 2010). Moreover, HS’s tertiary 
dimensional structure enable albumin to transport small molecules; i.e., sites 
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in domain I and II are the major binding sites for drugs, whereas amino-
terminus binding sites have a high affinity for metal ions including Co2+, Cu2+, 
Ni2+ (Rondeau and Bourdon 2011b). 
1.3.1 Conclusion 
 
Blood biomarkers are biological analytes that can be detected in the blood 
under defined and specific physiological conditions. As such, biomarkers are 
a rapid cost-effective way of peering through a patient’s physiological window 
and differentiating disease states without invasive techniques. As mentioned 
above, cardiac biomarkers of necrosis such as myoglobin, troponin and CK-
MB are well established; however, a reliable biomarker of cardiac ischaemia 
such as IMA remains to be demonstrated and is the focus of the current 
research project.  In addition, cardiac non-specific biomarkers for the diagnosis 
of AMI such as copeptin, h-FABP and NT-pro-BNP are still in research state 
and require further investigation. 
 
1.3.2 Ischaemia modified-albumin 
 
Human albumin presents a substantial genetic polymorphism similar to that of 
haemoglobin; this genetic polymorphism which is usually heterozygous can 
leads to a rare asymptomatic inherited disorder known as allo-albuminemia 
(Amoresano et al., 1998).  More than fifty structurally different variants of HA 
have been characterised by protein and/or DNA sequencing.  Some of these 
variants also exhibit amino acid changes in the pro-peptide, the N-terminus 
and in subdomains IIB and IIIB (Kragh-Hansen, Brennan, Minchiotti, & 
Galliano, 1994).  
More than 50 structurally different variants of HA have been characterised by 
protein and or DNA sequencing. These variants are categorised into three 
major type including single amino acid substitutions, glycosylated proteins and 
chain termination mutants (Madison et al. 1994).  In addition, these variants 
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exhibit amino acid changes in the pro-peptide, the N-terminus and in 
subdomains IIB and IIIB (Kragh-Hansen, Brennan, Minchiotti, & Galliano 
1994b). 
Commercial HA is kwon to exhibit damage and degradation to its N-terminus 
(Chan et al. 1995a).  N-terminal degradation in vitro is thought to be due pH 
and temperature; it is possible that this mechanism may also exist in vivo 
(Chan et al. 1995b).  HA and bovine albumin protein contain an N-terminus 
sequence X-Y-His which play a considerable role as a binding site for 
endogenous Cu (II) and toxic Ni (II) (Bal et al. 1998).  In contrast, other albumin 
from other species such as canine and porcine do not have the N-terminus of 
that of HA, instead they have His-3 substituted by Tyr which intern do not bind 
metal ions (Bal, Christodoulou, Sadler, & Tucker 1998). 
HA Is the major carrier for Co2+, Ni2+ and Zn2+ cations(Peters, Jr. 1985), the 
presence of variant significantly decrease the binding affinity HS to Ni2+ (pro-
peptide variant), Co2+(Blenheim and Varese variant) and Zn2+ (Christchurch 
and Redhill variant; Kragh-Hansen et al. 1994b).  Although, the presence of 
these variants decreases the binding site for Ca2+, Ni2+ and Zn2+ cations, it 
seems that Ca2+ concentration in the plasma is not effected, because Ca2+ 
concentration (2.1-2.6 mM) far exceed that of HA (Kragh-Hansen and Vorum 
1993).  On the other hand, Ni2+ and Zn2+ cations concentration is lower 0.044 
μM and 20 μM respectively than that of HA. This difference between Ni2+, Zn2+ 
cations and HA concentrations would suggest that bisalbuminaemia could 
have a greater biological and clinical significance (Kragh-Hansen, Brennan, 
Minchiotti, & Galliano 1994b). 
Reactive species capable of causing damage in vivo including hydrogen 
peroxide, organic hydroperoxide and hypohalous acids with half-life of 
minutes, pyroxyl radical and nitric oxide half-life second, peroxynitrite half-life 
millisecond, superoxide anion, singlet oxygen, and the alkoxyl radicals half-life 
in millisecond (Kehrer 2000).  The mechanism of action of these species is still 
unclear, because these species behave as initiators and product of cellular 
damage, making the determination of cause and effect challenging (Kehrer 
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2000).  In addition, study of these species requires a high concentration; which 
in vivo is not achievable (Kehrer 2000). 
Chronic disease and conditions such as cardiac ischaemia, chronic 
inflammation, cancer and aging, are known to trigger copper release (Cu II) 
and redox activity which can cause cellular damage due to the generation of 
reactive oxygen species (ROS) including hydroxyl radical (OH●) and 
superoxide (O2●-) (Halliwell & Gutteridge, 1990a).  In vivo hydroxyls radical is 
converted to hydrogen peroxide (H2O2) and superoxide. Superoxide is directly 
converted to either hydroxyl radical via the Haber-Weiss reaction or converted 
to H2O2 via Fenton reaction (see below) (Biaglow, Manevich, Uckun, & Held, 
1997).  Both reactions require transition metal such as copper and iron 
(Halliwell & Gutteridge, 1990b).  While, iron concentration in human serum is 
greater than copper, the latter is 60 times faster in generating hydroxyl radical 
than iron (Chevion et al., 1993).  Moreover, Cu II ions, when mixed with 
ascorbic acid or other reducing agents produce hydroxyl radicals (Biaglow et 
al., 1997). 
Transitional metal can participate in injury is demonstrated via metal-mediated 
and site-specific Haber—Weiss reaction (Chevion 1988;Samuni et al. 1983).  
• Haber—Weiss reaction (also known as iron catalysed reaction)  
O2● + H2O HO● + O2 + HO- 
 
The chemical generation of the OH-radical via the classical Fenton reaction 
(Biaglow, Manevich, Uckun, & Held 1997). 
Fe3+ + O2●-  Fe2+ + O2 
Fe2+ + H2O2 + H+                Fe3+ + H2O + OH●  
• Ascorbic acid or other reducing agents produce hydroxyl radicals 
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 2 Cu+ Ascorbate                             2 Cu+ + dehydroascorbate +2 H+ 
Cu+ + O2                    Cu2+ + O2 ●-  
Cu+ + O2 ●- + 2 H+      Cu 2+ H2O2 
Cu+ + H2O2                     OH- + OH● + Cu2+  
 
Copper is tightly regulated in both non-specific exchangeable and specific non-
reversible by a range of carried plasma protein including caeruloplasmin witch 
bind approximately 65% of copper, and albumin (Bar-Or et al., 2001a).  Once 
the copper is release to the circulation during ischaemia, it disrupts the cellular 
energy causing the conversion of pyruvate to lactate and subsequent local 
acidosis.  Localized acidic conditions are known to cause caeruloplasmin to 
release more copper (Cu II) (Lamb & Leake, 1994).  HA and specially its N-
terminus tetrapeptide (Asp-Ala-His-Lys) sequence is a non-exchangeable 
binding site for Cu (II) and is capable of sequestering Cu (II) ions and inhibiting 
the formation of ROS. Moreover, by sequestering Cu (II), HA prevents the 
conversion of Cu (II) to Cu (I) in the presence of reducing agents such as 
ascorbate (Marx & Chevion, 1986).  Free Cu (I) can react with oxygen to form 
Cu (II) and generate superoxide free radicals (O2●-). 
Although, the N-terminus of HA is the main site for irreversible binding of Cu 
(II), a “loose” non-specific binding site also exist and participate in the formation 
of ROS in the presence of reducing agents (Marx & Chevion, 1986).  Glycated 
albumin binds 3 fold the amount of copper and ion compared to non-glycated 
(Eaton & Qian, 2002).  The presence of non-specific binding site for Cu (II) 
reduces the benefit of using albumin as therapeutic agents for treating ROS 
related disease i.e. cardiac ischaemic diseases and copper toxicity (Quinlan, 
Coudray, Hubbard, & Gutteridge, 1992; Kreymann, Seige, Schweigart, Kopp, 
& Classen, 1999).  
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In vivo stability of alloalbumin is between 5% to 70% of the total serum albumin 
in heterozygote and may cause protein unbalance in circulation, thus abnormal 
alloalbumin may have a clinical and biological impact (Galliano et al. 1999).  
Two type of proalbumin shows high affinity to metal ions including Co2+, Cu2+, 
Zn2+ and Ni2+ (Kragh-Hansen et al. 1994a).  Proalbumin of Sterling type shows 
abnormal fatty acid binding property (Kragh-Hansen et al. 1996) (Nielsen et al. 
1997).  It is therefore possible that IMA in some patients may be a genetic 
variant of albumin. Until IMA is well characterised and purified the nature of 
IMA is presently not clear. 
1.4 The rational for using these novel biomarkers 
There is currently a deficiency of biomarkers that can reliably describe 
indirectly the abnormal extracellular matrix remodelling (ECMR) which 
ultimately leads to cardiovascular related pathology. The lack of early 
biomarkers of atherosclerotic progression and lack of early biomarkers of 
atheromatic formation lead to the suggestion that some novel biomarkers such 
as biomarker of early myocardium necrosis (hear fatty-acid binding protein); 
oxidative stress (ischaemia modified-albumin) and vascular stress (copeptin) 
may help in the detection of ACS.  Moreover, accurate monitoring of early 
cardiac ECMR could prompt early intervention and prevention of disease 
progression. 
While current biomarkers of necrosis have greatly improved the diagnosis and 
treatments of AMI patients; there is still scope for improvement especially in 
the area of early detection of cardiac ischaemia due to atherosclorosis or 
unstable thrombus (Figure 4). 
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Figure 4: The green zone: Biomarkers of ischaemia such as IMA and copeptin among 
others are first released prior to myocardium damage.  Yellow zone biomarkers of 
necrosis such as h-FABP, myoglobin and troponin early release myocardium can still 
be salvaged. Red zone irreversible myocardium damage at this stage AMI is 
unavoidable and biomarkers of necrosis predominantly troponins are detectable. 
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1.4.1 Clinical dilemma 
 
Rapid identification of AMI is important in order to initiate treatment for better 
prognosis.  Discriminating between genuine ACS and non-ACS patients is very 
challenging; especially in individuals without clear symptoms or history, ECG 
features and cardiac biomarkers. Routine diagnostic methods for risk 
stratification of patients presenting to ED with chest pain and ACS exist but 
none is adequately equipped to help clinicians to determine which patients can 
safely be discharged (Antman, 2000; Christenson, 2004).  In order to speed 
up the diagnosis and to safely discharge the correct low risk patients it has 
been suggested that other early sensitive non-cardiac specific and cardiac 
specific biomarkers such as biomarkers of myocardium necrosis (hear fatty-
acid binding protein), oxidative stress (ischaemia modified-albumin) and 
vascular stress (copeptin), might be used as stand alone or in combination with 
well-established cardiac biomarkers such as myoglobin, creatinine kinase 
isoenzyme MB (CK-MB) and hs-cTnI or hs-cTnT to rule-out ACS.  The 
hypothesis is if some of these cardiac specific and non-specific biomarkers 
either alone or in combination can help discharge low risk patients safely. Early 
and safe discharge can spare patients from prolonged ED observation, 
expensive rule-out protocols for the NHS, crowding and inconvenience 
(Goodacre, 2003). 
The rational for using IMA, H-FABP, copeptin and NT-pro-BNP is based on the 
promises that an early evaluation may predict the final diagnosis of AMI as 
defined by the elevation of hs-cTn at 0-3 h after the onset of chest pain. 
Among these biomarkers mentioned above only the albumin cobalt binding 
(ACB®) assay, which measures ischaemia modified-albumin (IMA®), is cleared 
by CE marking in Europe and the Food and Drug Agency (FDA) in the USA to 
be used for the purpose of detecting myocardial ischaemia (Jaffe, 2006; Chan 
& Pronovost, 2004; Jaffe, Babuin, & Apple, 2006).  The measurement of IMA 
concentration by the ACB assay was cleared by the American Food and Drug 
authority on the basis that it would help rule-out ACS, in low to moderate pre-
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test probability conditions with negative necrotic cardiovascular biomarkers 
and normal ECG. ACB has a high negative predictive value (NPV) of 96% 
[95% CI 91-98%], and  high sensitivity in predicting troponin negative or 
positive at 6 and 24 hours (Christenson et al. 2001b).  Therefore, it’s logical to 
study IMA and its contribution in the early diagnosis of AMI. 
In addition IMA has also being suggested as a biomarker for monitoring 
transient myocardial ischaemia induced by vasospasm (Cho,Choi,Kim et al., 
2007).  IMA is not a cardiac specific biomarker and can be found in various 
conditions including, renal disease, infection, inflammation, and liver disease 
(Abboud,Labreuche,Meseguer et al., 2007; Apple & Jaffe, 2001; 
Bodi,Sanchis,Llacer et al., 2005). Meta-analysis has shown that serum IMA 
could be used to monitor oxidative stress status in the development of diabetic 
retinopathy and thyroid pathology (Reddy,Bukke,Mahato et al., 2017). 
The importance of cardiac biomarker testing has been widely accepted as part 
of the initial assessment of patients presenting with chest pain suggestive of 
ACS. ACS pathophysiology is complex, thus presently it is unlikely that a single 
biomarker could be used to evaluate cardiovascular associated risks and for 
ACS diagnosis. Currently numerous evidence oppose to the single novel 
biomarkers use in an ED setting or in a chest clinic (Lin,Yokoyama,Rac et al., 
2012).  Multi-biomarker score system incorporating current available 
biomarkers could potentially be used to assess ACS related risk and help 
patient’s management (Bodi,Sanchis,Llacer et al., 2005; Sabatine,Morrow,de 
Lemos et al., 2002). 
1.5 Conclusion 
 
As describe previously ACS patients and NSTEMI/UA in particular present 
challenging dilemma to clinician in an ED setting. The current strategy 
deployed by the health professional is not entirely satisfactory in term of safely 
rule-in and rule-out patients presenting with chest pain suggestive of ACS 
(Christenson et al., 2004; Antman et al., 2000; Goldman et al., 1988; Tatum et 
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al., 1997). As mentioned before, normal ECG trace does necessary exclude 
AMI, moreover cardiac biomarkers of necrosis such as troponin I & T, CK-MB 
and myoglobin are not appropriate as these biomarkers are expressed only 
after cardiac cell death (Apple,Collinson & Biomarkers, 2012; 
Apple,Greenspan & Dietzler, 1982).  NSTEMI/UA risk assessment and 
diagnosis should not be categorised into a binary fashion, in fact the risk 
evaluation of these cohort should be treated as a continuum as they are 
significantly running a high risk of AMI, recurrent AMI or death. It is clear that 
a rapid blood cardiac biomarker for ischaemia is required. 
There is some evidence to suggest that multi-biomarker approach may be 
useful in ACS patient’s management especially in an ED. The following 
biomarker, BNP (Brown,Sease,Robey et al., 2007), copeptin 
(Reichlin,Hochholzer,Stelzig et al., 2009), h-FABP (Haltern,Peiniger,Bufe et 
al., 2010) and IMA (Collinson,Gaze,Bainbridge et al., 2006; 
Peacock,Morris,Anwaruddin et al., 2006) are currently under investigation. 
Collectively these biomarkers are known to increase during the inflammatory 
process or during cardiac ischaemia. The current guidelines proposed that 
clinician should tailor cardiac biomarkers for AMI patients based on prognostic 
biomarker such as cTn and IMA (Braunwald,Antman,Beasley et al., 2002).  
The rationale for using these biomarkers is that if combined with h-cTn may 
improve the diagnosis of ACS or potentially contribute to rule-out protocol and 
help shortening patient’s hospital stay thus saving resources. 
1.6 Acute echocardiographic changes in ACS patients 
 
The diagnosis of AMI is typically based upon patient’s history, ECG finding and 
cardiac blood-based biomarkers. However, it has been demonstrated that 
these diagnostic tools alone may detected only approximately 30% of acute 
ischaemic events as a large majority of patients that present of ED with chest 
pain suggestive of AMI have a typical chest pain, a normal ECG and an early 
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normal level of cardiac biomarkers of necrosis (Lancellotti,Price,Edvardsen et 
al., 2015). 
Echocardiography diagnostic modality is a powerful tool for monitoring patients 
with acute cardiovascular disease. Echocardiography is the most versatile and 
cost-effective imaging techniques used to assess unexplained or unstable 
cardiovascular diseases.  They are mobile and could be hand–held devices 
making them virtually useful every were. 
Echocardiography when used and ED setting was shown to change therapy in 
60 to 80% of patients presenting with acute cardiovascular disease 
(Neskovic,Hagendorff,Lancellotti et al., 2013).  Presently echocardiography is 
included in the universal definition of AMI and relevant international guidelines 
for the management of cardiac arrest (Douglas,Khandheria,Stainback et al., 
2007).  In an ED or critical care setting echocardiography can be utilised to 
monitor cardiac output, to determine abnormalities of cardiac physiology and 
coronary perfusion (Garcia-Fernandez,Macchioli,Moreno et al., 2001). 
Echocardiography is one of the tools used in ACS patients with unexplained 
haemodynamic changes that require immediate evaluation 
(Romano,Dagianti,Penco et al., 2000).  The role of echocardiography 
utilisation in assessing AMI patients is twofold, first it helps establish the 
location and the extent of AMI; and secondly it provides prognostic information 
that help in the risk stratification.  Echocardiography is an accurate non-
invasive test capable of identifying myocardial ischaemia or necrosis 
(Shiran,Blondheim,Shimoni et al., 2017). 
The American College of Cardiology, the American Heart Association, and the 
American Society of Echocardiography (ACC/AHA/ASE) guidelines (2003) for 
echocardiography recommended the use of echocardiography in the diagnosis 
of suspected acute ischaemic patients, those with inconclusive ECG or AMI 
patients without detectable cardiac blood biomarkers 
(Cheitlin,Armstrong,Aurigemma et al., 2003). 
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The 2011 appropriate use criteria for echocardiography allowed its use in the 
diagnostic of suspected AMI as appropriate (American College of Cardiology 
Foundation Appropriate Use Criteria Task,American Society of,American 
Heart et al., 2011). During severe ischaemic episode cardiac regional wall 
motion abnormalities can be visualised echocardiographycally within seconds 
(12 ± 5 and 19 ± 8) of coronary artery occlusion (Lythall,Gibson,Kushwaha et 
al., 1992).  Moreover, cardiac wall motion abnormalities due to cardiac 
ischaemia can be detected echocardiographycally before any ECG detectable 
changes (Sabia,Afrookteh,Touchstone et al., 1991).  It is important to note that 
not all cardiac wall abnormalities detected echocardiographycally can be 
attributed to cardiac ischaemia as other conditions such as myocarditis and 
Tako-tsubo cardiomyopathy can mimic cardiac ischaemia finding. Thus, 
echocardiographical finding should be interpreted with caution and in relation 
to other clinical findings. Moreover, echocardiography utilisation of ACS 
patients in ED setting should only be allowed if trained specialist is available 
(Breitkreutz,Price,Steiger et al., 2010). This could be a limitation in using 
echocardiography in rural or remote areas.  
1.7 Cardiovascular risk factors 
 
CVD is a chronic disease that can largely be prevented through lifestyle 
changes and reduction of behavioural risk factors such as unhealthy diet, 
physical inactivity, alcohol and tobacco smoking. Over time, these harmful 
lifestyle and behavioural risk factors individually or collectively lead to 
metabolic and physiological changes including dyslipidaemia, diabetes, 
hypertension and obesity. The long-term consequences of exposure to these 
risk factors from childhood to adult life can cause damage to the coronary 
arteries due to atherosclerosis formation.  Strong evidence suggests that 
reducing these cardiovascular risk factors can prevent fatal and non-fatal AMI 
(Cohen,Assyag,Boyer-Chatenet et al., 2014; Wald, 2003; Yusuf, 2004). 
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1.8 Clinical presentation of acute coronary syndrome 
 
Patients presenting to the ED with suspected ACS exhibit a wide range of 
prodromal symptoms table 1 (McSweeney,O'Sullivan,Cody et al., 2004). 
These include prolonged (> 20 min) anginal pain and retrosternal pressure or 
heaviness radiating to the left arm, neck or jaw. These symptoms can also be 
accompanied by nausea, abdominal pain, epigastric pain; recent-onset 
indigestion and chest pain (McSweeney,Cody,O'Sullivan et al., 2003).  Most 
of these complaints are frequently seen in younger adults (35-54 years), 
however atypical presenters are usually seen in older patients (> 75 years old), 
and those with existing co-morbidity such as diabetes, dementia and chronic 
renal failure (Canto,Fincher,Kiefe et al., 2002; Culic,Eterovic,Miric et al., 
2002b). Patients presenting with prodromal symptoms have a good prognosis 
and rigorous cardiac investigations (Graham,Westerhout,Kaul et al., 2008; 
Kloner, 1995).  However, patients without prodromes are likely to be 
discharged with a high risk of ACS (Graham,Westerhout,Kaul et al., 2008). 
Table 1: The following 5 groups of potential atypical prodromal symptoms as 
determined by ICD-9-CM diagnostic coding; based on the data used by 
McSweeney et al, (2003). 
 Prodromal symptoms 
1 Pain (an aggregate of chest, arm, shoulder, neck, jaw, throat, or leg 
complaints) 
2 Anxiety/fatigue (anxiety, sleep disturbances, weakness/fatigue) 
3 GI disturbances (nausea/vomiting, loss of appetite, indigestion) 
4 Head-related conditions (dizziness, headache, visual disturbances) 
5 Other (sweating, shortness of breath, heart racing, cough, 
numbness). 
 
The prevalence of chest pain and chest discomfort varies among the 
population in Western Europe. A British study of men (n = 7735) presenting 
with chest pain suggestive of AMI, found that in only 14% of cases, AMI was 
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responsible for the complaint and a further 24% experienced atypical chest 
pain (Lampe, 1998).  As identified by National Clinical Guideline Centre for 
Acute and Chronic Conditions March 2010; when compared, the symptoms of 
ACS in ethnic populations are not different from the European population. The 
National Institute for Health and Care Excellence (NICE) guidelines requires 
clinicians to assess symptoms of ACS same way as in men and women 
regardless of ethnicity. 
The circumstances leading to the misdiagnosis of ACS are multi-factorial 
including socioeconomic, gender, disease pathology, presentation and 
diagnostic limitations.  Typically patients who are more likely to be 
inappropriately discharged from the ED are women bellow the age of 55, the 
odds ratio (OR) for discharge was (OR 6.7; 95% CI, 1.4-32.5), non-white OR 
for discharge was 2.2; (95% CI, 1.1-4.3) and women with atypical chest pain, 
normal cardiovascular biomarkers and a non-diagnostic ECG had an OR of 
3.3, (95% CI, 1.7-6.3) (McSweeney,Cody,O'Sullivan et al., 2003; Pope, 2000). 
Approximately 25% of patients with non-classical symptoms or atypical 
presenters have suffered a silent AMI (Khafaji & Suwaidi, 2014).  Atypical 
presenters contribute to under-recognition of the disease 
(Brieger,Eagle,Goodman et al., 2004).  The diagnostic and therapeutic 
evaluation of an atypical presenter is extremely difficult especially when the 
main diagnostic pointers such as troponin or ECG changes are masked or 
exacerbated by an existing condition (Table 2) or abnormal results 
(Nikolaou,Arntz,Bellou et al., 2015). In addition, patients with acute chest pain 
but without persistent ST-segment elevation, NSTEMI or ECG changes are 
extremely difficult to identify and treat (Deshpande & Birnbaum, 2014).  
Delayed treatment is associated with a longer hospital stay and increased 
morbidity and mortality (Nikolaou,Arntz,Bellou et al., 2015). Moreover, failure 
to identify NSTEMI patients adds cost to the healthcare system, delays 
treatment, potential for patients expose to unnecessary irradiation or exposure 
to contrast agents (Deshpande & Birnbaum, 2014). 
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Table 2: Cardiac and non-cardiac conditions that can mimic non-ST-elevation 
ACS (Reproduced from ESC Guidelines 2007). 
Cardiac Pulmonary Haematological 
Myocarditis Pulmonary embolism Sickle cell anaemia 
Pericarditis Pneumonia - 
Myopericarditis Pleuritis - 
Cardiomyopathy - - 
Tako-tsudo syndrome - - 
Vascular Gastro-intestinal Orthopaedic 
Aortic dissection Oesophageal Spam rib fraction 
Aortic aneurysm spasm oesophageal Muscle injury 
Aortic coarctation Peptic ulcer  
Cerebrovascular 
disease 
Pancreatitis  
1.9  Misdiagnosed Patients 
 
In England and Wales chest pain is responsible for 700,000 admissions to the 
ED annually (Goodacre,Cross,Arnold et al., 2005).  Patients presenting with 
chest pain suggestive of ACS constitute the largest single cohort of patients in 
the UK emergency department’s (Gavalova, 2012). 
In the last four decades, the hospital mortality rate from AMI has seen a 
remarkable decline from 30-35% to 8-10% (Fox,Steg,Eagle et al., 2007; 
Wenger,Hellerstein,Blackburn et al., 1982). This decline, correlates with 
advances in patient management and the introduction of new therapies such 
as percutaneous coronary intervention (PCI), cutting edge analysers and the 
discovery of new cardiac biomarkers such as troponins and CK-MB (mass). 
The motivation for introducing these therapies was due to the realisation that 
thrombotic coronary occlusion progresses over a defined time frame of a few 
hours during which myocardial tissue can be salvaged.  After the onset of 
myocardial ischaemia, there is a time frame of approximately of < 1 hour before 
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the myocardium starts to die and it will take at least 3 hours before the 
cardiovascular biomarkers (i.e. troponins, CK-MB and myoglobin) for cell 
death or necrosis start to be detectable in the circulation (Simoons, Boersma, 
Maas, & Deckers, 1997).  
Before 1970s patients used to spend as much as 3 days in hospital for a 
definitive diagnosis of AMI; however, currently patients presenting to the ED 
from the onset of symptom to diagnosis is in the range of 1212 h in most cases 
(Kontos,Diercks & Kirk, 2010).  Encouraging chest pain patients to present to  
ED during the early signs of ACS has paid off as early treatment of AMI within 
1 h of onset of chest pain is associated with a mortality of 1-2% as opposed to 
that treated at 6 h and a mortality rate of 10-12% (Rawles, 1994).  
The thrombolytic era of 1970s was concerned with therapeutic approach to 
restore the oxygen supply to the myocardial tissue; thus reducing tissue 
damage (Braunwald,Maroko & Libby, 1974).  This strategy was validated in 
numerous trials and was proven to be valuable in the managements of ACS 
patients (Lomaestro, 1994).  The successful reduction in mortality and 
morbidity associated with early therapy and national awareness initiatives 
encouraged patients with chest pain to present to the ED much earlier. To early 
identify and treat potential ACS patients; the healthcare system inadvertently 
finds itself under pressure in terms of resource allocation. Thus, effective use 
patient management and risk stratification, while maintaining acceptable cost 
to the health system is of importance (Roberts, 1998).  Risk stratification starts 
with the first contact with the patients presenting to the ED with chest pain; 
generally those with < 5% probability of AMI can be identified from the 
presenting symptoms, past history and electrocardiogram (ECG) (Lee, 1985).  
The efficacy of this approach was supported by a study of 2271 low risk 
patients in which they found that 2.5% could be recognised (Farkouh, 2009). 
Non-cardiac chest pain is very common in the general population (Fass & 
Achem, 2011).  However, when dealing with patients presenting with chest 
pain suggestive of ACS, cardiologist’s priority is to exclude any acute life-
threatening cardiovascular condition; including AMI (STEMI), NSTEMI, UA, 
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SA, and pulmonary thromboembolism. ACS patients are clinically subdivided 
according to their family history, physical symptoms, ECG findings, 
cardiovascular biomarkers finding and risk-factor profile (Hamm, Bassand, 
Agewall, Bax, Boersma, Bueno, Caso, Dudek, Gielen, Huber, Ohman, Petrie, 
Sonntag, Uva, Storey, Wijns, & Zahger 2011). 
Patients presenting the ED with chest pain suggestive of ACS without the 
classical ECG changes and with normal cardiovascular biomarker of necrosis 
(i.e. troponin, CK-MB) represent a challenge to clinicians. As these patients 
are at risk of higher morbidity and mortality (Xing,Pei,Tang et al., 2018).  The 
ECG has a developed criterion for risk stratification to allow clinicians to make 
timely decision on patient’s management including pharmacological and 
coronary revascularization strategy if required. Currently, the leading precursor 
(symptom of chest pain) is the primary indicator that triggers the diagnostic 
and therapeutic intervention in the most ED.  At presentation these patients 
are classified into two groups:  
i. Patients with typical acute chest pain and persistent (>20 minute) ST-
segment elevation ACS. These cohorts usually reflect an acute total 
coronary occlusion and subsequently develop an ST-elevation 
myocardial infarction (STEMI). This cohort of patients will; receive 
immediate treatment such as PCI 
ii. Patients with acute chest pain but without persistent ST-segment 
elevation. These cohorts present with either persistent or transient ST-
segment depression or T-wave inversion, flat T-wave, pseudo-
normalisation of T-wave or no ECG changes at presentation. These 
patients are monitored with serial ECG and serial measurement of 
cardiovascular biomarkers of necrosis. Currently patients with no ECG 
changes (NSTEMI) are classified based on troponin measurement, and 
they will be further qualified into non-ST-elevation myocardial infarction 
(NSTEMI) or unstable angina (Figure 5). 
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Figure 5: Schematic representation of possible outcome of patients admitted 
to ED with chest pain of cardiac origin. 
 
Clinicians rely on physical examination, patients’ history, ECG, blood 
biomarkers (i.e. troponin) and imaging techniques (echocardiography) to 
diagnose cardiac ischaemia (Pope et al., 2000).  Despite the availability of 
these tools, diagnosis of ischaemic heart disease is still less specific or 
sensitive (Kaski & Garcia-Moll, 2002).  Furthermore, these techniques often 
fail to discriminate between ischaemic heart disease and non-cardiac related 
disease. Collinson et al ., demonstrated that 7% of patients discharged from 
ED after being assessed for ACS have high levels of troponin level (Collinson, 
Premachandram, & Hashemi, 2000).  A retrospective study of 10.689 patients 
admitted to ED with chest pain suggestive of ACS; found 2.1% were 
misdiagnosed among AMI cohort and 2.3% also misdiagnosed among UA 
patients (Pope et al., 2000). Moreover, between 2 and 8% of patients with AMI 
were mistakenly discharged (Cassidy et al., 2000). 
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Ideally, early biomarkers used in the ED should be highly sensitive, specific 
and should show a high NPV or PPV to rule-out or rule in AMI respectively. 
The C2010 International Liaison Committee on Resuscitation (ILCOR), 
support the use of biomarker of ACS only if they achieve sensitivity > 95% or 
specificity > 92% and a combined sensitivity of > 90% (Hazinski,Nolan,Billi et 
al., 2010; Nolan,Hazinski,Billi et al., 2010).  However, in the majority of 
biomarkers utilised currently do not subscribe to this  (Lippi & Guidi,2008).  As 
result false positive and negative are common finding (Pour-Ghaz,Bob-
Manuel,Marella et al., 2018). 
The conditions leading to the misdiagnosis of ACS patients is multifactorial 
including socioeconomic, disease pathology/presentation, inadequate training, 
patient’s educational level and diagnostic limitation (Pourafkari,Tajlil,Ghaffari 
et al., 2017).  Women were more likely than men to have been discharged with 
the wrong diagnosis because women generally appear to have a higher rate 
of atypical symptoms or presentation such as shortness of breath, congestive 
heart failure and abdominal pain than men (George,Rapsomaniki,Pujades-
Rodriguez et al., 2015). 
A study found that approximately 5.8% of black Americans with AMI were not 
admitted to cardiovascular department compared with 1.2 % of the white 
population; despite the evidence that suggest that black people have more risk 
factor for coronary disease than whites, this finding did not appear to have a 
strong influence on the diagnostic impression of clinicians (Cooper & Ford, 
1992; Maynard,Fisher,Passamani et al., 1986).  A UK study found that elderly 
men and women were less likely to be referred for angiography despite clinical 
indication.  The same study also highlighted the underuse of angiography 
across all patient groups (Bowling,Bond,McKee et al., 2001). 
The incidence of misdiagnosis of ischaemia in the ED may be reduced if 
clinicians interpret the ECG trace properly or address clinical factors or 
perception of unconscious or conscious bias that obscure the recognition of 
AMI in women and non-white population (George,Rapsomaniki,Pujades-
Rodriguez et al., 2015).  Survey conducted by the European Society of 
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Cardiology (ESC) has shown that some clinicians are not fully aware of the 
best practice and the current guidelines for the management of ACS patients 
especially when the attending clinician is not a cardiology specialist 
(Rapezzi,Biagini & Branzi, 2008; Taghaddosi,Dianati,Fath Gharib Bidgoli et al., 
2010). 
Occasionally some patients will not present with the classical symptoms in fact, 
1 in 20 patients with an AMI is an atypical presenter (Puleo, 1994; Ting, 1991).  
Atypical presenters contribute to under-recognition of the disease 
(Brieger,Eagle,Goodman et al., 2004).  The diagnostic and therapeutic 
evaluation of an atypical presenter is extremely difficult especially when the 
main diagnostic pointers are masked or exacerbated by existing conditions 
such as rib fraction, renal disease or abnormal results i.e. inconclusive ECG 
trace and normal troponin concentration (Apple,Murakami,Quist et al., 2003).  
Once cardiac source of chest pain is excluded other conditions should be 
considered, for example an individual who is taking part a vigorous exercise 
after a period of physical inactivity may experience heaviness, chest pain 
discomfort and even damage or trauma. Muscular skeletal causes are 
common source of chest pain. Chest pain can also be triggered by pulmonary 
conditions such as infection of the lungs. It is also known that anxiety or an 
underlying psychiatric disorder can present as non-cardiac chest pain in some 
patients (Katz & Castell, 2000). 
The majority of patients presenting to ED with chest pain suggestive of ACS 
are found to have an oesophageal related chest pain (Hong, 2010).  The three 
main causes of oesophageal chest pain results from an underlying disturbed 
nerve sensation, mucosal dysfunction and muscle.  Gastroesophageal reflux 
disease in particular when reflux of acid is involved can present with chest 
pain, swallowing difficulties or heartburn.  Oesophageal related chest pain can 
also be attributed to an oesophagus spasm or caused by a mobility disorder of 
the oesophagus.  Chest pain induced by oesophagus can also be caused by 
an abnormal sensory function of the oesophagus called hypersensitivity.  In 
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this condition the muscle nerve and receptors of the oesophageal wall are 
extremely sensitive (Hong, 2010; Rao, 2011). 
Some patients with CAD have chest pain that is unresponsive to conventional 
medical therapy and are considered to have a refractory chest pain.  This 
refractory chest pain is usually wrongly perceived to be of cardiac origin and 
poses a common clinical problem that induces anxiety in both patients and 
clinicians (Liu,He,Chen et al., 2013).   
Condition like pulmonary embolism (PE) is potentially life-threatening condition 
and is manifested due to blockage in a blood vessel that supplier the lungs. 
PE can cause chest pain and breathlessness similar to that seen in patients 
with ACS. 
To minimise the misdiagnosis of AMI, the European Society of Cardiology 
(ESC) guidelines for the management of ACS patients; requires that all 
patients admitted to ED with chest pain suggestive of ACS should have a 
resting 12-lead ECG carried out and interpreted by a qualified person within 
10 minutes of arrival. The problem with using ECG is that a completely normal 
ECG does not exclude AMI (50% sensitivity). Several studies found that 
approximately 5% of patients, who were sent home because of normal ECG, 
were subsequently readmitted with UA or AMI (Goodacre,Cross,Arnold et al., 
2005).  In addition,  up to 50% of patients presenting to ED with chest pain do 
not show STEMI in their ECG assessment (Apple & Murakami, 2005).  The 
current study is in agreement with previous ECG finding as approximately 75% 
of patients admitted to ED with chest pain suggestive of ACS had a normal 
ECG, only 3% had bundle branch block (BBB) and 8% had an inversion T-
wave. To complicate the diagnosis; cardiac Ischaemia is present in the territory 
of the circumflex artery thus not frequently detected by 12-lead ECG but may 
be recorded by the lead V3R, V4R and V7-V9 (Bassand, Hamm, Ardissino, 
Boersma, Budaj, Fernandez-Aviles, Fox, Hasdai, Ohman, Wallentin, & Wijns 
2007). 
42 
 
The ESC guidelines for the management of ACS and in particular patients with 
suspected NSTEMI requires the measurement of a biomarker of 
cardiomyocyte injury such as hs-cTnI or hs-cTnT. Cardiovascular biomarkers 
of cardiomyocyte injury are highly cardiac specific and are the “gold standard” 
biochemical test for the diagnosis of AMI. However, hs-cTnI and hs-cTnT are 
only released to the circulation after cardiomyocyte injury and it takes 6 to 12 
hours to reach the desired sensitivity and specificity.  The introduction of hs-
cTn technology has led to the quantification of myocardial injury; these assays 
increased the diagnostic efficiency of AMI patients on admission and reduced 
“troponin blind spot” e.g. the time a takes cTn to be detected in the circulation 
(Slawson, 2018).  To complicate the matter further, hs-cTn can also be 
detected in healthy population. Thus, the presence of hs-cTn is always 
associated with AMI; equally the absence of hs-cTn does not exclude ACS.  
Thus, hs-cTn needed to be interpreted with caution.  Generally, any troponin 
is always worse than no troponin, and more troponin is always worse than less 
troponin.  In the mean-time patients are required to stay in hospital for 
observation in order to confirm or exclude AMI and if no change is observed 
patients are discharged and sent home (Taghaddosi,Dianati,Fath Gharib 
Bidgoli et al., 2010). 
It is apparent that the clinician should not rely on clinical judgment alone to 
determine whether an individual patient who presents to ED with chest pain 
suggestive of ACS has indeed an ACS. Effort to reduce the number of 
misdiagnoses is urgently required and warranted. 
1.10 Summary of current treatment of stable angina 
 
Coronary artery disease (CAD) is major cause of death globally and is 
predicted to remain a leading cause of death in the next 20 years. CAD is 
responsible for approximately 3.8 million and 3.4 million men and women 
respectively worldwide (Mathers & Loncar, 2006).  
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CAD develops when the main blood vessels that supply the heart with blood, 
nutrients and oxygen become diseased or damaged by the presence of an 
atherosclerotic plaque and inflammation.  CAD is type of heart disease 
characterised and manifested by SA pectoris also known as angina of effect is 
a direct result of ischaemia caused by an imbalance between oxygen supply 
and demand to the myocardium (Figure 6).  SA patients may also present with 
atypical symptoms such as breathlessness, discomfort and pain to the front of 
the chest (this pain is believed to be due to lactic acid build up), nausea and 
gastrointestinal discomfort.  SA is the main symptom of myocardial ischaemia 
and is usually caused by atherogenesis and plaque formation in the epicardial 
arteries, spasm or normal or plaque containing arteries restricting blood flow 
and therefore oxygen to the myocardium. SA is a chronic condition with a low 
incidence of adverse acute coronary events (Task 
Force,Montalescot,Sechtem et al., 2013). 
 
 
Figure 6: Ischaemia as being the condition where the supply of oxygen to muscle is 
insufficient to meet the demand.  Atherosclerosis plaque formation reduces blood 
supply to the myocardium and if prolonged anginal pain is believed to be due to the 
lactic acid build-up.  
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In addition, SA is a type of ischaemic heart disease characterised by a 
predictive chest pain during physical activity that resolves with rest or 
pharmacological intervention like the administration of sublingual nitro-
glycerine. In severe cases other drug classes such as calcium antagonists and 
angiotensin-converting enzyme (ACE) may be used (Depre,Wijns,Robert et 
al., 1997). 
The diagnosis of SA is based on a detailed clinical history which includes 
assessing the location, severity, duration, magnitude and the precipitating 
factors of angina.  In most cases the diagnosis can be made based on the 
history and physical examination (Pryor,Shaw,McCants et al., 1993).  
Although, clinical history is useful in diagnosis of SA; other modalities such as 
coronary angiogram, cardiac magnetic resonance, and ECG can also be used. 
Non-invasive procedures such as the evaluation of haemoglobin levels can be 
of value; it has been demonstrated that low haemoglobin is associated with 
increased mortality in SA patients (Mishra,Ray,Dalal et al., 2016).  Moreover, 
features such elevated heart beat at rest (≥ 70 beat per minute) in SA patients 
is associated with a poor prognosis (Mishra,Ray,Dalal et al., 2016). The 
treatment of SA patients is for long term and requires supervision (Task 
Force,Montalescot,Sechtem et al., 2013). 
1.10.1 Possible treatments for stable angina 
 
Generally, the treatment of SA includes medication to modify atherosclerosis, 
anti-anginal drugs and aggressive treatment of causative risk factors such as 
lowering lipid. The overall managements of SA patients consist of promoting 
life style changes coupled with pharmacological interventions; however, in 
severe cases especially in the elderly, renal dysfunction and diabetes patients’ 
revascularisation procedures may be warranted.  
 
NICE guidelines require newly diagnosed SA patients to be put on Beta-
blocker and calcium channel blocker as the first line of treatment.  The 
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treatment strategy of SA is to improve the quality of life, by reducing the 
number and the severity of the anginal attacks and to protect against future 
adverse cardiac events.  Moreover, SA long term management strategy 
consists of practical measures to reduce the burden of risk factors such as 
cholesterol and lifestyle risks in order to slow disease progression (Kones & 
Rumana, 2016).  Thus, management of these risk factors is crucial for the 
secondary prevention of ischaemic cardiac events.  
 
1.11 Pharmacological interventions  
 
1.11.1 Beta-blockers 
 
The benefit of beta-blockers in SA patients is extrapolated from studies aimed 
at AMI patients, thus, to my knowledge there is no confirmatory trials of the 
merit of managing SA patients with this class of drugs (Andersson,Shilane,Go 
et al., 2014).  
Beta-blocker is a class of drugs designed to work by blocking the effect of the 
hormone epinephrine.  The effect of blocking epinephrine causes the heart to 
contract slowly with less force; thus, reducing blood pressure. Beta-blockers 
also help blood vessels to relax and to increase blood flow and oxygen to the 
myocardium.  Reduction in heart rate allows greater diastolic period 
consequently an increase coronary perfusion that also improves myocardial 
oxygen supply. Beta-blockers were also found to help control both 
asymptomatic and symptomatic ischaemic attacks 
(Heidenreich,McDonald,Hastie et al., 1999a). 
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1.11.2 Nitrate 
 
In 1867, Lauder Brunton described the anti-anginal property of nitrate and 
subsequently first used as a pharmacological agent in 1879; since then the 
agent is used worldwide until today (Boden,Padala,Cabral et al., 2015).  Nitrate 
is readily absorbed, and it is available in various formulation including, tablet, 
sprays and patches. 
 
Anti-ischaemic agents act by decreasing myocardial oxygen consumption, 
heart rate, blood pressure, or depressing the left ventricular contractibility 
and/or inducing vasodilatation.  Suspected SA patients with ongoing ischaemic 
discomfort are given sublingual nitro-glycerin (NTG) (0.4 mg every 5 min for a 
total of 3 dose) if not contraindicated. They are also given supplemental 
oxygen if their arterial saturation is less than 90% or if the show sign of 
respiratory distress or possible hypoxemia.  Oxygen therapy is only 
administered if arterial saturation is less than 90%, to minimise free radical 
generation. 
 
Glycerine tri-nitrate (GTN) and pentaerythritol tetranitrate (PETN) are 
converted to nitrate by the enzyme mitochondrial aldehyde dehydrogenase 
and also by a non-enzymatic pathway involving the reaction with thiol 
derivative (Munzel,Daiber & Gori, 2011).  Nitric oxide is a potent coronary 
vasodilator.  The major therapeutic benefit of nitrate is its effect as a 
vasodilator. Nitro-glycerin act by decreasing the myocardial pre-load and LV 
end diastolic volume, subsequently resulting in a decrease in myocardial 
oxygen consumption.  Moreover, nitrates also dilate normal as well as 
atherosclerotic coronary arteries and increase coronary flow. 
In the absence of any clinical contraindications nitrate might be administered 
intravenously to patients presenting with SA.  The dose is usually titrated 
upwards until symptoms are relieved, or side effects such as hypotension 
occur. 
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When symptoms are controlled or a side effect is noted, intravenous nitrates 
may be substituted by nitrate-like drugs such as sydnonimines or potassium 
channel activators (vasodilator) (Tamargo,Caballero,Gomez et al., 2004).  
However, the use of this class of drugs is not recommended for patients taking 
phosphodiesterase-5 inhibitors (sildenafil, vardenafil, tadalafil) because of the 
risk of profound vasodilatation and low blood pressure 
(Tamargo,Caballero,Gomez et al., 2004). 
 
1.11.3 Calcium antagonist 
 
Calcium antagonist (CAs) decrease angina discomfort by inhibiting inward 
calcium current through the cell membrane not only in the myocardium but also 
in various type of tissue including: vascular smooth muscle in both coronary 
arteries, cardiac conduction tissue and peripheral vessels.  Reduced 
intracellular calcium causes smooth muscle cell relaxation, vasodilatation and 
subsequently increases coronary blood flow. All CAs subclasses are potent 
vasodilators (table 3). 
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Table 3: Subclasses of calcium antagonist (adapted from the \European 
society of cardiology) 
Type Properties Drugs 
Dihydropyridines (DHPs) Peripheral and coronary 
vasodilators, negative 
inotropic action 
Amlodipine, 
nifedipine, 
felodipine, 
isradipine, 
nicardipine, 
nisoldipine 
Non-Dihydropyridines 
(DHPs) 
Phenylalkylamines Additional negative 
chronotropic and 
inotropic actions 
Verapamil 
Benzothiazepine Additional negative 
chronotropic and 
inotropic actions 
Diltiazem 
Mixed sodium and CA Non-selective blocking 
delayed rectifier K+ 
current and fast Na+ 
current. Also, 
inhomogeneous 
electrical effects.  
Bepridil 
Antihistamine Used for migraine 
prophylaxis, peripheral 
vascular disease, 
vertigo, but not for 
angina 
Funarizine 
1.11.4 Brief description of the mode of action of various calcium 
antagonist subclasses. 
 
1.11.4.1 Calcium channel blockers 
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Calcium channel blockers (CCBs) are class of drugs that non-competitively 
inhibit calcium movement through voltage-dependent L-type calcium 
channels, thus resulting in chronotropic, slower conduction, negative inotropic 
effects and smooth muscle relaxation. CCBs are available in two distinct types: 
dihydropyridine (DHP) and non-DHP.  The non-DHP CCBs which include 
verapamil and diltiazem and is characterised by its ability to inhibit sinus node 
activity; thus, reducing heart rate and act as an anti-anginal drug. A meta-
analysis found that CCBs when compared with placebo reduces the risk of 
heart failure in SA patients by 82% (95% CI, 73-92%) (Bangalore,Parkar & 
Messerli, 2009).  This meta-analysis also highlighted an association between 
CCBs and decreased risk of stroke and SA.  
1.11.4.2 Dihydropyridines (DHPs) 
This class of drugs reduced blood pressure (BP), myocardial oxygen 
consumption and myocardial wall tension.  As a consequence, DHPs action 
patients’ experience fewer anginal attacks, reduces the need for nitrate and 
improve ischaemic ST-segment changes (Heidenreich,McDonald,Hastie et al., 
1999b). 
CCBs therapy has been proven to be an effective anti-anginal drug and it is 
widely used for the management of hypertension.  However, the prognostic 
efficacy of CCBs for SA patients is limited. High dose of nifedipine was 
associated with increased mortality (Furberg,Psaty & Meyer, 1995). In contrast 
the ACTION study which conducted a long-term efficacy of nifedipine 
concluded that the latter safely relieves anginal pain and was not linked to 
adverse cardiac events in patients with SA and hypertension (Poole-
Wilson,Lubsen,Kirwan et al., 2004).  In addition, the ESC guidelines on stable 
coronary artery disease for the management of SA; concluded that both CCBs 
and beta-blocker are equally appropriate for SA management; the usual dose 
of CCBs and side effect are summarised in table 4. 
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Table 4: Common dose and side effect associated with calcium antagonist 
Drug  Duration 
action 
Usual dose Common side effect 
Dihydropyridines (DHPs) 
Nifedipine slow 
release 
Long 30-180 mg/d Hypotension, oedema, 
flashing, constipation, nausea  
Amlodipine Long 5-20 mg 
(daily) 
Headache, oedema 
Felodipine 
sustained 
release 
Long 5-10 mg 
(daily) 
Headache, oedema 
Isradipine 
sustained 
release 
Medium 2.5-10 mg 
(twice a 
day) 
Headache, fatigue 
Nicardipine Short 20-40 mg 
(3 times a 
day) 
Headache, oedema, 
dizziness, flushing 
Non-dihydropyridines (non-DHPs) 
 
Diltiazem 
immediate 
release 
short 30-80 mg  
(4 times a 
day) 
Hypotension, flashing, 
oedema, dizziness, 
bradycardia 
Diltiazem slow 
release 
Long 120-320 mg 
(daily) 
Hypotension, flashing, 
oedema, dizziness, 
bradycardia 
Verapamil 
immediate 
release 
short 80-160 mg  
(3 times a 
day) 
Hypotension, negative 
inotropic, oedema, HF, 
bradycardia 
Verapamil slow 
release 
Long 120-480 mg 
(daily) 
Hypotension, negative 
inotropic, oedema, HF, 
bradycardia 
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1.11.4.3 Angiotensin converting enzyme inhibitors 
 
The maintenance of the haemodynamic stability and the regulation of arterial 
blood pressure, water and electrolyte balance are controlled by the renin-
angiotensin-aldosterone system. Angiotensin-converting enzyme inhibitors act 
by inhibiting the conversion of angiotensin I to angiotensin II in the lung, thus 
preventing the potent action (vasoconstrictor) of angiotensin II and 
consequently prevents a narrowing of blood vessels and an increase of blood 
pressure.  ACE inhibitor also promotes vasodilatation and correct endothelial 
dysfunction by inhibiting the degradation of bradykinin (Landmesser & Drexler, 
2006).  Bradykinin is the active peptide for the kallikrein-kinin system and they 
are potent endothelium-dependent vasodilators that contribute to hypotension 
in the systemic circulation (Golias,Charalabopoulos,Stagikas et al., 2007).  
ACE also acts by lowering the total peripheral resistance. This is achieved by 
blocking the enzyme that convert angiotensin I to angiotensin II.  Currently 
there are three sub-classes of ACS inhibitors are available: 
1. Sulfhydryl group; e.g. captopril 
2. Decarboxylase group; e.g. Enalapril, lisinopril 
3. Phosphonate group; e.g. Fosinopril 
Based on animal models the ACE inhibitors are further classified according to 
their ability to cross the brain blood barrier, the two most common are 
summarised in table 5. 
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Table 5: Common ACE inhibitors based on their ability to cross the blood brain 
barrier 
ACE inhibitors that cross blood 
brain barrier 
ACE inhibitors that not cross 
blood brain barrier 
• Fosinopril  
• Lisinopri  
• Perindopril 
• Ramipril 
• Trandolapril 
• Benazepril  
• Enalapril  
• Moexapril  
• Quinapril 
 
Current evidence strongly suggests that patients with stable vascular disease 
such as SA are more likely to benefit from these class of drugs (Heart 
Outcomes Prevention Evaluation Study,Yusuf,Sleight et al., 2000; 
Latini,Tognoni,Maggioni et al., 2000). 
 
1.11.4.4 Chelation therapy 
 
Chelation therapy involves a series of intravenous infusion of disodium 
ethylene diamine tetra-acetic acid (EDTA) in combination with other 
substances.  Disappointing clinical studies could not confirm the efficacy of 
EDTA’s infusion.  However, a reduction of 18% in risk of cardiovascular events 
was observed (HR – 0.82; 95% CI, 0.69-0.99; p = 0.035) (Escolar,Lamas,Mark 
et al., 2014; Lamas,Goertz,Boineau et al., 2012; Lamas,Goertz,Boineau et al., 
2013).  To date chelation therapy is not offered to SA patients and additional 
studies are still pending regarding the utility of chelation therapy in SA patients. 
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1.11.4.5 Statins 
 
The efficacy of statin in reducing and preventing cardiovascular events is well 
documented. Several meta-analyses have showed a significant reduction in 
cardiovascular related death and can safely reduce the 5-year incidence of 
major adverse cardiac event (MACE) (Baigent,Keech,Kearney et al., 2005; 
Mills,Rachlis,Wu et al., 2008).  These meta-analyses also concluded that statin 
should be used as a primary therapy for cardiovascular related diseases.  
Moreover, a Cochrane meta-analysis assessing the potential harm and benefit 
of statin used by patients with no history of CVD; found that it’s use causes a 
reduction of all-cause of mortality (OR 0.86, 95% CI 0.79-0.94%) as well as in 
revascularization rates (RR 62, 95% CI, 54-72%) (Taylor,Huffman & Ebrahim, 
2013).  A meta-analysis looking at intensive vs. moderate use of statin therapy 
found a significant (16%) reduction of cardiovascular death or AMI; they also 
concluded statin high or moderate intensity should be prescribe to SA as a 
routine regardless of lipid levels (Cannon,Steinberg,Murphy et al., 2006). 
1.11.4.6 Revascularisation 
 
Coronary revascularisation involves restoring perfusion to ischaemic 
myocardium. In SA patients’ revascularisation is only carried out when all 
possible treatments fail to manage SA crisis, or a significant stenosis is 
detected (Task Force,Montalescot,Sechtem et al., 2013).  
Numerous meta-analyses showed that revascularisation may help control 
myocardial ischaemia more efficiently than medication alone in some patients 
(Stergiopoulos,Boden,Hartigan et al., 2014; Windecker,Stortecky,Stefanini et 
al., 2014). Coronary revascularisation involves two modalities one is coronary 
artery bypass grafting (CABG) and the other is PCI. 
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1.11.4.7 Coronary artery bypass grafting 
 
There were 17,600 coronary CABG operations in UK in 2013 compared with 
23,100 in 2004 (Farooq,Serruys,Zhang et al., 2013). Patients with significant 
and severe complex (SYNTAX >22) multivessel disease or left ventricular 
dysfunction may benefit from CABG surgery due to lower cardiac events 
associated with this procedure.  However, certain severe SA cases with 
existing comorbidity such as diabetes may require CABG.  Meta-analysis 
showed that over 5 and 10 year’s period the CABG group showed significantly 
lower cardiovascular related mortality compared to medical treatment group 
(10.2 vs. 15.8%; OR 61 [95% CI, 48-77%], p = 0.0001) and (26.4 vs. 30.5%; 
OR 83% [95% CI, 70-98%], p = 0.03) (Trikalinos,Alsheikh-Ali,Tatsioni et al., 
2009).  A meta-analysis showed that in high and medium risk patients, CABG 
was associated with a good survival benefit (Mohr,Morice,Kappetein et al., 
2013). 
 
1.11.4.8 Percutaneous coronary intervention  
 
Percutaneous coronary intervention (PCI) coupled with medical treatment in 
SA patients is the common outcome for most SA patients (Mack,Head,Holmes 
et al., 2013).  However, in terms of superiority of treatment, a recent meta-
analysis reviewed PCI vs. medical treatment found that PCI did not show 
significant improvement in all-causes of cardiovascular mortality (RR 0.85; 
95% CI 0.71-1.01), cardiac death (RR 0.71; 95% CI 0.47-1.06),  AMI (RR 0.93; 
95% CI 0.7001.24) , or repeat revascularisation (RR 0.93; 95%CI 0.76-1.14) 
during short or long term follow-up (Pursnani,Korley,Gopaul et al., 2012).  
However, PCI demonstrated a better angina relief compared to medical 
therapy.  These finding are consistent with numerous studies 
(Stergiopoulos,Boden,Hartigan et al., 2014; Task Force,Montalescot,Sechtem 
et al., 2013; Windecker,Stortecky,Stefanini et al., 2014). 
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1.11.4.9 Conclusion 
 
The medicine, angioplasty, or surgery study (MASS II) compared the efficacy 
of PCI, CABG and medical treatment in patients with SA; multi-vessel and 
preserved ventricular function found that CABG, PCI and medical therapy 
demonstrated a significantly higher incidence of AMI, additional 
revascularisation and cardiac death.  However, CABG was better than medical 
therapy at eliminating anginal symptoms (Windecker,Stortecky,Stefanini et al., 
2014). In addition, studies compared CABG and PCI concluded neither of 
these procedures could demonstrate effectiveness for the full spectrum of SA 
patients who requires revascularisation.  Even so, CABG demonstrated a 
better revascularisation than PCI (Mishra, 2016).  The incidence of 
revascularisation after PCI is higher that after CABG; in contrast, the incidence 
of strokes is higher after CABG surgery than after PCI. Moreover, a study 
noted a mild reversible cognitive decline was associated with CABG surgery. 
However, CABG remains essential for the treatments of patients with 
significant stenosis of 50% or more, triple-vessel disease, diabetes mellitus 
and impaired LV function. Detailed evaluation CABG is beyond the scope of 
this thesis and will not be discussed in detail.   
1.12 Life-style changes and risk factors  
 
Consensus and evidence have clearly demonstrated the importance of 
modifiable lifestyle factors such as diet, physical activities, obesity and 
smoking in the development of CVD (Micha,Kalantarian,Wirojratana et al., 
2012). Thus, intervention targeting these behaviours may improve outcomes 
for CVD and non-CVD patients. 
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1.12.1 Diet and weight loss 
 
A study of 31,600 high-risk patients conduct in 40 countries showed that 
higher-quality diet such as that of the Mediterranean countries reduces diet-
induced CVD (Smyth,Dehghan,O'Donnell et al., 2015). Dietary approach to 
stop hypertension i.e. diet rich in fruit, omega-3, vegetable and diet low in 
saturated fat has demonstrated a reduction in blood pressure and is effective 
nutrition-based strategy to prevent CVD (Lavie,Milani,Mehra et al., 2009). 
Obesity and overweight and related consequences such as high-density 
lipoprotein (HDL) hyper-triglyceridaemia, increased number of small low-
density lipoprotein (HDL) and dysglycaemia are known as a risk factors for 
CAD (Galper,Wang & Einstein, 2015; Wang,Zhou,Galper et al., 2015).   
1.12.2 Physical activity 
 
Sedimentary life style is a major risk factor of CVD (Warren,Barry,Hooker et 
al., 2010).  Regular physical activities and aerobic exercises have been linked 
with decreased CVD events (Terada,Johnson,Norris et al., 2016).  A meta-
analysis demonstrated that high occupational physical activity offer a 
protection against ischaemic stroke compared with inactive and moderate 
occupational levels (RR = 57%, 95% CI, 43-77%) and (RR = 77%, 95% CI, 60-
98%) respectively (Lollgen,Bockenhoff & Knapp, 2009). 
 
1.12.3 Smoking  
 
Tobacco smoking and second hand smoking increases the risk of CAD by 2.8 
to 3 fold and is associated with high mortality (Ramakrishnan,Bhatt,Dubey et 
al., 2013).  Abstaining for smoking reduces the risk of future cardiovascular 
events.  Providing Nicotine replacements and sustained release of bupropion 
SR are used to aid patients stopping smoking.   
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1.13 Conclusion 
 
Changing patient’s habits and lifestyle have been proven effective in reducing 
long-term cardiovascular related risks.  Smoking cessation, active counselling, 
in addition to drug intervention is necessary.  Weight reduction, regular 
physical exercise, such as aerobic activities if possible every day, low salt diet 
and reduced saturated fat intake is recommended. Regular intake of fruit and 
vegetable, and moderate alcohol intake may be beneficial (Mozaffarian,Appel 
& Van Horn, 2011; Terada,Johnson,Norris et al., 2016). Management of low-
density lipoproteins (LDL) and high-density lipoprotein (HDL) cholesterol as 
well as triglycerides are essential in long term SA management (European 
Association for Cardiovascular,Rehabilitation,Reiner et al., 2011).  Although, 
the long-term impact of lipid lowering agents is less well established; the best 
evidence of LDL reduction is achieved by using statins 
(Dorresteijn,Boekholdt,van der Graaf et al., 2013). 
 
The current data indicates that long-term statin therapy improves outcome for 
all forms of CAD. This beneficial effect was shown in all subgroups, including 
men, women, and elderly (European Association for 
Cardiovascular,Rehabilitation,Reiner et al., 2011).  Recent meta-analysis 
including 9 clinical trials concluded that early administration of statin decreases 
overall mortality (odds ratio 0.89, 95% confidence limits 0.82-0.96) when 
compared to the control group (Nunes, 2017). 
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1.14 The health economics of acute coronary syndrome 
 
Healthcare systems in the Western world have seen an increase in the 
introduction of new diagnostic laboratory tests designed to meet the need for 
individual patients (Caliendo,Gilbert,Ginocchio et al., 2013). The aim of the 
introduction of these new diagnostic techniques is to increase the sensitivity 
and specificity for the presence or the absence of a disease, prognostic 
information, patient’s managements and monitoring of treatment. However, 
clinicians have raised concern about the inappropriate utilisation of these new 
and traditional diagnostic tests; for example, creatine kinase isoform MB (CK-
MB) and myoglobin is no longer justified as an aid for the diagnosis of AMI, 
because the measurement of hs-cTn is diagnostically efficient and is the most 
cost-effective diagnostic strategy for AMI (Kim & Hashim, 2016; Price, 2008).  
A survey conducted in 28 countries and 303 laboratories looking at practices 
of using outdated cardiac biomarkers against current guideline found that 11% 
offer myoglobin 59% CK, 8.3% CK-MB. 30% lactate dehydrogenase 
isoenzyme 1 and 34% AST (Collinson,van Dieijen-Visser,Pulkki et al., 2012). 
Health commissioners are concerned about healthcare cost and question 
whether the benefit of introducing new diagnostic tests is cost effective and 
necessary (Appleby, 2013; Price, 2008).  In order to provide good value for 
money when introducing a new laboratory diagnostic test, rigorous and 
challenging new questions are being asked, including whether testing directly 
improves patient outcomes and whether the benefits of testing outweighs the 
risks? (Fang et al., 2011). Unfortunately, the UK does not have in place a 
formal system for the evaluation and the implementation of new diagnostic 
tests; however, it relies on the European Directive, Conformite Europeenne 
marking (CE) and Food and Drug Agency (FDA), the diagnostic industry, the 
National Institute for Health, Care Excellence (NICE) and various specialised 
organisations to appraise the clinical utility of new diagnostic tests (Price, 
2008). 
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Health authorities and healthcare commissioners have called for a ’value 
based‘ health care system, the latter requires healthcare suppliers to focus on 
care pathways, with the view of improving patient outcome and increasing 
value for money; therefore the payment will be based on value rather than cost 
(Lee, Neumann, & Rizzo 2010a).  Although, the usefulness of this system in 
not fully appreciated available evidence suggests that this system could 
reduce the overall US health spending by 30% without compromising quality 
(Garber et al. 2007).  The Healthcare providers generally react to medical 
conditions and injury only when they occur and do not spend resources on 
preventing them. This has contributed to a population health status that has 
not changed despite increasing spending (Trogdon,Finkelstein,Nwaise et al., 
2007). 
Since the 1980s the hospital mortality rate from AMI has seen a remarkable 
decline from 30-35% to 8-10% (Wenger,Hellerstein,Blackburn et al., 1982).  
This decline correlates with advances in patient management and the 
introduction of new therapies such as PCI, improvement in automation and the 
discovery of new cardiac biomarkers. 
The successful reduction of mortality and morbidity associated with early 
thrombolytic therapy encouraged patients with chest pain to present to 
emergency department (ED) much earlier. Laboratory medicine groups and 
cardiologists recommend a turnaround time of 60 min for cardiac biomarker 
analysis (Wu,Apple,Gibler et al., 1999).  The American College of Cardiology 
(ACC) and the American Heart Association (AHA) go further to recommend a 
turnaround time of 30 min. Encouraging chest pain patients to present early to 
ED has proven to be the right strategy; as early treatment of AMI within 1 h of 
onset of chest pain is associated with a mortality of 1-2% as opposed to that 
treated at 6 h and a mortality rate of 10-12% (Amsterdam,Kirk,Bluemke et al., 
2010; Rawles, 1994). 
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1.14.1 Welfare/Pareto economics 
 
Welfare economics is described as “achieving a social maximum derived from 
individual desires” it is also concerned with improving human welfare and 
social condition.  There are different points of view from which to perform 
economic evaluations including patient’s individual preference, society and tax 
payers.  Preference is presented by utility functions and subsequently the 
overall welfare is the product of all the individual preferences. Moreover, utility 
is considered the only outcome of interest and social welfare is the sum of all 
individual’s welfare.  Preferences of individuals are typically determined by 
how those individuals’ value and prioritise health benefit over other services. 
Pareto economics is a branch of welfare economics which considers 
preferences and is a method that groups utilities among individuals in order to 
determine whether a particular resource allocation could improve social 
welfare. It is of course when aggregating utility which represent individuals, 
there some numerous states that can be manifested, this can result in a society 
gaining or loosing utility. 
Pareto optimality effectively exists when “no further changes in the economy 
can make one person better off without at the same time making another worse 
off”. In contrast, Pareto efficiency is when “there is improvement in utilities for 
some; however, no one is worse off”.  The status of how “well-off” individual is 
can be measured in either concrete good or in natural units such as quality-
adjusted-life-year (QALY).  Pareto non-comparable states manifest when 
individuals gain utilities and the expenses of re-allocation for example funding 
for hs-cTnT while losing CK-MB test for the diagnosis of AMI. 
  
61 
 
1.14.2 Extra-welfarism 
 
Extra-welfarism also considers utilities and preferences, however, it also 
allows for consideration and inclusion of other health indicators such as 
patients satisfaction and the burden of caregivers.  As a result, healthcare 
providers and care personal can be a source included in how outcome will be 
valued by policy makers. It is of course different countries prefer to allocate 
their resources based on their population preference.  Generally, health 
authorities worldwide and health economic expert use cost-effectiveness 
analysis (CEA) as a standard method for evaluating whether a new health 
intervention provides value for money for the tax payer and society as a whole 
(Neumann et al. 2005). 
 
1.14.3 Theoretical basis of economic evaluation of healthcare 
 
An increasing number of health providers worldwide are adopting results from 
cost-effectiveness analysis (CEA) as one of the criteria to inform decisions on 
allocation of healthcare recourses. Identifying a fair and optimal allocation of 
continuously hard to come buy recourses to maximize health benefit will be 
key challenge to healthcare systems such NHS, government agencies and 
managed-care organisations. Medical innovation and research is expected to 
continue to produce new medical interventions and treatments of diseases.  
However, budgetary constraints will not allow healthcare systems to make all 
these interventions available to everybody.  It has been argued that the use of 
CEA threshold might lead to uncontrolled growth in health care expenditures 
(Gafni  A, 1993).  Although, most other countries do not include health 
economic analysis input into their decision making process; Australia, Canada, 
Sweden and UK have implemented guidelines for resources-allocation 
decision based on formal health-economic analysis; currently the most popular 
approach being the CEA (NICE, 2008). 
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The implementation of CEA during decision making and recourses-allocation 
will enable transparency, consistency and positively enhances healthcare 
policies. Inevitably this will clarify what policy-makers regard as an “acceptable 
threshold” of CEA below which they will make a medical intervention available 
to their citizens.  
Health economic evaluation is based on the recognition of the effectiveness of 
an intervention but not the limiting factor as decision-making also requires 
considering the cost to the tax payers. The implementation of CEA in 
healthcare decision making reduces the burden of responsibility upon those 
who previously made decision based on instinct and professional opinion 
(Devlin N, 2004). 
1.14.3.1 Cost-effectiveness analysis 
 
A cost-effectiveness analysis itemises the additional recourses consumed for 
an improvement in the effects for example survival or quality-adjusted life year 
(QALY) associated with a health intervention compared to another. It’s also 
involves the estimation of the cost and effect of an intervention and one or 
more alternative; once the cost and deference in effect is calculated it is then 
presented as ratio .i.e. the cost per unit of health outcome (Weinstein & Stason, 
1977).  Because this format is concerned with difference between two or more 
treatments or options, analyst refers to these evaluations as incremental costs, 
incremental effect, and the incremental cost-effectiveness ratio (ICER); for 
example, for treatment (a) and (b), we calculate their respective cost and 
effects, and we calculate the difference in cost and difference in effects. The 
effects of each event can be calculated using many different types of units for 
example IMA diagnostic test could be evaluated in term of cost and number of 
case detected per hundred patients screened.  This format of analysis is 
designed to help decision–makers allocate resources across the health 
system. ICER is effectively a measure of the additional cost per unit of health 
gained. The underlying calculation for the ICER comparing IMA assay versus 
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IMA plus hs-cTnT for the diagnosis of AMI could be calculated using the 
following equation:  
 
ICER = 
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐶𝑜𝑠𝑡 (£)𝐼𝑀𝐴−𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐶𝑜𝑠𝑡(£) ℎ𝑠−𝑐𝑇𝑛𝑇
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐸𝑓𝑓𝑒𝑐𝑡 𝐼𝑀𝐴−𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐸𝑓𝑓𝑒𝑐𝑡  ℎ𝑠−𝑐𝑇𝑛𝑇
  
 
Patients and health commissioners may value a new diagnostic test despite 
the fact it does not contribute to clinical decision i.e. does not change treatment 
(Lee et al. 2010a).  Schwartz et.al., found that 87% of adults favoured cancer 
screening even in the absence of effective treatment option (Schwartz et al. 
2004).  Policymakers may even consider adopting a “Soft threshold” which 
allows room for consideration of other preferences; it is problematic to deny a 
minority group with a rare disease new treatment based on cost.  
Healthcare economic based on CEA is in my view is a balancing act between 
the need of the community and the available recourses after all tax payers’ 
views should be considered. 
1.14.3.2 The concept of threshold 
 
The concept of “threshold” refers to the level of costs and effects that an 
intervention must achieve to be acceptable and implemented in a healthcare 
system. This is usually means ratio between monetary cost and measures of 
health gain in the denominator (Weinstein  M, 1973).  The recommended 
measure of health gain is usually expressed as Quality Adjusted Life-Years 
(QALY) which represent years of healthy life (Raisch, 2000).  QALY is usually 
involves the cost utility analysis. A QALY considers longevity and quality-of-
life. The number of QALYs accrued by a patient is estimated by multiplying the 
years of survival by quality of life measured on a scale from zero e.g. zero 
being dead to 1 been in good health. 
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Disability Adjusted Life-Year (DALY) was developed by the World Bank and 
WHO to estimate the burden of disease on society. DALY is a health outcome 
with two components the duration of life time lost due to premature death (year 
of life lost (YLL)) and the reduction in quality of life due a disability (years of 
life with disability (YLD)) (Murray 1994).  However, WHO base their CEA 
assessment on cost per DALY, though the method used to calculate the values 
for DALY has been questioned (Melse  JM, 2000). 
DALY’s primary scale is 0-1, with 0 perfect heath and no disability and 1 death. 
The duration of life lost due to premature death is calculated by comparing 
actual age at death with standard life expectancy i.e. 82.9 for women 79.2 for 
men in the UK (Applied method of CEA in health-Gray, page 108-109). 
Calculation in reduction of quality of life due to disability is based on six-level 
classification system, with weight allocated by expert for example class 2 those 
with limited ability to perform most activities in two of the following areas: 
recreation, education, procreation or occupation were given a weight of 0.40 
so each year in the state will lose 0.40 DALY.  The objective of DALY is to 
minimize the number of year lost were QALY to maximize the number of years 
a person accumulates (Applied method of CEA in health-Gray, page 108-109).  
 
1.14.3.3 Cost-consequence analysis (CCA) 
 
Involves the estimation of the cost and the consequences of two interventions, 
and the final decision on the right method is left to the decision-maker.  This 
model assumes that the decision-maker known what they are doing i.e. 
interpret and synthesis in some way. In addition, this model also assume that 
the decision-makers are the right people to decide how to prioritise different 
outcomes of an intervention i.e. lower cost but poorer health and long hospital 
admission, or better long-term quality of life but more frequent short-term 
complications. Because of the complex and knowledge required to make the 
right decision this model is rarely used. 
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1.14.3.4 Cost-minimisation analysis (CMA) 
 
Cost-minimisation analysis model assumes that the health outcomes and the 
interventions are equal, and the objective is to evaluate the cost, to choose the 
lowest.  Moreover, this format is usually used in parallel with a clinical trial that 
failed to demonstrate a clear outcome between two treatments.  The problem 
with using CMA is that it assumes that failure to prove the hypothesis in a trial 
applies that the two treatments are equal.  Moreover, CMA do not consider the 
statistical power used in that trial; it is possible to find some trials who may not 
have the right statistical power; as a result, the use of this type of format is 
usually infrequent and not appropriate for the current study as IMA assay 
detect ischaemia whereas, troponin is used to assess AMI. 
1.15.1 Decision analytic modelling: Markov models 
1.15.1.1 Markov models: what are they? 
 
Markov models (MM) analyse uncertain process over time. There are used 
when decision and timing of events is important and when events may happen 
more than ones for example in SA attacks in ACS. MM also is suited for 
modelling long term disease outcome, where cost and effect are spread over 
long period of time i.e. chronic disease or situation where event are likely to 
occur i.e. AMI. MM also suited in studies assessing the cost effectiveness of 
disease management including the diagnostic efficiency of the introduction of 
IMA plus hs-cTnT in an ED setting. 
MM comprises a set of health states in which an individual can be found i.e. 
SA. These states are framed in a way that at any given time patients can only 
be in one health state; thus, all individuals for example with undifferentiated 
chest pain can be categorised into one health state (Figure 7).  In this project 
the health state of interest is concerned with patients presenting with chest 
pain suggestive of AMI i.e. NSTEMI.  Thus, there is no need to examine actual 
AMI patients or UA patients as these patients will be considered an emergency 
and treated accordingly. MM is concerned with transition during a series of 
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cycles consisting of short time intervals. Moreover, individuals within given 
state are assumed to be identical this is the limitation of MM, because the 
transition probability only depend on the current health state and not changing 
health state- this is known as the Markovian assumption (Athanassoulis, 
2015).  It must be noted that the exact transition times between disease states 
are generally difficult to observed, and only a proportion of individual disease 
histories is usually observed for example in renal patients or in certain cancer. 
Thus, the transition of disease states in this project is based on blood 
biomarkers changes, because if patient’s history and ECG changes are 
consistent with AMI patients will start treatment immediately irrespective of 
blood biomarkers results. 
 
(1) Screen and /or examine
(2) Chest pain 
(4) Acute myocardial infarction
(2) Unstable angina
(3) Stable angina
(5) Death
 
Figure 7: Markov model (b) transition between sate are indicated by the arrows.  
Adapted from Kondo et al. Clin Exp Nephrol 2012. 
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1.16 Summary 
 
CEA according the World Health Organisation (WHO) recommend that the 
CEA should be tree time the gross domestic product (GDP) per capita (Kondo 
et al. 2012).  However, the application of CEA to the concept of threshold is 
controversial because of the type of cost that should be included; it has been 
argued that CEA should not include just the direct cost of the disease but also 
the total resources including the consequences resulting from mortality. Thus, 
CEA ratio should include the measures that increase life expectancy rather 
than improve the quality of life (Johannesson M, 1996).  Currently there is no 
global consensus on the definition outlining all cost that should be included in 
CEA.  The adoption of a threshold by healthcare system usually adopts an 
explicit threshold where by a group of decision-makers formally adopt and 
make public in advance any threshold by which their decisions on recourse 
allocation would be framed.  On the other hand, policymakers may adopt and 
implicit threshold which are not official or public. In the UK, implicit threshold 
are often challenged and undermine public confidence especially were a 
community is denied a given treatment (George B, 2001).  It reasonable to say 
that explicit threshold is not immune from challenges; thus policymakers need 
to meet the need of their community in a fair way (Hans-Georg, 2004). 
The research presented in this thesis is an attempt to provide an empirical-
based quantification of the costs the NHS faces when considering whether 
health benefit associated with new technologies are expected to offset health 
care cost that may be utilised elsewhere. Early identification and correct 
diagnosis of patients presenting with chest pain suggestive of AMI may save 
recourses (table.6) including hospitalisation e.g. bed occupancy, expensive 
treatments e.g. PCI, lifelong medication, lost revenue, social issues if the 
patient is the main “bread winner” and general wellbeing.  
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Table 6: Unit cost (adapted from BMJ) 
Unit cost Unit Base-case value (£) 
PCI 
CABG 
Repeat PCI 
Angiogram 
Non- cardiac ward 
CCU 
Outpatients 
Cardiac day case 
Non-cardiac day case 
Guildwire 
Stent 
Guilding catheter 
Blood  
Full blood account 
Blood 
Endoscopy 
Tirofiban 
Eptifibatide 
Clopidogrel 
Procedure 
Procedure 
Per –Item 
Procedure 
Day 
Day 
Day 
Visit 
Visit 
Visit 
Item 
Item 
Item 
Unit 
Unit 
12.5 mg vial 
20 mg vial 
75 mg vial 
28 tablet pack 75 mg 
1,410 
4,900 
3,000 
750 
160 
240 
460 
60 
109 
182 
62 
600 
37 
85 
4 
246 
146 
49 
35 
 
NICE has been reluctant to specify a single cost effectiveness threshold used 
in its decision. It has also argued that factor other than CEA are taken into 
consideration by various advisory committees. Since 2004, the NICE 
guidelines use a threshold range of £20,000 to £30,000 QALY gained.  The 
latest guideline indicates that a threshold of less than £20,000 is likely to lead 
to recommendation unless the evidence for it adoption is not robust or 
uncertain (Devlin N, 2004).  Of course, mortality is a more relevant outcome 
indicator for some interventions e.g. ACS than for others for example epilepsy 
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and for this reason NICE would expect a better evidence before a new 
intervention is applied.  It is apparent that if IMA plus hs-cTnT assay could 
identify AMI patients and reduce the mortality, a rate threshold greater than 
£20,000 may be justified. 
1.17 Summary review of cardiac biomarkers 
 
In modern medicine cardiac biomarkers play an important role in the diagnosis, 
risk assessment, management and treatment of patients.  The introduction of 
new cardiac biomarkers has been increasing and evolving since 1950s 
(Figure.8).  One of the earliest cardiac biomarkers was alanine amino-
transferase (AST) followed by myoglobin and creatine kinase (CK); since the 
introduction and the development of cardiac troponin (cTn) these biomarkers 
has fallen out of use. 
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Figure 8: Historical progressions of cardiac biomarkers used to assess acute 
coronary syndrome, myocardial infarction (MI), Aspartate transaminase (AST); 
creatine kinase (CK); creatine kinase-MB isoform (CK-MB); 
radioimmunoassay (RIA); cardiac troponin I (cTnI), cardiac troponin T; (cTnT); 
lactate dehydrogenase (Ld); WHO, World Health Organisation.  (Courtesy of 
David Gaze.  St George’s NHS Trust.  London). 
 
The importance of cardiac biomarker testing has been widely accepted as part 
of the initial assessment of patients presenting with an unexplained chest pain 
suggestive of ACS.  ACS pathophysiology is complex, thus presently it is 
unlikely that a single biomarker could be used to evaluate cardiovascular 
associated risks and for ACS diagnosis (Bali,Cuisset,Giorgi et al., 2008).  
Numerous evidences oppose to the single biomarkers use in an ED setting or 
in a chest clinic (Bali,Cuisset,Giorgi et al., 2008; Lin,Yokoyama,Rac et al., 
2012).  The current guidelines propose that clinician should tailor cardiac 
biomarkers for NSTEMI patients based on prognostic ability such as that with 
cTn (Braunwald,Antman,Beasley et al., 2002). 
71 
 
1.18 Conventional cardiac biomarkers 
1.18.1 Myoglobin 
 
Myoglobin is a 17.8 kDa cytoplasmic haem protein found in striated muscles, 
it constitutes 2% of the total muscle protein.  Myoglobin facilitates oxygen 
storage for the oxidative phosphorylation in the muscle fiber.  Myoglobin 
evaluation is considered as a primary biomarker for monitoring rhabdomyolysis 
patients, accidental trauma and until decade ago for AMI (Lindsay,Carr,Draper 
et al., 2015).  Myoglobin is a non-specific cardiac biomarker and can be 
present in a range of conditions including severe renal insufficiency, alcohol 
abuse and skeletal muscle trauma (Gilkeson et al., 1978) (Mair et al., 1992). 
The relationship between myoglobin release to the circulation and AMI was 
first observed by Kagen et al., in 1975 (Kagen,Scheidt,Roberts et al., 1975).  
Following an AMI myoglobin is elevated in the circulatory system within 1-2 h 
and peaks between 6 and 9 h before returning to normal within 24 h.  Although, 
myoglobin is useful in the early detection of AMI, it still has a major limitation 
including its rapid clearance, thus potentially misdiagnosing patients 
presenting > 24 h after AMI.  Patients presenting late > 24 h after their acute 
phase may have a falsely negative results within the normal range 
(Grenadier,Keidar,Kahana et al., 1983). 
A meta-analysis has shown that the clinical sensitivity of myoglobin for the 
diagnosis of AMI has reached 90% with serial sampling (Balk,Ioannidis,Salem 
et al., 2001).  However, the poor specificity is considered to limit myoglobin 
clinical use as biomarker in the ED setting to rule-in or rule-out AMI.  Despite 
poor specificity the ESC, the National Academy for Clinical Biochemistry and 
the ACC, has recommended the used of myoglobin as an early cardiac 
biomarker when troponin is not available (Alpert,Thygesen,Antman et al., 
2000). 
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1.18.2. Creatine kinase 
 
Creatine kinase (CK, E.C number 2.7.3.2) has a molecular weight of 86 kDa 
and exists as a dimer of two subunits, B and M.  CK isoforms molecular weights 
varies between 39 to 42 kDa and are synthesized in various tissues and cell 
types such as the brain and skeletal muscle.  Their role is to catalyze the 
transfer of high-energy phosphate from ATP to creatine.  Three different 
dimeric CK isoforms exist including CK-MB, CK-MM and CK-BB.  The CK-MM 
is mainly found in striated muscle including the heart.  The CK-MB isoform is 
predominantly found in the myocardium with only 1-3% located in skeletal 
muscle.  The CK-BB isoform is found only in the brain (Tsung, 1976).  Each 
subunit has a dedicated gene that encode for either the M or B subunit 
(Villarreal-Levy,Ma,Kerner et al., 1987).  Total creatine kinase (CK) activity 
refers to the cumulative activity of all three isoforms in a given sample. 
The discovery of substantial amount of CK-MB in the myocardium made it the 
most used cardiac biomarker in 1980s (Saenger & Jaffe, 2008).  The relative 
specificity of CK-MB refers to the ratio of CK-MB/CK-MM isoforms.  Relative 
increase of CK-MB concentration to values > 3-5% of total CK may indicate 
cardiac origin.  Until the last decades CK-MB isoform was the primary 
biomarker for the diagnosis of AMI and was considered the “Gold Standard” 
(Lee & Goldman, 1986). 
The advantage of small molecules such as CK-MB is that they are rapidly 
cleared from the circulation by renal system, and usually detected in the 
circulation in a small and predictable concentration; as a such a rapid increase 
of concentration of this analyte during AMI is clinically useful and noticeably 
detectable.  During AMI, serum CK and CK-MB begins to increase within 4-8 
h and reaches peak concentration around 24 h and it return to baseline within 
2 to 3 days (Ellis, 1991).  Increased CK-MB concentrations does not 
necessarily translate into AMI; in fact it could indicate potential myocardial 
injury (Saenger & Jaffe, 2008). 
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After the introduction of a very sensitive (level of detection (LoD) < 1 μg/L) 
automated immunoassays known as mass assays.  The measurement of CK-
MB using highly specific monoclonal antibody against MB dimer including M 
and B subunit; this has improved assay sensitivity to 50% at 3 h and 80% at 6 
h and 90-100% at 10-12 h after the onset of chest pain suggestive of AMI 
(Lee,Rouan,Weisberg et al., 1987).  However, highly sensitive CK-MB (mass) 
assay comes at the expense of an increased detection and frequency of CK-
MB concentration due to skeletal muscle injury and or renal failure 
(Mair,Artner-Dworzak,Dienstl et al., 1991).  As a result an estimated 20% of 
false negative due skeletal muscle injury or renal failure is recorded 
(Robbins,Epstein & Shah, 1997).  In addition, CK-MB estimation significantly 
varies among platforms due to lack of CK-MB standardization 
(Christenson,Vaidya,Landt et al., 1999). 
 
After the introduction of the high sensitivity cardiac troponin (hs-cTn) and the 
revision of the guidelines for diagnosing AMI in 2000 and the subsequent 
update in 2007; CK-MB as the biomarkers for AMI has been replaced with hs-
cTn for AMI patients’ management (Alpert,Thygesen,Antman et al., 2000; 
Thygesen,Alpert,White et al., 2007).  Recent guidelines published in 2014 by 
AHA and ACC clearly stated that CK-MB do not provide additional value for 
the diagnosis of ACS (Amsterdam,Wenger,Brindis et al., 2014).  In contrast, 
the ESC and the ACC state that any elevation above the reference range of 
troponin or CK-MB isoform is evidence of myocardial necrosis and that the 
patient should be classified as having AMI (Anderson,Adams,Antman et al., 
2007).  The reason for this is that cardiac troponin remains high for days 
whereas CK-MB return to base line within 24 h (Saenger & Jaffe, 2008). . CK-
MB is still offered across the UK, as I can aid in the diagnosis of AMI. 
1.18.3. Cardiac troponin 
 
Troponin (80 kDa) is a complex molecule comprising of three protein isoforms 
including troponin I, troponin T and troponin C.  These proteins are housed in 
the sarcomeric filaments and are essential for contraction and relaxation in 
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both cardiac and skeletal muscle (Figure 9).  The cardiac and skeletal isoforms 
of troponin T and troponin I; are encoded by separate genes 
(Anderson,Greig,Mark et al., 1995).  Interestingly, despite the difference in 
opinion an estimated 5-10% of free form of the total cardiac troponin I (cTnI) 
and cardiac troponin T (cTnT) is believed to be present in the cytosol 
(Katus,Remppis,Scheffold et al., 1991; Thygesen,Mair,Katus et al., 2010).  
The implication of free cTn detection revolutionizes our understanding of the 
presence of cTn in healthy population and this can be utilised as a biomarker 
of cardiac ischaemia. 
 
 
 
Figure 9: Regulatory cardiac troponin complex; the three subunits are troponin 
T, I and C. Troponin T binds and attach troponin complex to tropomyosin; 
whereas troponin I modulate the interaction of acting and myosin by inhibiting 
actomyosin adenosine triphosphate activity, and finally troponin C act as a 
calcium binding subunit of the troponin complex (courtesy of Clinical 
Biochemistry). 
 
Cardiac troponin T and I molecule is highly specific for the myocardium and 
contains a unique amino acid sequence that are translated by a dedicated 
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genes (Sheng & Jin, 2016).  This, unique amino acid sequence of cardiac 
isoform cTnT and cTnI allows the generation of highly specific monoclonal 
antibodies and a very reliable mode of detection of these isoforms after 
myocardial injury (Jaffe, 2001; Smith et al., 2013; Regwan et al., 2010). 
False-positives are known to exist in a condition where heterophilic antibodies 
are present, this antibodies effect only non-standardized cTnI immunoassays 
(Panteghini, 2009).  Using the current generation high sensitivity cardiac 
troponin (hs-cTnT) immunoassay in patients with skeletal muscle disorders 
has raised concerns regarding cardiac-specificity.  A controversial study found 
that some patients with skeletal myopathies but with no evidence of myocardial 
injury or raised CK-MB appear to exhibit a potential re-expression of cTnT 
isoforms or immunoreactivity to cTnT immunoassay (Jaffe et al., 2011).  
Generally, cTnT or cTnI are considered the biomarkers of choice for the 
diagnosis of AMI worldwide.  Utilisation of cTn evaluation in clinical settings 
complement clinical assessment and ECG in the diagnosis, risk stratification 
and treatment of low risk patients and those with suspected NSTEMI 
(Thygesen et al., 2010; Newby et al., 2012).  A series of meta-analysis and 
various studies confirmed that the estimation of cTnI or cTnT in patients with 
ACS has a superior diagnostic and a prognostic value than myoglobin and CK 
(Balk, Ioannidis, Salem, Chew, & Lau, 2001; Olatidoye, Wu, Feng, & Waters, 
1998; Thygesen,Mair,Giannitsis et al., 2012). 
 
The kinetic release of cTnT and cTnI concentrations after myocardial injury 
begin to rise between 3-6 h after the onset of AMI and reach a maximum peak 
concentration after 12-24 h (Collinson, 1998).  The cTnI or T in AMI patients 
usually shows a peak concentration within the first day after the onset of 
symptom and persists for approximately a week (Katus,Remppis,Scheffold et 
al., 1991; Michielsen,Diris,Kleijnen et al., 2007). 
The Universal Definition of Myocardial Infarction evaluated the use of cardiac 
troponin in patients presenting with chest pain suggestive AMI as a mandatory.  
The 99th percentile upper reference limit (URL) as established in apparently 
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healthy individuals, has been recommended as the clinical decision threshold 
for the diagnosis of AMI.  It must be noted that the definition and standarisation 
of healthy individuals has not been properly defined and is still debated 
(Chenevier-Gobeaux,Bonnefoy-Cudraz,Charpentier et al., 2015; 
Keller,Ojeda,Zeller et al., 2013; Panteghini, 2009). 
In recent years the sensitivity of cTn immunoassays has improved 
considerably and a new generation of hs-cTn immunoassay has been 
introduced to the market.  The introduction of these new improved hs-cTn 
immunoassays has the potential to speed up triage and treatment of patients 
presenting to the ED with chest pain suggestive of AMI (Apple, 2011; Reichlin 
et al., 2009; Keller et al., 2009). 
 
This new generation of hs-cTn can only be described as such if they comply 
with the 2007 guidelines of the universal definition of myocardial infarction 
(Thygesen,Alpert,White et al., 2007) and can demonstrate the following: 
1) < 10% total imprecision at the 99th percentiles of a reference population  
2) Able to quantitate (limit of detection (LoD)) at least 90% of healthy 
individuals (Apple, 2009; Thygesen,Alpert,Jaffe et al., 2012). 
 
The value of using the 99th percentile as a diagnostic cut-off of AMI was 
confirmed by several studies (Keller,Zeller,Peetz et al., 2009; 
Reichlin,Hochholzer,Bassetti et al., 2009).  Currently most laboratories in the 
UK offer hs-cTn as the first diagnostic cardiac biomarker for patients admitted 
to the ED with chest pain suggestive of AMI.  Commercially available hs-cTn 
immunoassays now achieve an analytical sensitivity of up to 100 times greater 
than conventional troponin assays (1 ng/L versus 100 ng/L) (Apple, 2009; 
Chenevier-Gobeaux,Bonnefoy-Cudraz,Charpentier et al., 2015).  In addition, 
measuring hs-cTn allows early detection of cardiac injury as soon as the 
cardiomyocyte membrane permeability occurs (de Lemos, 2013). 
Since the introduction of hs-cTn immunoassay the sensitivity has increased 
from 83% (95% CI, 76-90%) to 95% (95% CI, 90-98%), while the specificity 
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decreased from 93% (95% CI, 91-95%) to 80% (95% CI, 77-83%) (Reichlin et 
al., 2009).  These assays are now capable of detecting myocardial damage in 
healthy populations (Saenger et al., 2011; Todd et al., 2007).  The significance 
of detectable hs-cTn in healthy population is unclear (Carlton,Gamble & 
Greaves, 2013).  However, this increased sensitivity of hs-cTn immunoassay 
comes at the cost of decreased specificity and the power to rule-in AMI (Wu, 
Lu, Todd, Moecks, & Wians, 2009).  Other studies supported this observed 
general decrease in hs-cTn specificity (Januzzi, Jr. et al., 2010; Kavsak, Wang, 
Ko, MacRae, & Jaffe, 2009). 
To improve the specificity of hs-cTn and its diagnostic utility the current 
guidelines require serial blood sampling; ideally blood should be measured for 
hs-cTn concentration at the first sign of chest symptom and 3 h after admission 
(Hamm et al., 2011).  Repeated hs-cTn measurement in the second time 
maximizes the safety and certainty to rule-in or rule-out an AMI.  The 
measurement of the early absolute changes (second) of hs-cTn within 1 h can 
be used as a surrogate for 3 or 6 h to rule-in or rule-out diagnosis of AMI in 
NSTEMI patients (Thygesen et al., 2012c). 
The ESC guidelines recommend a single hs-cTn measurement where 
NSTEMI patients present with post 6 h chest pain and a GRACE score of < 
140 (Hamm et al., 2011).  The ESC also recommends that if the patient still 
shows signs suggestive of ACS a third hs-cTn measurements may be 
required.  The reason for this is that the presence of hs-cTn is not specific 
enough for diagnosing AMI, and especially patients with excising 
cardiovascular co-morbidities such as heart failure and renal failure (Reiter et 
al., 2011). 
Although, serial measurements of hs-cTn at admission and 3 h is useful; some 
evidence suggests these guidelines are not fully followed by professionals for 
various reasons.  Notably, the lack of clear definition of rise and a fall (delta 
changes) of hs-cTn concentration has led many clinicians to adopt a change 
of ≥ 20% as a practical cut-off.  Conversely, another study has showed that 
cut-off value of ≥ 20% needed to be reassessed and increased in patients with 
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hs-cTn in a lower range, older patient, and in-patients with existing co-
morbidities such as renal failure (Apple, 2009; Giannitsis,Becker,Kurz et al., 
2010).  The integration of ≥ 20% delta rules over 2 h period has increased 
specificity to 92.4% (95% CI, 90-94%) but reduced sensitivity to 56% (95% CI, 
48-63.2%) (Aldous,Pemberton,Richards et al., 2012). 
The full integration of hs-cTn has yet to be demonstrated in terms of its 
diagnostic utility, risk stratification and above all the implication of the presence 
of hs-cTn for healthy population.  The implementation and the introduction of 
hs-cTn have multiple advantages provided that there is a revised algorithm 
outlining the management of the ACS patients.  Most AMI patients will show 
substantial cTn concentration changes; however, cTn concentration change is 
not a diagnostic of AMI but an indication of myocardial injury (Hamm et al., 
2011; Thygesen et al., 2012a).  It is clear, that clinicians interpretation of hs-
cTn differ when considering clinical context (Newby,Jesse,Babb et al., 2012). 
1.19 Novel biomarkers in the assessment of acute coronary 
syndrome 
 
1.19.1 B-type natriuretic peptide 
 
Natriuretic hormones belong to the family of vasoactive peptides that regulate 
arterial and venous dilation.  B-type natriuretic peptide (BNP) is produced by 
the myocyte as a pro-hormone (Figure 10).  BNP consist of 32 amino acids 
(AA) which are release to the circulation in response to ventricular dilatation 
and hemodynamic stress (Christenson & Tang, 2006; Levin,Gardner & 
Samson, 1998). 
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Figure 10: B-type natriuretic peptide molecular processing.  NT-pro-BNP the 
stable portion of B-type natriuretic peptide is cleaved at amino acid position 
76. 
 
In the circulation the pro-hormone is cleaved into BNP the physiologically 
active form and into the N-terminal fragment of the NT-pro-BNP.  BNP exert 
its vaso-relaxant effect through its interaction with the rennin-angiotensin-
aldosterone system.  The clearance of NT-pro-BNP from the circulation is 
three times lower than BNP, making it ideal for monitoring congestive heart 
failure (CHF) and acute heart failure (AHF) patients.  These patients will 
typically show a minor variation in concentration which can be readily 
detectable (Buckley,Marcus,Yacoub et al., 1998).  Currently assay for both 
BNP and NT-pro-BNP are commercially available. 
The measurement of BNP concentration is mainly used to assess left 
ventricular pressure and act as an aid in the diagnosis of CHF 
(Qi,Mathisen,Kjekshus et al., 2001; Roberts,Ludman,Dworzynski et al., 2015).  
However, elevated BNP concentration is also present in ACS and is 
associated with high risk of adverse cardiac events (Arakawa,Nakamura,Aoki 
et al., 1996).  The mechanism of BNP release in ACS patients is not fully 
understood.  One explanation is that ischaemic attack during or pre-AMI may 
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contribute to the heart wall stretch inducing the neurohormonal activation 
(Marumoto,Hamada & Hiwada, 1995).  This hypothesis is supported by the 
detection of BNP gene expression in ischaemic and infarct region of the heart 
(Ndrepepa,Braun,Schomig et al., 2007).  During artery bypass grafting cardiac 
biopsies tissue show that BNP is over-expressed in ischaemic myocardium in 
comparison to non-ischaemic regions in STEMI (Ruck,Gustafsson,Norrbom et 
al., 2004). 
AHF reflects the cardiomyocyte integrity and it is usually associated with 
myocardial injury and elevated cardiac troponin.  TACTICS-TIMI 18 trial (Treat 
Angina with Aggrastat and Determine the Cost of Therapy with Invasive or 
Conservative Strategy - Thrombolysis in Myocardial) found that NSTEMI 
patients with elevated BNP concentration had more severe stenosis 
(Sadanandan,Cannon,Chekuri et al., 2004).  BNP release involving 
undamaged myocytes may have an advantage in assessing the physiological 
consequences of ischaemia and AMI (Wiviott,de Lemos & Morrow, 2004).  
Increased concentrations of BNP are associated with larger infarct size and 
poor prognosis in patients with STEMI (Arakawa,Nakamura,Aoki et al., 1996).  
Elevated BNP concentration was also found in older patients and patients with 
renal dysfunction; the exact mechanism of this is unclear 
(McCullough,Duc,Omland et al., 2003; Redfield,Rodeheffer,Jacobsen et al., 
2002).  NT-pro-BNP and hs-cTn evaluation for patients presenting to the ED 
with chest pain suggestive of ACS may add an incremental value in term of 
patients risk stratification, clinician informed decision regarding treatments and 
diseases monitoring (Ketchum & Levy, 2011).  However, how to estimate the 
risk utilising NT-pro-BNP and hs-cTn evaluation is unclear (Ketchum & Levy, 
2011). 
Several studies concluded the measurement of BNP or NT-pro-BNP, day 2 to 
5 after AMI is strongly associated with long and short-term mortality 
(Omland,Aakvaag,Bonarjee et al., 1996; Richards,Nicholls,Yandle et al., 
1998).  The Acute Decompensated Heart Failure National Registry 
(ADHERE) which includes information about 84,872 patients with AHF and 
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cardiac troponin (cTn) concentration on admission; found that 6% of this cohort 
had an elevated cTn (Fonarow,Peacock,Horwich et al., 2008).  However, no 
correlation exists between elevated BNP concentration and cTnT 
(Yamamoto,Sato,Yasutake et al., 2006).  Currently NT-pro-BNP is not 
recommended for diagnosis of AMI across the UK. 
1.19.2 Copeptin 
 
Copeptin was first described by Holwerda in 1972 (Holwerda, 1972).  Arginine 
vasopressin (AVP) is a vasoactive neuropituitary hormone secreted in the 
hypothalamus.  AVP is one of the main hormones involved in the 
hypothalamic-pituitary-adrenal axis; it is derived from a 164 amino-acid 
precursor, pre-pro-vasopressin that comprises AVP, signal peptide, copeptin 
and neurophysin 2 (Figure 11) (Brownstein, Russell, & Gainer, 1980).  
Copeptin separation from the AVP protein is a result of a multi-step enzymatic 
processing, reshaping of the precursor molecule, the cleavage of the signal 
molecule and finally the separation of the neurophysin II from copeptin 
(Acher,Chauvet & Rouille, 2002; Morgenthaler,Struck,Jochberger et al., 2008). 
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Figure 11: Structure of the vasopressin pre-pro-hormone consisting of the 
signal peptide, the vasopressin hormone, the carrier protein neurophysin II and 
the glycoprotein copeptin.  The numbers indicate the amino-acid position 
where the cleavages occur.  Copeptin consists of 39 amino-acid.  
 
The AVP released from the neurohypophysis into the circulation is primarily to 
induce water conservation by the kidney.  Although, the main secretion of AVP 
is in response to hyperosmolarity, it can also be secreted in response to 
endogenous stress including hypoxia, acidosis, infection and AMI (Reinstadler, 
Klug, Feistritzer, Metzler, & Mair, 2015, Lukaszyk & Malyszko, 2015). 
In vivo, 90 % of AVP is bound to circulating platelets, AVP has a short life of 
10 to 30 min. the rate of degradation means that AVP cannot be clinically 
measured (Balanescu,Kopp,Gaskill et al., 2011).  Copeptin is a stable glycol-
peptides consisting of 39 AA located in the C-terminal portion of the precursor 
pre-pro-vasopressin (pre-pro AVP) and can easily be measured.  Copeptin 
secretion is directly stimulated by the activation of AVP system.  Therefore, its 
measurement directly reflects AVP status and acts as a surrogate biomarker 
for AVP. 
Establishing the exact time of the onset of myocardial ischaemia is very 
difficult; because of patient related delay prior to hospital admission (Liebetrau 
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et al., 2013b).  Copeptin concentration is significantly increased after 30 min 
and 90 min from 16.0 pmol/L; IQR, 13.4-20.2 pmol/L and 31.9 pmol/L; IQR, 
16.4-117.1 pmol/L respectively and return to baseline after 24 h 
(Liebetrau,Nef,Szardien et al., 2013). 
NICE has recommended the use of copeptin in conjunction with cTn and ECG 
in the diagnosis of AMI.  NICE suggested that patients presenting to ED with 
chest pain suggestive of AMI could be discharged if copeptin, cTn and ECG 
are all negative.  Two recent controlled trials have showed that low risk patients 
can be safely discharged if both copeptin and troponin were negative 
(Maisel,Mueller,Neath et al., 2013; Mockel,Searle,Hamm et al., 2015).  The 
combined use of copeptin and hs-cTn may exclude the need for serial blood 
sampling, prolonged monitoring of patients and could be cost effective strategy 
in diagnosis of AMI (Reichlin,Hochholzer,Bassetti et al., 2009).  However, due 
to copeptin low specificity; its measurement cannot replace serial 
measurement of cTnT to rule in or to rule-out AMI (Nemec,Koller,Nickel et al., 
2010; Nickel,Bingisser & Morgenthaler, 2012).  Thus, despite the NICE 
recommendation copeptin is not routinely offered as a part of the diagnosis of 
AMI in NHS hospitals across the UK.  The current ACS/AMI management 
protocol is unlikely change until prospective studies such as RCT have been 
conducted and demonstrated that the addition of copeptin and hs-cTn can 
safely rule-out this cohort of patients (Lipinski,Baker,Escarcega et al., 2015). 
1.19.3. Heart fatty acid binding protein  
 
Fatty-acid binding proteins (FABP) also known as mammary-derived growth 
inhibitors are intra-cellular proteins expressed in tissue with active fatty acid 
metabolism such as in the heart and liver (Viswanathan, Hall, & Barth, 2012).  
Nine phenotypes of the FABP family have being identified; currently each 
FABP is referred to according to the origin of it synthesis for example adipose 
tissue (A-FABP), liver (L-FABP), intestine (I-FABP) and heart tissue (H-FABP).  
The H-FABP content is approximately 80%-90% lower in skeletal muscle than 
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that in heart muscle; and the amounts in the liver, brain and small intestine are 
insignificant (Ishii,Ozaki,Lu et al., 2005). 
H-FABP is a low molecular weight (15 kDa) cytoplasmic protein; that occupies 
5-15% of cytosolic protein of the cardiomyocyte (Charpentier et al., 2010).  H-
FABP participates in fatty acid metabolism by transporting fatty acid from the 
cell membrane to mitochondria for oxidation.  H-FABP also protect against free 
radical accumulation during myocardial ischaemia (Jones,Prasad & Das, 
1990) and is the main source of energy in the heart accounting for 10% of the 
total body turnover of fatty acid (Fournier & Richard, 1990). 
The first evidence to suggest that H-FABP can be used as cardiac biomarkers 
for the diagnosis of ischaemic heart disease was made in the 1990s when two 
independent groups showed that H-FABP concentration was significantly 
increased after AMI (Kleine,Glatz,Van Nieuwenhoven et al., 1992; 
Tanaka,Hirota,Sohmiya et al., 1991).  Despite this discovery initial studies 
performed using a non-specific polyclonal antibody assay were disappointing 
(Kilcullen,Viswanathan,Das et al., 2007).  As a result, only few studies were 
conducted, examining the role of H-FABP as an early biomarker of myocardial 
injury.  Since then most studies have focused on comparing the diagnostic 
efficiency of H-FABP and that of cardiac troponin (Bruins Slot,Reitsma,Rutten 
et al., 2010). 
H-FABP low molecular weight allows an early release of this protein into the 
circulatory system before larger molecules such as troponin.   Therefore, H-
FABP is used as an early biomarker of ischaemia (Chan,Sanderson,Glatz et 
al., 2004).  Conversely, small molecules such as H-FABP and myoglobin 
readily pass through the glomerular membrane, reabsorbed and metabolized 
in tabular epithelial cells, thus patients with renal disease may present with a 
falsely elevated H-FABP concentration (Tanaka,Hirota,Sohmiya et al., 1991).  
Older patients with normal renal function are also known to have higher 
concentration of H-FABP compared to younger adults 
(Bathia,Carless,Viswanathan et al., 2009). 
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During myocardial injury H-FABP is detected in the circulation within 30 min to 
1 h, reaches peak concentration within 6 to 8 h; and return to baseline around 
24 to 36 h (Kleine,Glatz,Van Nieuwenhoven et al., 1992; Pelsers & Glatz, 
2005). 
Chest pain patients must be assessed for other disease in order to establish 
the sources of H-FABP including skeletal muscle, brain, testis and ovaries 
(Servonnet,Delacour,Dehan et al., 2006).  The ratio of plasma concentration 
of myoglobin and H-FABP appears to be useful in differentiating H-FABP due 
to myocardial injury from that of skeletal muscle injury (Van 
Nieuwenhoven,Kleine,Wodzig et al., 1995; Yoshimoto,Tanaka,Somiya et al., 
1995).  Since myoglobin is no longer offered in the most UK laboratories, 
utilisation of the ratio calculation is less likely to be adopted in an ED setting.  
Myoglobin to H-FABP ratio may be subject to interference by the patient’s renal 
clearance capacity and is therefore unreliable. 
Experimental studies demonstrated that H-FABP is down regulated during 
ischaemic stress; the heart substitute its energy supply from fatty acid to 
glucose metabolism (Arumugam,Sreedhar,Thandavarayan et al., 2016).  The 
ability of the heart tissue to switch energy utilisation from H-FABP to glucose 
during ischaemia may lower the diagnostic efficiency of H-FABP determination 
especially in cardiac ischaemic patients. 
Meta-analysis suggest that H-FABP testing as a standalone test did not fulfill 
the diagnostic criteria in terms of sensitivity, specificity and the predictive 
values for a safe rule-out protocol in patients suspected of AMI (Bruins 
Slot,Reitsma,Rutten et al., 2010).  The combination of H-FABP and cTn is 
shown to increase the sensitivity and the negative predictive value (NPV) for 
diagnosing AMI (Lippi,Mattiuzzi & Cervellin, 2013).  In support of the meta-
analysis finding, Carroll colleagues, reported that combining H-FABP and cTn 
increases the sensitivity from 42%-75% to 76%-97%, but at a price of reduced 
specificity from 94%-100% to 65%-93% (Carroll,Al Khalaf,Stevens et al., 
2013). 
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Published studies showed that the diagnostic efficiency of H-FABP lacks the 
require methodological design including the inappropriate use of study 
population; one study used STEMI cohort and other did not use hs-cTn 
(Bhardwaj,Truong,Peacock et al., 2011; Body,McDowell,Carley et al., 2011; 
Chan,Sanderson,Glatz et al., 2004; Gururajan,Gurumurthy,Nayar et al., 2010; 
McCann,Glover,Menown et al., 2008).  However, H-FABP testing may be 
useful as a risk stratification tool.  The magnitude of the increase of plasma H-
FABP concentration correlate with the size of the infarct (Bajaj,Rathor,Sehgal 
et al., 2015). 
H-FABP evaluation as a routine test in and ED setting is unlikely; as its 
estimation does not have an incremental value superior to that of hs-cTn.  
Thus, currently H-FABP is not offered by NHS as a test for the diagnosis of 
AMI. 
1.19.4 Ischemia modified-albumin 
 
Human albumin (66.7 kDa) is a non-glycosylated single chain polypeptide 
containing 585 AA.  It is the most abundant protein in the human body (35-50 
g/L) and exerts a range of physiological and pharmacological functions 
including transport of small molecules such as drugs, fatty acids, and bilirubin 
and acts as an antioxidant (Evans, 2002; Rondeau & Bourdon, 2011).  Human 
albumins (HA) occupy 50% of total plasma proteins and serve to regulate 
oncotic pressure.  In physiological conditions HA exerts its buffering capability 
through its 16 histidine imidazole residues (Caironi and Gattinoni 
2009;Colombo et al. 2012a;Pavone et al. 2010). 
The liver is the main site of albumin biosynthesis.  Traces of albumin mRNA 
have been detected in the kidney and pancreas, however, there is no evidence 
of protein translation.  The presence and the origin of albumin in milk is still 
debatable (Peters T, 1996).  On the other hand, some evidence demonstrates 
that a small amount albumin can also be produced in bone tissue and the 
microglia cells in brain (Yamaguchi et al., 2010; Ahn et al., 2008). 
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The circulation of albumin between the interstitial spaces the intravascular 
environment, the lymph drainage and the blood stream is a dynamic and 
continuous process which eventually causes albumin to degrade (10-12 g/24 
h) ubiquitously at a rate equal to that of synthesis (Gattinoni, Carlesso, & 
Caironi, 2005).  However, during cardiac ischaemia, albumin is subject to 
modification by free radicals and reactive oxygen species (ROS); inhibiting and 
altering its function to sequester Cu (II) ions through its N-terminus and 
inhibition of ROS formation.  Modification of the N-terminus through acetylation 
or deletion of one or more residues makes cobalt or copper binding impossible.  
This damaged albumin is known as ischemia modified-albumin (IMA®). 
IMA can be indirectly measured using the cobalt-binding assay (Bar-Or, Lau, 
& Winkler, 2000a).  The IMA assay was cleared by FDA on the basis that it 
would help rule-out ACS, in low to moderate pre-test probability conditions with 
negative necrotic cardiovascular biomarkers such as cTn and a normal ECG. 
The use of IMA is based on the premise that an early evaluation of this 
biomarker may predict the final diagnosis of AMI.   IMA has being suggested 
as a biomarker for monitoring transient myocardial ischaemia induced by 
vasospasm (Cho,Choi,Kim et al., 2007).  IMA is not a cardiac specific 
biomarker and can be found in various conditions including, renal disease, 
infection, inflammation, and liver disease (Abboud,Labreuche,Meseguer et al., 
2007). 
Diseases and conditions such as cardiac ischaemia, chronic inflammation, 
cancer and aging, are known to trigger copper release (Cu II) and redox activity 
which can cause cellular damage due to the generation of reactive oxygen 
species (ROS) including hydroxyl radical (OH●) and superoxide (O2●-) 
(Halliwell & Gutteridge, 1990a).  In vivo, a hydroxyl radical is converted to 
hydrogen peroxide (H2O2) and superoxide.  Superoxide is directly converted 
to either hydroxyl radical via the Haber-Weiss reaction or converted to H2O2 
via the Fenton reaction (Biaglow, Manevich, Uckun, & Held, 1997).  Both 
reactions require transition metal such as copper and iron (Halliwell & 
Gutteridge, 1990b).  While, iron concentration in human serum is greater than 
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copper, the latter is 60 times faster in generating hydroxyl radical than iron 
(Chevion et al., 1993).  Moreover, Cu II ions, when mixed with ascorbic acid or 
other reducing agents produce hydroxyl radicals (Biaglow et al., 1997). 
Copper is regulated in both non-specific exchangeable and specific non-
reversible by a range of carrier plasma protein.  This, includes caeruloplasmin 
that bind approximately 65% of copper, and albumin (Bar-Or et al., 2001a).  
Once the copper is release to the circulation during ischaemia, it disrupts the 
cellular energy causing the conversion of pyruvate to lactate and subsequent 
local acidosis (Figure 12).  Localised acidic conditions causes caeruloplasmin 
to release more copper (Cu II) (Lamb & Leake, 1994). 
HA and specially its N-terminus tetra-peptide (Asp-Ala-His-Lys) sequence is a 
non-exchangeable binding site for Cu (II).  It is capable of sequestering Cu (II) 
ions and inhibiting the formation of ROS. HA prevents the conversion of 
sequestered Cu (II) to Cu (I) in the presence of reducing agents such as 
ascorbate (Marx & Chevion, 1986).  Free Cu (I) can react with oxygen to form 
Cu (II) and generates superoxide free radicals (O2●-).  It is also possible that 
IMA also act as an antioxidant to reduce injury during reperfusion 
(Sinha,Gaze,Tippins et al., 2003). 
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Figure 12: Mechanism of Ischaemia Modified Albumin generation. 1&2) Tissue 
hypoxia from anaerobic metabolism reduces ATP and causes a lower localized 
pH inducing acidosis.  3) Cu++ ions are released from plasma proteins such as 
caeruloplasmin. 4) In the presence of ascorbic acid, Cu++ is converted to Cu+. 
Cu+ reacts with O2 to form O2• –. 5&6) Superoxide dismutase dismutates the 
O2• – to H2O2, which in presence of Cu++ or Fe++, undergoes the Fenton reaction 
forming OH• hydroxyl radicals. 7) Free Cu++ is scavenged by HA, where it binds 
tightly to the N-terminus. 8) OH• radicals alter the amino acid N-terminus of HA 
rendering it incapable of binding Cu++.  9). This altered form is known as IMA. 
(From:  Human serum albumin.  Japan. Otagiri (2013) p 357). 
 
The generation of IMA through free radicals is widely accepted as the preferred 
theory; however, the exact mechanism is unclear.  Albumin from other species 
such as canine and porcine have a different N-terminus configuration and 
cannot bind metal ions such as copper (Bal et al., 1998).  A study found that 8 
patients with increased IMA had 11 amino-acid residues at the NH2 terminus 
when cleaved using rapid liquid-phase Edman degradation.  They also found 
that 6 out 7 patients had a normal NH2 terminal, except one non-ischaemic 
patient who appeared to lack two amino acid DA (Asp (D) or Asp-Ala (DA)) 
residues (table 7) (Bhagavan et al., 2003).  This study concluded that the 
missing AA may due to the presence of an albumin variants.  A group of an 
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independent researchers also found that some of these variants also exhibit 
amino acid changes in the pro-peptide, and the N-terminus (Kragh-Hansen, 
Brennan, Minchiotti, & Galliano, 1994).  The N-terminal degradation in vitro is 
thought to occur because of pH and temperature changes.  It is possible that 
this mechanism may also exist in vivo (Chan, Dodsworth, Woodrow, Tucker, 
& Harris, 1995b). 
 
Table 7: Human albumin N-terminal amino acid sequences from ischaemic 
and non-ischemic patients. (Adapted from (Bhagavan et al., 2003). 
Subject IMA Concentration 
(ABSU 470 nm) 
NH2-terminal HA 
Sequence of Human 
albumin 
Control (normal wild type) 0.35 DAHKSEVAHRF 
Non-ischaemic patient 0.80 …..HKSEVAHRF 
Ischaemic patient 0.76 DAHKSEVAHRF 
Ischaemic patient 0.76 DAHKSEVAHRF 
Ischaemic patient 0.74 DAHKSEVAHRF 
Ischaemic patient 0.70 DAHKSEVAHRF 
Ischaemic patient 0.93 DAHKSEVAHRF 
Ischaemic patient 0.73 DAHKSEVAHRF 
 
1.19.5 Kinetic and clinical utility of ischemia modified-albumin 
 
Bar-or et al., (2001b) found that IMA concentration was significantly (p < 0.001) 
higher immediately after PTCA and return to base line after 6 h.  A further study 
found that during PTCA procedure IMA rose within minutes, remained elevated 
at 6 h and returned to base line at 12 h (Quiles,Roy,Gaze et al., 2003; 
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Sinha,Vazquez,Calvino et al., 2006).  IMA concentration was not significantly 
different from base line at 6 h and 24 h; this, suggests that IMA occur in the 
first few minutes of transient coronary occlusion (Bar-Or et al., 2001b). 
The fluctuation of IMA concentrations has been found to correlate with the 
number of transluminal balloon inflations during PCI procedure 
(Quiles,Roy,Gaze et al., 2003).  Patients who undergo PCI procedures have a 
higher concentration of IMA following one hour of induced coronary ischaemia, 
and the concentration of IMA fall after 24 h to normal (Bar-Or et al., 
2001b)(Hjortshoj, Dethlefsen, Kristensen, & Ravkilde, 2009).  The rapid 
normalisation of IMA after PCI suggests a limited diagnostic window.  Thus 
patients presenting to the ED after 3 h may not benefit from the NPV of IMA 
(Hjortshoj et al., 2009).  No correlation was found between patients with post-
PCI elevated IMA and other cardiovascular biomarkers such as CK-MB, 
myoglobin and conventional cTn (Bar-Or et al., 2001b). 
Several studies demonstrated that exercise may induce fluctuation in IMA 
concentrations (Apple,Quist,Otto et al., 2002; 
Falkensammer,Stojakovic,Huber et al., 2007; Middleton,Shave,George et al., 
2006; Shave,George & Gaze, 2007; Zapico-Muniz,Santalo-Bel,Merce-
Muntanola et al., 2004).  The effect of skeletal muscle on IMA concentration 
may increase the rate of false positives and subsequently limit is utilisation for 
the diagnosis of AMI. 
Meta-analysis has shown that IMA has a 91% NPV for excluding AMI in an ED 
setting and 97% sensitivity when combined with cTnT and with normal ECG 
(Peacock et al., 2006).  Various studies also supported that IMA has superior 
NPV of 96%, (95% CI, 91-98%) and could be safely used to rule out chest 
patients in an ED setting (Christenson,Duh,Sanhai et al., 2001; 
Keating,Benger,Beetham et al., 2006; Roy,Quiles,Aldama et al., 2004), 
Govender, De, Delport, Becker, & Vermaak 2008).  Although, IMA has a good 
NPV this does not necessary translate into practical triage tools in an ED 
setting, it NPV merely indicate the disease prevalence in the studied 
population (Sbarouni,Georgiadou,Panagiotakos et al., 2008). 
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Bali and colleagues recruited 79 patients with NSTEMI who presented with 
chest pain within 3 h.  The mean age was 68.8 ± 14 years and 73.4% were 
men.  Fifty-three (67%) patients have significant ECG changes, sixteen (20%) 
presented at admission with detectable cTn of cut-off value 0.03 ng/L.  They 
found that the median IMA concentrations of 115 U/mL and predicted major 
adverse cardiovascular events (MACE) with 1 year (Bali,Cuisset,Giorgi et al., 
2008).  Conversely, Worster et, al., (2005) found that IMA is a poor predictor 
of cardiac events within 72 h of admission after chest pain (Worster et al., 
2005). 
Due to the non-specific nature of IMA some clinicians do not support the use 
of IMA evaluation as an effective risk stratification tool in patients presenting 
to the ED with chest pain suggestive of ACS (Keating,Benger,Beetham et al., 
2006).  IMA is a biomarker of ischaemia with rapid clearance and narrow 
diagnostic window; thus not useful as a diagnostic test for AMI 
(Hjortshoj,Dethlefsen,Kristensen et al., 2009).  IMA evaluation and its clinical 
utility studies have shown controversial results and produces a significant 
results when used as part of a panel of tests (Abadie et al., 2005). 
1.20 The challenge: is to correctly identify low risk patients 
 
In England, chest pain is annually responsible for 238,000 admissions to the 
ED (Bidmead, 2015).  Patients with chest pain suggestive of ACS constitute 
one of the largest single cohorts of patients presenting to ED in the UK 
(Bidmead, 2015; Gavalova, 2012).  Managing this cohort of patients is 
complicated and can lead to medical errors (Deshpande & Birnbaum, 2014). 
Discriminating between ACS and non-ACS patients is very challenging; 
especially in individuals without clear symptoms, ECG features and cardiac 
biomarkers.  Routine diagnostic methods for risk stratification of patients 
presenting to ED with chest pain and ACS exist but none is adequately 
equipped to help clinicians to determine which patients can safely be 
discharged (Antman, 2000; Christenson, 2004).  To expedite the diagnosis and 
to safely discharge the correct low risk patient’s various strategies have been 
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employed including continuous automated ECG recording, imaging, risk 
scoring systems and the introduction of hs-cTn (Collinson, 2006; 
Hascoet,Bongard,Chabbert et al., 2012).  Despite, the presence of a range of 
diagnostic and prognostic tests with improved sensitivity and specificity; the 
number of patients discharged with the wrong diagnosis is still unacceptably 
high (Collinson, 2000b; Hascoet,Bongard,Chabbert et al., 2012).  However, 
despite these attempts at improving the triage protocol, inappropriate 
discharge and the misdiagnosis of low risk patients across the UK are 
estimated to be between 2% and 7% (Cassidy,Carroll,Cote et al., 2000; 
Wildi,Zellweger,Twerenbold et al., 2015).  This, inappropriate discharged can 
be due to a various reasons including misinterpretation of ECG finding, atypical 
presentation, limited cardiac biomarkers sensitivity and specificity and 
inexperienced clinicians (Kontos,Diercks & Kirk, 2010).  Presently the correct 
diagnosis of NSTEMI patients is still challenging and requires considerable 
resources to manage. 
The aim of this study was to investigate the diagnostic potential of IMA in 
conjunction with other various biomarkers in assessing low risk patients with 
probable AMI.  Prior to this study and to the best of my knowledge, there is no 
other studies looking at the combined diagnostic efficiencies of IMA, hs-cTnI 
or hs-cTnT in low risk patients presenting with chest pain suggestive of AMI.  
There are limited studies targeting the combined diagnostic efficiency of IMA, 
copeptin, NT-pro-BNP and H-FABP. 
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1.21 Aim of the research project 
 
The overall aim of the present study was to investigate the diagnostic potential 
of IMA assay in conjunction with other biomarkers, in assessing AMI. 
 
I. To test the diagnostic efficiency of IMA assay alone and in combination 
with the hs-cTn. 
II. To test the diagnostic efficiency of IMA assay in combination with H-
FABP, copeptin and NT-pro-BNP. 
III. To test the predictive values of IMA and various biomarkers for major 
adverse cardiac events (MACE) at 30 days. 
IV. To consider the cost benefit of introducing IMA assay alone or in 
combination with a novel biomarker or hs-cTn in an ED setting. 
V. To explore the potential implication and future use of these new 
biomarkers at a professional level. 
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Chapter 2  
Meta-analysis 
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Title: Performance of Ischemia modified-albumin assay in the diagnosis of 
acute myocardial infarction in patients presenting with chest pain suggestive 
of acute coronary syndrome  
Abstract 
 
Background: This is an update of an early Cochrane meta-analysis review 
first published 2006. Ischaemia modified-albumin (IMA®) was first thought to 
be useful biomarker for assessing cardiac ischaemia.  Patients with ischaemic 
heart disease are at risk from a future coronary event.  Clinicians therefore find 
it difficult to safely discharge patients who present to accident and emergency 
department with chest pain suggestive of ACS; but without evidence of cardiac 
necrosis or ECG changes.  We though to conduct a meta-analysis to evaluate 
IMA assay in the diagnosis of AMI in patients presenting with chest pain 
suggestive of ACS. 
Methods: The searched MEDLINE, EMBASE and Cochrane database up to 
March 2018 and used bivariable random-effect modeling to obtain summary 
parameters for diagnostic accuracy. 
Results: We identified 26 studies (n = 4295) that assessed the use of 
Ischaemia modified-albumin assay.  The sensitivity and specificity of IMA 
assay in diagnosing AMI at presentation was 77.73% (95% CI, 72.21-83.24%) 
and 72.71% (95% CI, 64.09-81.34%) respectively.  The negative predictive 
value and positive predictive value for IMA assay in diagnosing AMI at 
presentation was 80.13 (95% CI, 73.18-87.08%) and 67.91 (95% CI, 58.47-
77.39%) respectively. 
Conclusion: IMA assay used at presentation has a good sensitivity and 
negative predictive value.  However, IMA assay has a reduced specificity.  IMA 
assay optimisation is required before prime-time use. 
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2.0 Introduction 
 
In England, chest pain suggestive of acute coronary syndrome (ACS) 
represent the largest single cohort and is responsible for approximately 
237,832 admissions to the emergency department (ED) per-year (Bidmead, 
2015). 
ACS is a sudden manifestation of an acute ischaemic cardiac disease which 
can include stable angina (SA), unstable angina pectoris (UA), non-ST-
segment elevation myocardial infarction (NSTEMI) and ST-segment elevation 
myocardial infarction (STEMI).  All these diseases have a common 
pathophysiological origin in that they all manifest as a consequence of a 
sudden rupture or erosion of atherosclerotic plaque (Libby, 2001; Toutouzas & 
Stefanadis, 2006). 
Patients presenting to the ED with suspected ACS exhibit a wide range of 
prodromal symptoms these include prolonged (>20 min) anginal pain and 
reterosternal pressure or heaviness radiating to the left arm, neck or jaw 
(McSweeney,O'Sullivan,Cody et al., 2004).  These symptoms can also be 
accompanied by nausea, abdominal pain, epigastric pain; recent-onset 
indigestion and chest pain (McSweeney,Cody,O'Sullivan et al., 2003).  
Patients presenting with prodromal symptoms have a good prognosis and 
rigorous cardiac investigations (Graham,Westerhout,Kaul et al., 2008; Kloner, 
1995).  However, patients without classical prodromes or with NSTEMI are 
likely to be discharged with a high risk of developing AMI 
(Graham,Westerhout,Kaul et al., 2008).  AMI is associated with poor 
prognosis; so immediate and accurate diagnosis is important in order to allow 
appropriate treatment and care as soon as possible 
(Bhardwaj,Truong,Peacock et al., 2011). 
Currently there are a number of cardiovascular biomarkers such as troponin, 
CK-MB and myoglobin that will detect myocardial necrosis.  However, a 
reliable ischaemic biomarker is not available.  Patients with ischaemic heart 
disease are at risk from a future coronary event.  Clinicians therefore find it 
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difficult to safely discharge those patients who present to ED with chest pain 
suggestive of ACS but without clear evidence of ECG changes and/or the 
presence of cardiovascular biomarkers such as cardiac troponins.  Diagnosis 
of these cohort of patients is further complicated; because chest pain 
experienced by these patients is not always due to a cardiovascular disease; 
it can also be caused by other conditions and diseases such as pulmonary 
embolism or myocarditis.  This is not ideal because if these vulnerable patients 
are positively identified, a proven and beneficial treatment is available; these 
treatments could prevent further complications such as AMI and expensive 
procedures such as percutaneous coronary intervention (Braunwald et al., 
2002). 
Inappropriate discharge of misdiagnosed AMI patients across the UK is 
estimated to be between 2% and 7% (Cassidy, 2000; Collinson, 2000a).  The 
challenge for clinicians is to correctly identify genuine high risk from low risk 
ACS patients. Although, a number of potential ischaemic cardiovascular 
biomarkers such as heart fatty-acid binding protein have been identified, only 
ischaemia modified-albumin (IMA) has received approval by the US Food and 
Drug Administration (Bar-Or, Lau, & Winkler, 2000) and European Directive, 
Conformite Europeenne marking (CE). IMA can be indirectly measured using 
Cobalt-binding assay (Bar-Or, Lau, & Winkler, 2000; Brown,Sease,Robey et 
al., 2007; Reichlin,Hochholzer,Stelzig et al., 2000;  Collinson,Gaze,Bainbridge 
et al., 2006; Peacock,Morris,Anwaruddin et al., 2006).  The albumin-cobalt 
binding assay (IMA assay) was cleared by the American Food and Drug 
Authority (AFDA) on the basis that it would help rule-out ACS, in low to 
moderate pre-test probability conditions with negative necrotic cardiovascular 
biomarkers such as cardiac troponin and normal ECG.  The mechanism of 
albumin-cobalt binding assay methodology and characteristics has been 
described previously (Bar-or D, 2001; Sinha,Roy,Gaze et al., 2004). 
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2.1 Ischaemia modified-albumin 
 
Human albumin (66.7 KDa) is a non-glycosylated single polypeptide chain 
containing 585 amino acids (AA).  The most abundant protein in the human 
body (35 to 50 g/l) and exert a range of physiological and pharmacological 
functions including transport of small molecules such drugs, fatty acids, and 
bilirubin and act as an antioxidant (Evans, 2002; Rondeau & Bourdon, 2011).  
Human albumin (HA) occupies 50 % of plasma protein and regulates oncotic 
pressure.  In physiological condition HA exert is buffering capability through its 
16 histidine imidazole residues (Caironi and Gattinoni 2009;Colombo et al. 
2012a;Pavone et al. 2010). 
The circulation of albumin between the interstitial spaces the intravascular 
environment, the lymph drainage and the blood stream is a dynamic and 
continuous process which ends up causing albumin to degraded (10-12 g/24 
h) ubiquitously with rate equal to that of it synthesis (Gattinoni, Carlesso, & 
Caironi, 2005).  However, in disease state for example during cardiac 
ischaemia albumin is subject to free radicals and reactive oxygen species 
(ROS) attack; which in turn damages its integrity to carry certain function such 
as sequestering Cu (II) ions through its N-terminus and inhibiting the formation 
of ROS.  Modification of the N-terminal through acetylation or deletion of one 
or more residues makes cobalt or copper binding impossible. This damaged 
albumin is known as ischaemia modified-albumin. 
Bar-or et al. observed that IMA concentration is elevated in patients admitted 
to ED with ACS compared to normal healthy individual.  Subsequently a pilot 
study of 139 patients attending ED department with acute chest pain, found 
that 99 patients with evidence of myocardial ischaemia had significantly 
elevated levels of IMA (mean ABSU ± SD; 0.52 ± 0.09) compared to 40 
patients with no evidence of ischaemia (mean ABSU ± SD; 0.31 ± 0.09, p < 
0.0001)(Bar-or D, 2001). 
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2.3 Methods 
2.3.1 Search strategy 
 
Medline (PubMed and Ovid), EMBASE and Cochrane database searches 
were conducted using combinations of the key trigger words and medical 
subject headings (MeSH) terms in the title only and title and/or abstract search 
limit fields.  Both English and American-English spellings were adopted to 
broaden the search strategy.  The search included all years between 2000 and 
2018; paper excluded if used in previous meta-analysis in order to allow direct 
study comparison.  All titles and abstracts were screened to determine 
relevance to the research question ‘what is the diagnostic efficiency of 
ischaemia modified-albumin levels in patients with AMI’.  Research letters, 
editorials and reviews were automatically excluded.  Other potentially relevant 
studies not highlighted by the Medline and EMBASE searches were 
investigated by hand searching the reference lists of the papers and published 
review articles identified. 
Medline and PubMed were used to acquire all IMA data; all the data were 
reviewed according to the Cochrane Collaboration Handbook for meta-
analysis.  Included studies were required to satisfy the inclusion criteria table 
8. 
Titles and abstracts were screened by me and independently by 
cardiovascular research scientist to ensure that they meet the inclusion 
criteria.  Agreement was estimated using kappa statistic (К = 92 CI%, 86 to 
98%) p = 0.001 indicating significant agreement according to Koch and Landis 
(Liberati,Altman,Tetzlaff et al., 2009).  Full texts of the selected articles were 
appraised by me. 
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Table 8: Meta-analysis inclusion criteria 
Meta-analysis inclusion criteria 
 
1 
 
IMA must be assessed for low risk patients presenting to ED with 
chest pain suggestive of ACS 
2 IMA must be measured on admission 
3 Study entry criteria must clearly be defined 
4 Ischemia modified-albumin must be measured by the automated 
Roche Mira Cobas plus analyzer or ACB test 
5 Ischemia modified-albumin must be measured according to the 
manufacturers recommendation and using albumin-cobalt binding 
assay (Ischemia technologies, Denver, CO) 
7 Study end points were clearly defined 
8 Adverse cardiac events were well documented 
9 Ethical approval was obtained 
 
2.3.2 Data analysis and meta-analysis statistics 
 
The diagnostic sensitivity, specificity, negative predictive value (NPV) and 
positive predictive values (PPV) where reported in the papers, were 
abstracted.  Sensitivity and specificity In the majority of cases, the dOR was 
calculated by construction of two-by-two contingency tables (Appendix 4).  
Patients were first dichotomised according to outcome (presence or absence 
of all cause of ACS during follow-up).  Each group was then dichotomised into 
those above (IMA positive) or below (IMA negative) the clinical cut-off quoted 
in the paper by the authors.  The sensitivity and specificity were calculated with 
construction of the 95% confidence interval (95% CI).  
All data was transferred from the data collection forms to the Comprehensive 
meta-analysis statistical package (version 2.2.057; Biostat, New Jersey, USA).  
Using the sort facility, studies were listed by year of publication then 
alphabetically by first authors surname for each analysis and sub-group 
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analysis.  The meta-analysis was performed to pool the data and calculate the 
overall weighted of sensitivity, specificity, NPV and PPV from the individual 
study. 
The random effects model calculated according to the methods of 
DerSimonian and Laird to incorporate between-study variability (DerSimonian 
& Laird, 1986)(8) was used.  This allows for more balanced study weights 
where large studies are assigned less relative weight and small studies are 
assigned more relative weight.  Forest plots were constructed for each meta-
analysis to display individual study and overall sensitivity, specificity, NPV, 
PPV and 95% confidence intervals.  
The presence of publication bias was formally tested by construction of Funnel 
plots of log ratio versus standard error.  Quantitative analysis was performed 
formally using Egger’s regression asymmetry test (Irwig,Tosteson,Gatsonis et 
al., 1994) and Begg & Mazumdar test for Kendall’s tau (Kendall, 1938).  
Assessment of heterogeneity was examined by the Q-test and I2 statistic 
(Christeinsen, 2005).  A value of Q was deemed significant if p = < 0.10 and I2 
values of 25, 50 and 75% were deemed small medium and large proportions 
respectively.  
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2.3.3 Results literature search 
 
The total searched yield 89 potentially relevant articles from which Medline 
produced 48 and EMBASE 41.  Unable to acquire 4 articles, 17 articles has 
data missing e.g. 95% confidence interval for NPV and PPV which is essential 
for meta-analysis.  One article used inappropriate STEMI patients.  The final 
articles included in the meta-analysis were 26 with complete data (Figure 13).  
Full list of articles considered are in appendix 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Selection of studies of Ischemia modified-albumin to rule out 
patients presenting to accident and emergency department with chest pain 
suggestive of acute coronary syndrome (Flow diagram adapted from PRISMA 
2009). 
Data base searching 
PubMed (n = 89) 
Potentially relevant articles 
(n = 27) 
Full text article assessed for 
eligibility 
(n = 27) 
Irrelevant records excluded (n = 
41) 
Unable to acquire 4 
17 articles had data missing 
Full-text articles excluded (n = 1) 
STEMI population used (n = 1) 
 
 
 
Studies included in 
quantitative synthesis 
(Meta-analysis) 
 (n = 26) 
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2.3.4 Study population and definition of outcome 
 
The final selected studies enrolled participants who presented to the ED with 
chest pain suggestive of AMI.  All the patients who presented to ED with chest 
pain were subject to local triage protocol which includes clinical assessment, 
12-lead electrocardiogram and physical examination.  Cardiac troponin levels 
and IMA were measured at presentation.  The final diagnosis was 
independently confirmed from medical record. 
AMI was defined in accordance with 2007 ESC/ACCF/AHA guidelines(Hamm, 
2011).  In a clinical scenario acute AM6I describes the combination of necrosis 
of cardiomyocyte and the presence of acute myocardial ischaemia (Thygesen 
et al., 2012).  To meet the current diagnostic criteria for AMI at least the 
clinician has to satisfy that a cardiovascular biomarker (preferably high 
sensitivity troponin I or T) is increased or decreased with at least one value 
above the 99th percentile of the upper reference limit and at least one of the 
followings: 
1. Symptom of ischaemia. 
2. New or presumed new significant ST-T wave changes or left bundle 
branch block on 12-lead ECG. 
3. Development of pathological Q wave on ECG. 
4. Imaging evidence of new or presumed new loss of viable myocardium 
or regional wall motion abnormality. 
5. Intracoronary thrombus detected on angiography or autopsy. 
 
Results 
 
The program lists the results of the individual studies included in the meta-
analysis: the estimate, its standard error and 95% confidence interval (CI).  
The pooled value for the estimate, with 95% CI, is given both for the fixed 
effects model and the Random effects model.  
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Random effects model 
 
Under the random effects model (DerSimonian and Laird) the true effects in 
the studies are assumed to vary between studies and the summary effect is 
the weighted average of the effects reported in the different studies (Borenstein 
M, 2009).  
The random effects model will tend to give a more conservative estimate (i.e. 
with wider confidence interval), but the results from the two models usually 
agree when there is no heterogeneity.  When heterogeneity is present the 
random effects model should be the preferred model.  
 
Forest plot 
 
The Forest plot shows the estimate (with 95% CI) found in the different studies 
included in the meta-analysis, and the overall effect with 95% CI.  
The random effects model will tend to give a more conservative estimate (i.e. 
with wider confidence interval), but the results from the two models usually 
agree where there is no heterogeneity.  If the test of heterogeneity is 
statistically significant (P < 0.05), then more emphasis should be placed on the 
random effects model (Petrie,Bulman & Osborn, 2003).  
When the option Marker size relative to study weight was selected, then the 
size of the markers that represent the effects of the studies vary in size 
according to the weights assigned to the different studies. 
When the option Diamonds for pooled effects was selected then the pooled 
effects are represented using a diamond. The location of the diamond 
represents the estimated effect size and the width of the diamond reflects the 
precision of the estimate. 
 
Heterogeneity 
Cohran's Q 
Q is the weighted sum of squares on a standardized scale.  It is reported with 
a P value with low P-values indicating presence of heterogeneity.  This test 
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however is known to have low power to detect heterogeneity and it is 
suggested to use a value of 0.10 as a cut-off for significance 
(Higgins,Thompson,Deeks et al., 2003).  Conversely, Q has too much power 
as a test of heterogeneity if the number of studies is large.  
I
2
 statistic 
I
2
 is the percentage of observed total variation across studies that are due to 
real heterogeneity rather than chance.  It is calculated as 
I
2
 = 100% x (Q - df)/Q, where Q is Cochran's heterogeneity statistic and df the 
degrees of freedom. Negative values of I
2
 are put equal to zero so that I
2
 lies 
between 0% and 100%.  A value of 0% indicates no observed heterogeneity, 
and larger values show increasing heterogeneity (Higgins,Thompson,Deeks et 
al., 2003).  
 
Funnel Plot 
 
A funnel plot is a graphical tool for detecting bias in meta-analysis (Davey 
Smith,Egger & Phillips, 1997).  In a funnel plot treatment effect is plotted on 
the horizontal axis and MedCalc plots the standard error on the vertical axis 
(Sterne & Egger, 2001).  The vertical line represents the summary estimated 
derived using fixed-effect meta-analysis. 
 
Two diagonal lines represent (pseudo) 95% confidence limits (effect ± 1.96 SE) 
around the summary effect for each standard error on the vertical axis. These 
show the expected distribution of studies in the absence of heterogeneity or of 
selection bias.  In the absence of heterogeneity, 95% of the studies should lie 
within the funnel defined by these diagonal lines. 
 
Publication bias results in asymmetry of the funnel plot.  If publication bias is 
present, the smaller studies will show the larger effects.  The funnel plot may 
not always be a reliable tool, in particular when the number of studies included 
in the analysis is small (Sterne,Sutton,Ioannidis et al., 2011) . 
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Table 9: Meta-analysis results summary 
Point variable Heterogenicity Rank correlation Regression test 
 Overall effect 
(95% CI) 
Q 
(p value) 
df I2 
(95%CI) 
Kendal’s 
Tau 
P 
value 
Eggers regression 
(95% CI) 
P 
value 
Sensitivity 77.73 
(72.21 to 83.24) 
14414.6 
(< 0.0001) 
25 99.83 
(99.81 to 99.84) 
-0.086 0.53 -8.73 
(-23.0 to 5.5) 
0.219 
Specificity 72.71 
(64.09 to 81.34) 
39072.6 
(< 0.0001) 
25 99.94 
(99.93 to 99.94) 
-0.227 0.05 -2.66 
(-24.3 to 19.08) 
0.401 
NPV 80.13 
(73.18 to 87.08) 
17928.8 
(<0.0001) 
23 99.87 
(99.86 to 99.88) 
-0.119 0.41 -1.32 
(-19.61 to 16.9) 
0.882 
PPV 67.92 
(58.47 to 77.39) 
23232.00 
(<0.0001) 
20 99.91 
(99.91 to 99.92) 
-0.2 0.204 7.67 
(-17.10 to 32.45) 
0.524 
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2.3.5 Overall IMA assay sensitivity 
 
 
 
 
Figure 14: Over all IMA assay sensitivity 77.73% (95% CI, 72.21 to 83.24%). 
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Figure 15: Funnel plots shows publication bias in the article included in the 
meta-analysis.  The data is not well distributed in the funnel shaped area the 
asymmetry appear to suggest a publication bias.  Increasing heterogeneity I2 
99.9; this bias may due to poor methodologies or analysis or study design. The 
sensitivity 77.73% (95% CI, 72.21 to 83.24%), specificity 72.71% (95% CI, 
64.09 to 81.34%), NPV 80.13% (95% CI, 73.18-87.08%) and PPV 67.91% 
(95% CI, 58.47-77.39%) for IMA assay in diagnosing AMI at presentation. 
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2.3.6 Overall IMA assay specificity 
 
 
Figure 16: Over all IMA assay specificity 72.71% (95% CI, 64.09 to 81.34%). 
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Figure 17: Funnel plots shows publication bias in the article included in the meta-
analysis.  The data is not well distributed in the funnel shaped area the asymmetry 
appear to suggest a publication bias.  Increasing heterogeneity I2 99.9; this bias may 
due to poor methodologies or analysis or study design.  The sensitivity 77.73% (95% 
CI, 72.21 to 83.24%), specificity 72.71% (95% CI, 64.09 to 81.34%), NPV 80.13% 
(95% CI, 73.18-87.08%) and PPV 67.91% (95% CI, 58.47-77.39%) for IMA assay in 
diagnosing AMI at presentation 
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2.3.7 Overall IMA assay negative predictive value 
 
 
Figure 18: Over all IMA assay negative predictive value 80.13% (95% CI, 
73.18 to 87.08%). 
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Figure 19: Funnel plots shows publication bias in the article included in the 
meta-analysis.  The data is not well distributed in the funnel shaped area the 
asymmetry appear to suggest a publication bias.  Increasing heterogeneity I2 
99.9; this bias may due to poor methodologies or analysis or study design. The 
sensitivity 77.73% (95% CI, 72.21 to 83.24%), specificity 72.71% (95% CI, 
64.09 to 81.34%), NPV 80.13% (95% CI, 73.18-87.08%) and PPV 67.91% 
(95% CI, 58.47-77.39%) for IMA assay in diagnosing AMI at presentation.  
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2.3.8 Overall IMA assay positive predictive value 
 
 
Figure 20: Overall IMA assay positive predictive value 67.92 (95% CI, 58.47 
to 77.39). 
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Figure 21: Funnel plots shows publication bias in the article included in the 
meta-analysis.  The data is not well distributed in the funnel shaped area the 
asymmetry appear to suggest a publication bias.  Increasing heterogeneity I2 
99.9; this bias may due to poor methodologies or analysis or study design. The 
sensitivity 77.73% (95% CI, 72.21 to 83.24%), specificity 72.71% (95% CI, 
64.09 to 81.34%), NPV 80.13% (95% CI, 73.18-87.08%) and PPV 67.91% 
(95% CI, 58.47-77.39%) for IMA assay in diagnosing AMI at presentation 
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2.4 Discussion 
 
There is no gold standard for detecting cardiac ischaemia, most studies that 
evaluate the utility of IMA assay has used cardiac troponin I or T, ECG, 
patients’ history and patient’s symptom at presentation as an outcome 
measure of ACS (Sinha, Roy, Gaze, Collinson, & Kaski, 2004b).  Christenson 
et al. conducted a multicenter study involving 256 ACS patients, in which they 
examined cardiac troponin I from samples taken at admission and 6 to 24 
hours after admission, and used it as an outcome measure; they found that 
IMA has a negative predictive value (NPV) of 96% and a positive predictive 
value (PPV) of 33% (Christenson et al., 2001). 
Our meta-analysis (n = 4259) shows that the use of IMA assay to diagnose 
AMI at presentation to the ED resulted in good sensitivity and a good NPV.  
The summary sensitivity and specificity of IMA assay in diagnosing AMI at 
presentation was 77.73% (95% CI, 72.21-83.24%) and 72.71% (95% CI, 
64.09-81.34%) respectively.  The summary negative predictive value and 
positive predictive value IMA assay was 80.13% (95% CI, 73.18-87.08%) and 
67.91% (95% CI, 58.47-77.39%) respectively.  the previous meta-analysis 
found that IMA values when used alone has a 91% NPV and this increases to 
97% when used with in combination with negative cTnT and normal or non-
conclusive ECG (Peacock et al., 2006). 
IMA levels change significantly (lower) after exercise-leg induced ischaemia in 
patients with peripheral vascular diseases (Roy et al., 2004).  In addition, a 
study looking at healthy subjects also found that IMA levels decrease 
immediately after exercise and peak after 24 to 48 hours (Bhagavan et al., 
2003).  This observed interference with IMA concentration during exercise is 
believed to be caused by the presence of lactic acid (Zapico-Muniz et al., 
2004). 
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The luck of IMA specificity and the potential increase of the false-positives test 
rate when used with other cardiovascular biomarkers and is particularly 
elevated in various diseases and conditions (table 10) might prove 
problematic.  This low specificity is believed to be attributed to the fact that IMA 
assay may be capable of detecting subclinical ischaemia, which is not detected 
by the current conventional methods (Keating et al., 2006) 
 
Table 10: Pathologies associated with increases in ischaemia modified-
albumin concentration. 
1. Cerebrovascular-ischaemic stroke, subarachnoid and intracranial 
haemorrhage 
2. Peripheral vascular disease-arterial occlusion, deep vein 
thrombosis, mesenteric infarct 
3. End-stage renal disease 
4. Advanced liver cirrhosis 
5. Acute infection 
6. Malignancies 
7. Systemic sclerosis 
8. Intrauterine disorders-normal pregnancies, endometriosis, 
complicated deliveries. 
 
 
Nevertheless, IMA’s negative predictive value may be of value especially if we 
can exclude ACS patients (Roy & Kaski, 2000;  Christenson,Duh,Sanhai et al., 
2001. 
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2.5 Limitations 
 
The use of various methods, analyzers and different clinical cut-off points 
associated with IMA assay prevent an accurate meta-analysis.  In addition, the 
use of previous troponin generations; this will eventually under estimate the 
sensitivity and specificity of IMA assay.  Relevant studies in non-English 
speaking word were excluded.  All studies used in this meta-analysis tested 
the diagnostic performance of IMA on the assumption of possible ACS.  This 
is not appropriate comparison because currently no standarised test part from 
ECG measures cardiac ischaemia.  The finding in this meta-analysis cannot 
be generalised. 
 
2.6 Future considerations 
 
Elevated IMA concentrations in non-cardiac and healthy subject warrant 
further studies into the levels of IMA in different clinical setting including the 
establishment of the optimal level of IMA in various organs during an ischaemic 
state (Kim et al., 2008b).  Furthermore, IMA assay is needed to be compared 
to the current high sensitivity troponin I, because recent study suggested that 
highly sensitive troponin I may be used to exclude patients with AMI within 1 
or 2 hours (Charpentier & Chenevier-Gobeaux, 2016).  The reliability of IMA 
evaluation in real clinical setting including the cut-off point and its incremental 
value, additional cost to the healthcare system is still to be established.  
Nevertheless, IMA evaluation is still worth developing and improving, because 
currently IMA measurement is the only test available and licensed for the 
diagnosis of patients suspected of cardiac ischaemia.  IMA assay in its current 
form is not reliable enough because of its low specificity. 
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Chapter 3  
Material and methods 
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3.0 Overview and study design 
 
The main aim of this thesis is to investigate the diagnostic potential of IMA 
assay in conjunction with other cardiac and novel biomarkers in assessing 
AMI.  The IMA study is also an opportunity to assess the overall usefulness of 
IMA and a number of novel biomarkers in improving and contributing to the 
existing information when assessing AMI in ED environment. 
 
3.1 Population 
 
The present investigations in this thesis are a sub-study within a multicenter 
pragmatic randomised control trial called the Randomised Assessment of 
Treatment using Panel Assay of Cardiac Biomarkers (RATPAC).  RATPAC 
trial is a multicenter pragmatic randomised control trial (RCT), primarily 
concerned with the economic evaluation of point-of-care testing (POCT) of 
cardiac biomarker panel in the management of patients with suspected, but 
not proven AMI (Goodacre,Bradburn,Cross et al., 2011; Goodacre, 2011). 
The hospitals participating (table 11) in the study were Barnesley District 
General Hospital, Derriford Hospital in Plymouth, Leeds General Infirmary, 
Leicester Royal Infirmary, Edinburgh Royal Infirmary and Frenchay Hospital in 
Bristol.  These participating hospitals were selected to include a range of 
different setting, thus providing a current NHS practice and a realistic variation 
in facilities available to UK patients presenting with chest pain suggestive of 
ACS. 
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Table 11: Characteristics of the participating centers 
Hospital Annual ED 
attendances: 
 1 April 2008 
to 31 March 
2009 
No. of 
acute 
medical 
beds* 
ED 
facilities 
On-site cardiology 
services 
Barnesley 
Derriford 
Leeds 
Leicester 
Edinburgh 
Frenchay 
71,678 
85,341 
109,362 
156,053 
105,378 
62,823 
462 
240 
491 
290 
843 
461 
- 
CDU 
CDU 
- 
- 
CDU 
CCU, rapid access clinic 
CCU, angioplasty, cardiac 
surgery, rapid access clinic 
CCU, angioplasty, cardiac 
surgery, rapid access clinic 
CCU, angioplasty, cardiac 
surgery, rapid access clinic 
CCU, angioplasty, cardiac 
surgery, rapid access clinic 
CCU, angioplasty 
CCU = coronary care unit.  CDU = clinical decision unit.  * = excluding escalation beds 
 
Potential participants were all recruited to the trial; and then excluded if they 
meet any of the exclusion criteria (table 12).  Once the clinical staff identified 
and recruited the eligible patients these patients were then randomised into 
either those receiving a diagnostic assessment using POCT biochemical 
biomarkers panel (CK-MB (mass), myoglobin and troponin I on admission and 
90 min after admission or those receiving standard laboratory based cardiac 
biomarker testing according to the protocol of the participating hospitals.  
Participating patients, career and clinicians were not blinded in the RATPAC 
study and day-to-day management of patients was left entirely to the discretion 
of clinicians. 
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3.2 Recruitment 
 
The research nurses or participating hospital staff screened all the patients 
presenting with chest pain and excluded those that satisfied the exclusion 
criteria.  The research nurses or ED staff explained the trial to the potential 
recruits and obtained their written consent.  Once the participants consented 
to the trial they were randomised into a single randomisation sequence.  The 
randomisation sequence was generated by the Clinical Trials Unit and 
accessed through a secure website to either receive the standard care or 
POCT. 
 
3.3 The objectives of the Randomised Assessment of 
Treatment using Panel Assay of Cardiac Biomarkers 
 
The RATPAC trial was designed to determine whether POCT in an ED setting 
could replace the current standard of care in terms of day-to-day management 
of patients presenting with chest pain suggestive of AMI.  To achieve this 
objective the RATPAC trial evaluated the following: the proportion of patients 
successfully discharged home within 4 h after ED assessment, health utility 
and satisfaction with care, the use of coronary care beds and cardiac 
treatments.  They also assessed the subsequent re-attendance at and/or re-
admission to hospital, major adverse cardiac events include death, non-fatal 
AMI, life-threatening arrhythmia, emergency revascularisation or 
hospitalisation for AMI, and social care cost.  Although, the decision to 
discharge or admit patients was based on the POCT protocol; the final decision 
in terms of care pathway was entirely left to the attending clinicians. 
Furthermore, the RATPAC trial also allowed for secondary analysis of data 
with the aim to include TIMI and GRACE.  In addition, the RATPAC trial had 
made a provision to create a bank of well characterised samples to be used 
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for research such as the assessment of novel cardiovascular biomarkers 
including IMA, copeptin and H-FABP (Collinson,Gaze,Thokala et al., 2013). 
 
3.4 Data management 
 
Baseline demographic data and the final outcome were recorded including 
blood results, clinical details, and adverse events up to a month.  Surviving 
participants were mailed a questionnaire at one month, measuring satisfaction 
with care, health utility, and social care resources used. 
Trial data from follow-up (30 days) was systematically recorded by authorised 
personnel and entered into a fully audited online secure data base.  Data 
management including a procedure for dealing with errors and quality control 
issues were dealt with in accordance with Sheffield Clinical Trials Research 
Unit (CTRU) standard operating procedures.  The final classification of patients 
with AMI and major adverse cardiac events was blindly conducted by an 
independent expert cardiologist. 
 
3.5 Ethical consideration 
 
Ethical approval for the RATPAC was granted by Leeds East Research Ethics 
Committee (07/Q12506/22) and the subsequent reviews were conducted by 
the local participating hospitals ethics committee.  The RATPAC trial complied 
with the Declaration of Helsinki and the Research Council Guidelines for Good 
Clinical Practice in Clinical Trial.  The trial was registered with the International 
Clinical Trials Authority and sponsored by the University of Sheffield. 
Potential participants were required to provide written consent, however in an 
emergency setting with limited time to consider trial information and its 
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potential benefit clinicians made no attempt to pressurise patients to 
participate in this study. 
Samples required for the successful trial were made anonymous by assigning 
a unique prime number known as an identifier.  Pre-prepared test packs were 
made available to the participating staff.  These test packs contained the 
following: four primary sample tubes comprising two lithium-heparin for POCT 
and two serum separator gel tubes for the standard laboratory arm and for 
bank (Becton Dickinson, Oxford, UK).  In addition, the serum samples were 
allowed to clot for 30 min at room temperature, centrifuged (5000 rpm) for 10 
min and decanted into two labeled (with unique identifier) long storage tubes 
and then frozen at -20 0C before transfer to St George’s Healthcare NHS Trust, 
Tooting, London, UK for further analysis.  At 90 min after admission the 
process described for sample handling at admission was repeated. 
 
3.6 Randomised Assessment of Treatment using Panel Assay 
of Cardiac Biomarkers trial 
 
The RATPAC study was primarily concerned with the economic evaluation of 
POCT of a cardiac biomarker panel comprising of myoglobin, CK-MB and 
cardiac cTnI for the management of low risk patients with chest pain.  Potential 
participants were excluded if they met any of the criteria given in table 12. 
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Table 12: Patient exclusion criteria 
• ECG changes for myocardial ischaemia (> 1 mm ST deviation or 
> 3 mm inverted T wave) 
• High risk ACS 
• Known coronary heart disease. 
• Recurrent episodes of cardiac type pain.  
• Confirmed or suspected serious non- cardiac pathology (e.g. 
pulmonary, embolus) 
• Co-morbidity or social problems that require hospital admission 
• Obvious non-cardiac cause (e.g. pneumothorax or muscular pain 
more than 12 h since their most significant previous episode of 
pain. 
• Participants who are unable to understand trial information or did 
not consent 
 
Once the clinical staff had identified, obtained written consent and recruited 
the eligible patients; they were then randomised into receiving either: 
1) Diagnostic assessment using POCT cardiac biomarker panel including 
CK-MB mass, myoglobin and cTnI, on admission (0 min) and at 90 min 
after admission. 
2) Standard laboratory based diagnostic assessment according to the local 
protocol of the participating hospitals. 
 
Participating clinicians were not blinded to the results and day-to-day 
management of patients was left entirely to the discretion of clinicians.  
Patient’s recruitment was prospective; although, the present study and other 
biomarkers studies were retrospective. 
The RATPAC cohort were assessed clinically an admission, fully characterised 
and further followed up at 30 days.  Retrospective analysis of biomarkers in 
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this thesis is a component of the RATPAC study allowing the original trial 
criteria to be transferred to the present study (Bhandari, 2006). 
 
3.7 Analytical methods 
 
The biochemical analyses for the standard arm were conducted in accordance 
with the local participating hospital trusts protocols and the local equipment.  
However, the Stratus® CS Analyser for POCT was used by all the participating 
trusts. 
The POCT for cardiac biomarker panel included CK-MB mass, myoglobin and 
cTnI; these multiple cardiac biomarkers were measured by trained ED staff 
using Stratus® CS analyser Siemens Healthcare Diagnostic (Camberley, UK) 
on admission and ninety minutes after admission. 
 
3.8 Point-of-care testing assays across all sites. 
 
The Stratus® CS was used to measure the following cardiac biomarkers, 
myoglobin, CK-MB mass and cTnI.  The analytical characteristics of the assays 
for each analyte are summarised in table 13. 
 
Table 13: Point-of-care testing analytical characteristics. 
Analyte Detection 
limit 
Analytical 
range 
Inter-assay 
CV% 
Reference 
interval  
Myoglobin 1 μg/L 1-900 μg/L 1.9-12.7 (56-
308 μg/L) 
21-98 μg/L 
(males)* 
19-56 μg/L 
(females)* 
20-82 μg/L 
(combined)* 
CK-MB 0.3 μg/L 0.3-150 μg/L 0.15-1.27 (3.7-
39.3 μg/L) 
0.3-3.5 μg/L* 
 
 
Troponin I 0.03 μg/L 0.03-50 μg/L 4.0-8.2 (0.067-
0.344 μg/L) 
0.07 μg/L (99th 
percentile) † 
 
* = 95% reference interval.  † = 99th percentile of the assay. 
127 
 
3.9 The present study secondary analysis 
 
The high sensitivity cardiac troponin, myoglobin, copeptin, IMA and H-FABP 
were analysed at St George’s Healthcare NHS Trust, manufacturer’s 
recommendations including 99th percentiles and equipment types.  The 
analytical characteristics of the assays for each analyte are summarised in 
Table 14 and 15.  In 2014 IMA evaluation study (appendix 3 for supplementary 
data) was conducted by me at St Georges Healthcare NHS trust.  London.  
Cobas Mira plus analyser was used the determine IMA concentrations for both 
the participant and reference range study participants.  Sample selection and 
analysis for reference range suitability was entirely conducted by me at St 
Georges Healthcare NHS. London.  Secondary outcome including the 
estimation of h-FABP, copeptin, hs-cTn and NT-pro-BNP were also analysed 
at St Georges Healthcare NHS, by separate team under the supervision of Dr 
David Gaze.  Data analysis was conducted with the assistance of Dr David 
Gaze using Analyst-it software.  My role also consists of categorising current 
project data in excel in accordance with project objectives i.e. matching 
complete paired samples, demographic and MACE and Dr Gaze role was to 
compute it on my behalf in analysed-it software and handover the graphs and 
data for analysis and interpretation by me.  The statistical requirements such 
as ROC, sensitivity, specificity, NPV, PPV and the required combination with 
different biomarkers for the current project were also specified by me.  Current 
project health economics was entirely conducted by me.   
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Table 14: Analytical characteristics of myoglobin, heart fatty-acid binding protein, IMA, NT-pro-BNP and copeptin. 
Analyte Detection 
limit 
Upper 
limit 
Analytical 
range 
Coefficient of variance 
(CV %) 
Percentile 
 
Myoglobin 
 
1.8 mg/L 
 
700 mg/L 
 
- 
 
 
 
8.8% at 83 mg/L 
9.4% at 119 mg/L 
9.5% at 125.9 mg/L 
 
 
66 mg/L (97.5th 
percentile) 
 
H-FABP 1.5 mg/L 100 mg/L - 9.1% at 3.1 mg/L 
7.5% at 17.6 mg/L 
9.8% at 44.1 mg/L 
 
2.5 mg/L (95th percentile) 
3.0 mg/L (99th percentile) 
 
 
NT-pro-BNP 
 
20 ng/L  35,000 ng/L 4.0-5.0 (32.1-40.9 ng/L) Not applicable 
Copeptin 
 
 
 
 
 
IMA 
4.8 pmol/L 
 
 
 
 
 
7 KU/L 
 
- 
 
 
 
 
 
211 KU/L 
 
4.8-500 
pmol/L 
 
 
 
 
7-211 KU/L 
 
12-17% at 20-50 pmol/L 
6% above 50 pmol/L 
 
 
 
5.09% at 56.67 to 66.57 
kU/L 
3.05% at 147.17 to 158.03 
kU/L 
17.4 pmol/L (97.5th 
percentile) 
19.1 pmol/L (Males) 
(97.5th percentile) 
12.9 pmol/L (Females) 
(97.5th percentile) 
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Table 15: Analytical characteristics of cTn according to manufacturers, in parentheses are the decision limit for diagnosis 
of AMI 
 
Analyte 
 
Detection 
limit 
 
Upper 
limit 
 
The 
claimed 
CV% 
 
99th percentile 
Participating 
hospitals 
& 
decision limit for diagnosis of AMI 
 
Analytical 
platform 
 
Roche® 
cTnT 
 
 
3 ng/L 
 
10,000 
ng/L 
 
13 ng/L 
 
 
14 ng/L 
 
Plymouth Derriford 
(20 ng/L) 
 
Elecsys® 
2010 
system 
Siemens® 
TnI 
 
6 ng/L 50,000 
ng/L 
30 ng/L 40 ng/L Barnesley (200 ng/L), Leeds (50 
ng/L) and Leicester (60 ng/L) 
 
ADVIA 
Centaur®XP 
system 
Beckman® 
AccuTnI 
 
 
Abbott® 
cTnI 
1 ng/L 
 
 
 
10 ng/L 
100,000 
ng/L 
 
 
50,000 
ng/L 
60 ng/L 
 
 
 
32 ng/L 
40 ng/L 
 
 
 
12 ng/L 
Bristol Frenchay 
(60 ng/L) 
 
 
Edinburgh 
(50 ng/L) 
 
Access 2 
system® 
 
 
 
Architect 
i2000SR 
system® 
 
CV% = Coefficient of variance 
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3.10 Core laboratory assays for the secondary objectives 
 
As part of the RATPAC study secondary objectives, hs-cTnI, hs-cTnT, 
copeptin, NT-pro-BNP and H-FABP were evaluated and described by the 
RATPAC-Contemporary Biomarker evaluation (RATPAC-CBE) team 
(Collinson, Gaze, Thokala, & Goodacre, 2013).  The analytical characteristics 
of IMA, NT-pro-BNP, H-FABP and copeptin are summarised in table 14. 
3.11 Analytical characteristics 
 
The measurements of myoglobin, CK-MB isoform mass, hs-cTn, copeptin, H-
FABP, NT-pro-BNP and IMA were performed according to manufacturer’s 
specification and standardised protocols.  The evaluation of hs-cTnI was 
performed using Siemens ADVIA Centaur® XP system, Abbott ARCHITECT 
stat i2000SR System® and Beckman-Coulter Access® 2 system; whereas, hs-
cTnT concentration was determined using Roche Diagnostics Elecsys® 2010 
System.  Although, most of these systems measure the same analyte; 
differences in detection mode, and assay protocol exist between 
manufacturers.  Thus, each analyte detection method will be illustrated 
individually. 
3.12 Brief description of the principle of sandwich 
immunoassay 
 
Quantification of myoglobin, CK-MB mass, hs-cTnI, hs-cTnT, copeptin and NT-
pro-BNP is based on a sandwich immunoassay (Figure 22).  Sandwich type 
immunoassay uses a format of a pair of matched high-affinity monoclonal 
antibodies (Abs) with the appropriate label usually an enzyme such as 
streptavidin and biotin.  This pair of matched high-affinity monoclonal Abs will 
usually consist of the primary Abs and its role is to bind to the antigen (Ags) 
for example CK-MB.  The secondary Abs and its role is to lock the Ags to from 
a complex (sandwich) hence the use of term sandwich immunoassay.  
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Secondary antibodies are usually labeled with an excitable visible label that 
can be measured (Figure 22). 
 
 
Magnetic beads
Primary antibody
Target antigen
Magnetic support
Substrate
Product
Signal
Secondary antibody
 
 
Figure 22: Principle of sandwich immunoassay.  Primary anti-antibody labelled 
with a magnetic bead is left to bind to the target antigen.  After incubation and 
wash the secondary enzyme labelled anti-antibody is added and allowed to 
form the immune-complex or sandwich.  After incubation and washing to 
remove non-specific proteins the immune-complex is left to interact with a 
substrate and the signal emitted is proportional to the antigen concentration. 
 
3.13 Evidence Cardiac Array® measured on the Evidence 
Investigator™ 
 
The analytical measurements of H-FABP, CK-MB mass and myoglobin were 
performed using the Evidence Cardiac Array® measured on the Evidence 
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Investigator™ (Randox Laboratories, Crumlin, UK).  Evidence investigator™ 
allows the simultaneous quantification of multiple analyte from a single sample.  
The analytical characteristics are summarised in table 14.  Evidence 
investigator™ quantification of H-FABP, CK-MB and myoglobin is based on 
sandwich chemiluminescent immunoassay.  Evidence investigator™ and 
biochip technology is based on a solid phase ceramic chip containing 25 
discrete test regions containing immobilised antibodies specific to H-FABP, 
CK-MB and myoglobin (Figure 23). 
Discrete test region 
on biochip surface
Labelled antibody
Antigen
Capture antibody
 
Figure 23: Biochip carrier allows the analysis of 9 patients simultaneously.  
Each biochip carrier is coated with capture agent which is usually an anti-
antibody.  The analyte repersents the antigen of interest, for example CK-MB.  
After incubation and washing stages the labelled secondary anti-antibody is 
added and allowed to incubate.  The final step involves a wash and the addition 
of the substrates; the light emitted is proportional to the concentration of the 
antigen. 
  
133 
 
3.13.1 Assay protocol 
 
Patient serum sample is diluted and 60 μL with unknown H-FABP, CK-MB and 
myoglobin is mixed, and transferred into the appropriate biochip wells (coated 
with the appropriate antibody) and allowed to incubate at 37 0C for 30 min.  
The biochip wells are washed 4 times with tris buffered saline to remove non-
specific unbound proteins.  Following the removal of the unbound proteins, 300 
μL of enzyme horseradish peroxidase conjugate antibody is added to each 
well and allowed to incubate for 30 min at 37 0C.  The biochip wells are washed 
(4 times) with tris buffer saline to remove the unbound horseradish peroxidase 
conjugate antibody.  Once the unbound horseradish peroxidase conjugate 
antibody is removed a final wash is carried out to allow the biochip well to soak 
in the buffer for 15 s.  Finally, 250 μL of working signal reagent-EV701 (1:1 of 
Luminol-EV701 and peroxide) is added to each biochip well while protect from 
light and the signal is measured.  The light emitted is proportional to the 
concentration of the antigen. 
 
3.14 Siemens ADVIA Centaur® XP system  
 
3.14.1 Ultra-sensitive cardiac troponin I 
 
The Advia Centaur® XP system TnI-Ultra assay is a three-site sandwich 
immunoassay using direct chemiluminometric technology for the quantification 
of human cardiac troponin I in serum or plasma (Figure 24).  In order to reduce 
nonspecific binding an ancillary reagent is incorporated in the assay 
procedure.  The Binary Lite reagent contains a polyclonal goat anti-troponin 
antibody labeled with acridinium ester and 2 biotinylated mouse monoclonal 
anti-troponin I antibodies.  The solid phase reagents contain magnetic latex 
particles conjugated with streptavidin. 
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Figure 24: ADVIA Centaur TnI-Ultra assay three-site immunoassay using 
direct chemiluminometric technology (courtesy of Siemens Healthcare 
Diagnostics). 
 
3.14.2 Assay principle 
 
In the first step a 100 μL of patient sera with the unknown cTnI concentration 
is mixed with 50 μL of the ancillary reagent, 100 μL of Binary Lite reagent and 
further, two biotinylated mouse monoclonal anti-troponin I antibodies.  The 
ancillary reagent helps to reduce nonspecific binding; whereas, the Binary Lite 
reagent which include polyclonal goat anti-troponin I antibody labeled with 
acridinium ester is designed to bind the unknown cTnI.  The second step 
consist of the addition of two biotinylated mouse monoclonal anti-troponin I 
antibodies.  The whole mixture is than allowed to incubate at 37 0C for 3.0 min.  
Finally, to immobilise the immune-complex a solid phase reagent of 150 μL 
which consists of magnetic latex beads conjugated with streptavidin is added 
and allowed to incubate at 37 0C for a further 6.3 min.  The unbound proteins 
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are washed with tris buffer.  Following the washing step 300 μL acids (reagent 
R1) and a 300 Base μL (reagent R2) is added to initiate and stop the 
chemiluminescent reaction.  Direct relationship exists between the amount of 
cTnI in the sample and the amount of relative light unit (RLUs) detected. 
3.15 Abbott ARCHITECT stat i2000SR System® 
 
3.15.1 High sensitivity cardiac troponin I 
 
The ARCHITECT stat hs-cTnI assay is a chemiluminescent microparticles 
immunoassay (CMIA) for the quantification of human cardiac troponin I in 
serum or plasma (Figure 25).  Hs-cTnI quantification using ARCHITECT stat 
i2000SR System® is a two-step immunoassay using CMIA technology (Figure 
25). 
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Figure 25: Abbott ARCHITECT stat highly sensitive troponin assay design 
(Produced from manufacturer insert Abbott Laboratories). 
 
3.15.2 Assay principle 
 
The first step consists of allowing patients sera and anti-troponin I antibody-
coated paramagnetic microparticles (solid phase) to combine in a vessel.  
Troponin I present in the sample binds the anti-troponin I antibody-coated 
paramagnetic microparticles.  After for 4 min incubation the unbound proteins 
are washed with a tris buffer.  In the second step immediately after washing, 
anti-troponin I acridinium labeled conjugate is added and allowed to incubate 
for a further 4 min.  After incubation the mix is washed with tris buffer.  Pre-
trigger and trigger solution is added.  The resulting chemiluminescent reaction 
is measured as relative light units (RLUs).  Direct relationship exists between 
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the amount of cTnI in the sample and the amount of RLUs detected.  The 
concentration of the unknown cTnI is read relative to the standard curve. 
3.16 Beckman Coulter Access® 2 system  
 
3.16.1 High sensitivity cardiac troponin I 
 
High sensitivity cardiac troponin I quantification using Beckman-Coulter 
Access® 2 system is a paramagnetic particle chemiluminescent immunoassay 
(Figure 26).  The Access AccuTnI assay is a two-site immuno-enzymatic 
(“sandwich”) assay. 
Detection
The sample
magnetic 
abs particles
and the
enzyme
abs are 
added to the RV
The fist 
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period allows 
immune-
complex
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into the
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and all
unbound
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added to the RV
The Second
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to allow signal
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The light
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present in the
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1 3 4 5 62
 
Figure 26: High sensitivity troponin I quantification by Beckman-Coulter 
Access 2 System using paramagnetic particle chemiluminescent 
immunoassay.  RV, reaction vessel.  (By Beckman-Coulter). 
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3.16.2 Assay principle 
 
Patient’s serum sample with unknown amount of cTnI is added to a reaction 
vessel, containing monoclonal anti-cTnI-antibody conjugated to alkaline 
phosphatase and paramagnetic particles coated with monoclonal anti-cTnI 
antibody.  The unknown human cTnI binds to the anti-cTnI antibody on the 
solid phase, whereas the monoclonal anti-cTnI antibody conjugated to alkaline 
phosphatase reacts with different antigenic sites on cTnI molecule.  After 
incubation, material bound to the solid phase are temporarily held by magnetic 
field to allow unbound material to be washed.  The chemiluminescent substrate 
Lumi-Phos® 530 is added to the vessel.  The light generated by the reaction is 
measured with luminometer.  The light produced is directly proportional to the 
concentration of cTnI in the sample.  The concentration of the unknown cTnI 
is determined from the stored multipoint calibration curve. 
 
3.17 Roche Diagnostics Elecsys® 2010 System  
 
3.17.1 High sensitivity cardiac troponin T 
 
Hs-cTnT quantification using Roche Diagnostics Elecsys® is an 
electrochemiluminescent immunoassay “sandwich” (ECLIA) (Figure 27). 
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Figure 27: Hs-cTnT Roche is an electrochemiluminescent immunoassay 
“sandwich”, utilising two different monoclonal antibodies with different label 
specifically directed against human cTnT.  These two monoclonal antibodies 
recognise two different epitopes located in the center of human cTnT.  The first 
monoclonal antibody recognises amino acid 125-131 and is labeled with 
ruthenium and the second recognises 136-147 and is labeled with biotin.  Once 
the immune-complex is formed streptavidin coated micro-particle is added 
(solid phase).  Finally, the application of a voltage causes the complex to emit 
light.  The amount of light is proportional to the concentration of the unknown 
troponin in patient’s sera.  (By Roche Diagnostics). 
  
140 
 
3.17.2 Assay principle 
 
The first incubation involves the introduction of 50 μL patient’s sera with a 
biotinylated monoclonal anti-cTnT antibody and a monoclonal anti-cTnT 
antibody labeled with a ruthenium to form a complex.  The second incubation 
involves the addition of streptavidin-coated microparticles; the complex 
becomes bound to the solid phase via the interaction of biotin and streptavidin.  
The reaction mixture is aspirated into the measuring cell where the micro 
particles are magnetically captured onto the surface of the electrode.  Unbound 
particles are then washed with tris buffer.  Application of a voltage to the 
electrode then induces chemiluminescent emission which is measured by a 
photomultiplier.  The results are determined by a 2-point calibration and a 
master multipoint (5-point) calibration curve. 
 
3.18 Roche Diagnostics Elecsys® 2010 System  
3.18.1 N-terminal pro B-type natriuretic peptide 
 
N-terminal pro B-type natriuretic peptide quantification using Roche 
Diagnostics Elecsys® is an electrochemiluminescent immunoassay (ECLIA) 
(Figure 28). 
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Figure 28: NT-pro-BNP Roche diagnostic is an electrochemiluminescent 
immunoassay “sandwich”; utilising polyclonal antibodies labeled with biotin 
and ruthenium and is specifically directed against human NT-pro-BNP.  
These polyclonal antibodies recognise the epitopes located in the N-terminal 
part (1-76) of NT-pro-BNP (1-108).  The biotinylated and the ruthenium 
polyclonal anti-NT-pro-BNP form a complex with human NT-pro-BNP (By 
Roche diagnostic). 
 
3.18.2 Assay principle 
 
NT-pro-BNP quantification is a two steps sandwich immunoassay.  The 
protocol is as follow: 
The first incubation involves the introduction of 20 μL of patient’s sera with 
biotinylated polyclonal anti-NT-pro-BNP antibody and a polyclonal anti-NT-
pro-BNP antibody labeled with a ruthenium.  The second incubation involves 
the addition of streptavidin-coated microparticles; the complex becomes bound 
to the solid phase via the interaction of biotin and streptavidin.  The reaction 
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mixture is aspirated into the measuring cell where the micro particles are 
magnetically captured onto the surface of the electrode.  Unbound particles 
are then washed with tris buffer.  Finally, the application of a voltage to the 
electrode induces chemiluminescent emission which is measured by a 
photomultiplier.  The results are determined by a 2-point calibration and a 
master calibration curve. 
3.19 The B-R-A-H-M-S Copeptin KRYPTOR® 
 
3.19.1 Time-Resolved Amplified Cryptate Emission Technology 
 
The B-R-A-H-M-S Copeptin KRYPTOR® (Brahms, Hennigsdorf, Germany) 
measured the C-terminal precursor portion of arginine vasopressin by a 
sandwich immunoassay. KRYPTOR® method uses Time-Resolved Amplified 
Cryptate Emission Technology (TRACE technology); which measure the 
signal from an immune-complex with time delay (Figure 29).  TRACE 
technology is based on a non-radioactive energy transfer between a donor 
typically Europium (Eu) cryptate and an acceptor such as algal light collecting 
protein XL665.  The assay uses two copeptin specific monoclonal antibodies 
labeled with either Eu or XL665.  During the immuno-complex formation, the 
emission from the cryptate (Eu) and the absorption from the acceptor (XL665) 
cause an increased fluorescent signal of the cryptate and subsequently extend 
the life span of the acceptor signal.  This immuno-complex interaction allows 
the measurement of temporarily delayed fluorescence.  The signal is 
proportional to the concentration of the analyte to be measured.  The analytical 
characteristic of the B-R-A-H-M-S Copeptin KRYPTOR® are summarised in 
table 14.  
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Figure 29: Copeptin detection using Eu cryptate labeled anti-human Abs and an anti-
human Abs labeled with XL665.  When the immuno-complex containing the protein of 
interest, in this case copeptin is excited with a nitrogen laser at 337 nm, the donor 
emits a long-life fluorescent signal (millisecond) in the range of 620 nm while the 
acceptor generates a short-life signal (nanosecond) at 665 nm.  The combined signal 
generated from the immuno-complex is measured at 665 nm; the long-life signal is 
proportional to the concentration of the analyte to be measured.  (Courtesy of Brahms, 
Hennigsdorf, Germany). 
 
3.20 The albumin cobalt binding (ACB®) assay 
 
3.20.1 Indirect colorimetric method 
 
The original biochemical test for IMA was known as the albumin cobalt binding 
assay (ACB®).  The assay is based on the principle that IMA cannot bind cobalt 
a consequence of damage to the N-terminus damage.  The assay measures 
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the cobalt binding capacity of albumin in a sample of serum.  A known amount 
of cobalt is added to the patient serum sample and allowed to interact with IMA 
if present.  Dithiothreitol (DTT) is added which binds any remaining unbound 
cobalt and the colorimetric change is measured spectrophotometrically.  In 
serum from non-ischaemic patients, cobalt binds to the N-terminus, leaving 
little free cobalt to react with DTT and form a colored product.  Conversely, in 
serum obtained from ischemic patients, cobalt does not bind to the N-terminus 
of IMA, leaving more free cobalt to react with DTT and form a darker color.  
The absorbance produced by the darker color is proportional to the amount of 
IMA present in the serum (Figure 30). 
 
3.20.2 Assay protocol 
 
200 μL of patient sera is allowed to mix with 50 μL cobalt chloride (1 mg/L).  
Incubate at room temperature for 10 min.  50 μL Dithiothreitol (1.5 g/L) is added 
an allowed to incubate for a further 2 min.  Finally, a 1.0 mL of NaCl (9.0 g/L) 
is added the solution to top the reaction.  The absorbance is measured at 470 
nm.  The absorbency is proportional to the concentration the antigen in this 
case cobalt and DTT. 
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Figure 30: Measurement of ischemia modified-albumin by the Albumin Cobalt Binding 
Assay (ACB®).  A known amount of cobalt chloride (CoCl2) is added to a serum 
sample.  Dithiothreitol is added which binds unbound Co++ causing a colorimetric 
change which can be read spectrophotometrically (Courtesy of Dr D Gaze St 
George’s Healthcare. London). 
 
3.21 Statistical methods 
 
Non-parametric statistics were used to analyse demographics and patient 
characteristics.  The receiver operating characteristics cure (ROC) and the 
calculation of the area under the curve (AUC) were used to examine individual 
biomarkers on admission and at 90 min after admission.  ROC curve was also 
used to assess the diagnostic efficiencies of delta changes in absolute 
concentration and percentages change values (on admission minus 90 min 
values).  Diagnostic test comparison was carried out using AMI as the 
dichotomous variable (negative or positive for AMI).  Contingency tables (using 
Non ischemic Sample Ischemic Sample
IMA
Cu++
Ischemia modified AlbuminUnbound Cobalt
HSA with 
Co++ at the 
N-terminus
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predefined cut-off values and delta values) for individual and multiple 
biomarkers were used to compare sensitivity, specificity, positive predictive 
value (PPV) and negative predictive value (NPV).  All statistical analysis 
including, 95% confidence interval, Fisher exact tests were performed using 
Analyse-it® for Microsoft Excel (version 2.21; www.analyse-it.com). 
 
3.22 Economic evaluation of ischaemia modified-albumin 
 
3.22.1 Economic analysis 
 
Economic analysis for the introduction of IMA was based on two scenarios.  
The first scenario cost minimization analysis (CMA) was used to establish 
whether a single cardiac biomarker i.e. IMA, H-FABP and copeptin would have 
the same diagnostic and prognostic efficiency compared to the existing cardiac 
biomarkers of necrosis such as hs-cTn or a panel of cardiac and novel 
biomarkers.  The second scenario a decision-analysis and cost benefit 
analysis were used; the aim was to establish whether single biomarkers or a 
combination of different biomarkers using the delta changes could be used to 
achieve high diagnostic and prognostic efficiency. 
This model applied (Figure 31) different scenarios in patients (n = 174) 
presenting to the ED with chest pain suggestive of AMI.  The model also 
assumes that the sample was taken on admission and the results were 
available within 90 min.  The model also assumes that medical staffs in the ED 
are available 24 h and a decision regarding patient’s management is made 
within 1 h of the results being available.  It was also assumed that hs-cTn is 
the “gold standard” for the diagnosis of AMI and the true positive would be 
confirmed at 10-12 h; whereas, the true negative and the false positive will be 
discharged at 10-12 h.  Standard hs-cTn testing at 10-12 h as recommended 
by NICE (NICE, 2010).  The cost accrued during a patient’s management will 
depend on the number of tests carried out and the length of time spent in 
hospital.  The use of hs-cTn is financially justified as an early accurate 
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diagnosis of AMI and its use can potentially reduce the duration of hospital 
admission.  In addition, discharging patients on the same day attracts a tariff 
benefit in the National Health Service (NHS) system (Health, 2012-2013; 
Thokala,Goodacre,Collinson et al., 2012). 
Demographics
Age
Gender 
AMI Status
True negative
and true positive
Diagnostic strategies
• No testing
•IMA at presentation
•On admission
•Combined 
biomarkers
& IMA
AMI patients
both true and 
false positive
Calculate cost of
testing 
in the ED setting
Short term
Cost to the ED 
and testing
Diagnostic cost
 
Figure 31: Basic cost-benefit analysis model structure.  (St George’s 
Healthcare NHS Trust. London) 
The following diagnostic strategies were applied only to the cardiac biomarkers 
with the appropriate diagnostic efficiency i.e. the best sensitivity and specificity 
for the diagnosis of AMI: 
1. Discharge without investigation. 
2. IMA negative discharge.  
3. Discharge if IMA and hs-cTn negative or admit if clinical suspicion 
exists. 
4. Admit if both IMA and hs-cTn are positive. 
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3.22.2 Current study sample size calculation 
 
Table 16: Current project sample size calculation using 
http://clincalc.com/stats/samplesize.aspx software. 
Study parameter 
Population incidence 7% 
Incidence study group 5% 
Alpha 0.05 
Beta 0.2 
Power 0.8 
Sample size 1168 
 
In the current project n = 1168 evaluable subjects on admission and at 90 min 
after admission would be expected to have 80% power to detect a 5% absolute 
difference in primary outcome at the two significant levels of 5%.  
Unfortunately, the samples (n = 174) acquired in this project was under 
powered and not expected to provide 80% power to detect 2% absolute 
difference (2% vs. 4%) in major adverse cardiac events.  
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Chapter 4 
Results 
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- 
This chapter describes the results of the present study utilising conventional 
biomedical tests and a range of novel biomarkers that could potentially be used 
in the ED for the diagnosis and triage of low risk patients with chest pain 
suggestive of AMI. 
 
4.1 Population 
 
The RATPAC trial recruited 2263 patients between 30 January 2007 and June 
2008; 1125 were randomised to POCT arm.  Two sets of blood were drawn; 
the first on admission (sample 1) and the second at 90 min from admission 
(sample 2).  Both sets of serum samples were measured by the participating 
center for conventional cardiac troponin I (AccuTnI) or T (Centaur cTnI), hs-
cTnI (Beckman) or hs-cTnT (Roche).  However, the following biomarkers 
including myoglobin, CK-MB mass, copeptin and H-FABP, and IMA were 
measured at St George’s Healthcare NHS trust.  The subjects were followed 
for major adverse cardiac events (MACE) and final outcomes were recorded 
as follows: 3% recorded AMI (36 patients), 1% death (6 patients), 2% ACS 
hospitalization without AMI (18 patients), <1% non-fatal AMI, 1% severe 
arrhythmia (6 patients), 1% emergency revascularization (10 patients).  The 
final recorded event i.e. AMI between two arms was not statistically significant, 
despite the fact that the study found more patients with AMI from the POCT 
compared with standard arm (90/1125 vs. 72/1118). 
Surplus samples were retained for the Randomised Assessment of Treatment 
using Panel Assay of Cardiac Biomarkers-Contemporary Biomarker 
Evaluation (RATPAC-CBE), in total 847 out of 850 participants had their cTn 
status established.  The available data includes median age, final diagnosis, 
cardiac biomarkers results and MACE.  They also had data regarding the 
median time (495 min range 95-46.6 min and the interquartile range (IQR) was 
310-738 min) from the onset of chest pain until the last cTn measurement. 
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When considering all participants 33.5% had blood taken in less than 6 h from 
chest pain 65.4% were taken ≥ 6 h from the onset of chest pain.  Thus, the 
majority of patients had their troponin measurement performed according to 
the ESC. 
The Stratus® CS analyser was not considered to be a high sensitivity cardiac 
troponin assay; however, it satisfied the criteria as outlined by the guidelines 
of an acceptable assay and therefore was used in the RATPAC-CBE study 
(Apple, 2009). 
The Roche Cobas MIRA® Plus analyser was used to measure IMA 
concentrations.  Surplus blood samples of n = 645 (76%) were available for 
this study and n = 210 where insufficient for analysis.  In total, 444 (69%) 
samples were included in the study and 348 (54%) samples had matched and 
full paired data i.e. two sets of blood were drawn on admission (sample 1) and 
the second samples at 90 min after admission (sample 2) and frozen at -20 0C 
until analysis (Figure 32).  Samples for this study (n = 444) were organised into 
batches of 10 samples and analysed within 30 min of thawing at room 
temperature.  Prior to sample thawing, external quality controls (low, medium 
and high) were included in every run.  IMA assay was calibrated according to 
manufacturer recommendation. 
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Figure 32: Sample available for IMA study.  A total of 645 out of 840 unmatched 
samples were available for analysis, a further, n = 210 were insufficient and 
not analysed.  The remaining n = 444 from which 253 were obtained on 
admission and another 191 at 90 min after admission.  A total of n = 444 
samples was analysed for hs-cTnT, hs-cTnI, cTnI (conventional), copeptin, H-
FABP, myoglobin, CK-MB and IMA.  A total of 348 out of the 444 available 
samples had a complete matched and paired data including concentration 
values for hs-cTnT, hs-cTnI, copeptin, H-FABP, myoglobin, CK-MB, IMA and 
final outcome of MACE on admission and 90 min after admission. 
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The simultaneous use of multiple biomarkers of cardiac injury (cTn), 
neurohormonal (NT-pro-BNP), cytoplasmic (myoglobin, CK-MB and H-FABP) 
and vascular stress (copeptin and IMA) was based on the argument that these 
biomarkers may rise before the release of hs-cTn and may also challenge the 
ECG when inconclusive (Giannitsis,Becker,Kurz et al., 2010; Goodacre, 2011; 
Hjortshoj,Kristensen & Ravkilde, 2010). 
The diagnostic strategies were compared with individual biomarkers values 
based on hs-cTnT > 99th percentile, CK-MB > 5 μg/L and myoglobin >95th 
percentile, delta CK-MB > 1.5 μg/L and myoglobin was defined as percentage 
of > 25% change from admission.  These ranges of biomarkers were then 
compared with a combination of individual cytoplasmic, hs-cTn, conventional 
cTn and novel biomarkers on admission and at 90 min after admission.  In 
addition, for each combination or delta value rule-in diagnostic of an AMI i.e. 
specificity and PPV and rule-out i.e. the sensitivity and NPV were calculated.  
The clinical cut-off for all biomarkers is summarised in table 17. Hs-cTnT was 
used as the predicate device as it is standardized.  The lack of standardization 
of hs-cTnI is generally due to the heterogeneous nature of the circulating cTn, 
the monoclonal antibodies engineered specificity and commercial pressures 
(Clerico,Fortunato,Ripoli et al., 2008).  Currently, cTnI immunoassay does not 
directly correlate from technique to technique.  Thus, consequently patient’s 
results produced by a particular assay are not transposable (Chenevier-
Gobeaux et al., 2015).  Changing patient’s management using different cTnI 
may become unreliable. 
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Table 17: Clinical cut-off values used to assess the diagnostic efficiency for 
all biomarkers. 
Test Manufacturer Clinical cut-off 
IMA Inverness Medical 127 KU/L 
AccuTnI (conventional) Beckman 42 ng/L 
hs-cTnI Beckman 27 ng/L 
TnI-Ultra(conventional) Siemens 40 ng/L 
Hs-cTnT Roche 14 ng/L 
H-FABP Randox 2.5 mg/L 
Myoglobin Randox 66 mg/L 
Copeptin Randox 17.4 pmol/L 
NT-pro-BNP Siemens 125 ng/L 
CK-MB Randox 5 μg/L 
 
The first phase of the evaluation aims at establishing reference population and 
the diagnostic efficiency of IMA measured on a Cobas Mira Plus analyser 
alone and utilising all the available data for hs-cTnI, hs-cTnT, copeptin, NT-
pro-BNP, CK-MB (mass), myoglobin and H-FABP.  The diagnostic efficiency 
of panel approach was compared with that of single biomarkers and single 
cardiac biomarker combinations utilising the final diagnosis.  The second 
phase of the evaluation aims at assessing the cost-benefit of IMA assay alone 
and in combination with hs-cTnT. 
 
4.1.1 Ischemia modified-albumin reference population 
 
Sixty-six samples obtained from normal, healthy individuals were used to 
estimate the reference ranges for IMA.  Normal, healthy individuals are defined 
as free of cardiac and renal disease (i.e. no history of myocardial infarction, 
heart failure, hypertension, dyslipidemia) and no history of cancer.  The 
population will consist of 35% male and 65% female.  Samples were analysed 
(Roche Cobas Mira Plus) for Ischaemia modified-albumin in replicate.  
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Redundant serum samples of only (n = 66) from patients attending general 
practice for routine checks were selected for inclusion in the reference range 
study.  Samples were included and stored at -20 0C in the present study if they 
meet the exclusion criteria (table 18).  The median age was 55 years 
(interquartile range 50 to 62 years), 23 (35%) subjects were male and 43 (65%) 
were female. There is no statistically significant difference between the two 
groups (p = 0.4) summary data in table 19. 
 
Table 18: Exclusion criteria for reference population for the present study. 
• Known coronary heart disease 
• Known coronary heart disease. 
• Confirmed serious non-cardiac pathology (e.g. pulmonary, embolus) 
• Co-morbidity that require hospital admission 
• Abnormal chemistry results (e.g. renal profile, liver profile and lipid 
profile) 
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Figure 33:  Age distribution of reference range subjects (n = 66).  The median 
IMA was 122 KU/L, (interquartile range, 121-124 KU/L).  The data was non-
parametrically distributed and there was no effect of gender on IMA 
concentration (p = 0.407) (table 19).  The non-parametric 95% (CI) upper limit 
of normal reference interval was 127 KU/L (95% CI, 126-127 KU/L). 
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Figure 34: 95% (CI) Upper limit of Normal (URL) for IMA is 127 KU/L calculated 
from the reference population (n = 66). 
 
Table 19: Control group summary data 
 Proportion Mean SD SE P value 
Female (n = 43) 65% 122.1 4.2 0.63 0.407 
Male (n = 23) 35% 121.2 4.2 0.87 0.407 
 
Table 19: Showed the proportion of female and male participation in the 
establishment of the reference interval.  It also summarises the mean IMA 
concentration by gender.  There is no statistically significant difference 
between the two groups (p = 0.4). 
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4.2 Analytical evaluation of IMA® assay, by Cobas Mira plus 
analyser 
 
Aim 
To evaluate the precision characteristic of the 3rd generation IMA® assay; 
according to the guidelines of the National Committee for Clinical Laboratory 
Standards (NCCLS) document EP5-A2 (Second edition 2004).  EP5-A2 
document is designed to harmonise the laboratory methods for a 
comprehensive establishment of the precision capability of a method (the 3rd 
generation IMA® assay) it is also designed to help user to verify the validity of 
performance claims of manufacturers and can also be used by those 
laboratories how want to improve or modify an existing method i.e. changes in 
protocol steps or reagents.  
 
4.2.1 Preliminary precision evaluation 
 
4.2.1.1 Device familiarisation 
 
This first step consists of five days and is designed to allow the operator to 
familiarise him/her self with the device characteristic including maintenance, 
reagent preparation, and program input.  The device familiarization is also 
designed to highlight any major problem with the device (Roche Cobas Mira 
plus).  Once the familiarisation period of the device (Cobas Mira plus analyser) 
is finished the evaluation of repeatability should commence.  The NCCLS also 
recommend that the five operating days could be exceeded until data were 
obtained without operational difficulties.  
Three IMA® samples (pooled from different patients) with three different 
concentrations (30/60 KU/mL, 66/105 KU/mL and > 211 KU/ml) will be 
evaluated for IMA.  The data obtained will be calculated for standard deviation 
(SD) and the coefficient of variance (CV %); if significant discrepancy is found 
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between the manufacturers and the assessing laboratory, the manufacturers 
will be contacted and the experiment (analytical evaluation of IMA® assay) will 
be stopped until the source of the problem is found and resolved.  In this stage 
even if problem is found the acceptability of the device will not be made based 
on these findings.   
 
4.2.1.2 Protocol familiarisation period 
 
The following steps should be performed each day for five days: 
 
1. Analyse two run or batches per day 
2. If run is rejected due to quality control non-conformance or operational 
errors/difficulties, an additional run after an investigation is carried out 
to identify and remedy the source of the problem.  
3. Within each run or batches, analyse two aliquot of test material for 
each concentration used.  
4.  Include at least one control in each run.   
5. Change the order of the analysis of quality control and test material 
each day or run. 
6. To replicate the actual operation, include a least ten patients in each 
run if possible. 
7. Segregate runs by at least two hours   
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4.2.1.3 Precision evaluation experiment 
 
The precision evaluation protocol according to the NCCLS EP5-A2 documents 
requires twenty days to achieve.  The NCCLS also recommend that the data 
collected during the five operating days without operational difficulties can be 
incorporated into the estimation of precision.  Establishing the precision in 
twenty days, allows the incorporation of day-to-day impression introduced 
through analytical errors. 
 
This involves estimating the repeatability and within-laboratory precision for a 
single device (Cobas Mira plus analyzer).  The objective of the precision 
evaluation is to estimate the precision of Cobas Mira plus analyzer.  The 
precision evaluation is designed to assess the precision of Cobas Mira plus 
analyzer when used over a long period of times, thus accounting for the 
influence of several source of variability including operator, temperature, and 
reagent stability.  
The NCCLS recommend a minimum of twenty operating days (using single lot) 
to achieve an acceptable precision evaluation.  ACB® evaluation using Cobas 
Mira analyzer is considered a short-run method since its duration is less than 
two hours.  However, NCCLS also allows for 5 days precision evaluation if the 
device is used every day; which would be the case with Roche Cobas Mira 
plus if IMA assay is implemented. 
Roche Cobas Mira plus analyzer requires calibration every 5 days or when 
internal control is outside the specified ranges or lot changes. Each day of the 
experiment requires two separate runs i.e. am and pm (or separated with at 
least two hours); each run must include two test samples with two different 
concentrations and at least two quality controls.  The 3rd generation ACB® 
assay precision evaluation will include three quality controls i.e. Low, medium 
and high.  Quality control procedure will be established using Westguard rules 
protocol.  The data obtained will be calculated for standard deviation (SD) and 
the coefficient of variance (CV %) every five operating days of the experiment.  
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Data may not be rejected without good reason as this could underestimate the 
precision of the method/device.  
 
4.2.2 Protocol of precision evaluation of IMA® assay (Cobas Mira 
analyzer). 
 
The following steps shall be taken each day: 
 
1. Analyse twenty aliquot of patient’s sample with tree different 
concentration. 
 
a. Level Low (30 to 60 kU/mL) in duplicate twice day 
(at least two hours between run) 
 
b. Level medium (66 to 105 kU/mL) in duplicate 
twice day. 
 
c. Level high (110-136 kU/mL) in duplicate twice day 
 
d. Include quality control (R1) from ACB® in every 
run and a negative control (serum from healthy 
individual IMA < 30 kU/mL). 
 
 
2. If run is rejected due to quality control non- conformance or operational 
errors/difficulties, an additional run after an investigation is carried out 
to identify and remedy the source of the problem.  
3. Within each run or batches, analyse two aliquot of test material (kit 
control) for each concentration used.  
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4. Change the order of the analysis of quality control and test material 
each day or run. 
5. Segregate runs by at least two hours   
6. Plot the quality control values in the chart according to Westguard rules. 
4.2.2.1 Linearity study 
 
Linearity is the “measure of the degree to which a curve approximates a 
straight line”. Linearity refers to overall system response (i.e., the final 
analytical answer rather than instrument output) (NCCLS, 1996).  Linearity 
(Figure 35) is measured by testing levels of ACB® concentrations that are 
known and relative to each other.      
 
Linear equation: 
y = α +β x 
 
• The variables x and y are the generalised input and 
output variables, β is the slop and α is the intercept.  
Slop (represented by β) the relationship between the change is y and the 
change is x between any two point (x1, y1 and x2, y2) along straight line.  
 
𝛽 =  
∆ 𝑦
∆ 𝑥
=  
y2 − y1 
𝑥2 − 𝑥1
 
 
There are many experimental approaches to evaluate linearity of a system 
(NCCLS, 1996).  The NCCLS recommend up to five concentrations of the 
analyte (IMA) to undergo multiple measurement of four replicate and should 
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take one day to establish.  The data obtained is plotted on the x and y axis and 
the outlier is visually inspected and if necessary removed.  Once the 
satisfactory data is obtained the controlled independent variable model is 
applied for the detailed statistical evaluation of linearity.  This includes the 
calculation of tolerance limits at various analyte (IMA) concentrations. 
The sample matrix (the best hierarchy) that will be used to establish the ACB® 
linearity should be close to the sample used in real clinical setting.  Thus, 
samples for ACB® linearity study will be drawn from patients.  The patient 
specimen will contain ACB® level of 30% higher than the upper linearity limit 
that will be diluted with another patient’s specimen with low IMA® 
concentration. 
Analytical sequence 
 
The analytical sequence should be random and separated by a blank if 
significant carryover is present.   
 
Sample preparation and value assignment  
  
The samples are coded as follows: 
1. Two IMA pools of (10 mL) of sufficient volume for linearity evaluation 
are obtained. 
2. The low concentration pool which is near the limit of linearity is code 
No. 1 on the other hand the highest IMA concentration pool is coded 
No. 5. 
3. The intermediate concentration pools are made from the dilution of pool 
No. 1 & No. 5.  These dilutions are related to each other and produce a 
constant interval.  To produce an intermediate pools dilution the 
following procedure should be followed:  
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1. Pool (No. 2) is a mixture of 3 parts of the low pool (No. 1) and 1 
part of the high pool (No. 5). 
2. Pool No. 3 is a mixture of 2 parts of the low pool (No. 1) and 2 
parts of the high pool (no. 5) 
3. Pool No. 4 is a mixture of 1 parts of the low pool (No. 1) and 3 
parts of the high pool (No. 5) 
 
The concentration of pool No. 1 is C1 and the volume of No. 1 is V 1; moreover, 
the concentration of pool No. 5 is C 5 and the volume part of pool No. 5 is V 5.  
The concentration for each pool is defined by the following formula: 
 
Concentration = (C1 * V1 + C5 * V5) ÷ (V1 + V5)  
 
All the concentration and volume unit must be the same for each pool.  Pre-
analytical parameters such as mixing, protecting the pools from dehydration 
and general deterioration must be minimised or eliminated. 
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Figure 35: The ACB® test calibration curve is linear over the range of the 
calibration. 
 
Table 20: ACB® assay imprecision study, reference ranges is between 
brackets.   
Day Low control 
(30-60 
kU/mL) 
Mean Medium 
control 
(66-105 
kU/mL) 
Mean High 
control 
(110-136 
kU/mL) 
Mean 
 Dup 
1 
Dup 
2 
 Dup 
1 
Dup 
2 
 Dup 
1 
Dup 
2 
 
1 (AM) 52 50 51 63 61 62 105 109 107 
1 (PM) 46 48 47 67 66 67 108 110 109 
2 (AM) 52 50 51 68 68 68 109 110 110 
2 (PM) 48 49 49 64 66 65 109 104 107 
3 (AM) 48 49 49 67 67 67 110 109 110 
3 (PM) 49 51 50 66 64 65 106 111 109 
4 (AM) 49 47 48 65 64 65 108 110 109 
4 (AM) 50 47 49 65 66 66 110 110 110 
5 (AM) 46 47 47 63 64 64 105 107 106 
5(PM) 49 48 49 63 59 61 103 107 105 
Mean 49 65 108 
STD 1.51 2.18 1.73 
CV% 3.11 3.36 1.60 
Manufacturers stated CV% 
CV% 5.4 5.7 4.4 
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Table 20 showed that the imprecision study of the albumin cobalt binding assay 
(ACB®).  CV% values for all three internal quality controls comparable to that 
specified by the manufacturers. 
 
4.2 IMA concentration on admission and 90 min after admission 
 
The difference in IMA concentration between admission and at 90 min after 
admission was statistically significant (p = 0.002) (Figure 36). 
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Figure 36: Distribution of IMA concentrations on admission (n = 174) and at 90 
min after admission (n = 174).  IMA 1 = on admission, IMA 2 = 90 min after 
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admission.  There is a statistically significant difference between IMA 
concentration on admission and 90 min after admission (P = 0.002). 
The box-and-whisker plot presented in Figure 36 above were used to present 
the preliminary data spread of IMA concentrations in both group of low risk 
patients presenting to ED with chest pain suggestive of AMI on admission and 
90 min after admission.  There is statistically significant difference between the 
two groups (p = 0.002). 
Table 21: Final diagnostic categorisation of patients who participated in the 
present study. 
Diagnostic 
categorisation 
Final diagnostic 
IMA subset 
(n = 174), 
 n (%) 
Biomarkers 
Subset 
(n=840), 
n (%)  
Final 
diagnostic 
All patients 
(n = 1125), 
 n (%)  
Median age (year) 52 (44-63) 54 (44-64) 53 (44-64) 
Male 82 (47) 507 (60) 683 (61) 
Female 92 (53) 343 (40) 442 (39) 
Angina, no-ACS 16 (9) 72 (9) 83 (7) 
Musculoskeletal pain 19 (11) 116 (14) 143 (13) 
Gastro-oesophageal 21 (13) 100 (12) 124 (11) 
ACS 7 (4) 68 (8) 90 (8) 
Anxiety 7 (4) 31 (4) 36 (3) 
Chest infection 5 (3) - - 
Non-specific chest pain 69 (40) 279 (33) 361 (32) 
Self-discharge 1 (1) - - 
Others 20 (12) 154 (18) 228 (20) 
Unknown 9 (5) 30 (4) 60 (5) 
Normal ECG 131 (75) - - 
Abnormal 
non-conclusive ECG 
26 (15) - - 
Pathological ECG 17 (10) - - 
Values in parentheses represent percentage  
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4.3 Novel biomarker and conventional biomarker evaluation of 
the diagnostic accuracy for acute myocardial infarction  
 
The diagnostic efficiency in detecting AMI on admission and 90 min after 
admission was calculated using the area under the curve (AUC) (Figure 37, 
38, 39 and 40).  On admission sample measured for novel biomarker of NT-
pro-BNP and H-FABP were diagnostically efficient with AUC of 93% (95% CI, 
88-97%) and 78% (95% CI, 68-89%) respectively (table 22).  IMA on admission 
has a diagnostic efficiency with AUC of the ROC curve of 54% (95% CI, 43-
66%) compared to 58% (95% CI, 35-81%).at 90 min after admission.  In 
contrast, collectively the samples measured on admission and at 90 min after 
admission for cTn were the most diagnostically efficient biomarkers with AUC 
of the ROC curve ranging from 85%-90% and 84%-88% respectively. 
Cardiac troponin measurement for diagnosis of AMI, were diagnostically 
superior to CK-MB, myoglobin and novel biomarkers on admission and 90 min 
after admission (table 22). 
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Table 22: Area under the ROC curve for all biomarkers. 
Test (n = 253) admission AUC 
% 
95% Confidence interval 
(95% CI) 
Myoglobin 76 (67-86) 
CK-MB 71 (59-83) 
AccuTnI 85 (76-94) 
hs-cTnI 88 (81-95) 
hs-cTnT  100 (-) 
TnI-Ultra 90 (83-97) 
H-FABP 78 (68-89) 
Copeptin 58 (48-68) 
NT-pro-BNP 93 (88-97) 
IMA 54 (43-66) 
Test (n = 191)  
90 min after admission 
 95% Confidence interval 
(95% CI) 
Myoglobin 72 (57-87) 
CK-MB 62 (32-92) 
AccuTnI 88 (71-100) 
hs-cTnI 78 (54-100) 
hs-cTnT  100 (-) 
TnI-Ultra 84 (65-100) 
H-FABP 65 (40-90) 
Copeptin 63 (38-89) 
NT-pro-BNP 52 (26-78) 
IMA 58 (35-81) 
(-) = predicate test 
Table 22: The area under the curve (AUC) of each biomarker on admission 
and 90 min after admission.  Hs-cTnT > 14 ng/L was chosen to classify patients 
having and AMI.  The diagnostic performances of myoglobin, CK-MB, 
conventional cTn, hs-cTn, copeptin, NT-pro-BNP and IMA on admission and 
at 90 min after admission were compared.  In this group IMA had a poor 
diagnostic efficiency on admission and at 90 min after admission with an AUC 
170 
 
of 54% (95% CI, 42-66%) and 58% (95% CI, 35-81%) respectively compared 
to other biomarkers.  On admission and 90 min after admission conventional; 
cTn and hs-cTn were diagnostically superior compared to all biomarkers.  
However, NT-pro-BNP was also diagnostically superior on admission with 
AUC of ROC curve of 93% (95% CI, 88-97%) but a poor diagnostic efficiency 
at 90 min after admission with AUC of ROC curve of 52% (95% CI, 26-78%). 
  
 
Figure 37: A ROC curve for Accu TnI 85% (95% CI, 76-94%), Beckman hs-TnI 
88% (95% CI, 82-95%), Beckman TnI 90% (83-97%), myoglobin 76% (95% 
CI, 67-86%) and CK-MB 71 (95% CI, 59-83%) measurement on admission for 
the diagnosis of an AMI (n = 253).  Hs-cTnT > 14 ng/L was chosen to classify 
AMI patients.  
 
A ROC curve constructed as shown in figure 37 indicates the diagnostic 
performance of hs-cTn, Accu TnI, Beckman hs-TnI, CK-MB and myoglobin.  
The clinical cut-off point for all biomarkers are summarised in table 17.  AUC 
results are summarised in table 22. Hs-cTnT > 14 ng/L was chosen to classify 
AMI patients. 
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Figure 38 A ROC curve for novel biomarkers H-FABP 78% (95% CI, 68-89%), 
copeptin 58% (95% CI, 48-68%), NT-pro-BNP 93% (95% CI, 88-97%) and IMA 
54% (95% CI, 43-66%) measurement on admission for the diagnosis of an AMI 
(n = 253).  Hs-cTnT > 14 ng/L was chosen to classify AMI patients.  
 
A ROC curve constructed as shown in figure 38 indicates the diagnostic 
performance of H-FABP, copeptin, NT-pro-BNP and IMA on admission.  The 
clinical cut-off point for all biomarkers are summarised in table 17 Hs-cTnT > 
14 ng/L was chosen to classify patients having and AMI. 
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Figure 39: A ROC curve for biomarkers Accu TnI 88% (95% CI, 71-100%), 
Beckman TnI 77% (95% CI, 54-100%), Centaur TnI 84% (95% CI, 65-100%), 
CK-MB 62% (95% CI, 32-92%) and myoglobin 72% (95% CI, 57-87%) 
measurement for the diagnosis of AMI at 90 min after admission (n = 191).  
Hs-cTnT > 14 ng/L was chosen to classify AMI patients. 
 
A ROC curve constructed as shown in figure 39 indicates the diagnostic 
performance of hs-cTn and convention cTn, CK-MB and myoglobin.  The 
clinical cut-off point for all biomarkers are summarised in table 17.  AUC results 
are summarised in table 22.  Hs-cTnT > 14 ng/L was chosen to classify AMI 
patients. 
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Figure 40: A ROC curve for novel biomarkers of h-FABP 51% (95% CI, 41-
60%), copeptin 53% (95% CI, 38-68%), NT-pro-BNP 52% (95% CI, 38-66%) 
and IMA 57% (95% CI, 43-72%) measurement for the diagnosis of an AMI (n 
= 191).  Biomarkers measured at 90 min after admission. 
 
A ROC curve constructed as shown in figure 40 indicates the diagnostic 
performance of H-FABP, copeptin, NT-pro-BNP and IMA at 90 min after 
admission.  The clinical cut-off point for all biomarkers are summarised in table 
17.  Hs-cTnT > 14 ng/L was chosen to classify patients having and AMI. 
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Table 23: Data used for the ROC curve construction when analysing various 
cardiac biomarkers at 90 min after admission.  Hs-cTnT was used as a 
predicate test.  SE is standard error. The ROC curve is presented as an area 
under the curve and 95% confidence interval (95% CI). 
Test Area 95% CI SE 
H-FABP 51 41 to 62 0.055 
Copeptin 53 38 to 68 0.075 
NT-pro-BNP 52 38 to 66 0.071 
IMA 57 43 to 72 0.074 
CI = Confidence interval.  SE = Standard error 
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Summary data of biomedical biomarkers that are translated into ROC 
curve.  (appendix 3 for additional data) 
 
 
Figure 41: A ROC curve for novel biomarkers IMA 52% (95% CI, 18-76%), H-
FABP 66% (43-89%), Myoglobin 76% (95% CI, 62-99%), copeptin 60% (95% 
CI, 41-89%), NT-pro-BNP 58% (95% CI, 29-87%) and CK-MB 55% (95% CI, 
29-80%) measurement on admission for the diagnosis of an AMI (n = 174).  
Hs-cTnT > 14 ng/L was used to classify AMI patients.  
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Table 24: Data used for the ROC curve construction when analysing various 
cardiac biomarkers on admission.  Hs-cTnT was used as a predicate test.  SE 
is standard error. The ROC curve is presented as an area under the curve and 
95% confidence interval (95%). 
Test Area 95% CI SE 
IMA  52 28 to 76 0.124 
H-FABP  66 43 to 89 0.120 
MYO  76 62 to 90 0.072 
Copeptin  60 41 to 80 0.098 
NT-pro-BNP  58 29 to 87 0.149 
CK-MB  55 29 to 80 0.130 
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Figure 42: A ROC curve for novel biomarkers measurement at 90 min after 
admission for the diagnosis of an AMI (n = 174).  Myoglobin 68% (95% CI, 47-
88%), CK-MB 60% (95% CI, 34-85%), H-FABP 55% (95% CI, 23-87%) and 
Copeptin 55% (95% CI, 32-78%), NT-pro-BNP 52% (95% CI, 24-85%) and 
IMA 55% (95% CI, 32-87%).  Hs-cTnT > 14 ng/L was used to classify AMI 
patients.  
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Table 25: Data used for the ROC curve construction when analysing various 
cardiac biomarkers at 90 min after admission.  Hs-cTnT was used as a 
predicate test.  SE is standard error. The ROC curve is presented as an area 
under the curve and 95% confidence interval (95%). 
Test Area 95% CI SE 
IMA  55 32 to 87 0.116 
h-FABP  55 23 to 87 0.145 
MYO  68 47 to 88 0.106 
Copeptin  55 32 to 78 0.118 
NT-pro-BNP  52 24 to 85 0.144 
CK-MB  60 34 to 85 0.130 
 
Table 26: Data used for the ROC curve construction when analysing various 
cardiac biomarkers on admission.  Hs-cTnT was used as a predicate test.  SE 
is standard error.  The ROC curve is presented as an area under the curve 
with 95% confidence interval (95%). 
Test Area 95% CI SE 
Accu TnI 1 65 44-86 0.107 
Beckman hs-TnI 1 57 36-78 0.107 
Centaur TnI 1 52 52-65 0.069 
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Figure 43: A ROC curve for novel biomarkers measurement on admission for 
the diagnosis of an AMI (n = 174).  Accu TnI 65% (95% CI, 44-86%), Beckman 
hs-TnI 57% (95% CI, 36-78%) and Centaur TnI 52% (95% CI, 52-67%).  Hs-
cTnT > 14 ng/L was used to classify AMI patients.  
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Figure 44: A ROC curve for novel biomarkers measurement at 90 min after 
admission for the diagnosis of an AMI (n = 174).  Accu TnI 65% (95% CI, 44-
86), Beckman TnI 57% (95% CI, 36-78) and Centaur TnI (95% CI, 52-65%).  
Hs-cTnT > 14 ng/L was used to classify AMI patients.  
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Table 27: Data used for the ROC curve construction when analysing various 
cardiac biomarkers on admission.  Hs-cTnT was used as a predicate test.  SE 
is standard error.  The ROC curve is presented as an area under the curve 
with 95% confidence interval (95%).  Hs-cTnT was used as a predicate, hence 
area under the cure of 1.00 (95% 0.99 to 1.00). 
Test Area 95% CI SE 
Accu TnI 2 88 71 to 1.00 0.086 
Beckman hs-TnI 2 78 56 to 1.00 0.113 
Centaur TnI 2 82 63 to 1.00 0.098 
Hs-cTnT 2 1.00 99 to 1.00 0.003 
Hs-cTnT is the predicate test 
 
Figure 45: Current project participants (n = 174) ECG finding on admission.  
Bundle brunch block 1.7%, no data 0.6%, normal 73.5%, other 14.9% and T-
wave inversion 7.5%.  
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Table 28: Current project summary data of ECG finding on admission 
First ECG in ED n Proportion 
Bundle branch block 3 0.017 (1.7%) 
No data 1 0.006 (0.6%) 
Normal 131 0.753 (75.3%) 
Other 26 0.149 (14.9 %) 
T wave inversion 13 0.075 (7.5%) 
 
Table 28: Approximately 75% (n=131) of the current project participants had a 
normal ECG on admission to ED with chest pain suggestive of ACS.  Only 
1.7% (n = 3) bundle blanch block (BBB).  7.5% (n = 13) had a t-wave inversion. 
 
4.4 Combined novel biomarker and conventional biomarker 
evaluation of the diagnostic accuracy for acute myocardial 
infarction  
 
The combination of the diagnostic efficiency of IMA, hs-cTn, cTn, H-FABP, NT-
pro-BNP and copeptin to rule-in or rule-out diagnosis of AMI was assessed by 
the construction of contingency tables utilising the 99th percentile cut-off for hs-
cTnT and the 95th percentile cut-off for H-FABP, IMA and copeptin (table 29).  
The combined sensitivity and specificity of all biomarkers are summarised in 
table 29. 
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Table 29: Combined diagnostic efficiency of IMA and other biomarkers 
Test (n = 253) Sensitivity % 
(95% CI) 
Specificity% 
(95% CI) 
PPV NPV 
IMA + Myoglobin 32 (21-45) 93 (88-96) 55 84 
IMA + CK-MB 38 (23-55) 91 (87-94) 39 91 
IMA + AccuTnI† 49 (33-65) 93 (89-96) 52 92 
IMA + hs-cTnI 47 (32-63) 94 (89-96) 55 91 
IMA + hs-cTnT 71(56-82) 100 (98-100) 100 94 
IMA + TnI-Ultra† 54(39-67) 96 (93-98) 74 91 
IMA + H-FABP 41 (27-56) 93 (89-96) 55 89 
IMA + Copeptin 13 (4-38) 88 (83-91) 6 94 
IMA + NT-pro-BNP 52 (39-65) 98 (94-99) 84 89 
Test (n = 191) Sensitivity % 
(95% CI) 
Specificity% 
(95% CI) 
PPV NPV 
IMA + Myoglobin 6 (2-18) 97 (93-99) 29 82 
IMA + CK-MB - 96 (92-99) - 90 
IMA + AccuTnI 14 (5-35) 98 (94-99) 43 90 
IMA + hs-cTnI 8 (2-25) 97 (93-99) 29 88 
IMA + hs-cTnT 16 (13-46) 99 (97-100) 86 91 
IMA + TnI-Ultra 15 (7-31) 98 (96-100) 71 85 
IMA + H-FABP 12 (4-30) 98 (94-99) 43 88 
IMA + Copeptin - 96 (92-98) - 91 
IMA + NT-pro-BNP 8 (2-24) 97 (93-99) 29 87 
 † = non-sensitive troponin assay.  Values in parentheses represent 95% 
confidence interval.  PPV = positive predictive value.  NPV = negative 
predictive value. 
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Table 29: presents the combined sensitivity and specificity of each parameter.  
Hs-cTnT > 14 ng/L was chosen to classify patients having and AMI.  The 
diagnostic performance of IMA plus Centaur cTnI on admission has a 
sensitivity of 54% (95% CI, 39-67%) and a specificity of 96% (95% CI, 93-
98%); the NPV and PPV were 91% and 74% respectively.  The combined 
diagnostic efficiency of IMA and other biomarkers at 90 min after admission 
were very poor with sensitivity of < 50%; in contrast the specificity was very 
good ranging from 91%-98%.  On admission the combined diagnostic 
efficiency for IMA plus hs-cTnT had sensitivity and a specificity of 71% (95 CI, 
56-82%) and 100% (95% CI, 98-100%) respectively. 
 
4.5 Prognostic role of ischemia modified-albumin when 
compared with other cardiac biomarkers 
 
Receiver operating characteristic curve (Figure 46, 47, 48 and 49) at 
admission and 90 min after admission were constructed using the combined 
MACE of death, readmission with AMI, urgent revascularisation and 
readmission with unstable angina as the dichotomous variable. 
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Table 30: Receiver operating characteristic curve, for conventional cardiac 
biomarkers for the prediction of MACE.  Biomarkers measured on admission 
and 90 min after admission. 
Biomarkers Area under the curve 
(AUC) 
95% confidence interval 
(95% CI) 
Sample 1 (n=253)   
TnI-Ultra 53 (43-64) 
AccuTnI 53 (41-64) 
hs-cTnI 52 (40-64) 
hs-cTnT 
CK-MB 
Myoglobin 
52 
59 
57 
(43-61) 
(47-71) 
(46-69) 
Sample 2 (n = 191)   
TnI-Ultra 56 (47-65) 
AccuTnI 64 (52-75) 
hs-cTnI 55 (40-71) 
hs-cTnT 
CK-MB 
Myoglobin 
54 
55 
52 
(45-64) 
(41-69) 
(40-64) 
 
Table 30: represents the AUC of each conventional biomarker for the 
prediction of MACE of death, readmission with AMI, urgent revascularisation 
and readmission with unstable angina as the dichotomous variable.  
  
186 
 
Table 31: Receiver operating characteristic curve, for novel biomarkers for the 
prediction of MACE.  Biomarkers measured on admission and 90 min after 
admission. 
Biomarker  
 
Area under the curve 
(AUC) 
95% confidence 
interval 
(95% CI) 
Sample 1 (n = 253)   
IMA 52 (39-66) 
H-FABP 50 (40-61) 
Copeptin 59 (46-73) 
NT-pro-BNP 51 (38-65) 
Number of no MACE = 234 
Number of MACE = 19 
  
Sample 2 (n = 191)   
IMA 57 (43-72) 
H-FABP 51 (41-62) 
Copeptin 53 (38-68) 
NT-pro-BNP 52 (38-66) 
Number of no MACE = 172 
Number of MACE = 19 
  
   
Table 31: Represent the AUC of each novel biomarker for the prediction of 
MACE of death, readmission with AMI, urgent revascularisation and 
readmission with unstable angina as the dichotomous variable. 
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Figure 46: A ROC curve for conventional biomarkers measurement for the prediction 
of MACE (n = 253).  Biomarkers measured on admission.  The following biomarkers 
of necrosis Centaur TnI 53% (95% CI, 48-64%), Accu TnI 53% (95% CI, 41-64%), 
Beckman hs-TnI 52% (95% CI, 40-64%), hs-TnT 52% (95% CI, 43-63%), CK-MB 59% 
(95% CI, 47-71%), and myoglobin 57% (95% CI, 46-69%), were assessed for the 
predication of MACE.  Revascularisation, UA, readmission with AMI and/or cardiac 
death was used as an outcome measure  
 
A ROC curve constructed as shown in Figure 46 indicates the predictive value 
for hs-cTn, conventional troponin, CK-MB and myoglobin; the AUC of each 
novel biomarker for the prediction of MACE of death, readmission with AMI, 
urgent revascularisation and readmission with unstable angina as the 
dichotomous variable.  The AUC values are summarised in table 31. 
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Figure 47: Receiver operating characteristic curve for novel biomarkers IMA 
52% (95% CI, 39-66%), H-FABP 50% (95% CI, 40-62%), copeptin 59% (95% 
CI, 46-73%) and NT-pro-BNP 51% (95% CI, 38-65%) measurement for the 
prediction of MACE (n = 253).  Biomarkers measured on admission. The 
following novel biomarkers of necrosis and cardiac ischaemia h-FABP, 
copeptin, NT-pro-BNP and IMA were assessed for the predication of MACE.  
Revascularisation, UA, readmission with AMI and/or cardiac death was used 
as an outcome measure. 
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Figure 48: Receiver operating characteristic curve for conventional biomarkers 
measurement for the prediction of MACE (n = 191).  Biomarkers measured on 
admission.  The following biomarkers of necrosis Beckman TnI 56% (95% CI, 
47-65%), Centaur TnI 53% (95% CI, 47-65%), Accu TnI 52% (95% CI, 40-
64%), hs-TnT 52% (95% CI, 43-61%), CK-MB 59% (95% CI, 47-71%) and 
myoglobin 57% (95% CI, 46-69%) were assessed for the predication of MACE.  
Revascularisation, UA, readmission with AMI and/or cardiac death was used 
as an outcome measure. 
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Figure 49: Receiver operating characteristic curve for novel biomarkers 
measurement for the prediction of MACE (n = 191).  Biomarkers measured on 
admission. The following novel biomarkers of necrosis and cardiac ischaemia 
h-FABP 50% (95% CI, 40-61%), copeptin 59% (95% CI, 46-73%), NT-pro-BNP 
51% (95% CI, 38-65%) and IMA 52% (95% CI, 39-66%) were assessed for the 
predication of MACE.  Revascularisation, UA, readmission with AMI and/or 
cardiac death was used as an outcome measure. 
 
4.5.1 Diagnostic efficiency of delta IMA concentration and other 
biomarkers, in paired samples  
 
Delta values were calculated using a total of 174 patients with the full data set. 
Receiver operating characteristic (ROC) curve on admission and at 90 min 
after admission were constructed using delta concentration values for all 
biomarkers (table 32 and 33).  The delta values were calculated using the 
following equation: 
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 ΔIMA = 100 x IMA (on admission) – IMA (90 min after admission) ÷ IMA  
  concentration on admission 
Table 32: Area under the curve of the absolute delta values and the percentage 
delta values of individual conventional and high sensitivity cardiac troponin 
biomarkers. 
Assays 
(n = 174) 
Area under the curve 
(AUC) 
95% confidence interval 
(95% CI) 
∆hs-cTnI 
∆hs-cTnI% 
61 
56 
(33-89) 
(24-88) 
 
∆TnI-Ultra 
∆TnI-Ultra% 
84 
84 
(67-100) 
(67-100) 
 
∆hs-cTnT  
∆hs-cTnT%  
72 
72 
(35-100) 
(36-100) 
 
∆AccuTnI  
∆AccuTnI % 
80 
73 
(56-100) 
(47-98) 
 
Table 32: As shown above represent the AUC of the absolute delta values and 
percentage delta values of troponins.  Centaur TnI and Accu cTnI both has the 
best AUC for absolute delta value of 84% (95% CI, 67-100%) and 80% (95% 
CI, 56-100%) respectively.  The AUC for the percentage delta values of 
Centaur TnI and Accu cTnI were 84% (95% CI, 67-100%) and 73% (95% CI, 
47-98%) respectively.  The global harmonised standardisation for cTnI is yet 
to be achieved.   
  
192 
 
Table 33: Area under the curve of the absolute delta value and the percentage 
delta values of individual novel biomarkers including myoglobin and CK-MB. 
Analyte  
(n = 174) 
Area under the curve 
(AUC) 
95% confidence 
interval 
(95% CI) 
 
∆IMA 
∆IMA% 
 
57 
57 
 
(39-76) 
(38-76) 
 
∆H-FABP 
∆H-FABP% 
55 
58 
(25-86) 
(30-87) 
 
∆Myoglobin 
∆Myoglobin% 
60 
62 
(31-89) 
(35-88) 
 
∆Copeptin 
∆Copeptin% 
53 
54 
(38-68) 
(38-69) 
 
∆NT-pro-BNP 
∆NT-pro-BNP% 
69 
66 
(49-89) 
(47-84) 
 
∆CK-MB 
∆CK-MB% 
61 
66 
(36-86) 
(47-86) 
 
 
Table 33: As shown above represent the AUC of the absolute delta values and 
percentage delta values of novel biomarker, myoglobin and CK-MB.  NT-pro-
BNP and CK-MB both has the best AUC for absolute delta value of 69% (95% 
CI, 49-89%) and 61% (95% CI, 36-86%) respectively.  The AUC for the 
percentage delta values of NT-pro-BNP and CK-MB were 66% (95% CI, 47-
84%) and 66% (95% CI, 47-86%) respectively.  The AUC for IMA for both 
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absolute delta value and percentage delta values were 57% (95% CI, 39-76%) 
and 57% (95% CI, 38-76%) respectively. 
 
4.6 IMA comparative predictive value on admission in the 
diagnosis of acute myocardial infarction using hs-cTnT as a 
predicate  
 
Table 34: IMA diagnostic efficiency characteristics on admission; combined 
AMI and hs-cTnT were used as a predicate test. 
IMA 1 by Biochem Dx AMI 
hs-cTnT 
Mean 95% CI SE SD 
AMI 
(n=7) 
111.9 101.1 to 122.6  4.4 11.65 
 
Non-AMI 
(n=166) 
111.4 109.3 to 113.4 1.05 13.59 
 
Table 35: IMA diagnostic efficiency characteristics on admission; combined 
AMI and hs-cTnT were used as a predicate test. 
IMA by 
Biochem 
Dx AMI hs-
cTnT 
1st 
Quartile 
Media
n 
95% CI 3rd 
Quartile 
Max IQR 
AMI 
(n=7) 
100.5 116 95 to 127 119.7 127 19.2 
 
Non-AMI 
(n=166) 
104.5 112 109 to 114 118.2 150 14.2 
  
194 
 
Table 34 & 35: As shown above represent IMA diagnostic efficiency in 
detecting AMI on admission; when AMI and hs-cTnT were used as a predicate.  
The IMA values are presented as mean and median.  95% CI and quartile is 
also calculated. 
 
4.7 IMA comparative predictive values on admission and at 90 
min after admission in the diagnosis of acute myocardial 
infarction using IMA as a predicate  
 
Table 36: IMA diagnostic efficiency characteristics at 90 min after admission; 
combined AMI and hs-cTnT used as a predicate. 
IMA by Biochem Dx AMI 
hs-cTnT 
Mean 95% CI SE SD 
AMI 
(n=7) 
112.7 103.4 to 122.0  3.79 10.03 
 
Non-AMI 
(n=166) 
111.6 112.5 to 116.7 1.05 13.55 
  
 
            
Table 36:  As shown above represent IMA diagnostic parameters at 90 min 
after admission; when AMI is used as a predicate.  The IMA values are 
presented as mean, 95% CI, standard error (SE) and standard deviation (SD). 
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Table 37: IMA diagnostic efficiency characteristics at 90 min after admission; 
combined AMI and hs-cTnT used as a predicate. 
IMA 2 by 
Biochem 
Dx AMI hs-
cTnT 
min 1st 
Quartile 
Median 95% CI 3rd 
Quartile 
Max IQR 
AMI 
(n=7) 
98 105.8 110 98 to 125 123 125 17.7 
 
Non-AMI 
(n=166) 
59 106.0 115 113 to 
117 
123.5 160 17.0 
 
Table 37: As shown above represent IMA diagnostic parameters at 90 min 
after admission; when AMI and Hs-cTnT were used as a predicate.  The IMA 
values are presented as median, 95% CI, and quartile. 
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Table 38: Comparison of the magnitude of putative biomarkers on admission. 
Contrast  Difference 95% CI P value 
IMA v H-FABP   -0.14 -0.53 to   0.25 0.4882 
IMA v MYO  -0.24 -0.51 to   0.03 0.0771 
IMA v Copeptin  -0.08 -0.35 to   0.19 0.5430 
IMA v NT-pro-BNP -0.06 -0.42 to   0.29 0.7303 
IMA v CK-MB  -0.03 -0.37 to   0.31 0.8747 
H-FABP v MYO   -0.10 -0.25 to   0.04 0.1654 
H-FABP v Copeptin  0.06 -0.22 to   0.33 0.6930 
H-FABP v NT-pro-BNP  0.08 -0.40 to   0.55 0.7511 
H-FABP v CK-MB  0.11 -0.06 to   0.29 0.2062 
MYO v Copeptin  0.16 -0.05 to   0.37 0.1290 
MYO v NT-pro-BNP  0.18 -0.22 to   0.58 0.3762 
MYO v CK-MB  0.22 0.05 to   0.39 0.0128 
Copeptin v NT-pro-BNP 0.02 -0.42 to   0.46 0.9255 
Copeptin v CK-MB 0.06 -0.15 to   0.26 0.5895 
NT-pro-BNP v CK-MB  0.03 -0.47 to   0.54 0.8933 
 
Table 38: showed a statistically significant difference between Myoglobin and 
CK-MB on admission (P = 0.01).  As indicated above the remaining biomarkers 
did not demonstrate a statistically significant difference P > 0.5. 
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Table 39: Comparison of the magnitude of putative biomarkers at 90 min after 
admission. 
Contrast  Difference 95% CI P value 
IMA v H-FABP   0.00 -0.25 to 0.25 0.9899 
IMA v MYO  -0.13 -0.41 to 0.16 0.3781 
IMA v Copeptin   0.00 -0.38 to 0.38 0.9983 
IMA v NT-pro-BNP  0.03 -0.33 to 0.39 0.8759 
IMA v CK-MB -0.05 -0.36 to 0.25 0.7434 
H-FAB v MYO   -0.13 -0.33 to 0.07 0.2128 
H-FABP v Copeptin   0.00 -0.40 to 0.40 0.9953 
H-FABP v NT-pro-BNP  0.03 -0.48 to 0.53 0.9158 
H-FABP v CK-MB   -0.05 -0.28 to 0.18 0.6552 
MYO v Copeptin  0.13 -0.12 to 0.38 0.3205 
MYO v NT-pro-BNP   0.16 -0.29 to 0.60 0.4898 
MYO v CK-MB   0.08 -0.05 to 0.21 0.2505 
Copeptin v NT-pro-BNP  0.03 -0.43 to 0.49 0.9034 
Copeptin v CK-MB   -0.05 -0.28 to 0.17 0.6551 
NT-pro-BNP v CK-MB  -0.08 -0.56 to 0.40 0.7423 
 
Table 39: As indicated above all biomarkers did not demonstrate a statistically 
significant difference P > 0.5. 
 
4.8 Summary 
 
The introduction of any novel biomarker into prime time use within the ED, 
must demonstrate the clinical usefulness with the aim of influencing patients 
management in a cost and effective manner.  Presently hs-cTn are the most 
successfully biomarkers in an ED setting.  The present study suggests that the 
combined diagnostic efficiency of IMA plus hs-cTnT or I may be clinically 
useful.  The current study found no correlation exists between participant ages 
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and the concentration of different biomarkers on admission and at 90 min after 
admission.  When using the combine diagnostic efficiency of hs-cTnT, and IMA 
as a predicate for the diagnosis of AMI, this was not statistically significant p > 
0.5.  On the other hand, hs-cTnT was statistically significant (p = < 0.0001) 
when predicting the final diagnosis of AMI.  Myoglobin and CK-MB on 
admission were statistically significant (p = 0.013).  A single reliable biomarker 
of cardiac ischaemia remains to be established. 
 
4.9 RATPAC proposed sample size 
 
The RATPAC trial estimated 3130 participants will be needed for the trial.  
Similar randomised trial estimated that 50% of the control group would be 
discharged (Goodacre,Nicholl,Dixon et al., 2004).  A total of 1565 participants 
in each arm and an estimated 80% power to detect a 5% an absolute 
difference in primary outcome (50% vs. 55%) at the two-sided significance 
level of 5% were expected.  The sample for the two arms is expected to provide 
80% power to detect 2% absolute difference (2% vs. 4%) in major adverse 
events e.g. non-fatal AMI or death.  Based on previous studies the RATPAC 
team estimated that at least six hospitals will be required to recruit 550 suitable 
participants per year (Goodacre,Mason,Arnold et al., 2001; 
Goodacre,Nicholl,Dixon et al., 2004).  Previous study has demonstrated an 
expected response rate of 70-80% for postal questionnaire 
(Goodacre,Nicholl,Dixon et al., 2004). 
In the current project we calculated (Appendix 5) n = 1168 evaluable subjects 
on admission and 90 min after admission would be expected to have 80% 
power to detect a 5% absolute difference in primary outcome at the two 
significant levels of 5%.  Unfortunately, the sample (n = 174) acquired in this 
project were under powered.  Thus, the samples used in this project were not 
expected to provide 80% power to detect 2% absolute difference (2% vs. 4%) 
in major adverse. 
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4.10 Summary of correlations between participant ages and 
various cardiac biomarkers 
 
Table 40: Summary of correlations between participant ages and various 
cardiac biomarkers 
Participants age vs., biomarkers concentration R2 value 
Age vs. IMA on admission 0.0039 
Age vs. IMA min after admission 0.0052 
Age vs. Accu TnI on admission 0.0105 
Age vs. Accu 90 min after admission 0.0031 
Age vs. Beckman hs-c TnT on admission 0.0054 
Age vs. Beckman hs-c TnT 90 min after admission 0.0054 
Age vs. Centaur TnI on admission 0.0004 
Age vs. Centaur TnI 90 min after admission 0.0011 
Age vs. h-FABP on admission 0.0206 
Age vs. h-FABP 90 min after admission 0.0031 
Age vs. Myoglobin on admission NC 
Age vs. Myoglobin 90 min after admission 0.0031 
Age vs. Copeptin on admission 0.0014 
Age vs. Copeptin 90 min after admission 0.0001 
Age vs. Roche hs-cTnT on admission NC 
Age vs. Roche hs-cTnT 90 min after admission 0.0031 
Age vs. NT-pro-BNP on admission 0.0008 
Age vs. NT-pro-BNP 90 min after admission 0.0031 
Age vs. CK-MB on admission 0.0036 
Age vs. CK-MB 90 min after admission 0.0040 
NC = Not calculated 
 
Table 40: As shown above represent correlation of participant age and 
different biomarkers on admission and 90 min after admission. No correlation 
exists between age and putative biomarkers. 
200 
 
4.11 Summary of correlation studies of participants 
biomarkers concentrations on admission and 90 min after 
admission 
 
Table 41: Summary of correlations between biomarkers on admission and 90 
min after admission 
Biomarker concentration on admission vs., 90 min 
after admission 
R2 value 
IMA on admission vs. IMA 90 min after admission 0.43 
 
Accu TnI on admission vs. Accu 90 min after admission 0.003 
 
Beckman hs-c TnT on admission vs. Beckman hs-c TnT 
90 min after admission 
0.012 
 
 
Centaur TnI on admission vs. Centaur TnI 90 min after 
admission 
0.0003 
 
h-FABP on admission vs. h-FABP 90 min after admission 0.71 
 
Myoglobin on admission vs. Myoglobin 90 min after 
admission 
0.86 
 
Copeptin on admission vs. Copeptin 90 min after 
admission 
0.002 
 
Roche hs-cTnT on admission vs. Roche hs-cTnT 90 min 
after admission 
0.21 
 
 
NT-pro-BNP on admission vs. NT-pro-BNP 90 min after 
admission 
 
 
CK-MB on admission vs. CK-MB 90 min after admission 0.94 
 
Table 41: As shown above represent correlation of different biomarkers on 
admission and 90 min after admission.  A statistically significant (p = 0.002) 
correlation between Copeptin on admission vs. Copeptin 90 min after 
admission. Also, a statistically significant (p = 0.05) correlation exist between 
Accu TnI on admission vs. Accu 90 min after admission, Centaur TnI on 
admission vs. Centaur TnI 90 min after admission and Beckman hs-c TnT on 
admission vs. Beckman hs-c TnT 90 min after admission (table 41).  
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Table 42: Current project participant ECG finding by gender.  
Participants 
(n = 174) 
Normal 
ECG 
BBB T-wave 
inversion 
AMI ER Hospitalisation 
from ACS 
ECG 
ischaemia 
Male 92 1 6 - 2 1 6 
Female 82 2 7 3 - 1 7 
Total days 
in hospital; 
 One male for 37 days 
One female for 7 days 
ER = Emergency revascularisation.  BBB = Bundle branch block 
 
Table 42: As shown above represent the current study participants clinical 
finding including ECG finding and days in hospital. 
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Table 43: Current summary data of positive patients, per biomarker on 
admission and at 90 min after admission. 
Assay 
Number of positive patients 
(n = 174) 
IMA on admission 21 (13%) 
IMA min after admission 14 (9%) 
Accu TnI on admission 0 
Accu 90 min after admission 0 
Beckman hs-c TnI on admission 4 (4%) 
Beckman hs-c TnI 90 min after admission 4 (4%) 
Centaur TnI on admission 0 
Centaur TnI 90 min after admission 0 
h-FABP on admission 9 (5%) 
h-FABP 90 min after admission 9 (5%) 
Myoglobin on admission 14 (8%) 
Myoglobin 90 min after admission 15 (9%) 
Copeptin on admission 0 
Copeptin 90 min after admission 0 
Roche hs-cTnT on admission 6 (3%) 
Roche hs-cTnT 90 min after admission 6 (3%) 
NT-pro-BNP on admission 8 (8%) 
NT-pro-BNP 90 min after admission 9 (5%) 
CK-MB on admission 4 (4%) 
CK-MB 90 min after admission 2 (2%) 
 
Table 43: As shown above represent the number of participants with results 
above the clinical cut-off for each biomarker on admission and at 90 min after 
admission.  IMA test scored 13% or 21 positive results in the current study.  
Copeptin, Centaur TnI and Accu TnI failed to identify positive participant.  Hs-
TnT was used a predicate. 
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Figure 50:  Decision tree (M = Markov model) Adapted from Kondo et al. Clin Exp Nephrol 2012.  
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Demographics
Age
Gender 
AMI Status
True negative
and true positive
Diagnostic strategies
• No testing
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Calculate cost of
testing and stay 
in ED setting
Short term
Cost to ED and 
testing
Diagnostic cost
 
Figure 51: Basic cost-effective analysis model structures 
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4.12 The cost-effectiveness planes 
 
The incremental cost and the incremental effect can be visualised using the 
incremental cost-effectiveness plan (figure 52) 
 
New diagnostic test (IMA)
More costly
New diagnostic test 
(IMA)
More effective
New diagnostic 
test (IMA)
Less effective
New diagnostic test (IMA)
Less costly
Existing diagnostic test (IMA)
dominates
New diagnostic test 
(IMA) less costly but 
less effective
New diagnostic test (IMA) 
more effective but more costly
New diagnostic test (IMA)
dominates
c
Incremental effect
In
c
re
m
e
n
ta
l 
c
o
s
t
Maximum acceptable 
incremental cost-
effectiveness ratio 
(ICER) (£20,000 )
NW (4)
SW (3)
NE (1)
SE (2)
B
A
 
 
Figure 52: The cost-effectiveness plane for ischaemia-modified albumin (IMA). 
(adapted from Applied Methods of CEA in Health Care by Alistair Gray page 12). 
 
The horizontal axis divides the plan according to incremental cost with a 
positive above and a negative below; on the other hand, the vertical axis 
divides the plane according to incremental effect the positive the right and the 
negative to the left.  The overall design divides the incremental cost 
effectiveness plane into four quadrants.  The role of each quadrant helps 
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improve and have an implication on the overall decision.  Interventions falling 
in the southeast quadrant with negative cost and positive effect are considered 
cost-effective.  In contrast, interventions falling in the northwest quadrant with 
positive cost and negative effect are not considered cost-effective and would 
be costlier. 
If we consider interventions that their ICER fell in the northwest quadrants, with 
positive cost and positive effects, or the southwest quadrants, with negative 
costs and negative effects are considered equivalents and usually both 
interventions are considered equal. 
 
4.12.1 Incremental effect of Ischaemia modified-albumin assay 
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Figure 53: The incremental cost-effectiveness plane.  NE = northeast quadrant; NW 
= northwest quadrant; SE = Southeast quadrant; SW = southwest quadrant. 
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Table 44: Summary cost estimation of IMA and hs-cTnT on admission  
Test Test Cost (£) per 
174 patients 
Effectiveness 
cost (£) 
Per high risk 
patients 
Incremental 
cost 
effectiveness  
ratio 
Hs-cTnT  696.00 464.00 -4.2 
 
IMA 4,698.00 1,424.00 4.2 
 
Table 44: IMA ICER fall in the north eats quadrant with a positive value of 
4.2.  
 
4.13 The cost-effectiveness-analysis of using ischaemia 
modified-albumin assay 
 
The objective 
 
• To evaluate the cost-benefit analysis of using IMA test alone or in 
combination with other biomarkers for the diagnosis of AMI on 
admission. 
• To evaluate the best strategies of using IMA in combination with other 
biomarkers. 
 
The cost for myoglobin, CK-MB to the trust is lower than hs-cTn; however, only 
hs-cTn is required by the universal definition of AMI.  At St George’s 
Healthcare NHS Trust, myoglobin, CK-MB and hs-cTnT tests can be 
measured using the existing analyser.  In contrast, IMA requires a standalone 
analyser or optimisation and integration into the current instrument; thus, 
additional cost.  It is well documented that measuring myoglobin, CK-MB and 
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hs-cTn as a cardiac panel has no diagnostic efficiency superior to that of single 
hs-cTn test (Goodacre,Bradburn,Cross et al., 2011).  The cost effectiveness 
analysis shows that measurement of hs-cTn alone was the most-effective 
diagnostic strategy (Goodacre,Bradburn,Cross et al., 2011).  Previous studies 
and the present study showed that measuring IMA as part of a cardiac panel 
may be useful (Mehta,Marwah,Ghosh et al., 2015; Pan,Tong,Lin et al., 2010; 
Patil,Banker,Padalkar et al., 2013).  Combined IMA plus hs-cTnT or Centaur 
cTnI measurement at admission has a superior sensitivity and specificity 
compared to other biomarkers on this study (table 49).  At St George’s 
Healthcare NHS Trust, hs-cTnT; is offered as routine using Roche platform.  
Moreover, IMA measurement can also be carried out in house using a Roche 
Cobas Mira plus or Hitachi 911 (Roche) analyzers.  Currently, Hitachi 911 is 
capable of interfacing with the current hospital information system ensuring 
continuity of clinical governance and does not require special training. 
Based on the present study, combined IMA plus hs-cTnT measurement on 
admission was the most diagnostically efficient panel therefore it may be useful 
in assessing low risk patients.  Thus, the cost-benefit analysis was based on 
the following strategies: 
1. Discharge patient without treatment or testing 
2. Discharge patient with IMA negative  
3. Discharge patients if IMA plus hs-cTnT are negative. 
 
The sensitivity and specificity of strategies tested are listed in table 45. 
Table 45: Combined sensitivity and specificity used in cost-benefit analysis. 
Strategy Sensitivity  
(95% CI) 
Specificity  
(95% CI) 
No testing 0 1 
IMA plus hs-cTnT 70% (55-82%) 100% (98-100%) 
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4.12.2 Cost benefit analysis 
 
The ED staffs are required to diagnose and refer AMI patients to the cardiac 
unit within 90 min or less after admission (door-to-balloon time) 
(Amsterdam,Wenger,Brindis et al., 2014).  It is therefore reasonable to suggest 
that the cost-benefit analysis could be based on the assumption of doctor on 
demand scenario.  Moreover, the cost benefit analysis is also based on the 
assumption that 174 present study patients will be treated.  Using this cohort 
allows a complete data measurement on admission and 90 min after 
admission. 
The current strategy of using hs-cTn as the first diagnostic test for AMI in low 
risk patients presenting to the ED with chest pain suggestive of AMI; will 
require at least two or more hs-cTn measurement and it could take up to 12 h 
to rule-in or rule-out AMI.  IMA testing (early biomarker) diagnostic window of 
opportunity passes after 90 min.  The cost of measuring IMA on admission is 
higher than hs-cTn (table 47).  However, IMA assay can only be cost effective 
if measured only on admission and in combination with hs-cTnT.  The reason 
for this is that hs-cTnT alone is capable of detecting patients AMI over time.  
As demonstrated by the AUC, IMA as a standalone test cannot compete with 
the diagnostic efficiency of hs-cTn on admission or 90 min after admission.  
However, combined IMA assay with Centaur cTnI or hs-cTnT may be useful 
and could be used to rule-out AMI.  The total cost of each patient’s 
management increases as sensitivity and specificity decreases and more 
patients require conventional admission, 3 h, 6 h, 10 and 12 h, hs-cTn testing.  
Cost of tests per manufacturer and cost benefit analysis are summarised in 
table 47. 
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4.12.3 Cost benefit analysis calculation 
 
The cost used to calculate the health economics in this study is provided by 
the manufacturers (table 46).  The current total cost of using hs-cTnT, if 
measured on admission, 3 h, 6 h and 12 h is approximately £16.00 per 
patients; whereas IMA test is £27.00 per test per patient when measured only 
once on admission.  The calculation is based on the assumption that IMA can 
only be accepted if low risk patients presenting with chest pain suggestive of 
AMI could be discharged in < 90 min and with testing IMA just on admission.  
Thus, potential saving due to reduced cost of observation, beds occupation 
(£300 per day), crowding and expensive investigations such as imaging. 
 
Table 46: Cost per test as provided by manufacturer. 
Assay Manufacturer Cost per sample 
AccuTnI Beckman £7.40 
Hs-cTnI Beckman  £7.40 
TnI Ultra Siemens  £6.20 
hs-cTnT Roche £4.00 
NT-pro-BNP Siemens £19.65 
H-FABP Randox  £4.95 
Myoglobin Randox  £2.78 
CK-MB Randox  £2.56 
ACB® (IMA®) Inverness Medical £27.00 
Copeptin Randox £15.00 
 
4.12.3.1 Current cost for screening n = 174 low risk patients on 
admission and 3 h after admission, using hs-cTnT alone 
 
• Cost exclude overhead 
• Hs-cTnT cost = £4.00 per test  
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• Total Cost (hs-cTnT) = (174 x £4.00 = £696.00) = £696.00 x 2 = 
£1,392.00 
 
4.12.3.2 Cost per high risk patients when using hs-cTnT 
 
• £1,392.00 ÷ 3 (high risk patients) = £464.00 
 
4.12.3.3 Total cost for screening n = 174 low risk patients using IMA and 
hs-cTnT on admission  
 
• Hs-cTnT cost = £4.00 per test  
• Total Cost (hs-cTnT) = (174 x £4.00 = £696.00) 
• IMA cost = £27.00 per test  
• Total cost (IMA) = (£27.00 x 174 = £4,698.00) 
• The total cost of screening this cohort of patients (n = 174) is 
 £ 4,698.00 + £696.00 = £5,394.00 
OR £31.00 per patient 
 
4.12.3.4 Single IMA testing on admission scenario 
 
• Cost of assays excluding overhead 
• IMA strategy for treating 174 low risk patients 
• 3 patients had the final diagnosis of AMI, thus three high risk patients 
 
4.12.3.5 Calculation of cost benefit of treating one high risk patient using 
IMA testing: 
 
Cost benefit = Cost of recommended strategy – cost of current strategy ÷ 3 
high risk patients 
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= £4,968.00 – 696.00 ÷ 3 = £ 1,424.00 per high risk patient 
The introduction of IMA test as a standalone will cost the healthcare system 
an estimated £ 1,424.00 per high risk patient or £31 per screened patients 
compared to £8 when hs-cTnT is measured on admission and 3 h after 
admission as per current protocol. 
4.12.3.6 Cost benefit per panel based on screening 174 patients on 
admission  
 
• Cost per combined IMA plus hs-cTnT per panel per patient: £27.00 + 
£4.00 = £31.00 
• Total cost for screening n = 174 using the combined diagnostic 
efficiency of IMA plus hs-cTnT is: £31.00 x 174 = £ 5,394.00 
 
4.12.3.7 Calculation of cost benefit of treating one high risk patient using 
IMA plus hs-cTnT panel 
 
Cost benefit = Cost of recommended strategy – cost of current strategy ÷ 3 
high risk patients 
= £5,394 – 696 ÷ 3 = £ 1,566 per high risk patient 
Combined IMA plus hs-cTnT if introduced will cost £1,566 per high risk 
patients.  The total cost for screening 174 low risk patients when using 
combined IMA plus hs-cTnT is as follow: £31 x £174 = £ 5,394.00. 
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Table 47: Cost benefit analysis on admission when using combined diagnostic 
efficiency of IMA and other biomarkers. 
Test 
combination 
Cost 
per test 
Current 
cost on 
admission 
(£) per 
panel 
Cost benefit 
on 
admission 
(£)  
Saving per 
high risk 
patients 
(£) 
No Testing 0 0 0 889.00* 
IMA admission 27.00 27.00 1,334.00 -1,102.00 
IMA + Myoglobin 2.78 29.78 1,495.24 -1,263.24 
IMA + CK-MB 2.56 29.56 1,482.48 -1,250.48 
IMA + Accu cTnI 7.40 34.40 1,763.20 -1,531.20 
IMA + Beckman 
cTnI 
7.40 34.40 1,763.20 -1,531.20 
IMA + cTnT 
(Roche) 
4.00 31.00 1,566.00 -1334.00 
IMA + Centaur 
cTnI 
6.20 33.20 1,693.60 -1,461.60 
IMA + H-FABP 4.95 31.95 1,621.10 -1,389.20 
IMA + Copeptin 15.00 42.00 2,204.00 -1,972.00 
IMA + NT-pro-
BNP 
19.65 46.65 2,473.70 -2,241.70 
(-) indicate extra cost to the healthcare system per high risk patients.  (*) 
£889.00 saving per patient prevented from admission (Byrne, 2014). 
 
Table 47 above compared the cost benefit analysis of IMA testing alone and 
in combination with other biomarkers.  Single IMA testing on admission will 
cost the healthcare system an additional £ 1102.00 per high risk patients in 
every 174 patients admitted.  The total cost to the healthcare system in term 
of screening 174 patients is £4,698.00. 
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4.12.3.8 Number needed to treat 
 
From 444 available samples, a total of 348 (78%) had complete matched and 
paired (i.e.  sample available on admission and 90 min after admission) data 
including concentration values for hs-cTnT, hs-cTnI, copeptin, H-FABP, 
myoglobin, NT-pro-BNP, CK-MB, IMA and outcome of MACE.  The number 
needed to treat (NNT) was based on n = 174 patients who, on admission, had 
a complete data set.  The current project found 7 cases of MACE when IMA 
plus hs-cTnT was used to predict the outcome of MACE.  In contrast the 
RATPC reported 4 cases.  Moreover, NNT was calculated using the combined 
diagnostic efficiency of IMA plus hs-cTnT, as IMA alone was not diagnostically 
efficient.  Thus, NNT calculation of IMA assay alone was not warranted. 
NNT was calculated using the outcome e.g. MACE.  The outcome (MACE) as 
established by the RATPAC study was considered the experimental events 
rate (EER) whereas IMA plus hs-cTnT diagnostic outcome was considered the 
controlled events rate (CER). 
Number needed to treat calculation: 
Table 48: Summary for NNT 
Variable IMA + hs-cTnT 
 (n = 174) 
RATPAC  
(n = 174) 
Total MACE 7 4 
 CER EER 
 
Number needed to treat (NNT) = 1 ÷ absolute risk reduction (ARR) 
= 1/ARR 
ARR = Controlled events rate (CER) – Experimental events rate (EER) 
ARR = CER – EER 
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       = 4% – 2% = 2% 
NNT = 1/0.02 = 50 
In order to diagnose and treat one patients at leats 50 patients (£1,550.00) 
needed to be screened for ACS using the combined diacnostic efficiency of 
IMA plus hs-cTnT.  
4.14 Summary finding  
 
The introduction of IMA assay as a standalone test provides no additional 
clinical information superior to that of hs-cTn and cost more than hs-cTnT or I 
strategy.  In addition, as it stands IMA assay alone is not suitable for the 
diagnosis of ACS or ischaemic cardiac patients in an ED setting.  However, 
the combined diagnostic efficiency of IMA plus hs-cTnT may be useful.   
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Table 49: Diagnostic efficiencies of individual biomarkers on admission (sample 1) and 90 minutes (sample 2). 
 Sensitivity  Specificity   PPV   NPV  
Sample (1) % 95% CI % 95% CI % 95% CI % 95% CI 
IMA  100 (59-100) 10.2 (6.1-15.9) 4.5 (1.8-9.0) 100 (80.5-100) 
AccuTnI  0 (0-41) 98.2 (94.0-98.6) 0 (0-70) 95.9 (91.7-98.3) 
Beckman hs-TnI 0 (0-52) 98.5 (94.8-99.8) 0 (0-84.2) 94.4 (91.9-98.8) 
Centaur TnI 14.3 (9.4-57.9) 89.8 (84.1-93.9) 5.6 (0.1-27.3) 96.1 (91.8-98.6) 
H-FABP 28.6 (3.7-71) 65.7 (91.3-98.2) 22.2 (2.8-60) 96.9 (92.9-99.0) 
Myoglobin 14.3 (0.4-57.9) 96.4 (92.3-98.7) 14.3 (0.4-57.9) 96.4 (92.3-98.7) 
Copeptin   57.1 (18.4-90.1) 46.2 (38.2-54.3) 4.5 (1.2-11.1) 96.1 (88.9-99.2) 
hs-cTnT   28.6 (3.7-71) 100 (97.8-100) 100 (15.8-100) 97.1 (93.3-99.0) 
NT-pro-BNP 28.6 (3.7-71) 96.4 (92.3-98.7) 25 (3.2-65.1) 97 (93.1-99.0) 
CK-MB 14.3 (0.4-57.9) 98.2 (94.8-99.6) 25 (0.6-80.6) 96.4 (92.4-98.7) 
Sample (2) % 95% CI % 95% CI % 95% CI % 95% CI 
IMA  0 (0-41.1) 86.7 (80.6-91.5) 0 (0-15.4) 95.4 (90.7-98.1) 
AccuTnI  42.9 (9.9-81.6) 97.6 (93.9-99.3) 42.9 (9.9-80.6) 97.6 (93.9-99.3) 
Beckman hs-TnI 20 (0.5-51.6) 97.8 (93.7-99.5) 25 (0.6-80.6) 97.1 (92.7-99.2) 
Centaur TnI 71.4 (29-96.3) 89.8 (84.1-93.9) 22.7 (7.8-45.4) 98.7 (95.3-99.8) 
H-FABP 42.9 (9.9-81.6) 96.2 (91.9-98.6) 33.3 (7.5-70.1) 97.4 (93.6-99.3) 
Myoglobin 14.3 (0.4-57.9) 95.7 (91.4-98.3) 12.5 (9.3-52.7) 96.3 (92.1-98.6) 
Copeptin   71.4 (29-96.3) 52.5 (44.5-60.4) 6.2 (2.0-13.8) 97.7 (91.9-99.7) 
Hs-cTnT   85.7 (42.1-99.6) 100 (97.8-100) 100 (54.1-100) 99.4 (96.7-100) 
NT-pro-BNP 28.6 (3.7-71.0) 95.7 (91.4-98.3) 22.2 (2.8-60) 96.9 (92.9-99) 
CK-MB 14.3 (9.4-57.9) 9.94 (96.5-100) 50 (1.3-98.7) 96.3 (92.1-98.6) 
IMA, ischaemia modified albumin; PPV, positive predictive value; NPV, negative predictive value; 95%CI, 95% confidence 
interval; CK-MB, creatine kinase isoenzyme MB; h-FABP, heart fatty-acid binding protein. 
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Table 50: Combined performance of cardiac biomarkers 
Sample 1 Sensitivity % Specificity % Positive likelihood Negative likelihood 
Tests 95%CI 95%CI 95%CI 95%CI 
IMA + Copeptin 71.4 (0.36-0.92) 46.4 (0.39-0.54) 1.332 (0.82-2.17) 0.616 (0.19-2.0) 
IMA + hs-TnT 42.9 (0.16-0.75) 88 (0.82-0.92) 3.557 (1.38-9.19) 0.650 (0.34-1.24) 
IMA + h-FABP 29 (0.08-0.64) 83.3 (0.77-0.88) 1.714 (0.51-5.81) 0.857 (0.53-1.38) 
Sample 2         
IMA + Copeptin 71.4 (0.36-0.92) 55.4 (0.48-0.63) 1.60 (0.97-2.63) 0.52 (0.15-1.67) 
IMA + hs-TnT 1.0 (0.06-1.0) 76 (0.69-0.82) 4.15 (3.1-5.4) - - 
IMA + h-FABP 57.1 (0.25-0.84) 87.3 (0.82-0.92) 4.51 (2.11-9.66) 0.49 (0.21-1.16) 
 
Table 50: Shows that IMA plus copeptin has the highest sensitivity on admission and at 90 min after admission 71.4% 
(95% CI, 0.36 to 0.92%) and 71.4 (0.36-0.92) respectively. The positive likelihood and the negative likelihood were 1.33% 
(95% CI, 0.82 -2.17) and 0.62 (95% CI, 0.19 – 2.0) respectively. 
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Chapter 5  
Discussion 
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5.0 Introduction  
 
This thesis describes the potential diagnostic value of the current conventional 
cardiac biomarkers and the novel biomarkers in detecting low risk patients with 
AMI.  This chapter includes the main discussion on the findings of IMA assay, 
conventional biomarkers and novel biomarkers. 
To reduce misdiagnosis of patients with AMI and the unnecessary 
investigations; healthcare professionals have considered the possibility of 
combining established cardiac biomarkers such as hs-cTn and novel 
biomarkers including biomarkers of ischaemia (whole blood choline), coronary 
plaque destabilisation (myeloperoxidase), coronary plaque formation 
(homocysteine), myocardial necrosis (H-FABP)), inflammatory biomarkers 
(cytokines), oxidative stress (IMA), and vascular stress (copeptin) for the 
diagnosis of AMI especially NSTEMI (Apple,Smith,Pearce et al., 2009; 
McLean & Huang, 2012).  Among these novel biomarkers outlined above, only 
the albumin cobalt binding (ACB®) assay, to determine IMA, has been CE 
marked in Europe and approved by the FDA in the USA for the detection of 
myocardial ischaemia.  The FDA authorised the use of IMA assay in an ED 
setting and in the clinical scenario where cTn and ECG are both negative.  
Since IMA assay has been authorised by the FDA, there remains a number of 
unresolved issues regarding its specificity and its molecular structure 
(Collinson & Gaze, 2008).  The ACB® assay is an indirect measurement of 
IMA; thus, in real terms IMA as a protein has not being directly measured 
(Bhagavan,Lai,Rios et al., 2003). 
Currently copeptin is authorised by NICE to aid the diagnosis of AMI when cTn 
and ECG are both negative.  Although, copeptin was authorised by NICE for 
the use in an ED setting, a number of issues including, its kinetic release, and 
its low specificity are still unresolved (Nemec,Koller,Nickel et al., 2010; 
Nickel,Bingisser & Morgenthaler, 2012).  Thus, currently copeptin and IMA are 
not offered as a routine test in ED across the UK. 
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There is some evidence to suggest that a multi-biomarker approach may be 
useful in ACS patient’s management especially in the ED 
(Apple,Pearce,Chung et al., 2007; Morrow & Braunwald, 2003).  The following 
biomarker, NT-pro-BNP (Brown,Sease,Robey et al., 2007), copeptin 
(Reichlin,Hochholzer,Stelzig et al., 2009), H-FABP (Haltern,Peiniger,Bufe et 
al., 2010) and IMA have been investigated (Collinson,Gaze,Bainbridge et al., 
2006; Peacock,Morris,Anwaruddin et al., 2006).  Collectively these biomarkers 
are known to increase during the inflammatory process and during cardiac 
ischaemia.  Previous studies have suggested that increases in these 
biomarkers upstream from biomarkers of necrosis may help in the diagnosis 
of AMI (Figure 54) (Morrow & Braunwald, 2003; Pai,Pischon,Ma et al., 2004; 
Vasan, 2006). 
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Figure 54: The kinetic release of IMA (dotted line) and cTn (solid line) and 
natriuretic peptide (dashed line) [bottom panel], in relation to time and tissue 
damage [top panel]. (By Dr D Gaze.  St George’s Healthcare NHS. London).  
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The rational for using these biomarkers is the possibility to improve the 
diagnosis efficiency of ACS, potentially improving the rule-out and rule-in 
protocol and help shorten the patient’s hospital stay thus saving resources 
(Roberts, 1998).  Prior to this study and to the best of my knowledge no 
research group has compared IMA plus hs-cTn in the diagnosis of low risk 
patients with AMI.  Moreover, studies regarding the evaluation of the diagnostic 
efficiency IMA plus H-FABP and IMA plus NT-pro-BNP are scares.  Therefore, 
a better understanding of this biomarker in combination with latest generation 
of hs-cTn assays is required before they could be considered for prime-time 
use. 
Before commencing the present study, it was necessary to establish the 
reference interval for IMA assay.  The current proposed IMA reference interval 
as determined by the manufacturer was carried out using the Cobas Mira plus 
analyser (Roche) and determined in 283 apparently healthy individuals.  The 
IMA concentrations ranged from 52-116 KU/L.  The 95th percentile was at 85 
KU/L.  Although, the preliminary clinical cut-off for IMA to rule-out ACS is 85 
KU/L, manufacturers (ISCHEMIA Technologies, Denver Colorado) suggested 
a higher value of 100 KU/L should be used.  They argued that reference 
population and the 85 KU/L value was not corrected for age, smoking and 
gender.  Using different instrument (Beckman Coulter LX-20) IMA 
concentrations for a reference population of 110 KU/L was also used for the 
diagnosis of AM (Maguire,O'Sullivan,Ryan et al., 2006).  Although, the present 
study did not look at IMA concentrations in different ethnic groups; our findings 
are in agreement with one study that found that gender had no significant 
influence on IMA concentrations; whereas race (black vs. Caucasian) has.  It 
must be noted that both studies used a small cohort of volunteers 
(Govender,De Greef,Delport et al., 2008). 
The optimum upper ACB® decision limit for evaluating diagnostic sensitivity, 
specificity and predictive value has not yet been established.  The ACB® test 
manufacturers recommend that laboratories should establish their own IMA 
clinical cut-off (Inverness, 2005).  In the present study the reference population 
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(n = 66) the median IMA was 122 KU/L, (interquartile range 121-124 KU/L).  
The median IMA value was higher than previously published data 
(Beetham,Monk,Keating et al., 2006).  However, this observed difference in 
concentration compared to recommended clinical cut-off (85 KU/L) may be due 
to the pre-analytical variable including temperature and long-term sample 
storage.  Samples stored at - 20 0C yielded IMA values on average 3 units 
higher than those analysed within 2.5 h (mean 90.5 vs. 87.5; P < 0.001) 
(Beetham,Monk,Keating et al., 2006).  Another, study also found that storage 
at -20 0C may increase IMA concentration by as much as 10% 
(Maguire,O'Sullivan,Ryan et al., 2006).  In the present study, samples were 
stored for at least four years, thus the difference in clinical cut-off may be 
accounted for by storage conditions.  However, throughout the present study 
we used the IMA clinical cut-off of 127 KU/L for diagnosis of AMI. 
In practical terms samples sent from ED to the laboratory at St George’s 
Healthcare NHS Trust are considered urgent and the local guidelines require 
trust to analyse ED samples within 45 min.  However, the current turnaround 
time for ED samples and in particular cTn is approximately 120 min.  In a real 
scenario, these samples may be subject to delays due to work load, staffing 
issues and pre-analytical errors.  Therefore, any delay in sample receipt may 
affect IMA results. 
 
5.1 Clinical utility of ischemia modified-albumin and high 
sensitivity cardiac troponin 
 
In our study the combined sensitivity and specificity of IMA plus hs-cTnT on 
admission was 71% (95% CI, 56-82%) and 100% (95% CI, 98-100%) 
respectively; the NPV was 94%.  The good diagnostic efficiency of hs-cTn 
when combined with IMA may be due to the lower detection limit of hs-cTnT.  
Since the introduction of hs-cTn immunoassay the sensitivity has increased 
from 83% (95% CI, 76-90%) to 95% (95% CI, 90-98%), (Reichlin et al., 2009). 
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There is a number of studies that have found that the combined diagnostic 
efficiency of IMA and conventional cTn at presentation has an excellent 
sensitivity close to 100% for predicting the final diagnosis of AMI (Collinson, 
2006; Keating,Benger,Beetham et al., 2006).  Contrary to these previous 
studies; our study found that the combined diagnostic efficiency of IMA plus 
conventional cTn on admission and at 90 min after admission ranged from 
49%-54% and 14%-15% respectively.  The reason for this difference is 
twofold: firstly, the definition of time zero is taken at admission which can 
greatly vary according to geographic location and local triage protocols, thus 
the diagnostic efficiency of cTn may vary between studies.  Also, the 
population used in this study is a very low risk cohort with low probability of 
AMI.  Secondly, in this study the median time from onset of chest pain to the 
last troponin measurement was 495 min or 8:25 h (interquartile range (IQR) 
310-738 min).  Samples taking at 3 h or more after the last onset of chest pain 
may be unsuitable for IMA analysis.  At this stage the IMA diagnostic window 
may be missed, and therefore IMA concentration may be normal 
(Cho,Choi,Kim et al., 2007; Dusek,St'asek,Tichy et al., 2006; Quiles,Roy,Gaze 
et al., 2003; Sinha,Vazquez,Calvino et al., 2006; Zapico-Muniz,Santalo-
Bel,Merce-Muntanola et al., 2004).  On the other hand, even samples that were 
collected in < 6 h would have an effect on the circulating concentration of 
various biomarkers including copeptin, NT-pro-BNP, hs-cTn, H-FABP, 
myoglobin and CK-MB.  The kinetic release of all the mentioned biomarkers is 
optimal in the first 2 to 4 h of the onset of chest pain 
(Eggers,Oldgren,Nordenskjold et al., 2004; Kavsak,MacRae,Lustig et al., 
2006; Tucker,Collins,Anderson et al., 1997). 
Various studies confirm that the diagnostic sensitivity of hs-cTn ranges 
between 82%-100% (Keller,Zeller,Ojeda et al., 2011; Keller,Zeller,Peetz et al., 
2009; Reichlin,Hochholzer,Bassetti et al., 2009).  In agreement with this 
observation, the present study found that the collective diagnostic efficiency of 
the conventional cTn ranged from 84%-88% on admission and from 78%-84% 
at 90 min after admission.  In contrast, the diagnostic efficiency of hs-cTn 
ranged from 85%-100% on admission and 78%-100% 90 min after admission.  
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Moreover, in agreement with previous findings hs-cTn is still the most reliable 
method for assessing low risk patients presenting to ED with chest pain (Apple, 
2011; Mills,Churchhouse,Lee et al., 2011). 
Generally, the findings in this study are in agreement with other studies. As 
demonstrated in a cumulative meta-analysis of these studies, the NPV of IMA 
can be used to rule-out ACS patients (Peacock,Morris,Anwaruddin et al., 
2006).  In our study, the IMA assay has an excellent NPV, which could be 
integrated into a risk score in conjunction with NT-pro-BNP and cTn 
(Bali,Cuisset,Giorgi et al., 2008).  Although, the IMA assay have a good NPV 
this does not necessary translate into a practical triage tool in an ED setting, 
its NPV merely indicates the disease prevalence in the studied population 
(Sbarouni,Georgiadou,Panagiotakos et al., 2008).  CTnT coupled with NPV of 
IMA was found to be an independent predictor of the risk of developing ACS 
(Talwalkar,Bon Homme,Miller et al., 2008).  In the present study, IMA, hs-cTn 
and the conventional cTn were not strong predictors of MACE at 30 days with 
AUC of the ROC curve varying from 52-53% on admission and 54-64% at 90 
min after admission.  The reason for this is not clear.  One probable 
explanation could be that the present study consists entirely of very low risk 
patients with low probability of MACE at 30 days. 
 
Our study found, that the diagnostic efficiency of IMA concentration on 
admission had an AUC of ROC curve of 57% (95% CI, 43-66%) and 58% (95% 
CI, 35-81%) at 90 min after admission.  The low diagnostic performance of IMA 
assay may be explained by the fact that IMA is not cardiac-specific and has a 
limited diagnostic window (Abboud,Labreuche,Meseguer et al., 2007; 
Talwalkar,Bon Homme,Miller et al., 2008).  Based on this finding IMA testing 
alone is not suitable for assessing chest pain patients. 
 
The utilisation of delta values in the present study did not improve the 
diagnostic efficiency of all biomarkers (table 32 & 33).  The rate of change 
(delta value) of myoglobin has been claimed to improve the diagnostic 
sensitivity (Straface,Myers,Kirchick et al., 2008).  Conversely, in the present 
225 
 
study a delta changes in both absolute and percentage change in myoglobin 
and CK-MB did not significantly helped to improve the diagnostic efficiency of 
AMI (table 327 33).  In agreement with our study a systematic-review of the 
diagnostic efficiency of myoglobin and CK-MB concluded that these 
biomarkers do not have an incremental value for early diagnosis of AMI 
(Keller,Zeller,Peetz et al., 2009). 
 
The evaluation of novel biomarkers including IMA was challenging given that 
in some cases most studies were heterogeneous in regards to methodology 
one study that used hs-cTn and IMA also used mixed ACS patients 
(Mehta,Marwah,Ghosh et al., 2015), serum sampling, the impact of the new 
definition of AMI, the introduction of hs-cTn, definition of clinical end point i.e. 
ACS or AMI.  In addition most studies looking at novel biomarkers were 
observational (Lin,Yokoyama,Rac et al., 2012). 
 
5.2 Novel biomarkers in assessing acute myocardial infarction 
 
5.2.1 Copeptin 
 
In the present study, copeptin was diagnostically comparable on admission to 
IMA with an AUC of ROC curve of 58% (95% CI, 48-68%) compared to 54% 
(95% CI, 43-66%) respectively.  At 90 min after admission copeptin was also 
diagnostically comparable to IMA with AUC of ROC curve of 63% (95% CI, 38-
89%) and 58% (95% CI, 35-81%) respectively.  Various studies found that 
copeptin is elevated in STEMI patients vs. NSTEMI; this difference is thought 
to be due to an acute endogenous stress and may suggest that copeptin 
elevation is of cardiac origin (Charpentier,Maupas-Schwalm,Cournot et al., 
2012; Gu,Voors,Zijlstra et al., 2011; Reichlin,Hochholzer,Stelzig et al., 2009).  
The utilisation of low risk patients in the present study may contribute to this 
low sensitivity.  Copeptin is a stress biomarker; thus, various haemodynamic 
conditions can influence its distribution in the circulation (Katan & Christ-Crain, 
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2010).  In addition, the lower diagnostic efficiency of copeptin reflects the fact 
that this biomarker cannot detect ischaemic myocardial infarction 
(Staub,Morgenthaler,Buser et al., 2009).  Moreover, the combined diagnostic 
efficiency of IMA plus copeptin did not improve the diagnosis of AMI with the 
AUC of ROC curve of 55% (95% CI, 38-71%).  Other studies suggested that 
copeptin may be used as a diagnostic and prognostic biomarker in patients 
admitted to the ED with a range of diseases such as diabetes mellitus, 
polycystic kidney disease, septic shock and HF (Dobsa & Edozien, 2013; 
Nickel,Bingisser & Morgenthaler, 2012).  Importantly, the interpretation of 
copeptin concentrations must be considered in clinical setting and patient 
history.  
 
The role of copeptin in the prediction of MACE is not well documented; 
however, in patients with CAD, copeptin was not a suitable predictor of MACE 
over three years (Schnabel,Schulz,Messow et al., 2010).  The present study 
also suggests that copeptin is not a suitable predictor of MACE with the AUC 
of ROC curve on admission of 59% (95% CI, 46-73%) and 53% (95% CI, 38-
68%) at 90 min after admission. 
 
In conclusion, the present study is in agreement with various studies that 
suggest that copeptin is a biomarker of non-specific stress response and 
cannot safely be used in an ED setting to rule-in or rule-out the diagnosis of 
AMI (Nemec,Koller,Nickel et al., 2010; Nickel,Bingisser & Morgenthaler, 2012). 
 
5.2.2 Heart fatty-acid binding protein 
 
H-FABP is detected early in the circulatory system as soon as the myocardial 
membrane is compromised; thus H-FABP may be used as an early biomarker 
of cardiac ischaemia and necrosis (Chan,Sanderson,Glatz et al., 2004; 
McLean & Huang, 2012).  In the present study moderate diagnostic efficiency 
of H-FABP with AUC of ROC curve of 78% (95% CI, 68-89%) may be due to 
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the utilisation of very low risk patients.  It is probable that H-FABP is released 
to the circulation before any necrotic damage. 
H-FABP was diagnostically superior on admission to IMA with an AUC of ROC 
curve of 78% (95% CI, 68-89%) compared to 54% (95% CI, 43-66).  H-FABP 
was also diagnostically efficient than IMA at 90 min after admission with AUC 
of 65% (95% CI, 40-90%) and 58% (95% CI, 35-81%) respectively.  In 
agreement with our study McMahon and colleagues, studied 1128 unselected 
patients presenting to the ED with chest pain found that H-FABP had sensitivity 
at 0-3 h of 64.3% and 3-6 h of 85.3% (McMahon,Lamont,Curtin et al., 2012).  
A similar study found that H-FABP did predict ACS diagnosis (OR 4.65; 95% 
CI 2.39-9.04) with specificity at 96.8% (95% CI, 95.4-98.1%) and sensitivity of 
13.5% (95% CI, 10.9-16.1%) (Charpentier,Ducasse,Cournot et al., 2010).  In 
agreement with our study, Charpentier and colleagues, concluded that H-
FABP did not add significant additional information superior to the currently 
available diagnostic tools for NSTEMI management (p = 0.40). 
The combined diagnostic efficiency of IMA plus H-FABP on admission had a 
sensitivity and specificity of 41% (95% CI, 27-56%) and 93% (95% CI, 89-96%) 
respectively, the NPV was 89%.  Conversely, the combined diagnostic 
efficiency of IMA and H-FABP at 90 min after admission had a very poor 
sensitivity and very good specificity of 12% (95% CI, 0.4-30%) and 93% (95% 
CI, 94-99%) respectively the NPV was 88%.  A similar study found that the 
combined sensitivity of IMA and H-FABP did not provide significant information 
for ACS diagnosis (Charpentier et al., 2010).  This low sensitivity at 90 min 
after admission could be explained by the ability of the heart tissue to switch 
energy utilisation from H-FABP to glucose during ischaemia may also lower 
the diagnostic efficiency of H-FABP (Arumugam,Sreedhar,Thandavarayan et 
al., 2016). 
 
The prognostic value for the outcome of MACE at 30 days on admission for H-
FABP was comparable to IMA with AUC of ROC curve of 50% (95% CI, 40-
61%) and 52% (95% CI, 39-66%) respectively.  The prognostic value of H-
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FABP at 90 min was also comparable to IMA with an AUC of ROC curve of 
51% (95% CI, 41-62%) and 57% (95% CI, 43-72%) respectively.  Various 
studies appear to suggest that H-FABP evaluation in ACS patients could 
predict long term mortality after one year (Kilcullen,Viswanathan,Das et al., 
2007; Viswanathan,Kilcullen,Morrell et al., 2010).  The present data 
demonstrates that H-FABP was a poor prognostic biomarker of MACE.  The 
reasons for this could be two-fold.  Firstly, the population studied was low risk 
with a low prevalence of MACE and secondly follow up was relatively short at 
30 days, compared to one year in previous studies (Kilcullen,Viswanathan,Das 
et al., 2007; Viswanathan,Kilcullen,Morrell et al., 2010). 
Published studies show that the diagnostic efficiency of H-FABP lacks the 
require methodological design including the inappropriate use of mixed 
population with higher percentage of patients diagnosed with ACS 
(O'Donoghue et al., 2006) or undefined population; one study used a STEMI 
cohort and other did not use hs-cTn (Body,McDowell,Carley et al., 2011; 
Chan,Sanderson,Glatz et al., 2004; Gururajan,Gurumurthy,Nayar et al., 2010; 
McCann,Glover,Menown et al., 2008).  In support of our study a meta-analysis 
also suggests that H-FABP testing as a standalone test does not fulfill the 
diagnostic criteria in term of sensitivity, specificity and the predictive values for 
a safe rule-out protocol in patients suspected of AMI (Bruins 
Slot,Reitsma,Rutten et al., 2010).  As described above the H-FABP testing 
either alone or in combination with IMA does not add an incremental value for 
the diagnosis of AMI comparable to that already achieved by hs-cTn 
measurement.  Presently H-FABP is not routinely available within the 
mainstream healthcare system in the UK. 
 
5.2.3 N-terminal pro B-type natriuretic peptide  
 
Measurement of NT-pro-BNP has been linked and was proposed as an early 
diagnostic test for patients presenting with chest pain (Bassan,Potsch,Maisel 
et al., 2005).  The Acute Decompensated Heart Failure National Registry 
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(ADHERE) registry, which includes information about 84,872 patients with 
acute heart failure (AHF) and cTn concentration at admission, found that 6% 
of this cohort had elevated cTn (Fonarow,Peacock,Horwich et al., 2008).  
Another study found no correlation exists between elevated BNP concentration 
and cTnT (Yamamoto,Sato,Yasutake et al., 2006).  The mechanism of the 
elevation of BNP concentration in ACS patients is not fully understood 
(Salama,El-Moniem,El-Hefney et al., 2011b).  One explanation is that 
ischaemic attack during or pre-AMI may contribute to heart wall stretch 
inducing the neuro-hormonal activation (Marumoto,Hamada & Hiwada, 1995).  
This hypothesis is supported by the detection of BNP gene expression in 
ischaemic and infarct region of the heart (Ndrepepa,Braun,Schomig et al., 
2007). 
 
In the present study, the NT-pro-BNP on admission was the most 
diagnostically efficient biomarker with an AUC of ROC curve of 93% (95% CI, 
88-97%).  A similar study also found that NT-pro-BNP on admission was 
diagnostically better then cTnT and CK-MB (Salama,El-Moniem,El-Hefney et 
al., 2011a).  The present study found that at 90 min after admission NT-pro-
BNP has a poor diagnostic efficiency, but comparable to IMA with an AUC of 
ROC curve of 52% (95% CI, 26-78%) and 58% (95% CI, 35-81%) respectively.  
In addition, the present study demonstrated that the combined diagnostic 
efficiency of IMA plus NT-pro-BNP had a sensitivity and specificity in the 
diagnosis of AMI on admission of 52% (95% CI, 39-65%) and 98% (95% CI, 
94-99%) respectively.  Whereas, the combined diagnostic efficiency of IMA 
and NT-pro-BNP at 90 min after admission had a sensitivity and specificity for 
the diagnosis of AMI of 8% (95% CI, 2-24%) and 98% (97% CI, 93-99%) 
respectively.  The low diagnostic efficiency of NT-pro-BNP at 90 min after 
admission can reflect cardiac ischaemic episode resolution i.e. restored 
circulation to the myocardium.  In addition, this low performance of NT-pro-
BNP can be explained by the fact that BNP is not stored in the cardiomyocyte 
rather it is expressed, thus it cannot be detected immediately after an 
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ischaemic episode because BNP is subject to DNA expression which may take 
hours to achieve (Hama,Itoh,Shirakami et al., 1995). 
 
Contrary, to previous studies, the present study demonstrated that NT-pro-
BNP is not suitable for the prediction of MACE with an AUC of ROC curve on 
admission of 51% (95% CI, 38-65%) and 52% (95% CI, 38-66%) at 90 min 
after admission (Bassan,Tura & Maisel, 2009; Haaf,Reichlin,Corson et al., 
2011).  The reason for low predictive value of NT-pro-BNP could be due to the 
inherited selection bias and the utilisation of low risk patients. 
 
5.3 Summary 
 
Advances in technological and pharmacological approaches to ACS have 
accelerated and caused rapid changes in the management of patients 
admitted with chest pain suggestive of ACS.  These changes have contributed 
to the introduction of various cardiovascular specific and non-specific 
biomarkers designed with different success to aid the clinician in the 
identification of low risk ACS patients.  Many so-called novel biomarkers 
including IMA are not routinely offered in laboratories across the UK for 
different reason including inadequate analytical suitability and clinical usability.  
Common statements such as “can be used for early diagnosis of AMI” and 
“may contribute to the current ACS patients’ managements”; a different set of 
question need to be answered before such comment could be made.  The “so 
what?” the introduction of new biomarkers have to convince clinician and 
health economist to change their current practice.  To do so new biomarkers 
must be sensitive, specific and with good predictive value. 
 
In the present study the AUC of ROC curve for copeptin and H-FABP ranged 
from 54-58% and from 52-65% on admission and at 90 min after admission 
respectively.  In contrast, the AUC of cTn, myoglobin and CK-MB ranged from 
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71-90% on admission and from 72-88% at 90 min after admission.  Clearly the 
present study does not support the use of these novel biomarkers as a 
standalone test in an ED setting.  The reason for this low performance of these 
novel biomarkers can be due to several factors including kinetic release of 
these biomarkers, specificity, utilisation of low risk patients in this current study 
and the clinical cut-off utilised.  Based on the present study finding IMA testing 
as a standalone assay is not ready for prime-time use.  However, in agreement 
with a published study; our study also found that the diagnostic efficiency of 
the combined IMA plus hs-cTn could be used for the diagnosis of AMI 
(Patil,Banker,Padalkar et al., 2013).  The present study also confirmed that the 
diagnostic efficiency of hs-cTn is superior to the current novel biomarkers.  
Thus, in conclusion IMA assay could not safely and reliably be used as a prime 
test for the diagnosis of chest pain suggestive of cardiac ischaemia or ACS.  
Furthermore, IMA assay is not suitable as prognostic test for the management 
of ACS patients. 
 
5.4 Case studies 
 
Aim: To discuss the clinical findings of the three patients who were 
misdiagnosed and subsequently died from AMI. 
 
5.4.1 Case study 1 (3105) 
 
A 62-year-old female presented (23/06/2008) to ED at Edinburgh Royal 
Infirmary with chest pain suggestive of ACS. She was recruited and entered 
RATPAC on POCT protocol.  On admission she was immediately triaged and 
an ECG was undertaken.  Blood samples were taken for cardiac troponin, 
myoglobin, creatinine and CK-MB.  The spare samples were later analysed for 
hs-cTnT/I, copeptin, H-FABP, NT-pro-BNP and IMA. 
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The patient’s ECG recording was normal.  Blood born biomarkers including 
cardiac troponins, myoglobin, NT-pro-BNP and CK-MB were normal on 
admission and 90 min after admission (table 51). The novel biomarkers, 
copeptin, IMA and H-FABP were below the clinical cut-off on admission and 
90 min after admission (table 51).  The patient’s TIMI score was 0; however, 
76 days (07/09/2018) from admission this patient died from an AMI.  The final 
diagnosis was registered as an ACS. 
 
Table 51: Patient results (case study 1) 
Tests Results Clinical cut-off 
Acu TnI 0 min 0.00 42 ng/L 
Acu TnI 90 min 0.00  
Cent TnI 0 min <0.002 40 ng/L 
Cent TnI 90 min <0.002  
H-FABP 0 min 0.76 2.5 mg/L 
H-FABP 90 min 0.71  
Myoglobin 0 min 38.86 66 mg/L 
Myoglobin 90 min 26.88  
Copeptin 0 min 9.8 17.4 pmol/L 
Copeptin 90 min 6.0  
Hs-cTnT 0 min 5.65 14 ng/L 
Hs-cTnT 90 min < 3  
Pro-BNP 0 min < 20 125 ng/L 
Pro-BNP 90 min < 20  
IMA 0 min 80 127 kU/L 
IMA 90 min 82  
CK-MB 0 min 1.1 5 µg/L 
CK-MB 90 min 0.9  
Creatinine 116 µmol/L 
TIMI 0  
ECG Normal on admission  
Final diagnosis ACS  
Days to death 76  
 
5.4.2 Case study 2 (3021) 
 
A 72-year-old female presented (14/02/2008) to ED at Edinburgh Royal 
Infirmary with chest pain suggestive of ACS. She was recruited and entered 
RATPAC on POCT protocol.  On admission she was immediately triaged, and 
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an ECG was undertaken.  Blood samples were also taken for cardiac troponin, 
myoglobin, creatinine and CK-MB and they were found to be normal on 
admission and 90 min after admission (table 52).  Blood samples for the patient 
were also analysed for other cardiac biomarkers including: copeptin, IMA, hs-
cTnT/I and H-FABP were below the clinical cut-off on admission and 90 min 
after admission (table 52)  
 
A risk assessment was carried out and TIMI score of 1 was recorded; as a 
result, this patient was considered low risk of CVD.  The ED clinicians 
diagnosed this patient with gastroesophageal reflux and subsequently 
discharged her back to the community.  76 days from admission this patient 
died from an AMI.  The final diagnosis was registered as an ACS. 
Table 52: Patient results (case study 2) 
Tests Results Clinical cut-off 
Acu TnI 0 min 0.00 42 ng/L 
Acu TnI 90 min 0.002 
Cent TnI 0 min < 0.002 40 ng/L 
Cent TnI 90 min < 0.002 
FABP 0 min 2.33 2.5 mg/L 
FABP 90 min 1.59 
Myoglobin 0 min 11.14 66 mg/L 
Myoglobin 90 min 22.32 
Copeptin 0 min 8.8 17.4 pmol/L 
Copeptin 90 min 10.3 
Hs-cTnT 0 min < 3 14 ng/L 
Hs-cTnT 90 min < 3 
Pro-BNP 0 min < 20 125 ng/L 
Pro-BNP 90 min < 20 
IMA 0 min 75 127 KU/L 
IMA 90 min 74 
CK-MB 0 min 3.36 5 µg/L 
 CK-MB 90 min 3.2 
Creatinine 114 µmol/L 
TIMI 1  
ECG Normal on admission  
Final diagnosis Gastro-oesophageal 
reflux 
 
 
Days to death 76  
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5.4.3 Case study 3 (6236) 
 
A 60-year-old female presented (06/01/2009) to ED at Leicester Royal 
Infirmary with chest pain suggestive of ACS.  She was recruited and entered 
RATPAC on POCT protocol.  On admission she was immediately triaged and 
taken to the cardiac department.  An ECG was undertaken and was normal.  
Blood samples were tested for cardiac troponin, myoglobin and CK-MB and 
they were found to be normal on admission and 90 min after admission (table 
53). She was discharged home on the day of admission.  Blood samples for 
the patient were also analyzed for other cardiac biomarkers including: 
copeptin, IMA, hs-cTn and H-FABP, and were below the clinical cut-off on 
admission and 90 min after admission (table 53). 
 
A risk assessment was carried out and TIMI score of 0 was recorded; as a 
result, this patient was considered low risk of CVD.  The ED clinicians 
diagnosed this patient with ACS and discharged her back to the community.  
87 days from admission this patient died (03/04/2009) from an AMI.  The final 
diagnosis was registered as an ACS. 
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Table 53: Patient results (case study 3) 
Tests Results Clinical cut-off 
Acu TnI 0 min 0.03 42 ng/L 
Acu TnI 90 min 0.00 
Cent TnI 0 min 0.03 40 ng/L 
Cent TnI 90 min < 0.02 
FABP 0 min 1.05 2.5 mg/L 
FABP 90 min 1.48 
Myoglobin 0 min 35.1 66 mg/L 
Myoglobin 90 min 44.54 
Copeptin 0 min 9.4 17.4 pmol/L 
Copeptin 90 min 6.9 
Hs-cTnT 0 min 8.2 14 ng/L 
Hs-cTnT 90 min 5.14 
Pro-BNP 0 min 45 125 ng/L 
Pro-BNP 90 min 49 
IMA 0 min 110 127 KU/L 
IMA 90 min 115 
CK-MB 0 min 1.3 5 µg/L 
 CK-MB 90 min 1.3 
Creatinine NA µmol/L 
TIMI 0  
ECG  Normal on 
admission 
 
Final diagnosis ACS  
Days to death 87  
5.5 Discussion 
 
In most cases, patients presenting to the ED with chest pain suggestive of ACS 
are considered high-priority triage cases.  Evaluation and treatment should 
follow a predetermined, institution-specific protocol for chest pain. The clinical 
cut-off for troponin by institution is summarised in table 53.  Chest pain can 
originate from various disorders.  However, chest pain of cardiac origin is the 
most concerning as it is the most life threatening and must be identified or 
excluded as matter of urgency. 
Patients presenting with abnormal vital signs and complaining of chest pain 
are usually triaged to a critical care area.  Intravenous access is established 
and abnormalities in oxygen saturation treated with oxygen.  The objective 
here is to meet the goal of less than 30-minute door-to-intervention time.  A 
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delay in treating genuine ACS patients is associated with high morbidity and 
mortality (Goss,Brachmann,Hamm et al., 2017).  All patients suspected of ACS 
require a 12-lead ECG performed within 10 min of arrival. Those cohorts with 
ECG changes e.g. STEMI are immediately treated. However, if the ECG 
changes are absent or not conclusive patients are subject to continuous ECG 
recording or ECG is often repeated after 6 to 24 hours.  The reason for this is 
to compare results (asymptomatic) vs. symptomatic.  If ST-segment 
depression ≥ 0.5 mm (0.05 mV) is recorded in more than one lead, this may 
suggest NSTEMI (Diercks et al. 2006).  NSTEMI is a retrospective diagnosis 
based on clinical history, troponin levels and ECG finding.  The ACC/AHA 
guidelines recommend that for those patients brought to ED by ambulance to 
have 12-lead ECG done prior to arrival in order to expedite care 
(Antman,Anbe,Armstrong et al., 2004). 
Table 54: Troponin threshold used by the participating center. 
Location Troponin assay 
(Troponin threshold used 
(μg/L)) 
Laboratory 
analyser 
Timing of 
troponin 
(hours *) 
Edinburgh 
(Medical 
assessment unit) 
Siemens Centaur troponin I 
Ultra 
(< 0.20) 
Siemens 
Centaur XP 
12 
Leicester 
(Inpatients ward) 
 
Siemens Centaur troponin I 
Ultra 
(< 0.06) 
Siemens 
Centaur XP 
12 
• = Timing after onset the worst symptom  
The clinician’s decision is required to assess chest pain patients’ in the ED 
setting, dependent on the nature of the attending clinician.  The ED clinician is 
usually concerned about early exclusion of AMI (rule-out), whereas, a 
cardiologist is most concerned with confirmation of AMI (rule-in).  Patients not 
showing characteristic ECG changes are assessed on the basis of ECG and 
clinical history/features into high, medium or low risk cohort.  High risk patients 
are always admitted for further investigation.  On the other hand, medium to 
low risk patients are those without clinical or ECG evidence of ischaemia and 
who require cardiac biomarkers measurement to exclude ACS.  The 
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confirmation of AMI in this cohort of patients requires time and serial troponin 
measurement to confirm or exclude AMI.  In these case studies all patients 
were categorised into low-risk patients with no ECG changes or abnormal 
troponin finding and appropriately discharged. 
 
While the ECG tends to underestimate the risk of disease in chest pain 
patients, the clinical history and the ECG findings tends to lead clinicians to 
overestimate the likelihood of ischaemia (Karlson,Herlitz,Wiklund et al., 1991).  
A study of 4,500 chest pain patients admitted for rule-out evaluation found that 
clinician’s impression with discharge diagnostic were more than 50% 
associated with “vague suspicion of AMI’.  Clinicians were unable to draw any 
firm conclusion about the presence or the absence of ischaemia.  Thus, the 
clinicians surveyed in this study felt that the risk was great enough that this 
cohort of patients should be admitted for extended workup.  Within this group 
47% of patients were eventually found not to have ischaemic disease 
(Karlson,Herlitz,Wiklund et al., 1991). 
 
Although, patients with chest pain should not be diagnosed based on 
symptoms alone; they tend to exhibit wide ranges of presentation and 
symptoms including prolonged (>20 min) anginal pain, recent destabilisation 
of previously known SA patients, post-AMI angina, reterosternal pressure or 
heaviness radiating to the left arm, neck or jaw.  This range of symptoms and 
presentation can also be accompanied by nausea, abdominal pain, dyspnoea, 
epigastric pain, recent-onset indigestion, stabbing chest pain, and chest pain 
with some pleuritic features.  Moreover, these symptoms appear to be 
frequently seen in younger adults (25-40 years), > 75 years patients, women 
and patients with diabetes, dementia and chronic renal failure 
(Canto,Fincher,Kiefe et al., 2002; Culic,Eterovic,Miric et al., 2002a).  Some 
NSTEMI patients do not exhibit the above symptoms and as a result this leads 
to under-recognition of the disease (Brieger,Eagle,Goodman et al., 2004).  The 
diagnostic and therapeutic evaluation of patients with NSTEMI becomes 
extremely difficult when the main diagnostic pointers are masked or 
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exacerbated by existing condition or abnormal results i.e. intraventricular 
conduction defect or LV hypertrophy, anaemia, infection, inflammation and 
absence of atypical symptom (Lev,Battler,Behar et al., 2003). 
Chest pain is one of the main symptoms of ACS; however, approximately 25% 
of patients with non-classical symptoms or atypical presenters have suffered 
a silent AMI (Khafaji & Suwaidi, 2014).  The diagnostic and therapeutic 
evaluation of an atypical presenter is extremely difficult such as that among 
patients with diabetes who may not sense pain due to peripheral neuropathy 
(Nikolaou,Arntz,Bellou et al., 2015).  Moreover, chest pain is a common 
presentation and is associated with a broad spectrum of conditions and has a 
broad differential diagnosis (table 55). 
A greater proportion of women than men with AMI die of sudden cardiac arrest 
before reaching hospital (Dunlay & Roger, 2012).  The prevalence of 
microvascular angina is higher in women than men 
(Hochman,Tamis,Thompson et al., 1999).  This finding suggests that gender 
differences may have an influence on cardiovascular disease progression and 
physiology (Dunlay & Roger, 2012).  Women’s Ischemia Syndrome Evaluation 
(WISE) study demonstrated that 1:100 women with normal coronary arteries 
had in fact approximately 80% defined coronary atherosclerosis that was 
concealed by positive remodeling.  This finding suggests that a better 
diagnostic tool tailored for women related diseases is required 
(Khuddus,Pepine,Handberg et al., 2010). 
The diagnostic of CAD in women presents a challenge not observed in men.  
Epidemiological studies of CAD in women suggest that women are generally 
of low risk until they reach the seventh decade of life (Berger,Elliott,Gallup et 
al., 2009).  In symptomatic low risk women, non-invasive diagnostic studies 
such as cardiac imaging are recommended (Fass & Navarro-Rodriguez, 
2008).  Thus, until adequate evidence is available; women with chest pain 
should be screened for CVD risk factors and treated using evidence-based 
protocols (Mishra,Ray,Dalal et al., 2016).  In all the above study cases other 
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diagnostic modalities such as resting echocardiography were not requested or 
carried out.  
Table 55: Chest pain-common differential diagnosis 
AMI 
Stable angina 
Unstable angina 
Oesophageal reflux 
Pulmonary embolic disease 
Musculoskeletal 
Cervical root compression 
Aortic dissection 
Chest wall pain 
Cholecystitis 
Pancreatitis 
Anxiety 
 
5.5.1 Sudden cardiac death and sudden cardiac arrest 
 
Sudden cardiac death (SCD) is defined as “death from an unexpected 
circulatory arrest, usually due to cardiac arrhythmia occurring within 1 h of the 
onset of symptoms”.  On the other hand, ACC/AHA/ESC 2006 describes and 
defines sudden cardiac arrest as “death from an unexpected circulatory arrest, 
usually due to a cardiac arrhythmia accruing within 1 h of the onset of 
symptom, in whom medical intervention (e.g. defibrillation) reverses the 
events” (Priori,Wilde,Horie et al., 2013). 
 
In the USA, cardiovascular disease was responsible of every 2.9 deaths in all 
fatalities in 2006.  50% of the overall death was classified as sudden.  Similar 
incidents are also observed in Europe, SCD is defined as death due to cardiac 
causes occurring within 1 h of the onset of symptom.  
240 
 
 
The most common cause of SCD is ischaemic heart disease (Modi & Krahn, 
2011).  Autopsy finding shows that such patients may have an occlusive recent 
thrombosis in a major artery but the largest group has no recent occlusion 
(Modi & Krahn, 2011).  Out-of-hospital SCD occurs among patients in whom 
cardiac disease has previously been identified but classified as low risk or in 
whom SCD is the first clinical expression.  The annual incidence of SCD 
increases as a function of advancing age (Myerburg & Junttila, 2012).  
Sudden cardiac arrest (SCA) can also be caused by coronary spasm with 
minimal or no pre-existing CAD.  Females tend to present with mitral valve 
prolapse with ECG repolarization abnormalities.  In general, SCA can also be 
triggered by poor air quality (pollution), pre-existing chronic diseases such as 
AIDS, lower socioeconomic groups, depression, anxiety, social isolation and 
acute emotional stress (Basso,Perazzolo Marra,Rizzo et al., 2015; 
Ensor,Raun & Persse, 2013; Modi & Krahn, 2011). 
Case study one and two could be the result of either SCD or SCA; it is difficult 
to establish the exact cause of death without an autopsy and some degree of 
speculation.  Moreover, the inability to obtain the patient’s notes makes an 
evidence-based judgment difficult (Lloyd-Jones,Hong,Labarthe et al., 2010).  
Nevertheless, it is likely that all these case study patients suffer from cardiac 
ischaemia.  To date there is no reliable cardiac biomarker for ischaemia. 
 
5.5.2 Can gastroesophageal reflux provoke or worsen myocardial 
ischaemia? 
 
Patient’s history and characteristics do not reliably distinguish between cardiac 
and oesophageal causes of chest pain (Locke,Talley,Fett et al., 1997).  
Gastroesophageal reflux disease (GERD) is characterised by symptoms and 
complications such as oesophageal stricture, Barrett oesophagus and 
esophagitis and is caused by the reflux of gastric contents (Hong, 2010).  Non-
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cardiac chest pain is a term that encompasses all causes of chest pain that 
are not of cardiac origin and after excluding cardiovascular disease.  The term 
includes aetiologies such as inflammatory disorders, musculoskeletal, 
pulmonary, neurological, and oesophageal diseases. In clinical practice, 
esophageal chest pain (ECP) is a common problem whose diagnosis and 
treatment remain challenging (Galmiche, 2006).  The Rome III criteria define 
ECP as an episode of unexplained chest pain of visceral quality and usually 
midline in location.  The exact prevalence of ECP is difficult to estimate; 
because its diagnosis requires the use of multiple diagnostic tests to exclude 
other conditions (Remes-Troche,Maher,Mudipalli et al., 2007).  However, 
some studies showed that ECP is diagnosed based on symptoms (Rao, 2011).  
A population-based survey in USA and Australia found that the annual 
prevalence was estimated to be between 23% and 33% respectively, with an 
equal sex distribution (Locke,Talley,Fett et al., 1997).  There is little consensus 
on how to diagnose a patient with ECP. 
Chest pain is a common complaint and cardiac and esophageal pains are often 
similar.  It has been suggested that esophageal dysfunction could itself trigger 
myocardial ischaemia (Liu,He,Chen et al., 2013).  Making differential diagnosis 
of chest pain and evaluating the symptoms is often difficult and not sufficient 
to predict the underlying disease in this cohort of patients.  This difficulties lies 
in the fact that the distal oesophagus and heart share common afferent vagal 
supply; thus mechanical and/or chemical stimulation of the oesophagus can 
provoke myocardial ischaemia leading to chest pain 
(Johansson,Wallander,Ruigomez et al., 2003).  Furthermore, non-cardiac 
chest pain gastroesophageal reflux occurs at the same frequency in patients 
with normal and pathological coronary angiographies (Fenster, 2004).  It is 
often difficult to distinguish between non-cardiac and cardiac chest pain based 
upon symptom at presentation alone because the nerves that supply the heart 
also supply the esophagus (Mudipalli,Remes-Troche,Andersen et al., 2007).  
It is possible that in case three the chest pain was in fact due gastroesophageal 
reflux and it is also possible that gastroesophageal reflux could provoke 
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myocardial ischaemia and subsequently AMI.  Without an autopsy it is 
impossible to determine the exact cause of AMI and death in this patient. 
 
5.5.3 Conclusion 
 
Unfortunate overreliance on negative hs-cTn, patient’s history, TIMI score and 
normal ECG is common reason for misdiagnosing AMI patients.  It is critical to 
remember that cardiovascular biomarkers are useful for risk stratification, but 
no test is capable of stratifying patients risk to zero.  Evaluation of patients with 
chest pain in an ED setting is expensive, time consuming and may results in 
uncertain diagnosis (Fox, 2005).  It is also a common misconception that the 
prognosis from NSTEMI is better than that for STEMI.  Hospital mortality is 
greater for STEMI than for any other ACS condition and this is largely due to 
the fact that STEMI is always associated with myocardium damage and cell 
death (Scholz,Maier,Maier et al., 2018).  However, mortality rate following 
discharges with NSTEMI is higher and approximately one third of these 
patients will suffer a further AMI, death or readmission with an ACS year later 
(Saaby,Poulsen,Hosbond et al., 2013; Scholz,Maier,Maier et al., 2018).  The 
simplest approach to reduce mortality with NSTEMI cohort is to offer 
angiography in all patients admitted.  A study looking at the cost of caring for 
69 patients in the 12 months before and after coronary angiography; showed 
the cost of the procedure would offset after 18 months if this cohort of patients 
were successfully treated. This approach is implemented in some centers 
(Newby,Fox,Flint et al., 1998). 
A study conducted by Bandstein et al., found in a large cohort (n = 14,636) of 
patients with the first hs-cTnT of < 5 ng/L combined with no sign of ischaemia 
on ECG is safe to rule-out AMI with nearly 100% NPV of AMI and a 100% NPV 
for death within 30 days, irrespective of sex, age or other cardiovascular risk 
factors (Bandstein,Ljung,Johansson et al., 2014).  Although, Bandstein et al., 
work is true in all these case studies, however, a reliable test which detected 
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ischaemia is still warranted.  In addition, in all three cases, novel biomarkers 
were all below the clinical cut-off on admission and 90 min after admission and 
if used at the time of admission they would not change the care pathway for 
these patients. 
 
Women and men differ in their genetic map by a single chromosome.  
However, this single chromosome out of the 46 in human affects both the 
expression of disease and behavioral characteristics; thus, may reduce or 
increase susceptibility to cardiovascular disease.  In future, gender specific 
cardiovascular biomarker, reference ranges, diagnostic algorithm, and 
treatment of cardiovascular disease may be required.   
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5.6 Cost-effectiveness-analysis of ischemia modified-albumin 
 
The National Health Service (NHS) is burdened with significant costs when 
patients present to the ED with chest pain suggestive of ACS/AMI.  
Biochemical testing is not a major expenditure in hospitals; however, hospital 
bed occupancy and intervention contribute significantly the NHS budget.  To 
reduce expenditure, these institutions have formulated strategies to rule-in or 
rule-out AMI in the shortest period of time (Chang,Shofer,Weiner et al., 2008).  
The use of hs-cTn is the main driver for this strategy because most patients 
can be discharged or admitted for investigation and treatments within 3 h, in 
alignment with the current ESC recommendations. 
 
In the scenario were a hospital uses multiple cardiac biomarker strategy, the 
combination of IMA plus hs-cTnT may be cost effective.  However, this strategy 
assumes that the diagnostic utility provided with IMA is equal to that of hs-
cTnT.  IMA study clearly demonstrates that this is not the case; moreover, IMA 
is a biomarker for ischaemia whereas hs-cTn indicates myocardial injury.  The 
outcomes are therefore not equivalent.  In this instance cost benefit analysis 
is the appropriate method to use because it ignores the clinical situation when 
the IMA will be used in the current clinical practice.  As demonstrated in the 
present study, IMA test alone is not diagnostically superior to hs-cTn; however, 
when combined with hs-cTnT or hs-cTnI it may be useful. 
 
The cost of a single IMA test (£27.00 per test) is five-fold more expensive than 
a single hs-cTnT (£4.00 per test).  However, despite the initial higher cost per 
test of IMA, the overall cost could be mitigated when we take into consideration 
serial hs-cTnT requirement to achieve the desired optimum diagnostic for AMI 
and average daily bed cost (£300.00 per day), the average cost of a day case 
(£696.00), the average cost of an ED day attendance (£114.00), the average 
cost of a non-elective inpatient short and long stay (£1,489.00), imaging cost, 
litigation and value of knowing (Chang,Shofer,Weiner et al., 2008; England, 
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2012-2013; Goodacre, 2003).  “Value of knowing” focus on the value of a 
diagnostic testing in resolving patients’ uncertainties about their medical 
condition (Lee, Neumann, & Rizzo 2010b).  The value of knowing is not usually 
fully integrated in the cost-effectiveness analysis. 
 
The objective of the health cost section in this study is to firstly demonstrate 
the hypothetical scenarios whereby IMA assay alone is introduced to the ED 
setting and secondly, when combine diagnostic efficiency panel of IMA plus 
hs-cTnT are also introduced to the main stream laboratory diagnostic in an ED 
setting.  Although, the cost benefit of IMA in combination with H-FABP, NT-
pro-BNP and copeptin is not warranted due low diagnostic efficiency.  In this 
thesis an overall cost benefit will also be calculated. 
 
It is well documented hs-cTn testing over a period of time reaches 100% 
sensitive and specificity (Keller,Zeller,Ojeda et al., 2011; 
Reichlin,Hochholzer,Bassetti et al., 2009).  Therefore, in order for IMA, H-
FABP, copeptin and NT-pro-BNP testing to contribute to ACS patient’s 
managements; their diagnostic efficiency must be assessed on admission and 
should be based on a single sampling i.e. only one blood sample collect on 
admission.  The incremental value of IMA combined with other biomarkers can 
only be adopted by healthcare professional in an ED setting if it demonstrates 
that low risk patients with chest pain suggestive of IMA can be discharged 
safely or admitted for further investigation at presentation. 
 
The present study identified three patients with AMI as confirmed by the final 
diagnosis.  In the scenario were IMA assay alone is introduced, in order to 
save one high risk patients out of 174 who present to ED with chest pain 
suggestive of AMI a total of £1,334.00 per high risk patients is required.  The 
cost could also be expressed as NNT, the current project finding suggests a 
total of 50 patients (£ 380,00 per high risk patients) needed to be screened in 
the view of detecting one correct ACS patient.  The introduction of IMA assay 
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testing to the main stream healthcare system would account for an increase of 
£1102.00 per high risk patient.  In contrast, the current cost is only £232.00 
per high risk patients when using hs-cTnT alone on admission and £464.00 
when measured on admission and 90 min.  This scenario is unlikely to be 
adopted in an ED setting because in this study IMA assay is not sensitive or 
specific enough for the diagnosis of AMI. 
 
When implementing the scenario of the combined diagnostic efficiency of IMA 
assay plus hs-cTnT; in order to save one high risk patients out of 174 patients 
presented to ED with chest pain suggestive of AMI a total of £ 1,566.00 is 
required.  The NHS will have to contribute an additional cost of £1,334.00 per 
high risk patient or an extra £31.00 per screened patients compared to £ 8.00 
when using hs-cTnT on admission and 90 min.  It is evident that even with a 
serial hs-cTnT measurement up to 3 h the latter would be cheaper than a single 
IMA testing.  Identifying high risk patients in a timely fashion preferably on 
admission may save the trust additional cost including AMI related 
complications, bed occupancy, imaging investigation, loss of earning and 
unnecessary stress to patients.  Correct identification of ACS patients on 
admission could contribute with a projected saving of £889.00 per patient 
successfully prevented from being admitted (Byrne, 2014).  In real terms the 
introduction of IMA plus hs-cTnT to healthcare systems may be cost neutral or 
beneficial, as the extra expenses will be offset by the cost of admitting this 
cohort of patients.  The true cost of the introducing both IMA and hs-cTnT in 
combination to the healthcare system requires further investigation and costing 
that take into consideration the cost of possible litigation, AMI related 
complications, bed occupancy and overhead expenditure.  Thus, future health 
economic evaluation is required. 
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5.6.1 Implementation of the combined diagnostic efficiency of 
ischemia modified-albumin plus highs sensitivity cardiac troponin 
for the diagnosis of acute myocardial infarction 
 
AMI is associated with poor prognosis so immediate and accurate diagnosis is 
important to allow appropriate treatment and care as soon as possible.  In 
some cases, the treatment for medium and high-risk patients with suspected 
ACS is usually started before a diagnosis is confirmed.  However, patients 
presenting to ED with chest pain suggestive of AMI at St George’s Healthcare 
NHS Trust will undergo ECG as first line of investigation, if ECG abnormalities 
is recorded patients will be transferred to a specialized cardiac unit for urgent 
treatment.  However, if ECG is inconclusive and AMI is still suspected; the 
patients will be asked to provide blood and stay for observation for up to 3 h.  
Moreover, if suspicion is still present, the patients may be required to stay in 
observation up to 12 h.  The triage algorithm used at St George’s Healthcare 
is as follow (Figure 55). 
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ED presentation
Chest pain ?ACS
ECG
STEMI ?NSTEMI
ADMIT 
Urgent PCI
Admission (0h) 
cTn
3h cTn
0 & 3h cTn <14 ng/L
DISCHARGE
0 & 3h ∆cTn <7 ng/L
DISCHARGE
0 or 3h cTn 
>14 ng/L
ADMIT
0 & 3h ∆cTn 
>7 ng/L
ADMIT
 
 
Figure 55: Positive ECG patients are immediately admitted to cardiac unit 
treatment and PCI.  Low risk patients with abnormal, normal or inconclusive 
ECG are required to stay for observation up to 3 h.  In this cohort blood sample 
is obtained on admission and 3 h after admission.  Patients with the absolute 
or delta changes of hs-cTn concentration on admission and 3 h are less than 
14 ng/L and 7 ng/L respectively are discharged or AMI is rule-out.  However, 
patients with the absolute or delta changes of hs-cTn concentration on 
admission and 3 h is greater than 14 ng/L and 7 ng/L respectively are admitted 
and referred for urgent treatment and PCI. (St George’s Healthcare NHS Trust, 
London). 
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The current algorithm utilised at St George’s Healthcare NHS Trust was 
adopted in order to improve the sensitivity and specificity of hs-cTn in the 
diagnosis of ACS, triage and to comply with the current guidelines (ESC, NICE 
and ACC) which require serial blood sampling.  As recommended by the 
current guidelines ideally blood should be measured for hs-cTn concentration 
at the first sign of chest symptom and 3 h after admission (Hamm et al., 2011).  
Repeated hs-cTn measurement in the second time maximizes the safety and 
certainty to rule-in or rule-out an AMI (Chenevier-Gobeaux et al., 2015, 
Thygesen et al., 2012c). 
 
The lack of clear definition of a rise and fall (delta changes) of hs-cTn 
concentrations has led many clinicians to adopt a change of ≥ 20% as a 
practical cut-off.  Conversely, a study has showed that cut-off value of ≥ 20% 
needed to be reassessed and increased in patients with hs-cTn in a lower 
range, older patient, and in-patients with existing co-morbidities such as renal 
failure (Apple, 2009; Giannitsis,Becker,Kurz et al., 2010).  The introduction of 
≥ 20% delta rules over 2 h period has increased specificity to 92% (95% CI: 
90-94%) but reduced sensitivity to 56% (95% CI, 48.0-63%) 
(Aldous,Pemberton,Richards et al., 2012).  The absolute value changes of hs-
cTn assays (Roche and Siemens) were diagnostically (2 h) superior to relative 
value changes (Reichlin et al., 2011); this finding were also supported and 
confirmed by other studies (Mueller et al., 2012; Wildi et al., 2013).  The 
implementation of delta value over 2 h is supported by the observation that 
early presenters (<2 h from chest pain) tend to have hs-cTn values at 
admission below the 99th percentile cut off compared to patient presenting with 
chest pain > 3 h (Patil,Banker,Padalkar et al., 2013; Rubini 
Gimenez,Twerenbold,Reichlin et al., 2014).  This finding may suggest a 
reduced diagnostic efficiency of hs-cTn if measured only on admission and 2 
h.  Thus, the introduction of 2 h measurement is not warranted as early 
presenters are underrepresented and further studies are required (Vorlat,Van 
Hoof,Hammami et al., 2015).  The above algorithm is the best strategy 
available; however, patients who do not fit the criteria of a classical ACS may 
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be kept in ED for observation up to 12 h.  Thus, admitting patients for 
observation will result in an increased cost to the health system. 
 
5.6.2 Proposed algorithm for triaging low risk patients presenting 
with chest pain suggestive of acute coronary syndrome 
 
Tools to help in risk stratification of patients presenting to ED with chest pain 
and ACS exist but none is adequately equipped to help clinicians to determine 
which patients can safely be discharged (Christenson et al., 2004; Antman et 
al., 2000; Goldman et al., 1988; Tatum et al., 1997).  The NICE guidelines 
require clinicians to offer PCI treatments to restore blood flow within 72 h only 
to medium and high-risk patients; whereas, low risk patients are excluded from 
these life-saving interventions.  Clinical presentation of low risk patients 
suspected of NSTEMI is challenging and requires a carful assessment of each 
patient from presentation, diagnosis, risk stratification, therapeutic strategy 
and response to treatment.  Long term follow-up of patients who survived and 
reached medical assistance showed a higher mortality rate of two-fold 
difference at 4 years of NSTEMI compared with STEMI 
(Terkelsen,Lassen,Norgaard et al., 2005).  One probable reason for this is that 
NSTEMI patients tend to be older with existing co-morbidities (Ren,Ye,Wang 
et al., 2014; Rosengren,Wallentin,A et al., 2004). 
 
The European Society of Cardiology (ESC) guidelines for the management of 
ACS patients; requires that all patients admitted to the ED with chest pain 
suggestive of ACS should have a resting 12-lead ECG carried out and 
interpreted by a qualified person within 10 min of arrival.  The problem with 
using ECG is that a completely normal ECG does not exclude ACS/AMI (50% 
sensitivity).  Several studies found that approximately 5% of patients, who 
were sent home because of normal ECG, were subsequently readmitted with 
UA or AMI (Goodacre,Cross,Arnold et al., 2005; Schreck & Fishberg, 2014).  
In addition, up to 50% of patients presenting to the ED with chest pain do not 
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show STEMI in their ECG assessment (Apple,Wu,Mair et al., 2005).  To 
compensate for the poor sensitivity of the ECG and the uncertainty associated 
with it; the ESC guidelines for the management of ACS and in particular 
patients with suspected NSTEMI requires the measurement of a biomarker of 
myocardial injury such as hs-cTnI or hs-cTnT.  The presence of hs-cTn is not 
considered an early biomarker of cardiac ischaemia, because hs-cTn is only 
detected after myocardial injury. 
 
Although, hs-cTn is highly specific for myocardial injury, it is also known to be 
elevated in non-cardiac related diseases such as sepsis, endocarditis, 
pulmonary embolism, cocaine abuse, chemotherapy, and renal disease.  Low 
hs-cTn specificity combined with detectable concentrations of hs-cTn in non-
cardiac diseases and healthy populations makes the interpretation of AMI 
difficult (Gamble,Carlton,Orr et al., 2013).  Currently there is no blood borne 
accepted “gold standard” test for cardiac ischaemia; although, blood lactate 
was previously used (Attana,Lazzeri,Picariello et al., 2012; Henning,Weil & 
Weiner, 1982).  Despite the introduction of hs-cTn with an increased 
sensitivity, the current opinion suggests that it is still unable to detect acute 
ischaemia before myocardial damage.  Controversially, there are various 
proposed mechanisms of cTn release that are apparently not related to 
cardiomyocyte injury including apoptosis, increased cell permeability with 
stress and the production of the membranous blebs that contain cTn 
(Piper,Schwartz,Spahr et al., 1984; White, 2011).  Moreover, the exact 
mechanism and the kinetic release of cTn is unknown, one suggestion is that 
the molecular weight difference between of cTnT (35 kDa) and cTnI (24 kDa) 
may be responsible (Wu,Feng,Moore et al., 1998).  The possibility of detecting 
cTn in ischaemic patients using the current analytical methods is still 
debatable. 
 
In the present study the combined sensitivity and specificity of IMA plus hs-
cTnT on admission was 71% (95% CI, 56-82%) and 100% (95% CI, 98-100%) 
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respectively and an NPV of 94%.  The proposed algorithm (Figure 56) appears 
to identify high risk patients before substantial, permanent myocardial damage 
occurs, and when potential for myocardial salvage is optimal (Burke & Virmani, 
2007).  The present study identified 3 out of 174 low risk patients, who had a 
final diagnosis of AMI including one fatality as confirmed by follow up RATPAC 
study.  This cohort of patients was used to estimate health cost and to develop 
an algorithm for the triage of low risk patients presenting with chest pain 
suggestive of AMI. 
 
Potential samples
For IMA study (n = 840)
Samples with matched and paired data (n = 348) 
analysed for hs-cTnT, IMA and MACE
Sample on admission
(n =174) analysed for 
combined IMA plus hs-cTnT 
diagnostic efficiency 
Total AMI 
Including false 
positive
(n =7)
Sample analysed
(n = 444)
Final diagnosis of AMI
(n =3) and one fatality 
Sensitivity
72% (95% CI, 56-82% )
Negative predictive 
value 94%
 
Figure 56: A total of 444 out of 840 unmatched samples were available for the 
present study, from which n = 174 samples were analysed for the combined 
diagnostic efficiency of IMA plus hs-cTnT.  The sensitivity was 72% (95% CI, 
56-82%), NPV of 94% and n = 7 patients were diagnosed with AMI using this 
protocol.  The n = 174 out of the 444 available samples had a complete 
matched and paired data including concentration values for hs-cTnT, hs-cTnI, 
copeptin, H-FABP, myoglobin, CK-MB, IMA and final outcome of MACE at 30 
days.  The final diagnosis of AMI as established by the RATPAC was n=3 AMI 
and one fatality. 
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The combined diagnostic efficiency of IMA plus hs-cTnT identified 7 AMI 
patients including the three correct patients as established by the final 
diagnosis.  Clearly the combined diagnostic efficiency of IMA plus hs-cTnT 
could be used to rule-in and rule-out AMI.  In terms of percentage the combined 
diagnostic efficiency of IMA plus hs-cTnT misclassified 4 patients as false 
positive out of 174 (< 3%).  This cohort of misclassified patients would benefit 
from further investigations as clinicians would be unable to draw any firm 
conclusion about the presence of the absence of cardiac ischaemia or AMI 
and they will have no choice but to admit these patients for extended 
investigation as per current protocol (Figure 56).  Based on the above 
evidence, the proposed algorithm using the combined diagnostic efficiency of 
IMA plus hs-cTnT could be as follows (Figure 57). 
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Hs-cTnT< 14 ng/L & 
IMA < 127 KU/mL
(0 & 3 h) hs-cTnT >14 ng/L
and
(0 & 3 h) Δhs-cTnT > 7 ng/L
Admit
Admit 
ED presentation 
chest pain ?ACS
STEMI
Hs-cTnT & IMA
On admission (0 h)
Discharge if no 
Suspicion 
? NSTEMI 
Yes
NO
Yes
 
Figure 57: Positive ECG patients are immediately admitted to cardiac unit 
treatment and PCI.  Low risk patients with abnormal, normal or inconclusive 
ECG will be required to stay for observation up to 3 h.  In this cohort blood 
sample is obtained on admission for hs-cTnT and IMA analysis.  Patients with 
hs-cTnT and IMA bellow the clinical cut-off will be discharged.  Patients with 
either IMA or hs-cTnT or both above the clinical cut-off are retested for hs-
cTnT after 3 h.  Patients with the absolute or delta changes of hs-cTn 
concentration on admission and 3 h is greater than 14 ng/L and 7 ng/L 
respectively are admitted and referred for urgent treatment. 
 
This proposed algorithm allows standardization of the clinical routine protocol 
and thereby improves workflow and quality of care.  However, bearing in mind 
the heterogeneous spectrum of ACS and patients with different risk in term of 
MACE, death, AMI and recurrent AMI.  Thus, it is important that in each patient, 
the clinician must make an individual decision regarding patients’ 
management, taking into account patients existing co-morbidity; thereby 
clinician may deviate from the proposed algorithm. 
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5.7 Advantages and disadvantages of IMA study 
 
The present study has adopted guidelines as stated by the AHA.  The AHA 
has produced these guidelines and recommendations for evaluating and 
researching the diagnostic and prognostic value of cardiovascular biomarkers 
(Moons, 2010).  These guidelines were produced in an attempt to regulate and 
control an early introduction of these potentially unnecessary and incomplete 
new biomarkers to the clinical profession.  Recently, Hlatky and colleagues 
issued a statement on behalf of the AHA outlining the criteria for evaluating a 
novel biomarker for cardiovascular risk assessment (Hlatky et al., 2009).  They 
suggested that follow-up studies, randomized or non-randomized studies are 
required for the assessment of cardiovascular biomarkers that will be used for 
screening and predicting treatment response.  Also the randomised control trial 
model is regarded as the “gold standard” method for testing the efficiency of 
medical interventions (Chow & Chang, 2008). 
 
The present study was a retrospective observational study generated from a 
prospective randomised controlled trial of point of care testing of cardiac 
biomarkers.  The advantages of this study within a larger RCT are twofold.  
Firstly, the surplus blood samples provided by the RATPAC study represent 
an opportunity to extend the findings of the RCT in a cost effective way 
compared to a further independent study (Biesheuvel et al., 2008b).  Secondly, 
the present study shares the same limitations as the RATPAC RCT trial 
including patients selection and bias (Chow & Chang, 2008). 
 
Although, patient’s enrolment is prospective, the present study including the 
cardiac biomarkers evaluation is retrospective.  Not only are the samples 
selected from RATPAC study are from well characterised patients, but these 
patients have also been followed up for MACE.  The RATPAC trial population 
is ideal for the present study, because patients were selected on the basis of 
a low probability of cardiac risk rather than high probability, representing a 
more realistic typical ED chest pain population (Bhandari et al., 2006).  The 
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samples collected for the present study were taken as part of routine 
management and therefore subjected to possible pre-analytical errors.  These 
include variations in time from blood draw to storage and variations in storage 
temperatures between different sites.  Following the RATPAC study, many 
samples were insufficient to allow for the measurement of albumin.  Thus, the 
ability to correct IMA concentrations by IMA/albumin ratio could not be 
performed. 
 
An adequately powered RCT, will detect important differences between IMA 
assay alone and compared with other ranges of cardiovascular biomarkers, 
including hs-cTn, H-FABP, NT-pro-BNP and copeptin (Whitsel, Boyko, & 
Siscovick, 2000).  However, the present study did not reach the desire power 
due to missing samples.  Although, the blood samples were collected on 
admission in nearly all the patients; the 90 min after admission samples were 
only collected in patients with lower likelihood of developing AMI.  Thus, there 
is a selection bias, as patients with a diagnosis of AMI may be under 
represented; however, this unintended bias reflects the current chest pain 
population experienced daily in the ED and this bias is also reflected in the 
results in present study. 
 
To mitigate the introduction of systematic errors, the RATPAC study was 
designed to include the participation of different hospitals thus ensuring that 
the overall clinical utility of IMA was generalised across a range of settings.  In 
addition, the exclusion of participants due to non-compliance in the RATPAC 
study and in particular in the standard care group was less than 1.1%, thus 
minimising the bias of the estimate of the true value.  Sampling error in the 
present study could have been reduced if a very large group of participants 
were used as originally planned. 
 
Prognostic information obtained from the present study may be liable to 
restricted generalisation because of strict eligibility criteria, low participation 
and large numbers of missing samples (Bhandari et al., 2006). 
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In a clinical setting when low risk patients present with chest pain suggestive 
of AMI using hs-cTn to rule-out (sensitivity and NPV) is not entirely satisfactory, 
because low level hs-cTn is detectable in healthy population.  Therefore, it may 
be logical to put the emphasis on specificity to rule-in AMI patients.  Thus, the 
combined diagnostic efficiency of IMA, H-FABP, NT-pro-BNP and copeptin 
may be useful. 
 
5.8 Implication for practice and future research 
 
According to the myocardial ischaemia national audit 2012; 80,000 NSTEMI 
patients were admitted annually compared to 30,000 STEMI (Gavalova & 
Weston, 2012).  The annual incidence of STEMI is 13 per 1000 habitants 
exceeding that of NSTEMI at 7 per 1000 habitants (McManus,Gore,Yarzebski 
et al., 2011).  One reason for this disparity is thought to be due to improved 
cardiac management and the introduction of hs-cTn 
(Melki,Lugnegard,Alfredsson et al., 2015).  The Swedish Web-system for 
Enhancement and Development of Evidence-based care in Heart disease 
Evaluated According to Recommended Therapies (SWEDEHEART) study of 
48,594 patients found that the introduction of hs-cTnT into clinical practice had 
resulted in the identification and reclassification of a large cohort (21.6%) of 
previously undetected AMI patients (hs-cTnT concentration of 14 ng/L and 49 
ng/L) (Melki,Lugnegard,Alfredsson et al., 2015).  Very low concentration of hs-
cTnT can now be detected in patients with stable angina (SA) (Omland,de 
Lemos,Sabatine et al., 2009).  However, detectable hs-cTnT in the SA cohort 
was significantly associated with the incidence of cardiovascular death and 
heart failure but not with AMI (Omland,de Lemos,Sabatine et al., 2009).  
Moreover, reclassifying these low risk patients with AMI resulted in better 
outcomes because these patients benefited from early treatment 
(Mills,Churchhouse,Lee et al., 2011).  Other studies suggested that since the 
introduction of hs-cTn across the UK, AMI diagnosis increased at an estimated 
rate between 10% and 47% (Aldous,Florkowski,Crozier et al., 2012; 
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Mills,Lee,McAllister et al., 2012).  It clear that hs-cTn is beneficial to ACS 
patient. 
The International Liaison Committee on Resuscitation support the use of 
biomarker of ACS only if they achieve sensitivity > 95% or specificity > 92% 
and a combined cardiac biomarker sensitivity of > 90% (Hazinski,Nolan,Billi et 
al., 2010; Nolan,Hazinski,Billi et al., 2010).  Ideally early biomarkers 
characterised by high sensitivity, specificity is essential to rule-out or rule-in 
AMI.  However, the majority of cardiac biomarkers utilised currently do not 
entirely subscribe to this (Lippi & Guidi,2008). 
Cardiac biomarkers for myocardial cell damage such as hs-cTn are an 
important tool for helping to differential AMI from non-AMI in most cases.  
Although these biomarkers are important, they are not ideal for detecting 
patients who are suffering from cardiac ischaemia.  Theoretically, the perfect 
ischaemic biomarker should be 100% sensitive and 100% specific for 
predicting AMI.  The ideal candidate biomarker should be released from 
disrupted cardiomyocyte prior to necrosis of the cell. 
The presences of biomarkers of cardiac necrosis such as hs-cTn are not 
beneficial to cardiac ischaemic patients as they are linked to poor prognosis.  
A surrogate cardiac biomarker such as IMA is ideal for this role.  However, the 
introduction of cardiac biomarkers into prime use in hospitals, need to achieve 
certain criteria which take into consideration evidence-based medicine.  In 
addition, the method should be available on large automated chemistry or 
immunoassay platforms to assist in laboratory workflow management.  The 
concentration of a preferred biomarker should prior to initiation of necrotic 
mechanisms indicate an AMI.  These criteria can be categorised into analytical 
suitability and clinical usability.  Although, IMA was not characterised in terms 
of protein structure or even purified for assay optimisation; a patent application 
for a method for IMA purification by high performance liquid chromatography 
(HPLC) has been granted in the USA (Patent No: WO00/20840).  There is also 
a commercially available ELISA kit for the determination of IMA, although not 
available for routine diagnostic use.  It is clear that further research into 
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characterisation of the IMA entity is required before new methods are 
appropriate for prime-time use. 
 
5.8.1 Future application for ischemia modified-albumin assay 
 
Cardiovascular biomarkers for cardiac cells injury or necrosis such as troponin 
T & I are gold standard for the diagnosis of AMI.  However, the only traditional 
diagnostic tools used for diagnosing cardiac ischaemia are physical 
examination, patient’s history, ECG; imaging techniques, which are less 
specific, less sensitive, not routinely available, and requires expertise.  The 
clinicians are aware of the fact that after the onset of myocardial ischaemia, 
there is time frame of approximately 1 h before the myocardium start to die 
and least takes 3 h before cTn could rule-in or rule-out AMI in most cases.  The 
challenge is to correctly identify these vulnerable patients and treat them using 
a range of drugs including thrombus-busting drugs such as streptokinase and 
tissue plasminogen activator (tPA).  A further challenge is time to access 
specialised cardiac healthcare.  Access in rural areas is often limited and 
involves a step-wise approach via district general hospitals followed by transfer 
to specialised cardiac units (Watt,Franks & Sheldon, 1994). 
The ideal placement of a combined IMA and hs-cTn testing strategy is as a 
POCT device ideally placed on board emergency vehicles.  Rapid pre-hospital 
access to such a device can generate biomarker results which would be 
available to ED clinicians on patient arrival.  Not only POCT is beneficial to 
critically ill patients, POCT could also be used in primary care setting.  
Identifying pre-AMI or cardiac ischaemic patients could improve patients’ 
management by shortening the need for waiting for life saving treatments and 
reduce cost to the healthcare system.  The case for the introduction of IMA at 
POCT is supported by the observation that low cTn concentration release in 
NSTEMI is related to a chronic and prolonged ischaemia and micro-
embolisation of atherothrombotic material (Hamm,Heeschen,Goldmann et al., 
1999). 
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The implementation of POCT within the emergency staff and in the community 
is needed to prevent ACS related co-morbidity and to reduce cost to the 
healthcare system.  Further development of POCT in the community and in 
primary care with the involvement of biomedical scientist community would 
allow wider service to the end users and might be advantageous in suspected 
low risk patients.  Future research which aims at introducing POCT must 
engage clinicians in the process of the redesign of the service distribution and 
workforce planning.  A successful introduction of POCT requires the service 
users to be less constrained by existing local conventions and institutional 
boundaries.  The stake holders need to shift focus on patients care and clinical 
management, in order to ensure high-quality effective service. 
 
Any novel cardiac biomarkers should demonstrate its clinical usefulness and 
must be cost effective, with a clear aim to reduce mortality and help patient’s 
managements.  Hs-cTn and NT-pro-BNP are the biomarker that changed the 
way we manage ACS and heart failure patients.  Currently, a reliable cardiac 
biomarker of ischaemia is still required and is subject to future research.  In 
addition, our study challenge investigator to perform additional basic science 
regarding IMA structure.  As J K Rowling said in Harry Potter and the Chamber 
of Secrets “Never trust anything that can think for itself if you can't see where 
it keeps its brain?”  
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Chapter 6  
Personal reflection 
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6.1 Introduction; a brief history of my career  
 
After 8 years of travelling around the word I met my lovely wife Louisa in 
Turkey, nearly 22 years ago.  My academic journey started when I decided 
that biomedical sciences was my chosen profession.  The journey from 
medical laboratory assistance (MLA), without a degree, to embarking on a 
Doctorate in Biomedical Science (DBMS) has been exciting, fascinating, hard 
work, and life changing. 
 
6.2 Education, training and professional development 
 
I started my career at the Royal Surrey County hospital NHS trust in 1999 as 
an MLA, and then year later I secured a trainee position in the Immunology 
Department at St Thomas’ Hospital NHS Trust London.  While training I was 
allowed to study part time for a degree in Biomedical Sciences at the University 
of Portsmouth. 
 
I developed a highly analytical mind because of my work place training and my 
education at the University of Portsmouth.  Studying and working at the same 
time allowed me to see the ‘bigger picture’ to a strategic level and prepared 
me throughout my career to work well within teams and autonomously. 
Embarking on a part time Masters in Biomedical Sciences (MSc) was very 
challenging because I was not supported at work and by then I had my lovely 
boy Noah now nearly 11 years old.  Family commitment meant that I had to 
study only when my son was asleep.  MSc studies meant no holiday for two 
years as I had to use my holiday entitlement to study.  I remember when I was 
awarded my MSc degree my son cried because he was overwhelmed with 
pride and emotion.  It was a proud moment for my family. 
 
Currently I am integral to the day-to-day running of manual biochemistry 
laboratory. My duties include running tests, advising clinicians regarding the 
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appropriate use of diagnostic tests, results authorisation, supervising new 
members of staff, providing formal training, troubleshooting, writing SOPs (to 
current ISO standard) and liaising with service users at all levels as required. 
 
Embarking on a professional doctorate in Biomedical Sciences increased my 
confidence in my ability to scientifically and systematically appraise and tackle 
a wide range of work-related issues. Including method development and formal 
staff training.  Following a merger of three NHS Trusts, St George’s Healthcare 
NHS Trust has successfully become the South West Pathology Hub.  In order 
to harmonise pathology services new equipment has been purchased from 
Roche.  To comply with ISO standards, I was asked to work in collaboration 
with the Pathology Quality Manager, General Managers and Lead biomedical 
scientists to design and implement the quality assurance and analytical 
evaluation of the new equipment.  Integral to the change management 
program I am also delivering a program of training to members of staff 
including Clinical Scientists, BMS (all grades) and Associate Practitioners.  I 
have also presented at department level at St George’s Healthcare NHS Trust. 
 
6.3 Reflection on the doctorate in biomedical sciences taught 
element part one 
 
The purpose for this unit is to expose student to research requirement at 
doctoral level.  This is achieved through the following modules: 
1. Advanced research techniques 
2. Publication and dissemination 
3. Professional review and development 
 
6.3.1 Advanced research techniques 
 
This module removed the ambiguities surrounding statistic whether qualitative 
or qualitative.  This taught module allowed me to manipulate data with 
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confidence.  The successful completion of this module requires a submission 
of three assignments: 
1) Data analysis 
2) Critical appraisal of literature 
3) Applying theory to practice 
 
The successful completion of these three assignments and the skill gained, 
contributed directly to my thesis and to my professional work.  Critical appraisal 
of literature unit taught me the skill required in vetting scientific research papers 
and to be able to utilise only good quality information; whereas, data analysis 
allowed me to use statistic in action.  The final assignment was critical in 
understanding my research mythology. 
 
6.3.2 Publication and dissemination 
 
This unit encouraged me to consider publishing my work in a professional 
capacity.  I also learned how to avoid many pitfalls and traps for the unwary.  
Moreover, during my doctorate study I was invited to contribute, as a co-author, 
to an international collaboration resulting in the publication of a professional 
reference book (Human Serum Albumin, New insight on its structural 
dynamics, functional impact and pharmaceutical applications (2013)) for the 
biotechnology and pharmaceutical industry (Appendix 6).  I have also provided 
expert opinion and peer reviewed for Science World, a journal with an 
international readership. 
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 6.3.3 Professional review and development 
 
Reflective practice is a multi-layered process involving reflection-on-
experience, reflection-in-action, reflection-within-the-moment, and 
mindfulness practice.  As famously quoted by Donald Schon, “reflection and 
reflexivity is a swamp that can unearth strong feeling of self-doubt, uncertainty 
and inconclusive outcomes”.  This module made me aware of the fact that I 
am always reflecting to some capacity just not aware of it in the formal way.  
Moreover, reflection is an essential part of biomedical scientist and a 
requirement for continuous professional development. 
 
6.3.4 Reflection on the doctorate in biomedical science taught 
element part two 
 
Advanced research techniques including statistical analysis (quantitative) 
lectures and assignment; made me appreciate medical statistics fully.  
Becoming competent in quantitative data analysis help me progress through 
my project and also improve my research skills.  This task was far the best, as 
for the first time I have actually started to understand what number in statistics 
means.  Learning how to use SPSS® before I could do my assignment was 
another challenge that I really enjoyed.  The confidence gained in this session 
allowed me to use my statistical skill to plan and write my thesis. 
 
6.4 Summary 
 
Since embarking on the DBMS course, I have been overwhelmed with the 
richness of it content and I have also enjoyed learning and debating with my 
peers and tutors.  Although, studying at doctorate level has made me question 
my learning style, which I previously never contemplated.  Studying at this level 
has made me aware of the current academic thinking and the very high degree 
of skill and autonomy required at this level.  It has become apparent that the 
tutorials, workshops, and lectures were only an introduction to a particular 
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subject, and the hard work is left to me.  The challenge is real and a great deal 
of organisational skill was required in order to achieve my goal to successfully 
finish my professional doctorate course and beyond. 
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Appendix 3: Supplementary data 
 
Two by two tables (sample 1) 
Combined ischaemia modified-albumin and heart fatty-acid-binding protein 
(h-FABP) on admission (Sample 1). 
N=169 
 AMI (Sample 1)  
+ - 
IMA+h-
FABP 
+ 2 27 29 
 - 5 135 140 
7 162 169 
 
Sample 1 % Confidence interval (95%) 
Sensitivity 29 (0.08-0.64) 
Specificity 83.3 (0.77-0.88) 
Positive likelihood ratio 1.714 (0.51-5.81) 
Negative likelihood ratio 0.857 (0.53-1.38) 
Diagnostic odd ratio 2.0 - 
Relative risk 1.93 (1.07-2.79) 
Combined ischaemia modified albumin and copeptin (Cop) (Sample 1). 
 
N=173 
 AMI (Sample 1)  
+ - 
IMA+Cop + 5 89 94 
 - 2 77 79 
7 166 173 
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Sample 1 % Confidence interval (95%) 
Sensitivity 71.4 (0.36-0.92) 
Specificity 46.4 (0.39-0.54) 
Positive likelihood ratio 1.332 (0.82-2.17) 
Negative likelihood ratio 0.616 (0.19-2.0) 
Diagnostic odd ratio 2.163 - 
Relative risk 2.10 (1.25-2.95) 
 
Combined ischaemia modified albumin and troponin T (hs-cTnT) (Sample 1). 
 
N=173 
 AMI (Sample 1)  
+ - 
IMA + hs-
TnT 
+ 3 20 23 
 - 4 146 150 
7 166 173 
 
 
Sample 1 % Confidence interval (95%) 
Sensitivity 42.9 (0.16-0.75) 
Specificity 88 (0.82-0.92) 
Positive likelihood ratio 3.557 (1.38-9.19) 
Negative likelihood ratio 0.650 (0.34-1.24) 
Diagnostic odd ratio 5.475 - 
Relative risk 4.89 (4.09-5.69) 
 
Combined ischaemia modified albumin and Troponin I (TnI) (Sample 1). 
N=143 
 AMI (Sample 1)  
+ - 
IMA+TnI + 0 11 11 
 - 5 127 132 
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5 138 143 
 
Sample 1 % Confidence interval (95%) 
Sensitivity 0.0 (0.0-0.43) 
Specificity 92 (0.86-0.95) 
Positive likelihood ratio 0.0 (1.38-9.19) 
Negative likelihood ratio 1.087 (1.03-1.14) 
Diagnostic odd ratio 5.475 - 
Relative risk 0.0 - 
 
Combined Ischaemia modified albumin, h-FAB and copeptin (Sample 1). 
N=169 
 AMI (Sample 1)  
+ - 
IMA+fab+cop + 6 91 97 
 - 1 71 72 
7 162 169 
 
Sample 1 % Confidence interval (95%) 
Sensitivity 86 (0.49-0.97) 
Specificity 43.8 (0.36-0.52) 
Positive likelihood ratio 1.526 (1.10-2.13) 
Negative likelihood ratio 0.326 (0.05-2.02) 
Diagnostic odd ratio 4.681 - 
Relative risk 4.45 (3.36-5.54) 
 
Two by two tables (sample 2) 
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Combined ischaemia modified albumin and cardiac troponin T (Sample 2). 
N=173 
 AMI (Sample 2)  
+ - 
IMA + hs-
TnT 
+ 7 40 47 
 - 0 126 126 
7 166 173 
 
Sample 2 % Confidence interval (95%) 
Sensitivity 1.0 (0.06-1.0) 
Specificity 76 (0.69-0.82) 
Positive likelihood ratio 4.15 (3.1-5.4) 
Negative likelihood ratio - - 
Diagnostic odd ratio - - 
Relative risk - - 
 
Combined ischaemia modified albumin and cardiac troponin I (Sample 2). 
N=142 
 AMI (Sample 2)  
+ - 
IMA+TnI + 2 11 13 
 - 3 126 129 
5 137 142 
 
Sample 2 % Confidence interval (95%) 
Sensitivity 40 (0.11-0.77) 
Specificity 92 (0.86-0.95) 
Positive likelihood ratio 4.98 (1.47-16.77) 
Negative likelihood ratio 0.65 (0.31-1.34) 
Diagnostic odd ratio 7.63 - 
Relative risk 6.62 (5.65-7.58) 
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Combined ischaemia modified albumin and copeptin (Sample 2). 
N=173 
 AMI (Sample 2)  
+ - 
IMA  
+  
Copeptin 
+ 5 74 79 
 - 2 92 94 
7 166 173 
 
Sample 2 % Confidence interval (95%) 
Sensitivity 71.4 (0.36-0.92) 
Specificity 55.4 (0.48-0.63) 
Positive likelihood ratio 1.60 (0.97-2.63) 
Negative likelihood ratio 0.52 (0.15-1.67) 
Diagnostic odd ratio 3.12 (2.12-3.83) 
Relative risk 2.97 - 
 
Combined ischaemia modified albumin and heart fatty-acid binding protein (h-
FABP) (Sample 2). 
N=165 
 AMI (Sample 2)  
+ - 
IMA 
+ 
h-FABP 
+ 4 20 24 
 - 3 138 141 
7 166 165 
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Sample 2 % Confidence interval (95%) 
Sensitivity 57.1 (0.25-0.84) 
Specificity 87.3 (0.82-0.92) 
Positive likelihood ratio 4.51 (2.11-9.66) 
Negative likelihood ratio 0.49 (0.21-1.16) 
Diagnostic odd ratio 9.2 - 
Relative risk 7.83 (7.0-8.6) 
 
Combined ischaemia modified albumin, TnT, TnI, h-FAB and copeptin 
(Sample 2). 
N=574 
 AMI (Sample 2)  
+ - 
Tests + 6 81 87 
 - 1 85 86 
7 166 173 
 
Sample 2 % Confidence interval (95%) 
Sensitivity 86 (0.49-0.97) 
Specificity 51.2 (0.43-0.59) 
Positive likelihood ratio 1.76 (1.25-2.47) 
Negative likelihood ratio 0.28 (0.04-1.72) 
Diagnostic odd ratio 6.30 - 
Relative risk 5.93 (4.84-7.02) 
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Correlation of biomarkers concentrations on admission and at 90 min 
after admission 
 
 
Figure 1: Correlation between ischaemia modified-albumin (n = 174) on admission 
and 90 min after admission 
 
 
Figure 2: Correlation between Roche Hs-TnT (n = 174) on admission and 90 min 
after admission 
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Figure 3: Correlation between Beckman hs-cTnI concentration (n = 174) on 
admission and 90 min after admission 
 
 
Figure 4: Correlation between Centaur TnI concentration (n = 174) on admission 
and 90 min after admission 
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Figure 5: Correlation between H-FABP concentration (n = 174) on admission and 90 
min after admission 
 
Figure 6: Correlation between myoglobin concentration (n = 174) on admission and 
90 min after admission 
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Figure 7: Correlation between copeptin concentration (n = 174) on admission and 90 
min after admission 
 
 
Figure 8: Correlation between NT-pro-BNP concentration (n = 174) on admission 
and 90 min after admission 
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Figure 9: Correlation between CK-MB concentration (n = 174) on admission and 90 
min after admission 
 
 
Figure 10: Correlation between Accu TnI concentration (n = 174) on admission and 
at 90 min after admission 
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Correlation between participant age and biomarker concentrations 
 
 
Figure 11: AGE vs. IMA on admission 
 
 
Figure12:  AGE vs. IMA at 90 min after 
admission 
  
 
 
Figure 13: AGE vs. Accu TnI on admission 
 
 
Figure 14: AGE vs. Accu at 90 min after 
admission 
 
 
Figure 15: AGE vs. IMA on admission 
 
 
Figure 16: Age vs, hs-TnI at 90 min after 
admission 
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Figure 17: AGE vs. Centaur TnI on 
admission 
 
 
Figure 18: AGE vs. Centaur at 90 min after 
admission 
 
 
Figure 19: AGE vs. h-FABP on admission 
 
 
Figure 20: AGE vs. h-FABP at 90 min after 
admission 
 
 
Figure 21: AGE vs. Myoglobin on 
admission 
 
 
Figure 22:  AGE vs. Myoglobin at 90 min 
after admission 
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Figure 23: AGE vs. Copeptin on admission 
 
 
Figure 24: AGE vs. Copeptin at 90 min 
after admission 
 
 
Figure 25: AGE vs. hs-cTnT on admission 
 
 
Figure 26: AGE vs. hs-cTnT at 90 min 
after admission 
 
 
Figure 27: AGE vs. NT-pro-BNP on admission 
 
 
Figure 28: AGE vs. NT-pro-BNP at 90 
min after admission 
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Figure 29: AGE vs. ICK-MB on admission 
 
 
Figure 30: AGE vs. CK-MB at 90 min after 
admission 
 
Control group (n = 66) age characteristics 
 
Figure 31:  reference range participant age distribution 
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Table 1: Sample Demographics 
Sample IMA DOB age Sex Sample IMA DOB age Sex 
948110R 124 21/09/1989 25 M 949294P 117 02/08/1960 54 M 
948343D 123 01/08/1987 27 F 948609M 125 11/04/1960 55 F 
947020C 115 26/05/1987 27 F 948504M 120 01/01/1960 55 F 
948556C 127 14/05/1986 28 F 948133G 126 18/06/1959 55 F 
947462R 125 16/04/1986 28 F 950078X 118 26/04/1958 56 F 
950036N 110 12/11/1983 31 F 948687Z 118 03/01/1957 58 F 
947977X 120 01/07/1983 31 F 949707S 115 24/03/1954 61 F 
948010G 125 15/03/1981 34 F 949613L 122 26/01/1954 61 M 
948040S 127 01/01/1981 34 F 950502Y 107 02/09/1953 61 M 
947283N 119 22/09/1979 35 M 947360D 117 02/11/1952 62 M 
947286H 123 29/11/1978 36 F 948336N 124 27/09/1952 62 F 
947093Z 124 05/06/1976 38 F 947392B 126 18/05/1952 62 M 
949300C 119 01/07/1975 39 M 949596R 118 02/12/1951 63 F 
948515K 125 18/06/1975 39 M 949467W 110 09/08/1950 64 F 
948937X 120 22/01/1975 40 M 947972M 118 14/06/1950 64 F 
949718L 122 10/07/1974 40 M 950169B 119 21/03/1949 66 F 
950496N 120 26/07/1972 42 M 947563M 121 13/03/1949 66 F 
949000B 122 24/11/1970 44 M 948465K 123 11/10/1946 68 M 
948062L 126 13/08/1970 44 F 948934V 120 22/02/1946 69 M 
949854A 121 01/05/1970 44 F 947700W 120 29/12/1945 69 F 
948056E 127 01/03/1970 45 M 949790Z 123 15/11/1945 69 F 
947691G 125 27/10/1966 48 F 947553V 124 01/05/1944 70 F 
948472P 124 28/12/1964 50 F 950076B 122 16/06/1942 72 F 
947787E 126 15/12/1964 50 F 946959F 126 10/12/1941 73 M 
947656M 124 10/07/1964 50 F 946765M 124 31/07/1940 74 M 
947703C 124 02/05/1964 50 F 949852W 127 14/02/1939 76 F 
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Sample IMA DOB age Sex Sample IMA DOB age Sex 
948462F 126 14/04/1964 51 F 948853V 120 24/08/1938 76 M 
949245X 122 06/01/1964 51 F 949519A 122 16/04/1934 81 F 
948445B 123 01/01/1964 51 M 946812C 125 19/07/1933 81 F 
949296F 122 13/01/1963 52 M 947081G 122 30/04/1932 82 F 
947348F 119 10/10/1960 54 M 949437K 121 29/08/1930 84 F 
948168S 126 13/08/1960 54 F 947240Y 121 26/08/1928 86 F 
948444V 127 14/08/1925 89 F 948949X 123 02/02/1926 89 M 
 
Over all study descriptive data 
 
Figure 32: Overall data distribution of all biomarkers on admission and at 90 
min after admission 
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Table 2: Study descriptive data 
 
n Mean 95% CI SE SD 
IMA 1  174 111.2 109.1 to 113.2 1.04 13.71 
IMA 2  174 114.5 112.5 to 116.5 1.01 13.39 
AccuTnI 1  174 0.002047 0.0 to 0.0 0.0007888 0.0104054 
AccuTnI 2  174 0.003372 0.0 to 0.0 0.0012339 0.0162768 
Beckman hsTnI 1  143 6.79989 -0.2 to 13.8 3.530085 42.213671 
Beckman hs TnI 2  143 6.62771 1.8 to 11.5 2.445310 29.241659 
Centaur TnI 1  174 0.0198 0.0 to 0.0 0.00033 0.00440 
Centaur TnI 2  174 0.0365 0.0 to 0.1 0.01088 0.14349 
FABP 1  170 1.293 0.8 to 1.7 0.2293 2.9896 
FABP 2  166 1.195 0.9 to 1.5 0.1540 1.9845 
MYO 1  173 36.4469 30.7 to 42.2 2.92366 38.45476 
MYO 2  171 34.373 29.5 to 39.3 2.4714 32.3172 
Copeptin 1  166 8.155 7.8 to 8.5 0.1768 2.2784 
Copeptin 2  168 7.843 7.5 to 8.2 0.1762 2.2840 
Hs-cTnT 1  173 3.608 3.1 to 4.2 0.2768 3.6413 
Hs-cTnT 2  173 3.915 3.4 to 4.4 0.2536 3.3360 
NT-pro-BNP 1  174 57.307 43.6 to 71.0 6.9617 91.8315 
NT-pro-BNP 2  171 63.094 45.0 to 81.2 9.1773 120.0090 
CKMB 1  174 1.56 1.4 to 1.7 0.089 1.176 
CKMB 2  165 1.49 1.3 to 1.7 0.086 1.105 
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Table 3: Study descriptive data on admission (1) and at 90 min after admission (2) 
 
n Min 
1st 
Quartile Median 95% CI 
3rd 
Quartile Max IQR 
IMA 1 174 63 103.9 112.0 109.0 to 114.0 118.2 150 14.3 
IMA 2  174 59 105.9 115.0 113.0 to 117.0 123.0 160 17.1 
AccuTnI 1  174 0.00000 0.000000 0.000000 0.0 to 0.0 0.000600 0.12860 0.000600 
AccuTnI 2  174 0.00000 0.000000 0.000000 0.0 to 0.0 0.000808 0.19000 0.000808 
Beckman hs-TnI 1  143 0.0000 0.00000 1.03100 0.3 to 1.5 2.79017 496.4950 2.79017 
Beckman hs TnI 2  143 0.0000 0.00000 0.84900 0.4 to 1.5 3.29767 292.9420 3.29767 
Centaur TnI 1  174 0.019 0.0190 0.0190 0.0 to 0.0 0.0190 0.070 0.0000 
Centaur TnI 2  174 0.019 0.0190 0.0190 0.0 to 0.0 0.0190 1.420 0.0000 
FABP 1  170 0.16 0.588 0.865 0.8 to 0.9 1.180 36.13 0.592 
FABP 2  166 0.14 0.520 0.810 0.7 to 0.9 1.164 20.00 0.644 
MYO 1  173 1.020 19.1000 26.7300 23.4 to 29.2 41.5800 360.590 22.4800 
MYO 2  171 4.82 19.488 25.760 23.3 to 28.5 40.735 285.04 21.247 
Copeptin 1  166 4.88 6.198 8.200 6.9 to 8.8 10.195 11.95 3.997 
Copeptin 2  168 0.00 5.995 7.260 6.7 to 8.2 9.968 12.00 3.973 
Hs-cTnT 1  173 2.99 2.990 2.990 3.0 to 3.0 2.990 45.28 0.000 
h--scTnT 2  173 2.99 2.990 2.990 3.0 to 3.0 2.990 28.93 0.000 
NT-pro--BNP 1  174 19.00 19.000 35.350 29.0 to 41.0 60.292 967.70 41.292 
NT-pro-BNP 2  171 17.00 19.000 36.000 34.0 to 45.0 67.000 1323.00 48.000 
CK-MB 1  174 0.0 0.80 1.30 1.1 to 1.4 2.01 8.3 1.21 
CK-MB 2  165 0.0 0.70 1.20 1.0 to 1.4 2.00 7.2 1.30 
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Table 4: Study Assays characteristics on admission 
Assay Mean 95% CI SE SD 
IMA  111.17 109.12 113.22 1.04 13.71 
AccuTnI 0.00 0.00 0.00 0.00 0.01 
Beckman hs-TnI  6.80 -0.18 13.78 3.53 42.21 
Centaur TnI  0.02 0.02 0.02 0.00 0.00 
H-FABP  1.29 0.84 1.75 0.23 2.99 
MYO  36.45 30.68 42.22 2.92 38.45 
Copeptin 8.15 7.81 8.50 0.18 2.28 
Hs-cTnT 3.61 3.06 4.15 0.28 3.64 
NT-pro-BNP 57.31 43.57 71.05 6.96 91.83 
CK-MB 1.56 1.38 1.74 0.09 1.18 
 
Table 5: Study assay characteristics at 90 min after admission 
Assay Mean 95% CI SE SD 
IMA 114.47 112.47 116.47 1.01 13.39 
AccuTnI  0.00 0.00 0.01 0.00 0.02 
Beckman hs-TnI 6.63 1.79 11.46 2.45 29.24 
Centaur TnI   0.04 0.02 0.06 0.01 0.14 
H-FABP   1.20 0.89 1.50 0.15 1.98 
MYO   34.37 29.49 39.25 2.47 32.32 
Copeptin   7.84 7.50 8.19 0.18 2.28 
Hs-cTnT   3.91 3.41 4.42 0.25 3.34 
NT-pro-BNP   63.09 44.98 81.21 9.18 120.01 
CK-MB  1.49 1.32 1.66 0.09 1.11 
 
Table 4: and 5 shows IMA comparative predictive value on admission and  at 
90 min after admission in the diagnosis of acute myocardial infarction using 
hs-cTnT as a predicate  
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Table 6: IMA diagnostic efficiency characteristics on admission (1-way 
ANOVA) using the combined AMI and hs-cTnT. 
  
      
 
IMA by Biochem Dx AMI 
hs-cTnT 
n Mean SE Pooled 
SE 
SD 
AMI  7 111.9 4.40 5.11 11.7 
Non-AMI  166 111.4 1.05 1.05 13.6 
  
     
Source of variation Sum 
squares 
DF Mean 
square 
F 
statistic 
p 
Biochem Dx AMI hs- cTnT  1.7 1 1.7 0.01 0.9235 
Residual  31278.9 171 182.9 
  
Total  31280.6 172 
   
 
 
Figure 33: IMA assay diagnostic predictive value for AMI on admission.  Hs-
cTnT was used as a predicate test 
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Figure 34:  IMA assay diagnostic predictive value for AMI on admission and 
90 min after admission.  Hs-cTnT was used as a predicate test 
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Table 7:  Summary of Hs-cTnT predictive value for the final diagnosis of AMI. 
  n Mean 95% CI SE SD 
   
Hs-cTnT by AMI - MI  3 17.767 -41.478 to 77.011 13.7693 23.8491 
   
Hs-cTnT by AMI - No-AMI  170 3.358 3.090 to 3.626 0.1359 1.7725 
   
Hs-cTnT by AMI - MI  3 13.073 -21.457 to 47.604 8.0254 13.9003 
   
Hs-cTnT by AMI - No-AMI  170 3.753 3.338 to 4.169 0.2104 2.7431 
   
          
  n Min 
1st 
Quartile Median 95% CI 
3rd 
Quartile Max IQR 
Hs-cTnT by AMI - MI  3 2.99 3.330 5.030 - to - 38.572 45.28 35.242 
Hs-cTnT by AMI - No-AMI  170 2.99 2.990 2.990 2.990 to 2.990 2.990 21.24 0.000 
Hs-cTnT by AMI - MI  3 2.99 3.708 7.300 - to - 25.325 28.93 21.617 
Hs-cTnT by AMI - No-AMI  170 2.99 2.990 2.990 2.990 to 2.990 2.990 20.08 0.000 
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Table 8: Area under the ROC curve of biomarkers of necrosis 
Test  Area 95% CI SE 
AccuTnI  0.88 0.71 to 1.00 0.089 
Beckman hs-TnI  0.78 0.54 to 1.00 0.120 
Centaur TnI  0.84 0.65 to 1.00 0.096 
CK-MB  0.62 0.32 to 0.92 0.153 
Myoglobin  0.72 0.57 to 0.87 0.076 
Hs-cTnT  1.00 - to - 0.000 
 
Table 9: Comparison of the magnitude of putative biomarkers on admission. 
Contrast  Difference 95% CI SE p 
IMA v H-FABP 1  -0.14 -0.53 to 0.25 0.201 0.4882 
IMA v MYO 1  -0.24 -0.51 to 0.03 0.137 0.0771 
IMA v Copeptin 1  -0.08 -0.35 to 0.19 0.137 0.5430 
IMA v NT-pro-BNP 1  -0.06 -0.42 to 0.29 0.181 0.7303 
IMA v CK-MB 1  -0.03 -0.37 to 0.31 0.175 0.8747 
H-FABP v MYO 1  -0.10 -0.25 to 0.04 0.075 0.1654 
H-FABP v Copeptin 1  0.06 -0.22 to 0.33 0.142 0.6930 
H-FABP v NT-pro-BNP 1  0.08 -0.40 to 0.55 0.243 0.7511 
H-FABP v CK-MB 1  0.11 -0.06 to 0.29 0.088 0.2062 
MYO v Copeptin 1  0.16 -0.05 to 0.37 0.105 0.1290 
MYO v NT-pro-BNP 1  0.18 -0.22 to 0.58 0.204 0.3762 
MYO v CK-MB 1  0.22 0.05 to 0.39 0.087 0.0128 
Copeptin v NT-pro-BNP 1  0.02 -0.42 to 0.46 0.224 0.9255 
Copeptin v CK-MB 1  0.06 -0.15 to 0.26 0.103 0.5895 
NT-pro-BNP v CK-MB 1  0.03 -0.47 to 0.54 0.260 0.8933 
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Table 10: Hs-cTnT predictive value of the final diagnosis of AMI on admission 
and 90 min after admission.  Hs-cTnT was used as a predicate thus was 
statistically significant (p = < 0.0001). 
 
        
 
  
 
Hs-cTnT  by Biochem Dx 
AMI hs-cTnT  n Mean SE 
 Pooled 
SE SD 
AMI  7 12.629 5.9634  1.1871 15.778 
Non-AMI  166 3.227 0.0840  0.2438 1.082 
        
 
    
Source of variation  
Sum 
squares DF 
Mean 
square 
 F 
statistic p 
Biochem Dx AMI hs-cTnT  593.632 1 593.632  60.18 <0.0001 
Residual  1686.885 171 9.865      
Total  2280.518 172        
 
          
 
Hs-cTnT 2 by 
Biochem Dx AMI hs-
cTnT  n Mean SE Pooled SE SD 
AMI  7 17.843 2.4008 0.6457 6.352 
Non-AMI  166 3.328 0.0968 0.1326 1.248 
            
Source of variation  
Sum 
squares DF 
Mean 
square F statistic p 
Biochem Dx AMI cTnT  1415.163 1 1415.163 484.96 <0.0001 
Residual  498.992 171 2.918     
Total  1914.155 172       
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Table 11: Over all data of biomarkers on admission (1) and at 90 min after admission (2) 
 
ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
2048 117 124 0.002 0.0852 15.69 56.856 0.019 1.29 0.9 1.85 
2059 115 103 0 0 0.2 0.308 0.019 0.019 0.87 1.05 
2105 118 120 0 0.0013 0 0.485 0.019 0.019 1.03 0.66 
2108 116 112 0 0 0.536 0.849 0.019 0.019 1.35 1.55 
2118 100 108 0 0.0001 0.159 0 0.019 0.019 0.91 1.03 
2131 104 113 0 0 0 0 0.019 0.019 0.86 0.37 
2140 150 133 0 0 1.961 2.427 0.019 0.019 1.39 1.64 
2150 117 126 0 0 0 0.028 0.019 0.019 1.76 1.6 
2154 109 104 0 0 3.29 0.172 0.019 0.019 0.71 0.56 
2157 106 93 0 0 1.582 1.521 0.019 0.019 0.71 0.89 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
2158 100 107 0 0 0.841 1.261 0.019 0.019 0.88 1.29 
2161 105 115 0 0 0.167 6.141 0.019 0.019 2.56 3.6 
2172 112 114 0 0 6.946 7.543 0.019 0.019 0.84 0.87 
2173 127 119 0 0 496.495 4.964 0.019 0.019 0.79 1.06 
2176 108 117 0.0239 0 22.329 2.711 0.02 0.019 1.4 1.23 
2181 84 103 0 0.0017 3.541 7.382 0.019 0.019 1.55 0.9 
2271 105 105 0 0 4.54 4.078 0.019 0.019 0.92 1.27 
2286 104 103 0.0002 0 4.173 8.154 0.019 0.019 1.91 2.01 
2293 88 97 0 0 7.011 3.291 0.019 0.019 1.36 1.22 
2298 72 108 0 0 5.051 2.613 0.019 0.019 1.2 1.02 
2303 108 125 0.0059 0 4.339 6.198 0.019 0.019 1.51 2.29 
2326 130 139 0.0165 0.0138 17.348 292.942 0.03 0.06 1.08 1.13 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
6002 111 103 0 0 0 0 0.019 0.019 0.81 0.47 
6007 80 87 0 0 0 0 0.019 0.019 0.32 0.28 
6020 92 106 0.0005 0 2.544 3.489 0.019 0.019 1.03 0.91 
6023 118 121 0.0072 0.0065 18.068 11.067 0.02 0.02 
 
1.02 
6038 109 104 0 0 0 0 0.019 0.019 0.41 0.49 
6041 97 118 0 0 0.89 0 0.019 0.019 0.43 0.65 
6044 114 101 0.0006 0 2.82 1.695 0.019 0.019 0.59 0.84 
6049 94 113 0 0 0 0 0.019 0.019 
 
0.23 
6060 79 122 0 0 26.299 20.614 0.019 0.019 0.88 0.68 
6061 89 90 0 0 0 0 0.019 0.019 0.28 0.24 
6063 97 94 0.0049 0 7.042 0 0.019 0.019 1.15 1 
6067 124 116 0.0001 0 0.212 0 0.019 0.019 0.85 0.79 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
6071 94 98 0.0028 0.0019 2.206 0.554 0.019 0.19 1.18 0.71 
6076 108 103 0.0006 0.0008 0 0 0.019 0.019 0.25 0.41 
6077 122 111 0 0 0 0.186 0.019 0.019 
  
6080 99 109 0 0 0 0.386 0.019 0.019 0.22 0.25 
6086 110 99 0.0027 0.0041 0.863 0 0.019 0.019 0.6 0.62 
6087 113 102 0.1286 0.0087 0 0 0.019 0.019 1.56 1.71 
6092 110 102 0.0004 0.0051 0 2.807 0.019 0.019 0.48 0.67 
6100 112 118 0.0048 0 0.112 1.598 0.019 0.019 0.94 0.96 
6172 123 121 0 0 0 0.186 0.019 0.019 0.37 0.44 
6174 116 121 0 0 0.129 0.329 0.019 0.019 1.12 2.14 
6177 107 110 0 0 0 0 0.019 0.019 0.65 0.98 
6179 124 117 0 0 0 0 0.019 0.019 0.71 0.55 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
6189 105 115 0 0 0 0.193 0.019 0.019 0.94 0.47 
6200 113 129 0 0 1.479 0 0.019 0.019 0.48 
 
6204 98 100 0 0 0 0 0.019 0.019 0.43 0.47 
6211 107 123 0 0.0007 1.468 1.159 0.019 0.019 0.71 0.77 
6222 104 108 0 0 0 0 0.02 0.019 0.56 20 
6239 117 111 0 0 0 0 0.019 0.02 1.54 1.26 
6247 98 112 0 0 0 0 0.019 0.019 0.85 1.24 
6249 101 105 0 0 0 0 0.019 0.019 0.74 0.9 
6252 118 105 0.001 0 0.3969 0.489 0.019 0.019 1.25 0.65 
6288 100 104 0 0 0 0 0.019 0.019 1.03 0.84 
6295 126 143 0.0009 0.001 1.2394 1.541 0.019 0.019 1.15 1.08 
6296 114 117 0 0 3.2965 3.115 0.019 0.019 1.55 1.3 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
6299 123 105 0 0 1.548 1.594 0.019 0.019 1.93 1.21 
6306 110 106 0.001 0 0.694 0.811 0.019 0.019 1.6 14.2 
6310 104 118 0 0.02 0 0.329 0.019 0.02 3.7 2.64 
6315 99 100 0 0 0 0 0.019 0.019 13.48 0.86 
6316 112 119 0 0 0 0 0.019 0.019 1.24 0.98 
6318 105 121 0 0 0 0 0.019 0.019 0.7 
 
6329 112 129 0 0 0 0 0.019 0.019 1.17 1.49 
6330 101 110 0 0 1.1894 1.293 0.019 0.019 0.93 0.52 
5012 114 98 0 0 0.859 0 0.019 0.019 0.41 1 
5020 113 114 0 0 1.885 2.264 0.019 0.019 0.52 0.67 
5023 102 112 0 0 1.862 1.245 0.019 0.019 1.2 2.02 
5031 125 115 0 0 1.176 0.553 0.019 0.019 0.51 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
5037 100 114 0.0026 0.00093 6.082 7.052 0.019 0.019 0.45 0.52 
5075 108 109 0 0 2.625 3.48 0.019 0.019 0.56 0.57 
5117 100 97 0 0 1.031 0.16 0.019 0.019 1.2 0.99 
3005 112 122 0 0 
  
0.019 0.019 1.12 0.34 
3006 127 110 0 0 
  
0.019 0.019 0.38 0.16 
3068 112 120 0 0 
  
0.019 0.019 0.31 0.21 
3157 123 128 0 0 
  
0.019 0.019 0.3 0.27 
3159 115 123 0 0 
  
0.019 0.019 0.54 0.43 
3167 139 153 0.006 0 
  
0.02 0.019 1.28 1.08 
3168 132 130 0 0 
  
0.019 0.019 0.97 0.66 
3169 117 116 0 0 
  
0.02 0.019 0.81 1.32 
3174 122 122 0.001 0 
  
0.019 0.019 0.16 0.44 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
3237 129 131 0.002 0 
  
0.019 0.019 0.8 0.47 
3241 105 112 0 0 
  
0.019 0.019 0.43 0.41 
3298 130 143 0 0 
  
0.019 0.019 0.82 1.52 
3300 149 160 0 0 
  
0.019 0.019 0.51 0.72 
3301 120 120 0 0.003 
  
0.019 0.019 0.59 0.94 
3312 121 124 0 0 
  
0.019 0.019 0.23 
 
3317 110 116 0 0 
  
0.019 0.019 0.48 0.33 
3343 127 125 0 0.03 
  
0.019 0.04 0.85 0.25 
3346 122 127 0 0.003 
  
0.019 0.019 0.78 0.62 
3358 126 124 0 0 
  
0.019 0.02 0.66 1.36 
3360 120 123 0 0 
  
0.019 0.019 1.16 1.14 
3370 126 109 0 0 
  
0.019 0.02 0.67 1.16 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
3404 112 151 0 0 
  
0.019 0.019 0.31 0.47 
3406 124 112 0 0 
  
0.019 0.019 0.68 0.72 
3410 135 122 0 0 
  
0.019 0.019 0.42 0.4 
3417 124 123 0 0 
  
0.019 0.019 3.03 0.99 
3418 128 112 0 0 
  
0.019 0.019 1.44 1.16 
4062 105 115 0 0 1.965 1.064 0.019 0.019 0.57 0.87 
4064 121 122 0 0 0 0 0.019 0.019 0.68 0.77 
4066 107 113 0.0035 0.0065 6.266 5.899 0.019 0.019 0.84 0.8 
4075 117 125 0 0 0 0 0.019 0.019 0.64 0.61 
4077 115 105 0.00656 0.0042 3.602 4.934 0.019 0.019 1.1 1.62 
4081 103 101 0.0011 0 1.94 0.217 0.019 0.019 0.71 0.7 
4082 110 121 0 0 0 0 0.019 0.019 0.89 0.7 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
4090 112 121 0 0 0 0.33 0.019 0.019 0.87 1.34 
4092 107 97 0 0 18.693 2.686 0.03 0.019 1.14 0.77 
4096 105 125 0.0021 0 1.592 0.759 0.019 0.019 1.02 0.69 
4109 130 125 0.0002 0 0.974 0.251 0.019 0.019 1.06 0.91 
4111 116 124 0 0 5.327 4.596 0.019 0.019 0.32 0.53 
4112 117 120 0 0 1.222 0 0.03 0.019 0.66 0.98 
4117 101 120 0 0 0 0 0.019 0.019 0.36 0.44 
4119 117 118 0 0 0 0 0.019 0.019 0.6 0.56 
4123 101 113 0 0 0.398 126.729 0.019 0.019 0.63 0.49 
4125 112 113 0 0.0088 2.356 14.342 0.019 0.019 0.71 0.79 
4130 136 131 0 0 0 0 0.019 0.019 0.88 0.83 
4135 105 111 0.0016 0.0004 14.879 15.671 0.03 0.02 0.67 0.41 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
1020 63 78 0 0 0 1.234 0.019 0.019 1.26 0.81 
1028 106 114 0 0 0.097 0.805 0.019 0.019 0.3 0.22 
1030 114 119 0 0 2.443 3.57 0.019 0.019 0.56 0.49 
1037 122 115 0.003 0 1.509 1.319 0.019 0.019 0.98 0.76 
1040 112 113 0 0 0.206 0 0.019 0.019 36.13 
 
1041 118 125 0.0034 0.0224 1.945 15.963 0.019 0.03 0.81 0.3 
1044 118 124 0 0 0.133 0 0.019 0.019 1.1 1.58 
1055 107 124 0.0001 0 1.298 1.739 0.019 0.019 0.76 
 
1060 96 111 0 0 1.265 1.528 0.019 0.02 0.38 0.6 
1245 101 101 0 0 1.703 2.232 0.019 0.019 0.7 0.57 
1247 88 117 0 0 0 1.315 0.019 0.019 0.53 0.14 
1252 104 59 0 0 0.866 0.464 0.019 0.019 0.72 0.78 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
1256 111 113 0 0 0 0 0.019 0.019 0.63 0.91 
1257 108 118 0.0032 0.0017 93.754 1.498 0.019 0.019 0.87 0.51 
1261 102 117 0 0 2.711 0.835 0.019 0.019 1.73 1.14 
1262 90 99 0 0 1.303 3.299 0.02 0.02 1.03 0.71 
1264 118 125 0.0003 0.008 2.051 3.951 0.019 0.019 1.11 1.32 
1268 75 80 0 0 0.102 2.228 0.02 0.019 1.76 1.81 
1271 114 124 0 0 1.303 1.981 0.019 0.019 1.25 1.22 
1274 104 99 0 0 2.129 1.483 0.019 0.019 0.7 0.67 
1281 114 110 0 0 0 0 0.019 0.019 0.6 0.51 
1287 102 111 0 0 19.686 0.364 0.02 0.019 0.33 0.17 
1289 104 108 0 0 0 0 0.019 0.019 0.36 0.38 
1290 99 106 0 0 0.517 2.024 0.019 0.019 1.14 0.82 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
1295 117 102 0 0 1.765 2.289 0.019 0.019 0.89 0.41 
1303 118 116 0 0.0006 0 0.385 0.019 0.019 0.39 0.43 
1304 131 129 0.0006 0.0032 1.282 1.041 0.019 0.019 1.31 1.11 
1308 129 132 0.0135 0.0122 8.808 8.35 0.019 0.03 0.62 0.44 
1312 113 119 0.0025 0.012 0 0 0.019 0.019 1.32 2.26 
1315 104 127 0.001 0.0009 0 0 0.019 0.019 0.97 0.61 
1319 114 123 0.0006 0 0 0 0.019 0.019 1.18 1.07 
1320 109 116 0 0 0 0 0.019 0.019 0.41 0.63 
1326 101 102 0.0008 0.0051 0.257 2.382 0.019 0.019 
  
1328 134 130 0 0 0 0 0.019 0.019 1.23 0.94 
1250 108 117 0 0.0039 2.92 3.508 0.019 0.019 0.38 0.61 
3073 126 124 0.003 0.002 
  
0.03 0.03 1 0.79 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
1284 113 111 0 0 1.053 1.397 0.019 0.019 0.94 0.84 
1311 125 129 0.0001 0 0 0.155 0.019 0.019 0.62 0.41 
1046 99 110 0.0052 0.0154 2.806 9.02 0.019 0.03 0.93 0.81 
6208 100 117 0.0046 0.0011 6.844 6.137 0.019 0.019 0.95 1.03 
1292 92 99 0.0077 0.0023 7.501 6.357 0.019 0.019 0.92 0.81 
3296 116 119 0 0.02 
  
0.019 0.019 1.57 1.34 
2111 136 131 0 0.0104 8.103 7.846 0.02 0.03 1.51 0.84 
2166 108 110 0 0.19 0 140.443 0.019 1.42 3.27 6.45 
1033 114 111 0 0.003 1.171 3.269 0.019 0.019 1.01 1.1 
1057 110 124 0.0057 0.0058 4.155 3.405 0.019 0.019 5.19 5.36 
4021 103 90 0.0192 0.0185 16.966 17.3325 0.07 0.09 0.39 0.5 
3416 141 138 0 0.001 
  
0.019 0.02 1.59 2.09 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
5004 136 145 0.0048 0.0047 8.105 6.82 0.019 0.019 3.36 3.43 
3311 116 105 0.001 0.01 
  
0.02 0.03 0.5 0.58 
6106 103 84 0.0118 0.0212 12.339 17.133 0.03 0.02 0.78 0.67 
6236 110 115 0.03 0 6.598 5.187 0.03 0.019 1.05 1.48 
3412 127 123 0 0.001 
  
0.019 0.019 2.25 1.32 
1024 95 98 0.0029 0.0026 1.637 1.054 0.019 0.019 2.1 2.75 
2114 120 116 0 0 1.624 0.829 0.019 0.019 8.94 5.33 
6014 76 105 0 0 0 0 0.019 0.019 0.34 0.42 
26.73 27.62 <4.8 <4.8 2.99 2.99 non-AMI 19 19 1.7 2.4 MI ACS 
41.62 30.83 6.61 6.18 2.99 2.99 non-AMI 19 19 5 4.9 No-AMI Musculoskeletal 
43.29 23.59 7.57 11.7 2.99 2.99 non-AMI 19 19 0.6 0.6 No-AMI Probable arterial 
81 104.75 9.35 9.34 2.99 2.99 non-AMI 19 19 1.4 
 
No-AMI Probable arterial 
30.32 43.54 9.77 10.7 2.99 2.99 non-AMI 67 22 0.3 0.5 No-AMI Unknown 
340 
 
ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
57.28 72.29 6.24 5.88 2.99 2.99 non-AMI 52 36 1.9 2.1 No-AMI Non specific 
38.32 52.26 9.58 11.28 2.99 2.99 non-AMI 40 22 0.7 0.6 No-AMI Non specific 
78.58 36.22 11.15 5.75 2.99 2.99 non-AMI 19 19 3.6 3 No-AMI Non specific 
26.22 26.71 6.53 8.61 2.99 2.99 non-AMI 19 19 1.4 1.3 No-AMI Non specific 
46.05 53.1 4.94 11.31 2.99 3.4 non-AMI 34 53 1.3 1.4 No-AMI Non specific 
70.46 64.03 11.84 6.55 2.99 2.99 non-AMI 19 19 3.8 
 
No-AMI Non specific 
86.93 115.8 4.99 5.07 2.99 2.99 non-AMI 64 19 2.7 2.7 No-AMI Non specific 
17.86 10.79 10.68 8.38 2.99 2.99 non-AMI 19 19 1.2 1.2 No-AMI Other-CVT 
23.12 26.97 9.34 4.82 2.99 2.99 non-AMI 19 19 0.8 0.9 No-AMI Anxiety 
71 43.35 11.15 5.75 2.99 2.99 non-AMI 19 19 1.6 1.6 No-AMI Non specific 
18.97 28.45 4.94 11.31 2.99 2.99 non-AMI 34 47 0.1 0 No-AMI Other-LRT 
12.49 11.26 11 7.59 2.99 2.99 non-AMI 19 19 0.9 1 No-AMI Non specific 
28.14 31.97 11.3 8.53 2.99 2.99 non-AMI 19 19 1 0.9 No-AMI Non specific 
44.41 43.91 5.84 5.09 2.99 2.99 non-AMI 19 19 2.1 1.8 No-AMI Gastro-oesophageal 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
20.45 21.17 11.03 9.53 2.99 2.99 non-AMI 19 19 1.4 1.2 No-AMI Non specific 
19.18 23.9 6.63 9.47 2.99 2.99 non-AMI 19 19 1.3 1.6 No-AMI Non specific 
9.43 8.78 9.46 10.97 2.99 2.99 non-AMI 41 38 1 1 No-AMI ACS 
42.77 54.25 5.57 5.28 2.99 2.99 non-AMI 34.7 29.7 2.1 2.2 No-AMI Skeletal 
18.69 13.45 11.8 6.81 2.99 2.99 non-AMI 29.7 25.3 0.7 0.8 No-AMI Non specific 
23.58 15.23 10.92 6.27 2.99 2.99 non-AMI 53.2 51.2 1.1 0.8 No-AMI Gastro-oesophageal 
 
21.09 9.68 5.1 2.99 2.99 non-AMI 60 54 0.8 0.9 No-AMI ACS 
22.25 17.08 9 5 2.99 2.99 non-AMI 44.39 48.25 1 1 No-AMI Gastro-oesophageal 
27.18 25.38 7.12 6.3 2.99 2.99 non-AMI 42.46 47.67 0.8 0.7 No-AMI ACS 
7.95 9.37 10.4 5.82 2.99 2.99 non-AMI 110 95 0.5 
 
No-AMI Other-known WPW stable 
10.76 6.84 9.34 4.82 2.99 2.99 non-AMI 58.2 98.05 0.3 0.3 No-AMI Chest infection 
32.88 25.52 11.84 6.55 2.99 2.99 non-AMI 35 47 1.1 1 No-AMI Non specific 
58.08 42 11.47 6.59 2.99 2.99 non-AMI 74 65 1.6 1.7 No-AMI Gastro-oesophageal 
28.97 11.46 4.99 5.07 2.99 3.65 non-AMI 55 95 1.3 1.3 No-AMI Non specific 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
154.58 110.74 6.72 6.35 2.99 2.99 non-AMI 56 67 3.3 3 No-AMI Non specific 
62.4 90.47 11.52 5.97 2.99 2.99 non-AMI 59 280.4 2.6 2.9 No-AMI Non specific 
21.78 26.33 9.39 6.73 2.99 2.99 non-AMI 69 82 0.5 0.5 No-AMI Pneumonia 
10.12 7.13 6.6 6.71 2.99 2.99 non-AMI 52 66.27 0.4 0.4 No-AMI Non specific 
33.52 37.06 11.8 6.11 2.99 2.99 non-AMI 83.98 93 2.1 1.9 No-AMI Non specific 
61.37 70.74 6.66 10.88 2.99 2.99 non-AMI 29 36 0.8 0.7 No-AMI Non specific 
121.16 86.48 5.53 7.89 2.99 3.65 non-AMI 330.4 
 
3.3 3.1 No-AMI  
56.89 72.01 5.28 9.46 2.99 2.99 non-AMI 967.7 143 1.6 1.5 No-AMI Muscularskeletal 
30.29 50.25 7.09 11.52 2.99 2.99 non-AMI 37 17 1 1 No-AMI other-mild pancreatitis 
12.54 17.94 6.71 8.2 2.99 5.87 non-AMI 19 19 1.2 1.2 No-AMI Non specific 
33.66 40.81 4.88 11.4 2.99 2.99 non-AMI 26.3 26.9 1.1 1.1 No-AMI Non specific 
22.12 22.83 7.03 6.71 2.99 2.99 non-AMI 26.7 32.1 0.9 0.7 No-AMI Non specific 
18.06 19.81 5.21 10.58 2.99 2.99 non-AMI 27 21.6 0.3 0.4 No-AMI Angina-No ACS 
75.82 38.96 5.84 8.6 2.99 2.99 non-AMI 35.5 26.9 1.6 1.4 No-AMI other-ACS ruled out 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
19.94 7.98 8.1 6.68 2.99 2.99 non-AMI 42.1 32.7 0.4 0.2 No-AMI Anxity 
17.16 22.14 11.34 6.97 2.99 2.99 non-AMI 44.8 34.2 0.7 0.6 No-AMI Non specific 
12.11 15.94 7.6 8.84 2.99 2.99 non-AMI 40.3 44.1 0.5 0.3 No-AMI gastro-oesophageal 
41.06 42.08 10.15 6.03 2.99 2.99 non-AMI 19 34 0.3 0.3 No-AMI Non specific 
19 26.34 6.4 11.18 2.99 2.99 non-AMI 19 19 1.9 2 No-AMI Anxity 
45.2 19.45 5.12 10.07 2.99 2.99 non-AMI 39.1 42.6 0.3 0.4 No-AMI Non specific 
18.31 18.87 9.54 6.03 2.99 2.99 non-AMI 44.8 42.5 1.3 1.3 No-AMI Self dischard before diagnosis 
19.96 18.33 8.69 4.88 2.99 2.99 non-AMI 51.1 47.7 1.2 1.1 No-AMI Non specific 
24.68 20.8 <4.8 <4.8 2.99 2.99 non-AMI 80.3 32.5 1.7 0 No-AMI Other?cariac arrythmia 
17.15 19.25 6.2 6.4 2.99 2.99 non-AMI 101.5 93.75 1 0.8 No-AMI 
 
18.25 20.54 <4.8 5.2 2.99 2.99 non-AMI 66.72 45.19 2.6 2.5 No-AMI Gastro-oesophageal 
102.12 81.08 <4.8 <4.8 2.99 2.99 non-AMI 63.5 65.09 2.1 2 No-AMI Muscularskeletal 
20.65 8.56 6.5 4.9 2.99 2.99 non-AMI 41 63 0.8 0.7 No-AMI Muscularskeletal 
162.22 114.25 5.4 5.9 2.99 10.98 non-AMI 25 1323 8.3 7.2 No-AMI Muscularskeletal 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
1.02 8.41 6.1 5.4 2.99 2.99 non-AMI 72 94 1.1 1.1 No-AMI Gastro-oesophageal 
17.09 20.24 4.9 5.3 2.99 2.99 non-AMI 48 59 2.3 2 No-AMI Muscularskeletal 
21.76 
 
6.4 5.2 2.99 2.99 non-AMI 68 59 0.5 0.5 No-AMI Non specific 
19.15 29.86 <4.8 5.2 2.99 2.99 non-AMI 307 70 2.2 2.3 No-AMI Other-hyperventilation episode 
13.6 5.52 <4.8 <4.8 2.99 2.99 non-AMI 45 101 0.5 0.5 No-AMI Angina-No ACS 
8.77 17.56 5.69 10.73 2.99 2.99 non-AMI 36 22 1 1 No-AMI Non specific 
34.26 43.77 8.98 6.2 2.99 2.99 non-AMI 29 46 0.7 0.7 No-AMI Non specific 
36.44 45.7 9.56 9.48 2.99 2.99 non-AMI 59 83 2.4 2.3 No-AMI Other-possible cardiac but MI ruled out 
11.46 
 
11.57 11.35 2.99 2.99 non-AMI 43 62 0.8 0.6 No-AMI Non specific 
25.621 23.82 6.94 10.33 2.99 2.99 non-AMI 59 84 2 1.9 No-AMI Other-possible cardiac but MI ruled out 
19.7 18.44 6.6 6.37 2.99 2.99 non-AMI 35.2 34.1 1.5 1.4 No-AMI Non specific 
32.14 28.73 10.25 10.59 2.99 2.99 non-AMI 47.3 34.9 1.5 1.3 No-AMI Angina-No ACS 
28.91 25.76 11.78 8.08 2.99 2.99 non-AMI 26 32 0.6 0.7 No-AMI Muscularskeletal 
22.27 21.53 8.61 5.73 2.99 2.99 non-AMI 19 19 0.7 0.6 No-AMI Gastro-oesophageal 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
41.96 12.4 5.73 11.33 2.99 2.99 non-AMI 73 19 1.8 1.7 No-AMI Gastro-oesophageal 
8.99 4.82 5.09 10.25 2.99 2.99 non-AMI 76.04 37 0.7 0.6 No-AMI Other- arrythmia 
30.01 22.94 5.75 11.03 2.99 2.99 non-AMI 23 52.45 3.2 2.9 No-AMI Muscularskeletal 
60.14 23.55 10.56 5.26 2.99 2.99 non-AMI 19 19 2.2 2.1 No-AMI Other-stress related 
22.2 24.18 8.76 6.95 2.99 2.99 non-AMI 32 19 1.4 1.4 No-AMI Othre-infection gram negative sptecaemia 
54.59 57.68 11.57 9.84 2.99 2.99 non-AMI 19 28 1.1 0.7 No-AMI Non specific 
22.09 26.43 5.28 9.73 2.99 2.99 non-AMI 19 19 0.9 1 No-AMI Non specific 
26.16 28.71 5.45 8.81 2.99 2.99 non-AMI 82 54 1.8 1.6 No-AMI Gastro-oesophageal 
48.03 20.19 5.52 6.72 2.99 2.99 non-AMI 19 19 2.2 2 No-AMI Non specific 
35.94 45.22 10.19 5.08 2.99 2.99 non-AMI 36 54 3.2 3.4 No-AMI Other- LRTI 
31.02 43.04 11.2 5.08 2.99 2.99 non-AMI 19 28 1.7 1.7 No-AMI Muscularskeletal 
22.44 29.26 7 9.7 2.99 3.35 non-AMI 19 19 0.9 0.9 No-AMI Unknown 
25.73 45.05 11.88 5.38 2.99 2.99 non-AMI 19 19 2.4 2.3 No-AMI Gastro-oesophageal 
19.98 21.66 9.76 5.57 2.99 2.99 non-AMI 19 19 0.9 0.9 No-AMI Gastro-oesophageal 
346 
 
ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
50.01 28.66 6.71 8.2 2.99 16.85 AMI 26 43 1.1 1 No-AMI Non specific 
37.42 34.28 <4.8 <4.8 2.99 2.99 non-AMI 92 103 1.2 1 No-AMI Non specific 
20.11 29.44 11.35 11.91 2.99 5.55 non-AMI 81 67 3.2 3.2 No-AMI Gastro-oesophageal 
33.14 31.33 <4.8 <4.8 2.99 2.99 non-AMI 37 61 0.9 0.8 No-AMI Muscularskeletal 
33.64 35.96 8.14 5.85 2.99 2.99 non-AMI 91 74 1.1 1.1 No-AMI Non specific 
41.56 37.8 10.55 10.29 2.99 2.99 non-AMI 49 75 1.1 1 No-AMI Gastro-oesophageal 
38.48 51.97 5.99 5.34 2.99 2.99 non-AMI 29 34 1.8 1.5 No-AMI Non specific 
46.37 21.62 5.29 6.63 2.99 2.99 non-AMI 33 48 0.7 0.6 No-AMI Angina-No ACS 
28.99 28.73 5.12 10.07 2.99 2.99 non-AMI 19 19 1.4 1.4 No-AMI Gastro-oesophageal 
29.18 22.15 9.54 6.03 2.99 2.99 non-AMI 19 19 0.8 0.8 No-AMI Non-specific 
8.15 33.64 6.6 6.17 2.99 2.99 non-AMI 36 35 0.4 0.4 No-AMI Non-specific 
20.35 24.2 8.43 7.26 2.99 2.99 non-AMI 32 43.84 2.3 2 No-AMI Angina-No ACS 
41.38 27.91 6.65 8.96 2.99 2.99 non-AMI 42 53 2.7 2.8 No-AMI Unknown 
24.56 21.48 8.34 9.46 2.99 2.99 non-AMI 46 78 0.9 0.8 No-AMI Gastro-oesophageal 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
24.2 27.16 5.96 10.79 2.99 2.99 non-AMI 88 
 
1.9 1.9 No-AMI Angina-No ACS 
67.52 46.27 5.73 11.78 2.99 2.99 Non-AMI 79 73 4.1 4.1 No-AMI Angina-No ACS 
20.62 23.29 6.18 8.61 2.99 2.99 Non-AMI 53 86 1.5 3 No-AMI Angina-No ACS 
18.41 22.91 11.7 6.61 2.99 2.99 Non-AMI 33 
 
2 1.8 No-AMI Unknown 
22.64 28.64 9.92 9.35 2.99 2.99 Non-AMI 98 72 2.1 1.9 No-AMI Muscularskeletal 
27.69 24.18 5.82 11.5 2.99 2.99 Non-AMI 52 82 2.8 2.5 No-AMI Gastro-oesophageal 
25.9 30.67 8.89 9.77 2.99 2.99 Non-AMI 29 24 3.7 
 
No-AMI Gastro-oesophageal 
13.37 11.85 7.01 6.93 2.99 2.99 Non-AMI 53 82 2.8 2.8 No-AMI Angina-No ACS 
14.25 31.89 11.14 10.64 2.99 2.99 Non-AMI 38 42 1.8 
 
No-AMI Muscularskeletal 
18.48 23.73 9.43 5.39 2.99 2.99 Non-AMI 85 76 0.6 
 
No-AMI Unknown 
10.76 14.91 11.01 6.99 2.99 2.99 Non-AMI 76 64 1.1 1 No-AMI Non specific 
18.26 17.69 4.9 7.53 2.99 2.99 Non-AMI 26 40 1.4 1.4 No-AMI Anxity 
25.94 19.68 8.94 4.89 2.99 2.99 Non-AMI 24 29 1 1.2 No-AMI Angina-No ACS 
21.91 22.1 10.02 7.32 2.99 2.99 Non-AMI 66 72 2.5 2 No-AMI Gastro-oesophageal 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
25.45 28.77 8.31 8.27 2.99 2.99 Non-AMI 78 72 0.6 0.7 No-AMI Unknown 
30.65 26.5 8.36 6.77 2.99 2.99 Non-AMI 19 19 0.6 0.7 No-AMI Other-chest infection 
32.3 31.53 6.6 6.17 2.99 2.99 Non-AMI 34 39 0.6 0.6 No-AMI Non specific 
41.76 18.42 8.43 7.26 2.99 2.99 Non-AMI 19 29 1.4 1.3 No-AMI Other-URTI 
52.06 44.45 10.99 9.15 2.99 2.99 Non-AMI 45 49 1.2 1 No-AMI Other-chest infection 
10.71 
 
6.53 0 2.99 2.99 Non-AMI 23 34 1 0.8 No-AMI Non specific 
32.08 27.74 8.75 10.06 2.99 17.66 AMI 19 29 1 1.2 No-AMI Angina-No ACS 
209.47 285.04 8.21 8.15 2.99 2.99 Non-AMI 19 19 2.1 2.4 No-AMI Other-left sided pneumonia 
30.32 27.03 5.09 10.25 2.99 2.99 Non-AMI 19 19 1.8 1.5 No-AMI Angina-No ACS 
19.66 17.87 6.32 6.64 2.99 2.99 Non-AMI 29 34 1.1 1 No-AMI Non specific 
19.6 18.65 5.06 6.18 2.99 2.99 Non-AMI 19 35 1.5 1.3 No-AMI Non specific 
12.11 9.12 8.6 7.8 2.99 2.99 Non-AMI 19 19 1.3 1 No-AMI Non specific 
17.16 22.37 7.48 11.3 2.99 2.99 Non-AMI 19 19 1.3 1.1 No-AMI Non specific 
24.25 22.49 6.68 6.3 2.99 2.99 Non-AMI 19 19 1.4 
 
No-AMI Muscularskeletal 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
22.58 13.17 4.94 5.1 2.99 2.99 Non-AMI 19 19 0.8 1 No-AMI Other-?ACS ?PE 
27.21 21.37 11.84 6.55 2.99 2.99 Non-AMI 19 19 1.2 
 
No-AMI Muscularskeletal 
41 22.85 11.47 6.59 2.99 2.99 Non-AMI 19 19 3.4 2.7 No-AMI Angina-No ACS 
36.25 32.91 4.99 5.07 2.99 2.99 Non-AMI 19 19 2 1.9 No-AMI Angina-No ACS 
46.7 28.82 5.45 8.81 2.99 2.99 Non-AMI 19 19 0.9 0.8 No-AMI Muscularskeletal 
16.98 17.55 11.6 5.52 2.99 2.99 Non-AMI 55 45 1.2 1.2 No-AMI Muscularskeletal 
16.1 34.58 11.52 5.97 2.99 2.99 Non-AMI 77 79 1.7 1.5 No-AMI Anxity 
22 44.2 9.39 6.73 2.99 2.99 Non-AMI 105 94 2.2 2.3 No-AMI Anxity 
40.39 40.36 11.8 6.11 2.99 2.99 Non-AMI 23 34 0.5 0.5 No-AMI Non specific 
14.55 13.69 9.09 9.52 2.99 3.9 Non-AMI 93 95 0.3 0.3 No-AMI Muscularskeletal 
29.09 20.89 5.99 7.88 2.99 3.85 Non-AMI 35 70 0.5 0.5 No-AMI Non specific 
19.48 42.05 10.99 9.15 2.99 2.99 Non-AMI 25 22 1.6 1.4 No-AMI Anxity 
10.86 11.42 8.75 10.06 2.99 2.99 Non-AMI 121 80 1.2 1.2 No-AMI Non specific 
16.1 17.69 8.21 8.15 2.99 2.99 Non-AMI 100 111 0.5 0.6 No-AMI Non specific 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
22.14 26.91 6.45 4.84 2.99 5.41 Non-AMI 123 152 5.1 4.7 No-AMI ACS 
22.96 28.95 4.92 10.47 2.99 2.99 Non-AMI 19 19 2.5 2.4 No-AMI Gastro-oesophageal 
46.59 36.26 10.25 10.59 2.99 2.99 Non-AMI 19 19 1.5 1.4 No-AMI Non specific 
42.43 32.86 5.75 11.03 2.99 2.99 Non-AMI 19 19 1.8 1.7 No-AMI Non specific 
18.93 15.31 6.32 6.64 2.99 2.99 Non-AMI 19 19 0.8 0.6 No-AMI Gastro-oesophageal 
12.47 17.53 8.19 9.82 2.99 2.99 Non-AMI 22 34 0 0 No-AMI ACS 
42.74 43.38 7.17 8.03 2.99 2.99 Non-AMI 19 19 0.6 0.6 No-AMI Non specific 
12.56 25.53 10.14 5.84 3.3 3.5 Non-AMI 19 19 3.6 3.6 No-AMI Non specific 
28.1 18.27 9.38 10.14 3.36 6.03 Non-AMI 88 69 1.4 1.6 No-AMI Anxity 
32.75 20.62 6.6 6.71 3.44 4.72 Non-AMI 85 96 1.1 1.3 No-AMI Muscularskeletal 
15.16 16.91 11.09 7.14 3.65 5.65 Non-AMI 29 36 0.6 
 
No-AMI Non specific 
29.36 22.85 6.45 4.84 3.66 17.63 AMI 19 19 0.3 0.3 No-AMI Other-SUT 
23.4 24.56 10.43 11.03 3.8 4.9 Non-AMI 37.3 43.4 1.4 1.2 No-AMI Non specific 
48.86 43.7 6.66 10.88 3.9 2.99 Non-AMI 39 54 1.3 1 No-AMI Angina-No ACS 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
57.32 58.08 8.82 12 3.97 5.36 Non-AMI 19 19 3.2 3.4 No-AMI Non specific 
27.94 11.37 11.47 5.82 4.11 3.23 Non-AMI 24 28 0.5 0.6 No-AMI Unknown 
55.16 71.85 6.72 6.35 5.03 28.93 AMI 19 19 2.1 2.9 MI ACS 
60.32 44.4 6.5 10.06 5.04 2.99 Non-AMI 19 24 3.1 2.9 No-AMI Non specific 
201.81 227.96 5.75 11.03 5.19 4.39 Non-AMI 67 84 0.9 1 No-AMI Other-porforated D/V-chest infection 
20.48 23.25 5.06 4.93 5.41 8.94 Non-AMI 229 164 4.3 3.1 No-AMI Non specific 
51.88 55.3 6.4 11.18 6.35 7.19 Non-AMI 69 86 3 2.7 No-AMI Non specific 
10.46 15.65 5.73 11.33 6.37 3.17 Non-AMI 248 295.9 0.4 0.4 No-AMI Unknown 
26.9 21.12 10.62 8.4 7.21 20.08 AMI 19 19 1.1 1.2 No-AMI Non specific 
39.43 20.05 8.27 8.96 7.59 12.99 Non-AMI 218.2 492.9 0.5 0.6 No-AMI Non specific 
35.11 44.54 9.37 6.91 8.2 5.14 Non-AMI 45.3 48.7 1.3 1.3 No-AMI Angina-No ACS 
26.92 22.14 10.85 5.2 13.58 2.99 Non-AMI 26 34 1.4 1.5 No-AMI Unknown 
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ID IMA 1 IMA 2 AccuTnI 1  AccuTnI 2 Beckman hs-TnI 1 Beckman hs TnI 2 Centaur TnI 1 Centaur TnI 2 FABP 1 FABP 2 
55.37 81.47 10.06 7.83 21.24 16.45 AMI 541 632 2.6 2.5 No-AMI Muscularskeletal 
360.59 109.9 11.95 11.83 45.28 7.3 AMI 203 306 7.3 6.9 MI Angina-No ACS 
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Appendix 4: Meta-analysis of Ischemia modified-albumin supplementary 
data 
Table 12: Example of 2x2 table used to extract sensitivity and specificity. 
 
 
 
 
Authors  
Title  
  
Year of publication    
Abstract in folder    
Abstract  
Number of 
subjects 
 
ACS group studied  
Length of follow up  
Mean age at 
enrolment 
 
% male  
Sample storage  
IMA  Assay 
generation 
 
IMA cut off used 
for diagnosis 
   Assay 
generation 
 
Odds ratio quoted  Lower 95% CI  Upper 95% CI  
2 x 2 data 
contingency table 
or 
Odds ratio check 
 
Reference 
standard is 
positive 
Reference 
standard is 
negative  
Test is 
positive  
  
 
Test is 
negative  
  
 
    
    
 
Odds ratio 
calculated 
 Lower 95% CI  Upper 95% CI  
Sensitivity  Lower 95% CI  Upper 95% CI  
Specificity  Lower 95% CI  Upper 95% CI  
Data input in excel 06/07/2017 Double entry  Data check  
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Authors Study reference N Sensitivity
Lower 
95%
Upper 
95%
Sen SE Specificity
Lower 
95%
Upper 
95%
Spec 
SE
NPV
Lower 
95%
Upper 
95%
NPV SE PPV
Lower 
95%
Upper 
95%
PPV SE Comments
(Aparci,Kardesoglu,Ozmen et al. , 
2007)
Prognostic significance of ischemia-modified albumin in patients 
with acute coronary syndrome
95 70.0 69.0 71.0 0.5102 82.0 81.0 83.0 0.5102
(Lee,Kim,Cho et al. , 2007)
Application of albumin-adjusted ischemia modified albumin index 
as an early screening marker for acute coronary syndrome
413 98.4 97.9 98.9 0.2551 34.5 34.0 35.0 0.2551 98.0 97.5 98.5 0.2551 40.6 40.1 41.1 0.2551
Bali,Cuisset,Giorgi et al. , 2008)
Prognostic value of ischaemia-modified albumin in patients with 
non-ST-segment elevation acute coronary syndromes
79 75.0 73.9 76.1 0.5612 74.6 90.6 92.8 9.2859 91.7 90.6 92.8 0.5612 44.4 43.3 45.5 0.5612
(Consuegra-Sanchez,Bouzas-
Mosquera,Sinha et al. , 2008)
 Ischemia-modified albumin predicts short-term outcome and 1-
year mortality in patients attending the emergency department for 
acute ischemic chest pain
207 75.7 66.1 83.8 4.8980 74.1 64.8 82.0 4.0307 76.9 69.8 82.8 3.6225 72.8 65.7 79.0 3.6225
(Liyan,Jie,Yonghua et al. , 2008)
Assay of ischemia-modified albumin and C-reactive protein for 
early diagnosis of acute coronary syndromes
113 94.4 93.5 95.3 0.4592 82.6 81.7 83.5 0.4592 79.2 78.3 80.1 0.4592  
PPV not reported. Cannot 
abstract data for 2 x 2
(Talwalkar,Bon Homme,Miller et al. , 
2008)
Ischemia modified albumin, a marker of acute ischemic events: a 
pilot study
89 53.9 25.1 80.8 14.2094 75.0 63.7 84.2 4.6940 90.5 83.9 94.6 3.3674 26.9 16.3 41.0 5.4083
(Manini,Ilgen,Noble et al. , 2009)
Derivation and validation of a sensitive IMA cut-point to predict 
cardiac events in patients with chest pain
106 80.9 58.0 94.6 11.6839 36.5 26.3 47.6 5.4338 88.6 75.4 95.1 6.7348 23.9 19.5 29.1 2.2449
(Charpentier,Ducasse,Cournot et al. , 
2010)
Clinical assessment of ischemia-modified albumin and heart fatty 
acid-binding protein in the early diagnosis of non-ST-elevation 
acute coronary syndrome in the emergency department
677 69.2 65.7 72.7 1.7857 36.0 32.4 39.6 1.8368 75.6 72.4 78.9 1.6582 28.9 25.5 32.3 1.7347
(Pan,Tong,Lin et al. , 2010)
Ischemia-modified albumin measured with ultra-filtration assay in 
early diagnosis of acute coronary syndrome
169 79.8 79.0 80.6 0.4082 65.2 64.5 65.9 0.3571 69.4 68.9 70.5 0.2551 77.7 76.9 78.4 0.4082
MA takhshid, J Kojuri, SMB Tabei
Early Diagnosis of acute coronary syndrome with sensitive 
Troponin I and Ischemia Modified Albumin
123 84.0 81.0 93.0 1.5306 85.0 75.0 92.0 3.5715 88.0 77.0 94.0 5.6123 81.0 68.0 90.0 6.6328
(Wudkowska,Goch & Goch, 2010)
Ischemia-modified albumin in differential diagnosis of acute 
coronary syndrome without ST elevation and unstable angina 
pectoris
121 77.6 64.7 87.5 6.5818 23.8 14.6 36.2 6.3266 53.6 37.6 68.9 7.9848 48.4 43.5 53.3 2.5000
(Hjortshoj,Kristensen & Ravkilde, 
2010)
Diagnostic value of ischemia-modified albumin in patients with 
suspected acute coronary syndrome
107 86.0 69.0 95.0 8.6736 49.0 36.0 60.0 5.6123 88.0 72.0 96.0 8.1634  
PPV not reported. Cannot 
abstract data for 2 x 2
(Dawie,Chawla,Worku et al. , 2011)
Diagnosis of ischemic heart disease using CK-MB, troponin-I and 
ischemia modified albumin
55 100.0 98.7 101.3 0.6633 71.1 69.8 72.4 0.6633 100.0 98.7 101.3 0.6633 80.6 79.3 81.9 0.6633
(Maneewong,Mekrungruangwong,Lua
ngaram et al. , 2011)
Combinatorial Determination of Ischemia Modified Albumin and 
Protein Carbonyl in the Diagnosis of Non ST-Elevation Myocardial 
Infarction
33 51.5 33.5 69.2 9.1073 87.9 71.8 96.0 4.1327 64.4 62.7 66.1 0.8674 80.9 79.2 82.7 0.8929
(Shen,Lin,Han et al. , 2011)
Assessment of ischemia-modified albumin levels for emergency 
room diagnosis of acute coronary syndrome
113 89.0 88.1 89.9 0.4592 94.4 83.5 85.3 5.5613 96.2 95.3 97.1 0.4592 83.4 82.5 84.3 0.4592
(Zhong,Wang,Xu et al. , 2012)
Ischemia-modified albumin in stable coronary atherosclerotic heart 
disease: clinical diagnosis and risk stratification
129 49.0 48.1 49.8 0.4592 90.0 89.1 90.8 0.4082 45.0 44.1 45.9 0.4592 91.0 90.1 91.9 0.4592
(Sokhanvar,Mellati,Mousavinasab et 
al. , 2012)
The clinical assessment of ischaemia modified albumin and 
troponin I in the early diagnosis of the acute coronary syndrome
226 54.0 51.0 56.0 1.5306 87.0 83.0 92.0 2.5511 62.0 59.0 66.0 1.5306 82.0 78.0 88.0 2.0409
(Ertekin,Kocak,Defne Dundar et al. , 
2013)
Diagnostic value of ischemia-modified albumin in acute coronary 
syndrome and acute ischemic stroke
90 83.0 71.0 90.0 6.1226 90.0 77.0 97.0 3.5715 84.0 73.0 91.0 5.6123 89.0 76.0 97.0 6.6328
(Kountana,Tziomalos,Semertzidis et 
al., 2013)
Comparison of the diagnostic accuracy of ischemia-modified 
albumin and echocardiography in patients with acute chest pain
33 60.0 58.3 61.7 0.8674 89.3 87.6 91.0 0.8674 92.6 90.9 94.3 0.8674 50.0 483.0 51.7
(Patil,Banker,Padalkar et al. , 2013)
The clinical assessment of ischaemia modified albumin and 
troponin I in the early diagnosis of the acute coronary syndrome
102 88.0 87.0 88.0 0.5102 93.0 92.0 93.0 0.5102 89.6 88.6 91.0 0.5102 92.8 91.8 93.8 0.5102
(Sygitowicz,Janas,Bialek et al., 2013)
Prognostic value of ischaemia-modified albumin in patients with 
non-ST-segment elevation acute coronary syndromes and 
negative cTnI
88 72.1 56.3 84.7 8.0614 75.6 60.5 87.1 5.8675 73.9 58.9 85.7 7.6532 73.8 58.0 86.1 8.0614
(Gurumurthy,Borra,Yeruva et al. , 
2014)
Estimation of Ischemia Modified Albumin (IMA) Levels in Patients 
with Acute Coronary Syndrome
675 88.0 87.6 88.4 0.2041 89.0 88.6 89.3 0.1531   
(Bhakthavatsala Reddy,Cyriac & 
Desle, 2014)
Role of "Ischemia Modified Albumin" (IMA) in acute coronary 
syndromes
89 92.0 91.0 93.0 0.5102 87.0 86.0 88.0 0.5102 94.0 93.0 95.0 0.5102 88.0 87.0 89.0 0.5102
Arun Kumar. K, Sheila Uthappa, 
Sudarshan Surrendran
Correlation of albumin concentration and ischemia modified 
albumin in the diagnosis if acute myocardial infarction
120 69.2 68.3 70.1 0.4592 67.7 66.8 68.6 0.4592 68.7 67.8 69.6 0.4592 68.2 67.3 69.1 0.4592
(Mehta,Marwah,Ghosh et al. , 2015)
A synergistic role of ischemia modified albumin and high-
sensitivity troponin T in the early diagnosis of acute coronary 
syndrome
120 91.3 90.4 92.2 0.4592 81.1 80.2 82.0 0.4592 93.9 93.0 94.8 0.4592 74.4 73.5 75.2 0.4592
(Bakula,Milicevic,Bakula et al. , 2016)
Kinetics of Ischemia-Modified Albumin Following Exercise-Induced 
Myocardial Ischemia
87 70.0 60.0 80.0 5.1021 64.0 45.0 80.0 8.1634 52.0 36.0 65.0 8.1634 79.0 68.0 88.0 5.6123
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Appendix 5: Current study sample size calculation 
 
Current study sample size calculations 
 
http://clincalc.com/stats/samplesize.aspx used to calculate the sample size for 
the current study. 
  
356 
 
Appendix 6: Publication dissemination  
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I. INTRODUCTION 
 
Ischemia (from the Greek ισχαιμία, ischaimía; isch- root denoting a restriction or 
thinning or to make or grow thin, haema blood) is the restriction of blood supply 
and thus the inadequate delivery of oxygen and removal of carbon dioxide from 
cellular tissue. This imbalance may lead to dysfunctional or permanent damage 
to the affected tissue and organ.  
 
Cardiac ischemia occurs when there is a supply versus demand mismatch in 
coronary blood flow. In patients who present with unstable angina, ischemia 
occurs due to partial or total occlusion of a coronary artery due to plaque 
rupture. In stable angina however, there is progressive vascular occlusion 
resulting ultimately in a luminal stenosis of greater than 70%, impeding blood 
flow to the distal tissue. If the ischemia is reversible, no permanent myocardial 
damage occurs.  If however the ischemic episode is prolonged; there will be 
cellular necrosis which will lead to acute myocardial infarction (AMI) or a heart 
attack.  The immediate clinical challenge is to be able to identify acutely 
impaired myocardial perfusion before the necrotic process starts.  Currently, the 
only strategy for this is to detect ST-segment changes on the electrocardiogram 
(ECG), however the ECG is non-diagnostic in many cases. The sensitivity of the 
admission ECG is typically around 50%.  Reperfusion, be it pharmacological or 
surgical, is the essential life-saving intervention with the aim of salvaging 
myocardial tissue localised at the affected site. Many patients however who 
present with chest pain to the emergency department (ED) do not have a final 
diagnosis of AMI.  There is therefore a need for a strategy which could detect 
cardiac ischemia before necrosis occurs and result in prompt revascularisation. 
Blood borne biomarkers for ischemia may be of diagnostic and prognostic 
value.  
 
To date, a number of candidate biomarkers of ischemia are being researched. 
However, one, Ischemia modified albumin (IMA), has been developed into a 
commercially available cardiac biomarker assay and licensed for routine clinical 
application both by CE marking in Europe and Food and Drug Administration 
(FDA) approval in the United States. This chapter will explore the rational for the 
necessity of cardiac ischemia biomarker testing and detail the development of 
the IMA assay with emphasis on its clinical and prognostic utility.  
 
The cardiovascular disease epidemic 
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Cardiovascular disease (CVD) accounts for the majority of global deaths. CVD 
was responsible for 29% of all global deaths in 2004. According to the World 
Heart Federation, CVD is responsible for 17.1 million deaths globally each year. 
Surprisingly, 82% of these deaths occur in the developing world. Such numbers 
are often difficult to comprehend. CVD is responsible for one in every five 
deaths disease kills one person every 34 seconds in the USA alone. 35 people 
under the age of 65 die prematurely in the United Kingdom every day due to 
CVD. It is predicted that by 2030 23 million people will die from a cardiovascular 
related disease. Data from the USA suggests that CVD was responsible for 
34% of all deaths in 2006 and over 151,000 Americans who died were under 65 
years of age.  
 
Acute chest pain 
 
Patients with chest pain constitute the largest single category of patients 
admitted to hospitals in the UK 1). In the USA, registry data recoded 11.2 million 
chest pain presentations to the ED in 2008 alone. The presentations are also 
diagnostically challenging. The majority of admissions have either stable 
ischemic heart disease (IHD) or no ischemic heart disease 2). Such admission 
episodes are often short and clinically inappropriate. Conversely, it has been 
estimated that between 2 and 7% of patients with acute myocardial infarction 
(AMI) are inappropriately discharged from the ED 3;4) and suffer 
disproportionate morbidity and mortality. Attempts to improve diagnosis have 
included risk scoring systems 5), computerised decision support 6;7) and 
automated ECG interpretation 8). Although clinical assessment remains integral 
to assessment of the patents with chest pain, cardiac biomarker measurement 
has become an essential component in the diagnostic armamentarium.  
 
Pathophysiology of cardiac ischemia 
 
The mechanisms involved in the development of cardiovascular disease are 
multifactorial and include abnormalities in cholesterol and lipid metabolism, 
inflammation and oxidative stress processes within the vascular wall, cellular 
disruption to the endothelium and intra-lumenal platelet activation/aggregation. 
The ischemia cascade from initiation of local ischemia to the development of 
symptomatic chest pain is depicted in figure 1.  The pathological processes 
responsible for the development of atherosclerotic lesions and endothelial 
dysfunction are advanced far earlier than when patients typically become 
symptomatic and present with chest pain. The disease process does not occur 
in distinct episodes but rather is a continuum from asymptomatic vascular 
dysfunction thorough to angina in those with myocardial ischemia, which, 
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without intervention can progress to non-ST segment elevation myocardial 
infarction (NSTEMI) or cumulate into ST segment elevation myocardial 
infarction (STEMI). Patients presenting at any stage in the process may be 
diagnosed with acute coronary syndrome (ACS). The earlier in the disease 
continuum the presentation is; the greater the opportunity for successful 
myocardial tissue preservation. As there is no definitive biomarker for ischemia, 
current treatment focuses on the need for urgent therapeutic revascularisation 
in patients with established cardiac necrosis, identified by the cardiac troponins.     
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Fig 1: Development of Ischemia in the ischemia cascade.  
 
The pathological process unless disrupted by therapeutic intervention results in 
the death of cardiac myocytes. Predisposing this terminal event, a vulnerable 
atherosclerotic plaque becomes disrupted exposing the thrombogenic lipid core 
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and sub endothelium to the luminal milieu. Exposure results in platelet 
activation and aggregation and along with the coagulation cascade, an 
intracoronary thrombus forms. The thrombus may not obstruct the lumen and 
the patient is asymptomatic, however if the lumen is totally occluded AMI will 
ensue. A partially occluded lumen and reduced oxygen supply both contribute 
to the development of ischemic myocardium.       
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II. CLINICAL DETECTION OF CARDIAC ISCHEMIA 
 
The clinical presentation of cardiac ischemia is difficult to definitively diagnose.  
Currently there is no gold standard test to detect ischemia however a number of 
reliable tests exist. Historically patients were admitted for monitoring or 
discharged on the basis of clinical interpretation by the ED physician. It is 
accepted that this is no longer acceptable clinical practice.  
 
The typical presentation is exertional or stress induced central chest pain. 
These episodes usually last from a few minutes to hours and can resolve upon 
rest. Common descriptions by the patient include tightness, crushing stabbing 
or burning pain. Patients may also have nausea and vomiting, dyspnoea, 
palpitations. Typical symptoms increase the likelihood of an AMI however 
atypical presentations can not be used to exclude AMI. Women, the elderly and 
those with diabetes mellitus often present with atypical chest pain.    
 
The clinical history and physical examination will assess the presence of risk 
factors for AMI, however alone; the initial clinical examination is insensitive and 
unspecific for diagnosis. It may however give insight to differential or alternative 
diagnoses in those patients who, upon further investigation do not have an AMI. 
The 12 lead ECG is additive to the physical examination. The majority of ECG 
traces performed at admission are non-diagnostic with approximately 5% of 
suspected AMI patients having a diagnostic trace indicative of AMI. Although 
relatively insensitive, ST segment elevation however is 100% diagnostic for AMI 
and serves as the criterion for induction of fibrinolytic therapy.    
 
A. Cardiac imaging 
 
Recently cardiac imaging has played an important role in the detection of 
ischemia. Perfusion abnormalities can be detected by single-photon emission 
computer tomography (SPECT) myocardial perfusion imaging (MPI) and 
mechanical dysfunction can be detected by echocardiography or gated MPI. 
Gated SPECT MPI can identify regional and global dysfunction of the left 
ventricle as ischemia impairs myocellular contractility. SPECT requires uptake 
of an isotope by active membrane transport mechanisms and caution should be 
advised in those patients with impaired renal clearance. Both echocardiography 
and SPECT are sensitive and specific and have a high negative predictive vale 
for the diagnosis and prognosis of patients with suspected ACS. These 
diagnostic modalities however are grossly expensive, time consuming, 
technically more challenging and are not as widely available as compared to the 
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simple ECG or a blood borne biomarker; therefore, their use in the ED on a 24 
hour basis is therefore compromised. 
 
B. Candidate biomarkers 
  
There have been progressive developments within basic and clinical research 
to identify candidate biomarkers of ischemia and to develop simple to use 
assays. Any such assay needs to have similar analytical (limit of detection, 
precision, reference intervals) and clinical performance (sensitivity, specificity, 
risk stratification and predictive value) compared to that of markers of necrosis, 
such as high sensitivity cardiac troponin assays. A number of candidate 
biomarkers have been identified. Malondialdehyde low density lipoprotein 
(MDA-LDL) is a sensitive biomarker for ACS patients with unstable angina and 
AMI. MDA is a candidate compound which causes oxidative modification of 
LDL. MDA (propanedial, C3H4O2) is a reactive aldehyde produced by 
degradation of polyunsaturated lipids or released during prostanoid metabolism. 
This reactive oxygen species causes oxidative modification to LDL. MDA-LDL 
reacts with the charged amino group of B-100 protein lysyl residues. Plasma 
concentrations of MDA-LDL identify patients with coronary artery disease. 
Modified LDL may also instigate an immune response leading to autoantibody 
and LDL immune complex production. MDA-LDL not only serves as an 
oxidative stress marker but as a marker of plaque destabilisation.  
 
Myeloperoxidase (MPO, 150 kDa, EC 1.11.1.7) is a white blood cell enzyme, 
stored in azurophilic granules of polymorphonucleocytes and macrophages. 
MPO catalyses the conversion of chloride and hydrogen peroxide into 
hypochlorite. MPO may contribute to the pathophysiology of ACS, as the 
hypochlorite end product is an oxidizing agent of low density lipoprotein (LDL) 
and play a key role in the degradation of collagen and contributing to the 
destabilisation of the plaque. Patients with ACS who have elevated MPO are at 
risk of short and long-term adverse outcomes. A study of the ED population 
demonstrated that MPO was associated with a 4 fold risk of major adverse 
cardiac events at 30 and 180 days in patients who were cardiac troponin 
negative.  
 
Choline is a product of phosphodiesteric cleavage of membrane phospholipids 
such as phosphatidylcholine and sphingomyelin; catalysed by phospholipase D 
(EC 3.1.4.4). Physiologically choline provides cell structural integrity, is the 
precursor for acetylcholine production and a source of methyl groups that 
participate in the S-adenosylmethionine synthesis pathway.  
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Whole blood (WBCHO) and plasma choline concentrations increase after 
stimulation of phospholipase D and the activation of coronary plaque cell 
surface receptors or ischemia. Phospholipase D activation in coronary plaques 
causes stimulation of macrophage by oxidised LDL, secretion of matrix 
metalloproteinase enzymes and activation of platelets. WBCHO can be 
measured by high performance liquid chromatography coupled to mass 
spectrometry (HPLC-MS). In a study of over 300 patients with suspected ACS, 
WBCHO measured at admission was a significant predictor of cardiac death, 
cardiac arrest, arrhythmia, heart failure or the need for percutaneous coronary 
intervention at 30 day follow up 9). The predictive power was enhanced by the 
addition of either cTnT or cTnI and served not as a marker of myocardial cell 
necrosis but identified patients at high risk with unstable angina. WBCHO is 
therefore a better predictive tool than plasma choline for early risk stratification 
in patients who are cardiac troponin negative on admission. The current 
detection methodology using HPLC-MS is not suitable for urgent clinical use.  
 
Free fatty acids are produced from the breakdown of triglyceride. The majority 
of free fatty acids (FFA) circulate bound to albumin with a very small percentage 
appearing as the unbound free fatty acid (FFAu) form 10). The circulating level of 
FFA is limited to the availability of the albumin binding sites.  The mechanism of 
FFAu release is not fully understood however increased catecholamines 
following cardiac ischemia may activate FFA release following lipolysis in 
adipocytes. FFAu are 14-fold higher post percutaneous coronary intervention 
(PCI), compared to pre procedural concentrations and were higher in those with 
associated ischemic ST segment changes on the ECG 11). Using a recombinant 
fatty acid binding protein bound to a fluorescent tag (ADIFAB) 12;13) has been 
developed and a second generation assay using a fluorescent molecular probe 
(ADIFAB2) and a portable reader makes this a potential early marker for the 
point of care setting. Whilst this marker shows promise in the early phase of 
ischemia induced ACS, further trials are required to evaluate the diagnosis and 
prognostic value of FFAu in the chest pain population.   
 
A reduction in oxygen supply versus causes localized acidosis and the 
generation of free radicals. Copper and zinc ions, normally bound to proteins in 
the plasma are released from protein binding sites to circulate in the free form 
14-16). The N-terminus of albumin binds transition metals. The N-terminus 
however, is susceptible to biochemical alteration 17). The altered form is referred 
to as ischemia modified albumin (IMA). Following a period of ischemia, a 
reduction in the ability of albumin to bind cobalt is apparent. This is the basis of 
the albumin cobalt-binding test (ACB test) for IMA. IMA has been extensively 
studied in the basic science and clinical research settings and is an FDA 
cleared CE marked clinical assay for the detection of cardiac ischemia.  
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III. BIOCHEMISTRY OF ISCHEMIA MODIFIED ALBUMIN 
 
A. Mechanism of IMA generation 
 
The NH2-terminal of human serum albumin (HSA, 66.5 kDa, 585 amino acids) is 
known to be a binding site for transition metal ions such as cobalt, copper and 
nickel 18). Using one and two dimensional 1H-NMR studies, Sadler and 
colleagues demonstrated binding of Ni++, Cu++, Co++, Cd++ and Al+++ to bovine 
and human serum albumin. Strong binding was associated with three N-
terminal amino acid residues (Asp-Thr-His in bovine albumin and Asp-Ala-His in 
human albumin). A Lysine residue designated Lys4 is also involved in the 
binding site. The authors demonstrated for the fist time selective reduction in 
the intensities of resonances to the CH2 resonance of Lys4 on the addition of 
Co++ to HSA.  There are in fact, four metal-binding sites with different 
specificities in HSA. In addition to the NH2-terminal, three other sites occur at (i) 
reduced cysteine at residue Cys34, (ii) site A, including histidine at His67 as a 
ligand and (iii) the non-localized site B. Cu++ and Ni++ preferentially bind the 
NH2-terminus site. Cd++ bind sites A and B, Zn++ binds site A and Au+ and Pt++ 
bind at residue Cys34.  
 
It is currently not known if there are any significant changes in total human 
serum albumin between ischemic and non ischemic patients in the general 
chest pain population. Many divalent metals bind HSA in the circulation but in 
concentrations far lower than that required to impact albumin directly.  The N-
terminal portion of HSA is susceptible to biochemical degradation and is less 
stable than the albumin of other species 17) including bovine, dog, goat, horse, 
pig rabbit, rat and sheep but not Chicken. Using electrospray-mass 
spectrometry and N-terminal sequencing, Chan and colleagues have 
demonstrated degradation corresponding to the first two resides (Asp-Ala) 
which is dependent both on temperature and the N-terminal alpha-amino group.  
 
 IMA however is a form of HSA where the N-terminal amino acids are unable to 
bind transition metal ions. Myocardial ischemia is known to generate free 
radicals 16;19), induce localised acidosis 15) and the release of free iron and 
copper ions bound to enzymes and proteins. 20;21). Direct evidence of Cu/Fe 
mobilization in the coronary flow following prolonged (25-60 minute) ischemia 
but not short (15-21 minute) ischemia has been demonstrated 21). Both copper 
and iron concentrations in the first coronary flow fraction were 50-fold and 15-
fold higher respectively following prolonged ischemia, compared to pre-ischemic 
concentrations. This suggests that both copper and iron play a causative role in 
ischemic cardiac injury by their ability to catalyse the production of free radicals 
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and could be the target of therapeutic intervention to salvage tissue damage 20). 
It was therefore postulated that following a period of cardiac ischemia, these 
processes would result in a change in the ability of the N-terminus of HSA to 
bind transition metal ions. The release of these ions likely initiates one potential 
pathway for IMA generation, rather than be considered an interference that may 
negatively affect IMA. In support of this suggestion, decreased albumin cobalt 
binding was reported in 99 acute chest pain patients with myocardial ischemia 
22) compared to 44 chest pain patients with no evidence of myocardial ischemia. 
Albumin cobalt binding was also assessed in 41 patients undergoing elective 
coronary artery angioplasty. Samples were tested using the Albumin Cobalt 
Binding (ACB) assay before, immediately after, 6 and 24 hours post procedure 
and compared to results from 13 patients undergoing cardiac catheterization 
without balloon angioplasty, thus serving as the control group. ACB 
concentrations were significantly elevated immediately post procedure, 
compared to the control population and ACB concentrations returned to 
baseline after six hours 23); suggesting that HSA undergoes a significant 
reduction in the capacity to bind exogenous Co++ immediately after coronary 
artery occlusion induced during elective angioplasty. Modification of the Asp-
Ala-His-Lys site by N-terminal acetylation or deletion of one or more residues 
abolishes this cobalt binding 24).  
 
The postulated mechanism (figure 2) of IMA generation is that localised 
ischemia results in acidosis. The localised acidotic environment stimulates the 
release of Cu++ ions from weak binding sites on circulating proteins such as 
caeruloplasmin.  Caeruloplasmin (EC 1.16.3.1, 151kDa) is a ferroxidase 
enzyme encoded by the CP gene located on Chromosome 3. The enzyme is 
synthesised in the liver and carries approximately 70% of the total copper in 
human plasma (a further 15% carried by HSA and the remainder by 
macroglobulins). Each enzyme molecule contains 6 atoms of copper within  
 
In the presence of a reducing agent such as ascorbic acid, free copper II is 
converted to copper I which can react with oxygen to form copper II and 
generate superoxide free radicals (O2•–). Superoxide dismutase (EC 1.15.1.1) 
converts the superoxide free radical to hydrogen peroxide which is then 
degraded by catalase. The copper II ions released are immediately scavenged 
by human serum albumin but they are tightly bound to the N-terminus.  Copper 
bound albumin is then damaged by hydroxyl free radicals (OH•), causing 
removal of the three N terminal amino acids and release of the copper II ion to 
repeat the process in a chain reaction 25).  Marx and Chevion demonstrated by 
SDS/polyacrylaminde gel electrophoresis the site specific alteration of HSA in 
the presence of 50 M Cu++ and increasing portions of 0.2 mM ascorbate; 
where after the addition of 5 portions, bands at 3, 18, 22, 47 and 50 kDa were 
observed and also demonstrated that degradation does not occur in the 
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absence of Cu++ or in the addition of 1 mM ethylenediaminetetraacetic acid 
(EDTA) or citrate chelating agents 25).  
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Fig 2: Mechanism of Ischemia Modified Albumin generation. (1)Tissue hypoxia 
from anaerobic metabolism reduces ATP and causes a (2)lower localized pH 
inducing acidosis. (3)Cu++ ions are released from plasma proteins such as 
caeruloplasmin. In the presence of ascorbic acid, (4)Cu++ is converted to Cu+. 
Cu+ reacts with O2 to form (5) O2•–. Superoxide dismutase dismutates the O2•– to 
(6)H2O2, which in presence of Cu++ or Fe+, undergoes the Fenton reaction 
forming (7)OH•  hydroxyl radicals. Free Cu++ is scavenged by (8)HSA, where it 
binds tightly to the N-terminus. OH• radicals alter the amino acid N-terminus of 
(9)HSA rendering it incapable of binding Cu++. These two altered forms are 
known as IMA.  
 
This postulated mechanism, although theoretically attractive has not been borne 
out in practice.  In a study of patients with increased IMA, the N-terminal portion 
of albumin was sequenced in 8 cases 26) by cleavage of the 11 amino acid 
resides at the NH2 terminus, by rapid liquid-phase Edman degradation. The N-
terminal amino acid sequence showed normal residues for 6 of 7 patient 
samples with elevated IMA and one non-ischemic sample. The remaining 
patient sample with high IMA demonstrated two missing amino acids at the N-
terminus. Clinically the patient did not have an ischemic cardiac event (table 1).    
Table 1 
NH2-terminal HSA sequence analysis from 6 ischemic patients, a control (wild 
type) and one non ischemic patient with a high serum IMA (Source: Adapted 
from Bhagavan et al, Clin Chem 2003;49:581-585)  
Subject NH2-terminal HSA Sequence 
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Control (wild type) DAHKSEVAHRF 
Non-ischemic patient, high serum 
IMA 
--HKSEVAHRF 
Ischemic patient, high serum IMA DAHKSEVAHRF 
Ischemic patient, high serum IMA DAHKSEVAHRF 
Ischemic patient, high serum IMA DAHKSEVAHRF 
Ischemic patient, high serum IMA DAHKSEVAHRF 
Ischemic patient, high serum IMA DAHKSEVAHRF 
Ischemic patient, high serum IMA DAHKSEVAHRF 
 
Furthermore, the in vivo half life of HSA is 19-20 days. HSA with a truncated 
NH2-terminus would presumably have similar in vivo half life properties and yet 
IMA returns to baseline rapidly after an ischaemic cardiac event. This indicates 
that the alteration to albumin to create IMA is transient and reversible, rather 
than a finite chemical alteration.  Recent physicochemical studies using 
electronic absorption EPR and NMR spectroscopy of Co-binding to HSA under 
anaerobic conditions to prevent Co++ oxidation have suggested a different 
explanation. Using competition experiments with cadmium (Cd++) which binds 
sites A and B and Cu++ which binds the NH2-terminus, three binding sites for 
Co++ were identified on HSA. Sites A and B showed greater avidity for Co++ 
binding than the NH2-terminal binding site 27). Fatty acid binding to albumin 
occurs at one of the additional cobalt binding sites with a negative allosteric 
interaction. It is hypothesised, that in myocardial ischemia the release of fatty 
acids results in binding of fatty acids to albumin. This would then reduce the 
ability of albumin to take up cobalt hence account for the presence of IMA 27). If 
this also produced a conformational change in the albumin affecting the N 
terminal site, this would also reduce cobalt binding. 
B. Kinetic release of Ischemia Modified Albumin 
 
Studies in patients receiving angioplasty where ischemia is induced in a 
controlled manner, have defined the kinetics of IMA production.  There is a 
rapid rise in IMA values after balloon inflation with a subsequent fall at 6 hours 
and return to normal by 24 hours 28;29). The rise in IMA occurs earlier than the 
rise in cardiac troponin and natriuretic peptides (figure 3) and occurs early after 
the onset of plaque rupture.  
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Fig 3. Kinetic release of Ischemia modified albumin (IMA, dotted line) and other 
cardiac markers, cardiac troponin (cTn, solid line) and natriuretic peptide 
(NTproBNP, dashed line) [bottom panel], in relation to extent and timing of 
tissue damage [top panel]  
 
The magnitude of IMA elevation has been found to correlate with the number 
and frequency of transluminal balloon inflations during the PCI procedure 30). 34 
patients received standard routine care for elective single vessel PCI for the 
management of stable angina pectoris. 44% of patients received 1-4 balloon 
inflations whilst, 56% received >5 inflations. IMA concentrations were higher in 
those with more balloon inflations, higher pressure load of the balloon and the 
longer the duration of the inflation, thus IMA is not only a marker of the 
occurrence of ischemia but is also an indicator of the severity of the ischemic 
episode.  
 
Furthermore, IMA concentrations are lower in patients who demonstrate 
angiographic evidence of collateral vessels present in the coronary circulation, 
according to Rentrop’s classification 31). IMA levels post PCI are higher than 
baseline, however post-PCI values are lower compared to post-PCI values in 
those patients without a collateral circulation; irrespective of the extent of 
coronary artery disease or those who underwent a large number of balloon 
inflations for longer duration. 32)   The lower IMA concentrations in patients with 
a collateral circulation likely represent a cardioprotective effect against PCI-
induced ischemia. IMA elevation is also correlated to the need for subsequent 
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revascularization 33). Elevated IMA greater than 130 kU/L was associated with a 
higher frequency of target lesion revascularization at 4-years follow-up in 60 
patients who underwent a successful elective single vessel PCI for stable 
angina pectoris at baseline. The accepted gold standard blood marker for 
myocardial ischemia is myocardial lactate extraction. Simultaneous IMA and 
lactate was measured in 10 patients undergoing PCI for chronic stable angina. 
Post-PCI IMA concentrations paralleled that of transmyocardial lactate29). 
 
Elevation in serum IMA has been recorded following coronary vasospasm 34). 
Twenty six patients with variant angina underwent intracoronary ergonovine 
spasm provocation testing. Arterial IMA concentrations were measured pre and 
post procedure and compared to 18 patients undergoing elective PCI and 10 
patients with normal coronary angiography. IMA was significantly elevated 
following drug induced coronary vasospasm compared to baseline and elevated 
values detected coronary vasospasm with an area under the ROC curve of 0.98 
(95%CI 0.92-1.00). Other studies involving invasive cardiac procedures have 
shown rises in IMA where ischemia might occur, occurring concurrently with 
ECG changes in cardioversion 35), but show a variable picture when there is 
non-ischaemic myocardial damage as in cardiac ablation 36;37). 
C. Measurement of Ischemia Modified Albumin 
 
The original biochemical test for IMA was known as the albumin cobalt binding 
(ACB®) assay. This was developed by Ischemia Technologies Inc, Colorado, 
USA). The assay measures the cobalt binding capacity of albumin in a sample 
of serum. A known amount of cobalt is added to the patient serum sample. 
Dithiothreitol (DTT) is added which binds any remaining unbound cobalt and the 
colorimetric change is measured spectrophotometrically. In serum from non-
ischaemic patients, cobalt binds to the N-terminus of HSA, leaving little free 
cobalt to react with DTT and form a coloured product. Conversely, in serum of 
patients with ischemia, cobalt does not bind to the N-terminus of modified HSA, 
leaving more free cobalt to react with DTT and form a darker colour. As normal 
albumin will bind cobalt, the amount of free cobalt, hence the absorbance will be 
proportional to the amount of IMA present (figure 4). 
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Fig 4. Measurement of Ischemia Modified Albumin by the Albumin Cobalt 
Binding (ACB) assay.  A known amount of CoCl2 is added to a serum sample. 
DTT is added which binds unbound Co++ causing a colorimetric change read 
spectrophotometrically.  
The first generation assay was semi-automated and required a sample pre-
treatment step where 500 L of serum sample was added to an Eppendorf tube 
containing 0.45g CaCl2. The sample was inverted twice and centrifuged at 
1200g for 10 minutes. 300 L of supernatant was removed for assay of IMA.  
For the assay, powdered DTT was provided which required reconstitution in the 
ratio 15mg DTT: 10 mL diluent. The reconstituted reagent and power required 
storage at 2-8oC and the working solution had a shelf life of 3-5 days. The 
second generation of the assay used 7.5mg DTT to 10mL diluent. The third 
generation assay which became commercially available did not contain the 
sample pre treatment step and the assay kit contained a concentrated liquid 
form of DTT which was reconstituted in buffer with a fixed volume 200 L 
pipette. This assay has been approved by the Food and Drug Administration (FDA) in 
the USA as an adjunct test to rule out myocardial ischemia. The assay is also CE 
marked in Europe.  The assay can be performed manually with a 
spectrophotometer, however it was also initially automated on the Cobas MIRA 
Plus (Roche Diagnostics) automated spectrophotometer 38). The assay has 
since been adapted for other automated clinical chemistry platforms including 
the LX-20 (Beckman Coulter, Brea, CO, USA ) 39), Hitachi 911 (Hitachi, Japan) 
40)Hitachi 7600 (Hitachi, Japan) 41) and the Konelab 20 (Thermo Scientific, 
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United Kingdom) 42). To date a commercialised point of care device for IMA 
remains to be developed however a pre-commercial portable 
spectrophotometer and IMA assay has been developed by (Microwells 
Biotechnology Co Ltd, Shanghai, China). In the Microwells assay, the DTT has 
been replaced with a more stable azo dye chromogen in the Microwells assay. 
An automated method to measure ischemia induced alterations of the binding 
capacity of HSA for nickel 43) has been described 44). The nickel binding assay 
correlated well to the ACB assay (r=0.5387, p<0.001) however the area under 
the curve (AUC) of the Receiver Operating Characteristic (ROC) curve was 
higher for the nickel binding assay (0.7582) compared to the ACB assay 
(0.7289) suggesting the nickel binding has a superior ability to discriminate 
between ACS and non-ACS compared to the ACB assay. There are rumours of 
an ELISA assay for IMA. This assay is not validated for clinical diagnostic or 
therapeutic use and an independent performance validation and comparison to 
the ACB assay does not appear in the literature. The development of an ELISA 
however is probably not valid given the rapid alteration and return to baseline of 
IMA following ischemia, suggesting the alteration is transient and not a 
permanent change to a specific epitope which could be detected by an 
antibody.  
 
The in vitro stability of the IMA has been shown to be two hours at either 4oC or 
20°C, but values increase significantly after four hours irrespective of the 
storage temperature 30).  It is likely that the changes are due to in vitro pH 
changes altering the metal binding capacity of human serum albumin. Samples 
frozen at -20° C are stable although values have been reported to be slightly 
higher once thawed, compared to freshly analysed samples 45).  
 
A study of 109 subjects (55 men and 54 women; age range, 20 to 85 years) to 
determine the 95th percentile reference range for IMA has been performed 46). 
The concentrations ranged from 25.7 to 84.5 kU/L with an upper 95th percentile 
of 80.2 kU/L. This study used the first generation of the assay utilising the pre-
handling sample preparation step. Further studies of healthy subjects have 
reported higher IMA ranges. Abadie and colleagues demonstrated a mean IMA 
value of 89 kU/L from 69 subjects with a mean age of 49 years 47) whilst 
Maguire and colleagues demonstrated a 97.5th percentile of 110 kU/L 39) from a 
population of 81 healthy volunteers (28 men and 53 women aged 22-86 years). 
Values ranged from 82.0 to 110 kU/L and values were similar between males 
and females (99.1 vs 100.7 kU/L, p=0.12). The biological variation of IMA has 
been studied 48).  In a population of 17 apparently healthy individuals (7 male, 
10 female, aged 26-61 years), the within subject coefficient of variation was 
2.89% and the between subject coefficient of variation was 6.76%, calculated 
from weekly blood draws performed at the same time by the same phlebotomist 
for 5 consecutive weeks. Again there was no specific gender difference in IMA 
concentrations however the authors reported statistically different IMA 
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concentrations between Caucasian and Black populations, with higher IMA 
concentrations in Black males and females compared to Caucasian 
counterparts.  
 
Total serum albumin concentrations might be expected to affect the 
performance of IMA measurement. There is a relationship between IMA values 
and serum albumin concentration, although this is much less marked across the 
reference interval for albumin 49). The use of an albumin adjusted correction has 
been proposed 50) although a reference interval study found albumin correction 
to have little impact compared to other analytical factors 39). It has been 
reported that the changes in IMA observed in patients with chest pain was 
attributable only to changes in the serum albumin concentration 51).  
 
IV. UTILITY OF ISCHEMIA MODIFIED ALBUMIN IN CHEST PAIN PATIENTS 
 
Clinical validation of any test for ischemia is difficult as there is currently no 
accepted diagnostic gold standard, although blood lactate has been used 
previously.  In addition, there is no predicate test which can be used against 
which to perform an initial validation. The initial studies using IMA were based 
on the ability of an early measurement to predict the final diagnosis of AMI as 
defined by the elevation of cardiac troponin at 6-12 hours post chest pain. Two 
studies utilised the first generation pre-release ACB test and a third study 
manufactured an in-house method. The first study examined acute coronary 
syndrome (ACS) patients and utilised serial sampling on admission and two 
subsequent samples 52). Diagnostic sensitivity of the admission sample for a 
final diagnosis of AMI was 23.9% for cardiac troponin I (cTnI) alone, 39.1% for 
IMA alone and 55.9% for the two combined.  The second study examined 
enrolled 256 ACS patients 53). AUC of the ROC curve for the ACB test was 0.78 
with a sensitivity and specificity of 83% and 69% respectively at the optimised 
decision threshold for AMI. The third study enrolled 75 patients with ischemia 
and 92 non-ischaemic patients 26). IMA had poor predictive power in 
discriminating between AMI and non-AMI in patients with underlying ischaemic 
heart disease (AUC of 0.66). However, the test gave good discrimination 
between patients with or without ischemia. The AUC for the ROC curve for 
diagnosis of ischemia was 0.95 with sensitivity of 94% and specificity of 88%. In 
these initial studies there were significant problems with sample stability and the 
assay involved in addition of calcium chloride and centrifugation as part of the 
routine method.  This made the method unsuitable from routine analysis and the 
assay was reformulated. 
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The majority of patients who present to hospital with chest pain and suspected 
ACS are eventually ruled out for acute myocardial infarction and active unstable 
coronary disease. The ideal role of an ischemia marker would therefore be as 
rule out test.  The most logical place to use such a test is therefore in the ED.  A 
study of ED presentations examined 208 patients the diagnostic sensitivity of 
IMA measurement alone was 82% at 46% specificity in samples taken within 
the first 3 hours. The combination of ECG, cardiac troponin T (cTnT) and IMA 
showed 95% sensitivity for diagnosis of ACS at presentation 54). One year 
follow up performed on this population demonstrated a survival disadvantage in 
patients with IMA greater than the median concentration of the study group 55). 
A subsequent study of 538 patients admitted to a chest pain evaluation unit 
found admission measurement of IMA plus cTnT had 100% sensitivity for 
prediction of a final diagnosis of AMI 1). The presence of an elevated IMA and 
an elevated cTnT on admission predicted 21% risk of major adverse cardiac 
events (MACE) compared to patients where both were not elevated, even in 
patients where the final diagnosis excluded AMI by troponin based criteria. IMA 
measurement appears to work best as part of a panel of other tests or a test 
sequence 47). Admission measurement of IMA has been found to be superior to 
biomarkers of necrosis and to show 97% sensitivity when combined with them. 
Not all investigators have considered the diagnostic performance of IMA either 
alone or in combination with cardiac troponin, or other biomarkers of necrosis, 
to be adequate.  A prospective ED study enrolling 277 patients and using a 
positive IMA or troponin as the index test and an 8 hour troponin as the 
definitive test found only a 97.6% sensitivity with 97% negative predictive value.  
The investigators did not consider this to be adequate when compared with 
troponin but did not provide any follow-up data 56). A second large study 
prospectively enrolling 189 patients presenting to the ED with chest pain and 
found an elevated IMA was a poor predictor of cardiac events within the next 72 
hours 57). Conversely, another study found elevated IMA predicted long-term 
cardiac events 58). The most consistent finding across all studies of IMA is of a 
high negative predictive value.  This has been highlighted in a meta-analysis 
specifically examining the role of IMA as a rule out test 59). The summarised 
data of over 1800 patients demonstrated a triple negative prediction test (non-
diagnostic ECG, negative cTn and negative IMA) with a sensitivity and negative 
predictive value for ACS of 94.4% and 97.1% respectively.  
 
The prognostic value of IMA in the ACS setting has been investigated 55;58;60;61). 
Using a ROC derived cut off of 477 KU/L, Aparci and colleagues found 
significantly higher mortality at one year in those who had serum IMA >477 
KU/L, compared to those with IMA <477 KU/L 58). Furthermore, using cox 
regression modelling, IMA was related to mortality, independently of the 
presence of hypertension, diabetes or advanced age. In a larger cohort of 245 
consecutive attendances to the ED, in which there were 31 composite endpoint 
(cardiac death, AMI or recurrent angina) at 30-days from presentation and 16 
deaths at one year; the short and long term ability of IMA to predict outcome 
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was assessed. Short term survival was significantly compromised in those with 
IMA > 93.3 KU/L compared to those with lower IMA concentrations at both 30 
days and 1 year 55). Using the cohort of the French Nationwide OPERA study 
IMA, cTn, CRP and BNP were measured within 24hours from admission in 471 
patients hospitalized with AMI. Using a primary end point of death, resuscitated 
cardiac arrest, recurrent AMI or ischemia, heart failure or stroke, 75 in-hospital 
events and 144 events at 1 year were recorded. Using quartile analysis, 40% of 
patients reached the end point with IMA concentrations in the highest quartile 
(>104 KU/L), compared to only 20% of patients in the lowest quartile of 83 KU/L 
61). In those STEMI patients who are treated with primary PCI, IMA is a powerful 
predictor of 30-day mortality however it does not add to the validated 
Thrombolysis In Myocardial Infarction (TIMI) risk score 62). 
       
V. UTILITY OF ISCHEMIA MODIFIED ALBUMIN IN NON-CHEST PAIN 
PATIENTS 
 
Any marker associated with pathological processes upstream of cardiac 
necrosis will invariably suffer from a lack of specificity; unlike the cardiac 
troponins for cardiac necrosis. The further upstream in the ischemic continuum 
the more likely is the lack of cardiac specificity of the biomarker.  Elevations in 
circulating IMA concentrations are not specific for myocardial ischemia. 
Mechanistically, IMA can be generated during any ischemic process within the 
body. A comprehensive review of IMA elevations in non-cardiac conditions is 
beyond the scope of this chapter but an in-depth summary is given in table 2.  
Those conditions that have been studied most are explained in more detail 
below.  
Table 2 
Alteration to serum IMA concentrations in conditions other than acute coronary 
syndrome. 
 
Skeletal muscle ischemia 
Studies of subjects with skeletal muscle ischemia have produced contradictory 
results. In healthy subjects undergoing arduous physical exertion, IMA has been 
reported to fall immediately post exercise and then subsequently rise 63-65) or 
return to normal 66). Subjects undergoing a forearm ischemia test when the 
forearm muscles are exercised for 1 minute with the external compression of 
the arm blood supply showed a fall in IMA, maximal at 3 minutes from the test, 
returning to baseline by 30 minutes 67). A similar rise in serum lactate occurred. 
Conversely during standardized exercise in a plantar flexion pedal combined 
with inflation of a femoral blood pressure cuff (at 0, 60, 90, 120 and 150 mmHg) 
to induce calf muscle ischemia an increase in IMA was observed after release 
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of the cuff and returned to baseline within 30 minutes 68). Peri-operative skeletal 
muscle ischemia induced by femoral blood pressure cuff being inflated to 300 
mmHg in 23 patients undergoing arthroscopic knee surgery. Increased IMA and 
myoglobin and decreased albumin were observed following release of the cuff 
69). In patients with peripheral vascular disease (PVD) undergoing a treadmill 
walk test, a decrease in serum IMA immediately post-test has been 
documented 70;71). In 40 consecutive patients undergoing exercise 
electrocardiography, a significant decrease in IMA at peak exercise then a 
subsequent rise in IMA has been observed, however there was no difference in 
IMA concentrations between those patients with positive and negative stress 
test results 72). Revascularisation for PVD is accompanied by a post procedural 
rise in IMA 70;71;73). In skeletal muscle ischemia, an initial fall with subsequent 
rise appears to be a consistent finding without adequate explanation.  Smooth 
muscle ischemia does not appear to be associated with a rise in IMA 74). The 
effect of skeletal muscle on ischemia will limit the application of IMA 
measurement after cardiac stress testing for detection of myocardial ischemia 
and may explain the inconsistent findings51;72;75;76). 
Ischemic Stroke  
Patients with acute ischemic stroke demonstrate abnormalities in a number of 
biomarkers of nitrosative and oxidative stress. In 41 patients with ischemic 
stroke, Senes and colleagues demonstrate that nitrate, IMA and thiobarbituric 
acid-reactive substances (TBARS) concentrations are significantly increased 
compared to 37 age and gender matched controls 77). In a larger cohort of 118 
patients presenting within 3 hours of neurological deficit, IMA was elevated in 
those with cerebral infarction and intracranial haemorrhage (ICH) but normal 
reference values were observed in those with transient ischemic attacks (TIA) 
lasting less than 1 hour or those with epileptic seizures 78). Within 24 hours of 
injury IMA increased during cerebral infarction but not in intracranial 
haemorrhage and may offer diagnostic utility in the differential diagnosis of 
neurological deficit. IMA also correlated with National Institutes of Health Stroke 
Scale (NIHSS) Score in both cerebral infarction and ICH. Conversely, Herisson 
and colleagues did not demonstrate a causal relationship between IMA or heart 
type fatty acid binding protein and NIHSS score or stroke volume. Ahn and 
colleagues have utilised an albumin-adjusted IMA index for the early detection 
of ischemic stroke 79). In 52 patients, 28 (54%) with Ischemic stroke, 24 (46%) 
non-stroke, the AUC of ROC curve analysis was 0.928 for IMA but 0.99 for 
albumin-adjusted IMA index. The sensitivity and specificity of the IMA index was 
superior to IMA concentration alone.   
 
Pulmonary embolus 
Pulmonary embolus (PE) is an acute medical emergency estimated to occur in 
3.5/1000 hospitalized patients. Patients experience sudden onset dyspnoea, 
tachypnoea, pleuritic-type chest pain, cyanosis and haemoptysis. PE has an 
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associated mortality of 26%. Diagnosis is primarily based on typical clinical 
presentation using the Wells and Geneva clinical probability scores. D-dimer 
measurement and pulmonary angiography are often clinically useful. The ECG 
can demonstrate acute cor pulmonale in large PE’s but lacks specificity. IMA 
has been measured in a number of studies of PE patients. Turedi and 
colleagues 80) have demonstrated that IMA was significantly elevated in 30 PE 
patients compared to 30 healthy controls and adequately discriminated between 
the presence and absence of PE. The positive predictive value of IMA for PE is 
higher than that for D-dimer (79.4% compared to 69.4%) and in combination 
with the Wells and Geneva criteria, IMA offers an alternative to D-dimer testing 
81).  
  
Chronic kidney disease 
Patients with chronic kidney disease (CKD) have a reduced life span compared 
to those without renal disease. Mortality rates are highest in those receiving 
haemodialysis as renal replacement therapy (RRT). Cardiovascular mortality 
accounts for the majority of renal deaths. Between 2001 and 2006, 24% of 
deaths in UK RRT patients were due to ischemic heart disease 82). This rate is 
consistent with data from other countries.  Cardiovascular morbidity is also 
increased. 55% of patients receiving haemodialysis RRT also have concomitant 
congestive cardiac failure. 83). IMA levels have been determined in patients with 
CKD 84-86) and in patients receiving haemodialysis (HD) 87-91).  
 
In 2006, Sharma and colleagues demonstrated that patients with elevated IMA 
have a significantly large left ventricle, decreased systolic function and greater 
estimated left ventricular filling pressure 85). Further, in multivariate analysis, a 
positive dobutamine stress echocardiogram (DSE) combined with elevated IMA 
and cTnT and E/Ea ratio were independent prognostic factors for death. IMA 
values increase significantly in those patients with a positive DSE compared to 
those with no ischemic response 84). In a modestly small study of 17 anaemic 
CKD patients and 19 controls, Cichota and colleagues demonstrated that IMA 
increased in patients compared to the control group. IMA correlated to lactate, 
haemoglobin and creatinine 86).  
 
Pre and post-HD IMA concentrations are significantly correlated 87), however in 
this study IMA concentrations were not significantly different between those 
CKD patients with or without ischemic heart disease, diabetes mellitus or 
peripheral vascular disease. Fast intravenous iron administration during HD is 
associated with oxidative stress and inflammation. In a study of 20 HD patients 
receiving slow intravenous iron administration, IMA concentrations were 
significantly increased across three HD sessions independently of slow i.v. iron 
administration 88).  Following adjustment of albumin by two methods, post 
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dialysis IMA levels remain significantly increased following HD 89). Paroxonase-
1 (PON-1) is a calcium dependent esterase (arylesterase, aromatic esterase 1, 
serum aryldialkylpohosphatase 1, EC 3.1.8.1) is a major anti-atherosclerotic 
component of HDL cholesterol. PON-1 concentrations are lower in CKD 
patients with and without haemodialysis RRT compared to controls suggesting 
chronic oxidative stress and accelerated atherosclerosis are a feature of CKD.   
In a pilot study of CKD patients receiving HD, PON-1 concentrations were 
significantly and inversely correlated to IMA suggesting an oxidative stress and 
ischemic process occurs during HD 90). Recently Albarello and colleagues have 
evaluated the effect of IMA and protein carbonyl groups as markers of protein 
oxidation in 23 CKD patients receiving HD. The authors confirm previous 
reports of higher IMA post-HD than pre-HD and observed a significant 
correlation between IMA and protein carbonyl groups, attributed to oxidative 
stress associated with HD 91).  
 
Hyperlipidaemia and Obesity  
IMA measurement may be of benefit in hypercholesterolaemic patients. IMA is 
correlated to cholesterol, low density lipoprotein (LDL) and antibodies to 
oxidised LDL (ox-LDL) 21). In a study of 37 subjects with hypercholesterolaemia 
compared to 37 controls, Duarte and colleagues 92) confirm these findings 
observing IMA correlations to cholesterol, LDL ox-LDL antibodies and to high 
sensitivity C-reactive protein, suggesting that hypercholesterolaemia is 
associated with inflammatory and oxidative stress processes, contributing to the 
advancement of atherosclerosis. IMA is related to the presence of metabolic 
syndrome independently of age, gender, presence of diabetes or 
hypercholesterolaemia 93). Furthermore, the use of 10 mg/day ezetimibe 
immunotherapy for a duration of 12 weeks in 31 hypercholesterolaemic patients 
reduced both LDL cholesterol and IMA 94). The reduction of IMA was 
independent of the reduction in LDL suggesting that ezetimibe may reduce the 
burden of oxidative stress in hypercholesterolaemia.  
IMA concentrations are higher in obese subjects, with a positive correlation 
between IMA and body mass index (BMI).  In a large study of 148 volunteers in 
Brazil; subjects were classified as normal, overweight or obese, defined as BMI 
of 18.5-24.9, 25.0-29.9 and >30 kg/m2 respectively. IMA concentrations 
increased exponentially between the three groups, the highest being in those 
subjects with BMI >30 kg/m2. Similar findings have been demonstrated in obese 
postmenopausal women where IMA and IMA:Albumin ratio are higher in those 
subjects with BMI 26-32 kg/m2 compared to those with BMI 21-25 kg/m2. The 
obese concentrations were similar to those with documented coronary artery 
disease but normal BMI. In the obese women IMA was positively correlated to 
BMI, hs-CRP, insulin concentrations and homeostasis assessment model score 
95).   
 
380 
 
Diabetes Mellitus  
Patients with type 2 diabetes mellitus who demonstrate poor glycaemic control 
have higher IMA concentrations than those with good glycaemic control. IMA 
was significantly higher in 76 diabetic patients compared to 25 control subjects 
and IMA concentrations are correlated to HbA1c 96), glucose and hs-CRP 97). 
Conversely, Dahiya and colleagues suggest no significant changes in IMA 
occur in 60 newly diagnosed type 2 diabetics, compared to 30 control subjects 
98). Diabetic patients who undertake chronic exercise for three months 
demonstrate lower post exercise IMA concentrations suggesting that exercise 
alleviates some of the oxidative stress associated with diabetes mellitus 99).  
Bowel Ischemia 
Bowel (mesenteric) ischemia occurs infrequently however if not recognised 
early, carries a devastatingly high mortality. The presentation is often 
characterised by generalised abdominal pain, fever, diarrhoea or constipation, 
tachycardia, hematochezia (blood per rectum), nausea and vomiting. Diagnosis 
is difficult due to non-specific signs and symptoms, plain x-ray or laboratory 
tests (increased white blood cell count and serum lactic acid). Mesenteric 
angiography is considered to be the gold standard test which can differentiate 
between embolic, thrombotic or nonocclusive ischemia. In a preliminary study of 
26 patients presenting with symptoms of internal ischemia, Polk and colleagues 
100) identified 12 with a positive clinical diagnosis. Positive patients had higher 
IMA concentrations than those without intestinal ischemia. IMA detected bowel 
ischemia with a sensitivity of 100% and a specificity of 86%. In a case-
controlled study from Turkey, Gunduz and colleagues 101) demonstrated that 
pre-operative IMA concentrations were significantly higher in patients with 
thromboembolic occlusion of the superior mesenteric artery (SMA) compared to 
an age-matched control group of healthy volunteers.  A number of animal 
studies of mesenteric ischemia have provided conflicting results. In a Wistar rat 
model 102) a time dependent response in IMA in mesenteric ischemia has been 
demonstrated. 36 mature female rats underwent either simple laparotomy in the 
control groups or laparotomy followed by clamping of the SMA in the subject 
group. IMA concentrations were highest 6 hours from ischemic onset, however 
IMA at 30 minutes and 2 hours were also significantly higher in the clamped 
group compared to the control group. Elevations of IMA tracked changes in both 
lactate and malondialdehyde. A similar time dependent change in IMA was 
demonstrated in New Zealand rabbits undergoing ligation of the SMA compared 
to either a control group or those undergoing a sham procedure 103)with 
elevation of IMA at 2 and 6 hours significantly higher than baseline and higher 
than IMA concentrations in the control rabbits. IMA concentrations mimicked 
elevations in serum IL-6 with elevated IL-6 in the ischemia group at 1, 3 and 6 
hours, but no elevations in the sham operated or control group. In a further 
study of mesenteric ischemia in a Wistar rat model, Uygun and colleagues 
demonstrated similar IMA concentrations in control, sham, 2-hour and 6-hour 
post-SMA ischemia refuting the previous animal studies. It seems likely that 
IMA may offer additional diagnostic value in the early presentation of 
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mesenteric ischemia. Further prospective studies are required to assess both 
the diagnostic and prognostic ability of IMA in conjunction with mesenteric 
angiography to detect bowel ischemia. Obstetric and gynaecological use of IMA 
 
The care of women and their unborn child during pregnancy is greatly 
challenging for obstetricians.  The adult can interact and provide a history of 
signs and symptoms whereas the unborn child can only be examined indirectly 
by means of imaging, foetal heart monitors and a limited number of direct 
interventions.  Women achieving spontaneous preterm (<37 weeks) labour 
account for 10% of all births and are attributable to 75% of neonatal deaths. The 
foetus relies entirely on the maternal placenta for O2/CO2 exchange.  This 
delicate dependence, between the placenta and the foetus is crucial to normal 
healthy growth. Any malfunction or disruption to the adequate supply of oxygen 
can cause hypoxia and potentially fatal acidosis.  A limited degree of acidosis is 
well tolerated by the foetus; however chronic acidosis or hypoxia may lead to a 
significant mortality and morbidity with potential log-term sequelae.  Currently 
the mechanism of foetal hypoxia and acidosis is unclear, and physiological 
consequence of foetal acidosis is believed to target the cell energy availability 
and /or cell poisoning.  
 
During pregnancy plasma proteins change markedly due to increased plasma 
volume, increased renal blood flow and altered protein synthesis in response to 
hormonal changes. Plasma volume expansion of up to 45% (1300mL) 
compared to the non-pregnant state causes an overall net decrease in plasma 
protein concentration by 10-12 g/L which is reached around week 28 of 
gestation. The predominant cause of lowered albumin is dilutional, oestrogen is 
known to affect albumin.  The alteration to plasma albumin concentrations 
throughout the pregnancy period is shown in table 3. The lower concentration of 
albumin also results in an apparent decrease in substances normally bound to 
this protein.  
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Table 3 
Alteration to plasma HSA concentrations during the gestational period. 
 
Time point Mean albumin 
concentration (g/L) 
Reference interval 
(g/L) 
Non-pregnant 
control 
41 36-46 
12 weeks 38 33-43 
18 weeks 35 30-39 
24 weeks 33 29-37 
28 weeks 32 28-37 
32 weeks 32 38-36 
36 weeks 32 38-36 
Full term 32 26-38 
1 day post partum 29 23-38 
6 weeks post 
partum 
42 37-47 
 
The HSA reference interval in the full term healthy neonate between term and 
day 4 is 28-44 g/L. Albumin concentrations increase a little from birth to puberty 
where the adolescent reference interval (day 4 to 14 years) is 38-54 g/L.  
 
Current experimental studies suggest that foetal development occurs in a 
hypoxic intrauterine environment and the presence of reperfusion and oxidative 
stress is believed to be crucial for trophoblast development 104;105). Trophoblast 
invasion of the maternal spiral arteries allows the increase of uterine blood 
supply necessary to maintain the pregnant state. Serum IMA during normal 
pregnancy is elevated compared to non-pregnant controls 106-109). Prefumo and 
colleagues 106) demonstrate supra-physiological IMA concentrations in early 
normal pregnancy (11-13 weeks of gestation) suggesting that trophoblast 
development occurs in a hypoxic uterus. In a large population of 117 pregnant 
women compared to non-pregnant healthy women, Guven and colleagues 
demonstrated a cross-sectional elevation in IMA in pregnant women. IMA 
increased significantly through each trimester. Further, there the authors 
demonstrated a significant negative correlation between IMA and HSA, 
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suggesting that elevated IMA in pregnancy represents a physiologic state of 
oxidative stress.  
 
Increased intrauterine hypoxia predisposes to defective endovascular 
trophoblast invasion of the maternal spiral arteries which may possibly lead to 
the development of pre-eclampsia; a hypertensive state (>140/90 mmHg) 
associated with significant proteinuria (>300mg/dL). Pre-eclampsia affects 6-8% 
of pregnancies worldwide.  Papageorghiou and colleagues have demonstrated 
that first trimester serum IMA are significantly higher in women who develop 
pre-eclampsia compared to those with a normal pregnancy 110). Both IMA and 
normalised IMA (IMA:Albumin,  ratio) were higher in 20 pre-eclamptic women 
compared to 22 normal pregnancies 109). These data suggest IMA could be a 
biological marker of pre-eclampsia however larger studies are required to fully 
characterise the supra-normal IMA and normalised IMA reference interval in 
normal pregnancy.   
     
Maternal IMA and normalised IMA concentrations are also increased in women 
with recurrent pregnancy loss (two or more unexplained miscarriages in the first 
trimester) compared to healthy pregnancy 111), suggesting that an increase of 
intrauterine oxidative stress and hypoxia contribute to placental deficiency and 
subsequently recurrent early miscarriage. 
 
The use of umbilical cord blood for IMA has also been examined. Neonatal cord 
blood IMA concentrations are higher than IMA concentrations in healthy adults 
112) but is not attributable to changes in HSA concentration. Elevated fetal IMA 
may reflect transient localised ischemia from external forces exerted on the 
foetus during labour. In a case-control study of 26 newborns, 12 delivered at 
normal term and 14 with complicated labour or delivered pre-term; cord blood 
IMA concentrations were significantly higher (50%) than those with uneventful 
deliveries, suggesting IMA is a marker of fetal distress. Doubly-clamped cord 
blood IMA concentrations are similar in intrauterine growth restriction, compared 
to those delivered with appropriate for gestational age full-term pregnancies 113). 
The similar IMA concentrations may be due to the ‘brain sparing effect’ 
accompanied by oligohydraminos (deficiency in amniotic fluid), which is 
characterised by rerouting the blood supply and the nutrient to vital organs such 
as the heart, brain and adrenal glands. IMA concentrations in cord blood are 
higher following caesarean section compared to vaginal delivery and in 
multigravida compared to primigravida 113) and may be attributable to higher 
oxidative stress on both accounts. Cigarette smoking during the gestational 
period alters the oxidant/antioxidant balance in favour of oxidative stress. In 
response, IMA and MDA concentrations in pregnant smokers are significantly 
higher and vitamins A and E, SOD and total antioxidant capacity  are 
significantly lower, compared to non-smoking pregnant women 114). 
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VI. CONCLUSIONS 
 
Although there are a number of postulates, the mechanisms by which IMA is 
generated remain unexplained. Indeed the evidence that intact HSA exists in 
patients with ischemia and the remarkably rapid return of IMA concentrations to 
pre-ischemic levels questions the N-terminal deletion theory. It has been 
suggested that IMA is in fact a marker of oxidative stress as conditions 
associated with raised IMA can be associated with other markers of oxidative 
stress such as carbonyl residues, nitrate and TBARS. Unfortunately such 
markers may also be associated with elevated markers of cardiac damage and 
dysfunction, such as cardiac troponin and natriuretic peptides.  
 
Despite this, ischemia modified albumin currently remains the only ischemia 
assay to have reached the clinical validation stage and obtained CE marking 
and FDA approval for the diagnosis of cardiac ischemia. The most suitable 
clinical role for IMA in the acute chest pain population is in conjunction with the 
ECG and cTn for a triple negative rule out test. IMA alone due to its lack of 
cardiospecificty cannot be used as a single rule in or rule out cardiac biomarker. 
For non acute populations it seems that IMA is associated with oxidative stress 
and may identify affected patients. Furthermore, as some studies have shown, 
patients who receive anti-oxidative agents demonstrate lower IMA 
concentrations post therapy. IMA therefore may be useful in the monitoring and 
guidance of anti-oxidant therapy.  
 
IMA has the potential to be enormously valuable in assessing both chest pain 
patients and those with conditions associated with oxidative stress. A better 
understanding of this marker is required before it is acceptable for prime time 
use.  
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